



(11) **EP 3 168 304 A1**

(12) **EUROPEAN PATENT APPLICATION**

(43) Date of publication:
17.05.2017 Bulletin 2017/20

(51) Int Cl.:
C12N 15/11 (2006.01)

(21) Application number: **16002068.1**

(22) Date of filing: **26.08.2004**

(84) Designated Contracting States:
**AT BE BG CH CY CZ DE DK EE ES FI FR GB GR
HU IE IT LI LU MC NL PL PT RO SE SI SK TR**
Designated Extension States:
AL HR LT LV MK

(30) Priority: **27.08.2003 US 498407 P**
26.03.2004 US 556837 P

(62) Document number(s) of the earlier application(s) in
accordance with Art. 76 EPC:
10013061.6 / 2 281 885
04782166.5 / 1 660 057

(71) Applicant: **Ophthotech Corporation**
New York, NY 10119 (US)

(72) Inventors:
• **SHIMA, David T.**
Barnet EN4 0ES
Hertfordshire (GB)

• **CALIAS, Perry**
Melrose, MA 02176 (US)
• **ADAMIS, Anthony P**
Hillsborough, CA 94010 (US)

(74) Representative: **Bösl, Raphael Konrad**
Isenbruck Bösl Hörschler LLP
Patentanwälte
Prinzregentenstraße 68
81675 München (DE)

Remarks:

- This application was filed on 23-09-2016 as a divisional application to the application mentioned under INID code 62.
- Claims filed after the date of filing of the application / after the date of receipt of the divisional application (Rule 68(4) EPC).

(54) **COMBINATION THERAPY FOR THE TREATMENT OF OCULAR NEOVASCULAR DISORDERS**

(57) The invention features methods for treating a patient diagnosed with, or at risk of developing, a neo-vascular disorder by administering a PDGF antagonist and a VEGF antagonist to the patient. The invention also

features a pharmaceutical composition containing a PDGF antagonist and a VEGF antagonist for the treatment or prevention of a neovascular disorder.

EP 3 168 304 A1

Description**RELATED APPLICATIONS**

5 **[0001]** This application claims priority to U.S. Provisional Application Serial No. 60/498,407, filed August 27, 2003, Attorney Docket No. EYE-013P, and U.S. Provisional Application Serial No. 60/556,837, filed March 26, 2004, Attorney Docket No. EYE-013P2, both of which are hereby incorporated in its entirety by reference.

FIELD OF THE INVENTION

10 **[0002]** This invention relates to the fields of ophthalmology and medicine. More specifically, this invention relates to the treatment of neovascular disorders of the eye using a combination of agents that inhibit both platelet-derived growth factor (PDGF) and vascular endothelial growth factor (VEGF).

BACKGROUND OF THE INVENTION

15 **[0003]** Angiogenesis, also called neovascularization, involves the formation of sprouts from preexistent blood vessels and their invasion into surrounding tissue. A related process, vasculogenesis, involves the differentiation of endothelial cells and angioblasts that are already present throughout a tissue, and their subsequent linking together to form blood vessels.

20 **[0004]** Angiogenesis occurs extensively during development, and also occurs in the healthy body during wound healing in order to restore blood flow to tissues after injury or insult. Angiogenesis, however, has also been implicated in cancer and tumor formation. Indeed, the quantity of blood vessels in a tumor tissue is a strong negative prognostic indicator in breast cancer (Weidner et al., (1992) J. Natl. Cancer Inst. 84:1875-1887), prostate cancer (Weidner et al., (1993) Am. J. Pathol. 143:401-409), brain tumors (Li et al., (1994) Lancet 344:82-86), and melanoma (Foss et al., (1996) Cancer Res. 56:2900-2903). Angiogenesis has also recently been implicated in other disease states in many areas of medicine, including rheumatology, dermatology, cardiology and ophthalmology. In particular, undesirable or pathological tissue-specific angiogenesis has been associated with certain specific disease states including rheumatoid arthritis, atherosclerosis, and psoriasis (see e.g., Fan et al., (1995) Trends Pharmacol. Sci. 16: 57; and Folkman (1995) Nature Med. 1: 27). Furthermore, the alteration of vascular permeability is thought to play a role in both normal and pathological physiological processes (Cullinan-Bove et al., (1993) Endocrinol. 133: 829; Senger et al., (1993) Cancer and Metastasis Reviews 12: 303). Although the angiogenic process in each of these diseases is likely to share many features with developmental angiogenesis and tumor angiogenesis, each may also have unique aspects conferred by the influence of surrounding cells.

35 **[0005]** Several ocular disorders involve alterations in angiogenesis. For example, diabetic retinopathy, the third leading cause of adult blindness (accounting for almost 7% of blindness in the USA), is associated with extensive angiogenic events. Nonproliferative retinopathy is accompanied by the selective loss of pericytes within the retina, and their loss results in dilation of associated capillaries and a resulting increase in blood flow. In the dilated capillaries, endothelial cells proliferate and form outpouchings, which become microaneurysms, and the adjacent capillaries become blocked so that the area of retina surrounding these microaneurysms is not perfused. Eventually, shunt vessels appear between adjacent areas of micro aneurysms, and the clinical picture of early diabetic retinopathy with micro aneurysms and areas of nonperfused retina is seen. The microaneurysms leak and capillary vessels may bleed, causing exudates and hemorrhages. Once the initial stages of background diabetic retinopathy are established, the condition progresses over a period of years, developing into proliferative diabetic retinopathy and blindness in about 5% of cases. Proliferative diabetic retinopathy occurs when some areas of the retina continue losing their capillary vessels and become nonperfused, leading to the appearance of new vessels on the disk and elsewhere on the retina. These new blood vessels grow into the vitreous and bleed easily, leading to preretinal hemorrhages. In advanced proliferative diabetic retinopathy, a massive vitreous hemorrhage may fill a major portion of the vitreous cavity. In addition, the new vessels are accompanied by fibrous tissue proliferation that can lead to traction retinal detachment.

40 **[0006]** Diabetic retinopathy is associated primarily with the duration of diabetes mellitus; therefore, as the population ages and diabetic patients live longer, the prevalence of diabetic retinopathy will increase. Laser therapy is currently used in both nonproliferative and proliferative diabetic retinopathy. Focal laser treatment of the leaking microaneurysms surrounding the macular area reduces visual loss in 50% of patients with clinically significant macular edema. In proliferative diabetic retinopathy, panretinal photocoagulation results in several thousand tiny burns scattered throughout the retina (sparing the macular area); this treatment reduces the rate of blindness by 60 percent. Early treatment of macular edema and proliferative diabetic retinopathy prevents blindness for 5 years in 95% of patients, whereas late treatment prevents blindness in only 50 percent. Therefore, early diagnosis and treatment are essential.

55 **[0007]** Another ocular disorder involving neovascularization is age-related macular degeneration (AMD), a disease

that affects approximately one in ten Americans over the age of 65. AMD is characterized by a series of pathologic changes in the macula, the central region of the retina, which is accompanied by decreased visual acuity, particularly affecting central vision. AMD involves the single layer of cells called the retinal pigment epithelium that lies immediately beneath the sensory retina. These cells nourish and support the portion of the retina in contact with them, *i.e.*, the photoreceptor cells that contain the visual pigments. The retinal pigment epithelium lies on the Bruch membrane, a basement membrane complex which, in AMD, thickens and becomes sclerotic. New blood vessels may break through the Bruch membrane from the underlying choroid, which contains a rich vascular bed. These vessels may in turn leak fluid or bleed beneath the retinal pigment epithelium and also between the retinal pigment epithelium and the sensory retina. Subsequent fibrous scarring disrupts the nourishment of the photoreceptor cells and leads to their death, resulting in a loss of central visual acuity. This type of age-related maculopathy is called the "wet" type because of the leaking vessels and the subretinal edema or blood. The wet type accounts for only 10% of age-related maculopathy cases but results in 90% of cases of legal blindness from macular degeneration in the elderly. The "dry" type of age-related maculopathy involves disintegration of the retinal pigment epithelium along with loss of the overlying photoreceptor cells. The dry type reduces vision but usually only to levels of 20/50 to 20/100.

[0008] AMD is accompanied by distortion of central vision with objects appearing larger or smaller or straight lines appearing distorted, bent, or without a central segment. In the wet type of AMD, a small detachment of the sensory retina may be noted in the macular area, but the definitive diagnosis of a subretinal neovascular membrane requires fluorescein angiography. In the dry type, drusen may disturb the pigmentation pattern in the macular area. Drusen are excrescences of the basement membrane of the retinal pigment epithelium that protrude into the cells, causing them to bulge anteriorly; their role as a risk factor in age-related maculopathy is unclear. No treatment currently exists for the dry type of age-related maculopathy. Laser treatment is used in the wet type of age-related maculopathy and initially obliterates the neovascular membrane and prevents further visual loss in about 50% of patients at 18 months. By 60 months, however, only 20% still have a substantial benefit.

[0009] Multiple molecular mediators of angiogenesis have been identified including basic and acidic fibroblast growth factors (aFGF, bFGF), transforming growth factors alpha and beta (TGF α , TGF β), platelet-derived growth factor (PDGF), angiogenin, platelet-derived endothelial cell growth factor (PD-ECGF), interleukin-8 (IL-8), and vascular endothelial growth factor (VEGF). Other stimulators implicated in angiogenesis include angiopoietin-1, Del-1, follistatin, granulocyte colony-stimulating factor (G-CSF), hepatocyte growth factor (HGF), leptin, midkine, placental growth factor, pleiotrophin (PTN), progranulin, proliferin, and tumor necrosis factor-alpha (TNF-alpha). In addition, control of angiogenesis is further mediated by a number of negative regulators of angiogenesis produced by the body including angioarrestin, ngiostatin (plasminogen fragment), antiangiogenic antithrombin III, cartilage-derived inhibitor (CDI), CD59 complement fragment, endostatin (collagen XVIII fragment), fibronectin fragment, gro-beta, heparinases, heparin hexasaccharide fragment, human chorionic gonadotropin (hCG), interferon alpha/beta/gamma, interferon inducible protein (IP-10), interleukin-12, kringle 5 (plasminogen fragment), metalloproteinase inhibitors (TIMPs), 2-methoxyestradiol, placental ribonuclease inhibitor, plasminogen activator inhibitor, platelet factor-4 (PF4), prolactin 16kD fragment, proliferin-related protein (PRP), retinoids, tetrahydrocortisol-S, thrombospondin-1 (TSP-1), vasculostatin, and vasostatin (calreticulin fragment).

[0010] Among these angiogenic regulators, VEGF appears to play a key role as a positive regulator of the abnormal angiogenesis accompanying tumor growth (reviewed in Brown et al., (1996) Control of Angiogenesis (Goldberg and Rosen, eds.) Birkhauser, Basel, and Thomas (1996) J. Biol. Chem. 271:603-606). Furthermore, recently the role of the PDGF-B member of the PDGF family of signaling molecules has been under investigation, since it appears to play a role in the formation, expansion and proper function of perivascular cells, sometimes referred to as mural cells, *e.g.*, vascular smooth muscle, mesangial cells, and pericytes.

[0011] While much has been learned about angiogenesis, or neovascularization, accompanying development, wound healing and tumor formation, it remains to be determined whether there are differences between these forms of angiogenesis and ocular angiogenesis. Significantly, while angiogenesis accompanying, *e.g.*, collateral blood vessel formation in the heart, may be beneficial and adaptive to the organism, pathological ocular neovascularization accompany, *e.g.*, AMD, has no known benefit and often leads to blindness (for review, see Campochiaro (2000) J. Cell. Physiol. 184: 301-10). Therefore, although advances in the understanding of the molecular events accompanying neovascularization have been made, there exists a need to utilize this understanding to develop further methods for treating neovascular diseases disorders, including ocular neovascular diseases and disorders such as the choroidal neovascularization that occurs with AMD and diabetic retinopathy.

SUMMARY OF THE INVENTION

[0012] It has been discovered that the combination of anti-VEGF and anti-PDGF agents surprisingly affords synergistic therapeutic benefits for treating an ocular neovascular disease.

[0013] Accordingly, the invention features a method for treating a patient diagnosed with or at risk for developing a neovascular disorder. This method includes administering to the patient an anti-VEGF agent and an anti-PDGF agent

as a primary or adjunct therapeutic treatment.

[0014] In one aspect, the invention provides a method for suppressing a neovascular disorder in a patient in need thereof, by administering to the patient a PDGF antagonist and a VEGF antagonist, simultaneously, or within about 90 days of each other, in amounts sufficient to suppress the neovascular disorder in the patient.

[0015] In another aspect, the invention provides a method for treating a patient diagnosed with, or at risk for developing, a neovascular disorder in a patient in need thereof, by administering to the patient a PDGF antagonist and a VEGF antagonist, simultaneously or within 90 days of each other, in amounts sufficient to treat the patient.

[0016] In particular embodiments of these aspects, the method of the invention involves administering the PDGF antagonist and the VEGF antagonist within about 10 days of each other. In another embodiment of the method of the invention, the PDGF antagonist and the VEGF antagonist are administered within 5 days of each other. In yet another embodiment of the method of the invention, the PDGF antagonist and the VEGF antagonist are administered within about 24 hours of each other. In a particular embodiment of the method of the invention, the PDGF antagonist and said VEGF antagonist are administered simultaneously.

[0017] In another embodiment, the method of the invention involves administration of a PDGF antagonist that is a PDGF-B antagonist. In still another embodiment, the method of the invention involves administration of a VEGF antagonist that is a VEGF-A antagonist.

[0018] In certain embodiments, the method of the invention involves administration of a PDGF antagonist that is a nucleic acid molecule, an aptamer, an antisense RNA molecule, a ribozyme, an RNAi molecule, a protein, a peptide, a cyclic peptide, an antibody, a binding fragment of an antibody fragment, a sugar, a polymer, or a small organic compound. In another embodiment, the method of the invention involves administration of a VEGF antagonist that is a nucleic acid molecule, an aptamer, an antisense RNA molecule, a ribozyme, an RNAi molecule, a protein, a peptide, a cyclic peptide, an antibody, a binding fragment of an antibody fragment, a sugar, a polymer, or a small organic compound.

[0019] In a particular embodiment, the method of the invention involves administration of a VEGF antagonist that is an aptamer, such as an EYE001 aptamer. In another embodiment, the method of the invention involves administration of a VEGF antagonist that is an antibody or binding fragment thereof.

[0020] In a particular embodiment, the method of the invention involves administration of a PDGF antagonist that is an aptamer, an antibody or a binding fragment thereof. In another particular embodiment, the method of the invention involves administration of a PDGF antagonist that is an antisense oligonucleotide.

[0021] In yet another embodiment of this aspect of the invention, the PDGF antagonist and/or the VEGF antagonist are pro-drugs.

[0022] In one embodiment, the method of the invention provides a means for suppressing or treating an ocular neovascular disorder. In some embodiments, ocular neovascular disorders amenable to treatment or suppression by the method of the invention include ischemic retinopathy, iris neovascularization, intraocular neovascularization, age-related macular degeneration, corneal neovascularization, retinal neovascularization, choroidal neovascularization, diabetic retinal ischemia, or proliferative diabetic retinopathy. In still another embodiment, the method of the invention provides a means for suppressing or treating psoriasis or rheumatoid arthritis in a patient in need thereof or a patient diagnosed with or at risk for developing such a disorder.

[0023] The invention also provides a pharmaceutical composition that includes both a PDGF antagonist and a VEGF antagonist, as well a pharmaceutically acceptable carrier. In this aspect, the PDGF and VEGF antagonists are present both in amounts sufficient to suppress the neovascular disorder in the patient.

[0024] In one embodiment of this aspect, the pharmaceutical composition includes a PDGF antagonist that is a PDGF-B antagonist. In another embodiment, the pharmaceutical composition includes a VEGF antagonist that is a VEGF-A antagonist.

[0025] In certain embodiments, the pharmaceutical composition of the invention includes a PDGF antagonist that is a nucleic acid molecule, an aptamer, an antisense RNA molecule, a ribozyme, an RNAi molecule, a protein, a peptide, a cyclic peptide, an antibody, a binding fragment of an antibody fragment, a sugar, a polymer or a small organic compound. In another embodiment, the pharmaceutical composition of the invention includes a VEGF antagonist that is a nucleic acid molecule, an aptamer, an antisense RNA molecule, a ribozyme, an RNAi molecule, a protein, a peptide, a cyclic peptide, an antibody, a binding fragment of an antibody fragment, a sugar, a polymer, or a small organic compound.

[0026] In other particular embodiments, the pharmaceutical composition of the invention includes a VEGF antagonist that is an aptamer, such as an EYE001 aptamer. In one embodiment, the pharmaceutical composition of the invention includes a VEGF antagonist that is an antibody or binding fragment thereof.

[0027] In a particular embodiment, the pharmaceutical composition of the invention includes a PDGF antagonist that is an antibody or binding fragment thereof. In another particular embodiment, the pharmaceutical composition of the invention includes a PDGF antagonist that is an antisense oligonucleotide.

[0028] The pharmaceutical composition the invention may include a pharmaceutically acceptable carrier which includes a microsphere or a hydrogel formulation.

[0029] In yet another embodiment, the PDGF antagonist and/or the VEGF antagonist are pro-drugs.

[0030] In another embodiment, the pharmaceutical composition of the invention provides a means for suppressing or treating an ocular neovascular disorder. In some embodiments, ocular neovascular disorders amenable to treatment or suppression by the pharmaceutical composition of the invention include ischemic retinopathy, iris neovascularization, intraocular neovascularization, age-related macular degeneration, corneal neovascularization, retinal neovascularization, choroidal neovascularization, diabetic retinal ischemia, or proliferative diabetic retinopathy. In still other embodiments, the pharmaceutical composition of the invention provides a means for suppressing or treating psoriasis or rheumatoid arthritis in a patient in need thereof, or a patient diagnosed with or at risk for developing such a disorder.

[0031] The invention also provides a pharmaceutical pack that includes both a PDGF antagonist and a VEGF antagonist. In one embodiment of this aspect, the pharmaceutical pack includes a PDGF antagonist that is a PDGF-B antagonist. In another embodiment of this aspect, the pharmaceutical pack includes a VEGF antagonist that is a VEGF-A antagonist.

[0032] In another embodiment, the PDGF antagonist and VEGF antagonist of the pharmaceutical pack are formulated separately and in individual dosage amounts. In still another embodiment, the PDGF antagonist and VEGF antagonist of the pharmaceutical pack are formulated together.

[0033] In some particular embodiments, the pharmaceutical pack of the invention includes a VEGF antagonist that is an aptamer, such as an EYE001 aptamer. In other embodiments, the pharmaceutical pack of the invention includes a VEGF antagonist that is an antibody or binding fragment thereof.

[0034] In some embodiments, the pharmaceutical pack of the invention includes a PDGF antagonist that is an antibody or binding fragment thereof. In other particular embodiment, the pharmaceutical pack of the invention includes a PDGF antagonist that is an antisense oligonucleotide. In yet another embodiment of this aspect, the PDGF antagonist and/or the VEGF antagonist are pro-drugs.

BRIEF DESCRIPTION OF THE DRAWINGS

[0035]

Figure 1 (A) is a schematic representation of the nucleic acid sequence of a human PDGF-B (GenBank Accession No. X02811) (SEQ ID NO: 1).

Figure 1 (B) is a schematic representation of the amino acid sequence of a human PDGF-B (GenBank Accession No. CAA26579) (SEQ ID NO: 2).

Figure 1 (C) is a schematic representation of the nucleic acid sequence of a human PDGF-A (GenBank Accession No. X06374) (SEQ ID NO: 11).

Figure 1 (D) is a schematic representation of the polypeptide sequence of a human PDGF-A (GenBank Accession No. CAA29677) (SEQ ID NO: 12).

Figure 2 (A) is a schematic representation of the nucleic acid sequence of a human VEGF (GenBank Accession No: NM_003376) (SEQ ID NO: 3).

Figure 2 (B) is a schematic representation of the amino acid sequence of a human VEGF polypeptide (GenBank Accession No. NP_003367) (SEQ ID NO: 4).

Figure 3 (A) is a schematic representation of the nucleic acid sequence of a human PDGFR-B (GenBank Accession No. NM_002609) (SEQ ID NO: 5).

Figure 3 (B) is a schematic representation of the polypeptide sequence of a human PDGFR-B (GenBank Accession No. NP_002600) (SEQ ID NO: 6).

Figure 3 (C) is a schematic representation of the nucleic acid sequence of a human PDGFR-A (GenBank Accession No. NM_006206) (SEQ ID NO: 13).

Figure 3 (D) is a schematic representation of the polypeptide sequence of a human PDGFR-A (GenBank Accession No. NP_006197) (SEQ ID NO: 14).

Figure 4 (A) is a schematic representation of the nucleic acid sequence of a human VEGFR-1 (Flt-1) (GenBank Accession No. AF063657) (SEQ ID NO: 7).

Figure 4 (B) is schematic a representation of the polypeptide sequence of a human VEGFR-1 (Flt-1) (GenBank Accession No.) (SEQ ID NO: 8).

Figure 4 (C) is a schematic representation of the nucleic acid sequence of a human VEGFR-2 (KDR/Flk-1) (GenBank Accession No. AF035121) (SEQ ID NO: 9).

Figure 4 (D) is a schematic representation of the polypeptide sequence of a human VEGFR-2 (KDR/Flk-1) (GenBank Accession No. AAB88005) (SEQ ID NO: 10).

Figure 5 is a graphical representation of the results of a corneal neovascularization assay comparing a control treatment (cont), Gleevec treatment (an anti-PDGF agent), and Macugen™ treatment (*i.e.* pegaptanib treatment, an anti-VEGF agent), to the results of a combination treatment with Macugen™ and Gleevec (anti-PDGF/anti-VEGF combination therapy).

Figure 6 (A) is a photographic representation of a fluorescent-microscopic image of corneal neovascularization

occurring in control (PEG-treated) mouse cornea.

Figure 6 (B) is a photographic representation of a fluorescent-microscopic image of corneal neovascularization occurring in a Gleevec-treated mouse cornea.

Figure 6 (C) is a photographic representation of a fluorescent-microscopic image of corneal neovascularization occurring in a Macugen™ -treated mouse cornea.

Figure 6 (D) is a photographic representation of a fluorescent-microscopic image of corneal neovascularization occurring in a mouse cornea treated with both Macugen™ and Gleevec.

Figure 7 (A) is a photographic representation of a fluorescent-microscopic image showing that normal corneal vasculature is unaffected by administration of APB5 (PDGFR antibody, an anti-PDGF agent).

Figure 7 (B) is a photographic representation of a fluorescent-microscopic image showing that normal corneal vasculature is unaffected by administration of Gleevec.

Figure 7 (C) is a photographic representation of a fluorescent-microscopic image showing that normal corneal vasculature is unaffected by administration of Macugen™ (Mac) and Gleevec together.

Figure 7 (D) is a photographic representation of a fluorescent-microscopic image showing that normal corneal vasculature is unaffected by administration of PEG.

Figure 8 is a graphical representation of the results of a laser-induced choroidal neovascularization assay comparing a control treatment (cont), Gleevec treatment (an anti-PDGF agent), and Macugen™ treatment (*i.e.* pegaptanib treatment, an anti-VEGF agent), to the results of a combination treatment with Macugen™ and Gleevec (anti-PDGF/anti-VEGF combination therapy).

Figure 9 is a graphical representation of the results of a laser-induced choroidal neovascularization assay comparing a control-treated (cont), APB5-treated (an anti-PGFR antibody, which acts as an anti-PDGF agent), and Macugen treatment (*i.e.* pegaptanib treatment, an anti-VEGF aptamer), to the results of a combination treatment with Macugen and APB5 (Mac+APB5).

Figure 10 is a graphical representation of the results of a retinal developmental model comparing a control treatment (cont), ARC-127 treatment (an anti-PDGF agent), and Macugen treatment (*i.e.* pegaptanib treatment, an anti-VEGF agent), to the results of a combination treatment with Macugen and ARC-127 (anti-PDGF/anti-VEGF combination therapy).

Figure 11 is a graphical representation of the results of a corneal neovascularization assay comparing a control treatment (cont), ARC-127 treatment (an anti-PDGF agent), and Macugen treatment (*i.e.* pegaptanib treatment, an anti-VEGF agent), to the results of a combination treatment with Macugen and ARC-127 (anti-PDGF/anti-VEGF combination therapy).

Figure 12(A) is a photographic representation of a fluorescent-microscopic image of corneal neovascularization occurring in control mouse cornea.

Figure 12(B) is a photographic representation of a fluorescent-microscopic image of corneal neovascularization occurring in a ARC-127-treated mouse cornea.

Figure 12(C) is a photographic representation of a fluorescent-microscopic image of corneal neovascularization occurring in a Macugen-treated mouse cornea.

Figure 12(D) is a photographic representation of a fluorescent-microscopic image of corneal neovascularization occurring in a mouse cornea treated with both Macugen and ARC-127.

Figure 13 is a graphical representation of the results of a corneal neovascularization assay comparing a control treatment (cont), APB-5 treatment (an anti-PDGF agent), and Macugen treatment (*i.e.* pegaptanib treatment, an anti-VEGF agent), to the results of a combination treatment with Macugen and APB-5 (anti-PDGF/anti-VEGF combination therapy).

Figure 14 is a graphical representation of the results of a corneal neovascularization assay comparing a control treatment (cont), APB-5 treatment (an anti-PDGF agent), and Macugen treatment (*i.e.* pegaptanib treatment, an anti-VEGF agent), to the results of a combination treatment with Macugen and APB-5 (anti-PDGF/anti-VEGF combination therapy).

DETAILED DESCRIPTION OF THE INVENTION

[0036] All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference.

Definitions

[0037] As used herein, the following terms and phrases shall have the meanings set forth below. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood to one of ordinary skill in the art to which this invention belongs.

[0038] By "antagonist" is meant an agent that inhibits, either partially or fully, the activity or production of a target molecule. In particular, the term "antagonist," as applied selectively herein, means an agent capable of decreasing levels of PDGF, PDGFR, VEGF or VEGFR gene expression, mRNA levels, protein levels or protein activity. Exemplary forms of antagonists include, for example, proteins, polypeptides, peptides (such as cyclic peptides), antibodies or antibody fragments, peptide mimetics, nucleic acid molecules, antisense molecules, ribozymes, aptamers, RNAi molecules, and small organic molecules. Exemplary non-limiting mechanisms of antagonist inhibition of the VEGF/VEGFR and PDGF/PDGFR ligand/receptor targets include repression of ligand synthesis and/or stability (e.g., using, antisense, ribozymes or RNAi compositions targeting the ligand gene/nucleic acid), blocking of binding of the ligand to its cognate receptor (e.g., using anti-ligand aptamers, antibodies or a soluble, decoy cognate receptor), repression of receptor synthesis and/or stability (e.g., using, antisense, ribozymes or RNAi compositions targeting the ligand receptor gene/nucleic acid), blocking of the binding of the receptor to its cognate receptor (e.g., using receptor antibodies) and blocking of the activation of the receptor by its cognate ligand (e.g., using receptor tyrosine kinase inhibitors). In addition, the antagonist may directly or indirectly inhibit the target molecule.

[0039] The term "antibody" as used herein is intended to include whole antibodies, e.g., of any isotype (IgG, IgA, IgM, IgE, etc.), and includes fragments thereof which recognize and are also specifically reactive with vertebrate (e.g., mammalian) protein, carbohydrates, etc. Antibodies can be fragmented using conventional techniques and the fragments screened for utility in the same manner as described above for whole antibodies. Thus, the term includes segments of proteolytically cleaved or recombinantly-prepared portions of an antibody molecule that are capable of selectively reacting with a certain protein. Non-limiting examples of such proteolytic and/or recombinant fragments include Fab, F(ab')₂, Fab', Fv, and single chain antibodies (scFv) containing a V[L] and/or V[H] domain joined by a peptide linker. The scFv's may be covalently or noncovalently linked to form antibodies having two or more binding sites. The subject invention includes polyclonal, monoclonal, or other purified preparations of antibodies and recombinant antibodies.

[0040] The term "aptamer," used herein interchangeably with the term "nucleic acid ligand," means a nucleic acid that, through its ability to adopt a specific three dimensional conformation, binds to and has an antagonizing (*i.e.*, inhibitory) effect on a target. The target of the present invention is PDGF or VEGF (or one of their cognate receptors PDGFR or VEGFR), and hence the term PDGF aptamer or nucleic acid ligand or VEGF aptamer or nucleic acid ligand (or PDGFR aptamer or nucleic acid ligand or VEGFR aptamer or nucleic acid ligand) is used. Inhibition of the target by the aptamer may occur by binding of the target, by catalytically altering the target, by reacting with the target in a way which modifies/alters the target or the functional activity of the target, by covalently attaching to the target as in a suicide inhibitor, by facilitating the reaction between the target and another molecule. Aptamers may be comprised of multiple ribonucleotide units, deoxyribonucleotide units, or a mixture of both types of nucleotide residues. Aptamers may further comprise one or more modified bases, sugars or phosphate backbone units as described in further detail herein.

[0041] By "antibody antagonist" is meant an antibody molecule as herein defined which is able to block or significantly reduce one or more activities of a target PDGF or VEGF. For example, an VEGF inhibitory antibody may inhibit or reduce the ability of VEGF to stimulate angiogenesis.

[0042] A nucleotide sequence is "complementary" to another nucleotide sequence if each of the bases of the two sequences matches, *i.e.*, are capable of forming Watson Crick base pairs. The term "complementary strand" is used herein interchangeably with the term "complement." The complement of a nucleic acid strand can be the complement of a coding strand or the complement of a non-coding strand.

[0043] The phrases "conserved residue" "or conservative amino acid substitution" refer to grouping of amino acids on the basis of certain common properties. A functional way to define common properties between individual amino acids is to analyze the normalized frequencies of amino acid changes between corresponding proteins of homologous organisms. According to such analyses, groups of amino acids may be defined where amino acids within a group exchange preferentially with each other, and therefore resemble each other most in their impact on the overall protein structure (Schulz, G. E. and R. H. Schirmer, Principles of Protein Structure, Springer-Verlag). Examples of amino acid groups defined in this manner include:

- (i) a charged group, consisting of Glu and Asp, Lys, Arg and His,
- (ii) a positively-charged group, consisting of Lys, Arg and His,
- (iii) a negatively-charged group, consisting of Glu and Asp,
- (iv) an aromatic group, consisting of Phe, Tyr and Trp,
- (v) a nitrogen ring group, consisting of His and Trp,
- (vi) a large aliphatic nonpolar group, consisting of Val, Leu and Ile,
- (vii) a slightly-polar group, consisting of Met and Cys,
- (viii) a small-residue group, consisting of Ser, Thr, Asp, Asn, Gly, Ala, Glu, Gln and Pro,
- (ix) an aliphatic group consisting of Val, Leu, Ile, Met and Cys, and
- (x) a small hydroxyl group consisting of Ser and Thr.

[0044] In addition to the groups presented above, each amino acid residue may form its own group, and the group formed by an individual amino acid may be referred to simply by the one and/or three letter abbreviation for that amino acid commonly used in the art.

[0045] The term "interact" as used herein is meant to include detectable relationships or association (e.g., biochemical interactions) between molecules, such as interaction between protein-protein, protein-nucleic acid, nucleic acid-nucleic acid, and protein-small molecule or nucleic acid-small molecule in nature.

[0046] The term "interacting protein" refers to protein capable of interacting, binding, and/or otherwise associating to a protein of interest, such as for example a PDGF or a VEGF protein, or their corresponding cognate receptors.

[0047] The term "isolated" as used herein with respect to nucleic acids, such as DNA or RNA, refers to molecules separated from other DNAs, or RNAs, respectively that are present in the natural source of the macromolecule. Similarly the term "isolated" as used herein with respect to polypeptides refers to protein molecules separated from other proteins that are present in the source of the polypeptide. The term isolated as used herein also refers to a nucleic acid or peptide that is substantially free of cellular material, viral material, or culture medium when produced by recombinant DNA techniques, or chemical precursors or other chemicals when chemically synthesized.

[0048] "Isolated nucleic acid" is meant to include nucleic acid fragments, which are not naturally occurring as fragments and would not be found in the natural state. The term "isolated" is also used herein to refer to polypeptides, which are isolated from other cellular proteins and is meant to encompass both purified and recombinant polypeptides.

[0049] As used herein, the terms "label" and "detectable label" refer to a molecule capable of detection, including, but not limited to, radioactive isotopes, fluorophores, chemiluminescent moieties, enzymes, enzyme substrates, enzyme cofactors, enzyme inhibitors, dyes, metal ions, ligands (e.g., biotin or haptens) and the like. The term "fluorescer" refers to a substance or a portion thereof, which is capable of exhibiting fluorescence in the detectable range. Particular examples of labels which may be used under the invention include fluorescein, rhodamine, dansyl, umbelliferone, Texas red, luminol, NADPH, alpha - beta -galactosidase and horseradish peroxidase.

[0050] The "level of expression of a gene in a cell" refers to the level of mRNA, as well as pre-mRNA nascent transcript(s), transcript processing intermediates, mature mRNA(s) and degradation products, encoded by the gene in the cell, as well as the level of protein translated from that gene.

[0051] As used herein, the term "nucleic acid" refers to polynucleotides such as deoxyribonucleic acid (DNA), and, where appropriate, ribonucleic acid (RNA). The term should also be understood to include, as equivalents, analogs of either RNA or DNA made from nucleotide analogs, and, as applicable to the embodiment being described, single (sense or antisense) and double-stranded polynucleotides, ESTs, chromosomes, cDNAs, mRNAs, and rRNAs are representative examples of molecules that may be referred to as nucleic acids.

[0052] The term "oligonucleotide" refers to an oligomer or polymer of nucleotide or nucleoside monomers consisting of naturally occurring bases, sugars and intersugar (backbone) linkages. The term also includes modified or substituted oligomers comprising non-naturally occurring monomers or portions thereof, which function similarly. Incorporation of substituted oligomers is based on factors including enhanced cellular uptake, or increased nuclease resistance and are chosen as is known in the art. The entire oligonucleotide or only portions thereof may contain the substituted oligomers.

[0053] The term "percent identical" refers to sequence identity between two amino acid sequences or between two nucleotide sequences. Identity can each be determined by comparing a position in each sequence, which may be aligned for purposes of comparison. When an equivalent position in the compared sequences is occupied by the same base or amino acid, then the molecules are identical at that position; when the equivalent site occupied by the same or a similar amino acid residue (e.g., similar in steric and/or electronic nature), then the molecules can be referred to as homologous (similar) at that position. Expression as a percentage of homology, similarity, or identity refers to a function of the number of identical or similar amino acids at positions shared by the compared sequences. Various alignment algorithms and/or programs may be used, including Hidden Markov Model (HMM), FASTA and BLAST. HNiM, FASTA and BLAST are available through the National Center for Biotechnology Information, National Library of Medicine, National Institutes of Health, Bethesda, Md. and the European Bioinformatic Institute EBI. In one embodiment, the percent identity of two sequences that can be determined by these GCG programs with a gap weight of 1, e.g., each amino acid gap is weighted as if it were a single amino acid or nucleotide mismatch between the two sequences. Other techniques for alignment are described in Methods in Enzymology, vol. 266: Computer Methods for Macromolecular Sequence Analysis (1996), ed. Doolittle, Academic Press, Inc., a division of Harcourt Brace & Co., San Diego, California, USA. Where desirable, an alignment program that permits gaps in the sequence is utilized to align the sequences. The Smith Waterman is one type of algorithm that permits gaps in sequence alignments (see (1997) Meth. Mol. Biol. 70: 173-187). Also, the GAP program using the Needleman and Wunsch alignment method can be utilized to align sequences. More techniques and algorithms including use of the HMM are described in Sequence, Structure, and Databanks: A Practical Approach (2000), ed. Oxford University Press, Incorporated and in Bioinformatics: Databases and Systems (1999) ed. Kluwer Academic Publishers. An alternative search strategy uses MPSRCH software, which runs on a MASPAC computer. MPSRCH uses a Smith-Waterman algorithm to score sequences on a massively parallel computer. This approach improves ability to pick up distantly related matches, and is especially tolerant of small gaps and nucleotide sequence errors.

Nucleic acid-encoded amino acid sequences can be used to search both protein and DNA databases. Databases with individual sequences are described in Methods in Enzymology, ed. Doolittle, *supra*. Databases include Genbank, EMBL, and DNA Database of Japan (DDBJ).

[0054] "Perfectly matched" in reference to a duplex means that the poly- or oligonucleotide strands making up the duplex form a double stranded structure with one other such that every nucleotide in each strand undergoes Watson-Crick basepairing with a nucleotide in the other strand. The term also comprehends the pairing of nucleoside analogs, such as deoxyinosine, nucleosides with 2-aminopurine bases, and the like, that may be employed. A mismatch in a duplex between a target polynucleotide and an oligonucleotide or polynucleotide means that a pair of nucleotides in the duplex fails to undergo Watson-Crick bonding. In reference to a triplex, the term means that the triplex consists of a perfectly matched duplex and a third strand in which every nucleotide undergoes Hoogsteen or reverse Hoogsteen association with a base pair of the perfectly matched duplex.

[0055] The term "RNA interference," "RNAi," or "siRNA" all refer to any method by which expression of a gene or gene product is decreased by introducing into a target cell one or more double-stranded RNAs, which are homologous to the gene of interest (particularly to the messenger RNA of the gene of interest, *e.g.*, PDGF or VEGF).

[0056] Polymorphic variants also may encompass "single nucleotide polymorphisms" (SNPs) in which the polynucleotide sequence varies by one base (*e.g.*, a one base variation in PDGF or VEGF). The presence of SNPs may be indicative of, for example, a certain population, a disease state, or a propensity for a disease state.

[0057] The "profile" of an aberrant, *e.g.*, tumor cell's biological state refers to the levels of various constituents of a cell that change in response to the disease state. Constituents of a cell include levels of RNA, levels of protein abundances, or protein activity levels.

[0058] The term "protein" is used interchangeably herein with the terms "peptide" and "polypeptide." The term "recombinant protein" refers to a protein of the present invention which is produced by recombinant DNA techniques, wherein generally DNA encoding the expressed protein or RNA is inserted into a suitable expression vector which is in turn used to transform a host cell to produce the heterologous protein or RNA. Moreover, the phrase "derived from," with respect to a recombinant gene encoding the recombinant protein is meant to include within the meaning of "recombinant protein" those proteins having an amino acid sequence of a native protein, or an amino acid sequence similar thereto which is generated by mutations, including substitutions and deletions, of a naturally occurring protein.

[0059] As used herein, the term "transgene" means a nucleic acid sequence (encoding, *e.g.*, one of the target nucleic acids, or an antisense transcript thereto), which has been introduced into a cell. A transgene could be partly or entirely heterologous, *i.e.*, foreign, to the transgenic animal or cell into which it is introduced, or, is homologous to an endogenous gene of the transgenic animal or cell into which it is introduced, but which is designed to be inserted, or is inserted, into the animal's genome in such a way as to alter the genome of the cell into which it is inserted (*e.g.*, it is inserted at a location which differs from that of the natural gene or its insertion results in a knockout). A transgene can also be present in a cell in the form of an episome. A transgene can include one or more transcriptional regulatory sequences and any other nucleic acid, such as introns, that may be necessary for optimal expression of a selected nucleic acid.

[0060] By "neovascular disorder" is meant a disorder characterized by altered or unregulated angiogenesis other than one accompanying oncogenic or neoplastic transformation, *i.e.*, cancer. Examples of neovascular disorders include psoriasis, rheumatoid arthritis, and ocular neovascular disorders including diabetic retinopathy and age-related macular degeneration.

[0061] As used herein, the terms "neovascularization" and "angiogenesis" are used interchangeably. Neovascularization and angiogenesis refer to the generation of new blood vessels into cells, tissue, or organs. The control of angiogenesis is typically altered in certain disease states and, in many cases, the pathological damage associated with the disease is related to altered, unregulated, or uncontrolled angiogenesis. Persistent, unregulated angiogenesis occurs in a multiplicity of disease states, including those characterized by the abnormal growth by endothelial cells, and supports the pathological damage seen in these conditions including leakage and permeability of blood vessels.

[0062] By "ocular neovascular disorder" is meant a disorder characterized by altered or unregulated angiogenesis in the eye of a patient. Exemplary ocular neovascular disorders include optic disc neovascularization, iris neovascularization, retinal neovascularization, choroidal neovascularization, corneal neovascularization, vitreal neovascularization, glaucoma, pannus, pterygium, macular edema, diabetic retinopathy, diabetic macular edema, vascular retinopathy, retinal degeneration, uveitis, inflammatory diseases of the retina, and proliferative vitreoretinopathy.

[0063] The term "treating" a neovascular disease in a subject or "treating" a subject having a neovascular disease refers to subjecting the subject to a pharmaceutical treatment, *e.g.*, the administration of a drug, such that at least one symptom of the neovascular disease is decreased. Accordingly, the term "treating" as used herein is intended to encompass curing as well as ameliorating at least one symptom of the neovascular condition or disease. Accordingly, "treating" as used herein, includes administering or prescribing a pharmaceutical composition for the treatment or prevention of an ocular neovascular disorder.

[0064] By "patient" is meant any animal. The term "animal" includes mammals, including, but is not limited to, humans and other primates. The term also includes domesticated animals, such as cows, hogs, sheep, horses, dogs, and cats.

[0065] By "PDGF" or "platelet-derived growth factor" is meant a mammalian platelet-derived growth factor that affects angiogenesis or an angiogenic process. As used herein, the term "PDGF" includes the various subtypes of PDGF including PDGF-B (see Figure 1 (A) and (B)), and PDGF-A (see Figure 1 (C) and (D)). Further, as used herein, the term "PDGF" refers to PDGF-related angiogenic factors such as PDGF-C and PDGF-D that act through a cognate PDGF receptor to stimulate angiogenesis or an angiogenic process. In particular, the term "PDGF" means any member of the class of growth factors that (i) bind to a PDGF receptor such as PDGFR-B (see Figure 3 (A) and (B)), or PDGFR-A (see Figure 3 (C) and (D)); (ii) activates a tyrosine kinase activity associated with the VEGF receptor; and (iii) thereby affects angiogenesis or an angiogenic process. As used herein, the term "PDGF" generally refers to those members of the class of growth factors that induce DNA synthesis and mitogenesis through the binding and activation of a platelet-derived growth factor cell surface receptor (*i.e.*, PDGFR) on a responsive cell type. PDGFs effect specific biological effects including, for example: directed cell migration (chemotaxis) and cell activation; phospholipase activation; increased phosphatidylinositol turnover and prostaglandin metabolism; stimulation of both collagen and collagenase synthesis by responsive cells; alteration of cellular metabolic activities, including matrix synthesis, cytokine production, and lipoprotein uptake; induction, indirectly, of a proliferative response in cells lacking PDGF receptors; and potent vasoconstrictor activity. The term "PDGF" is meant to include both a "PDGF" polypeptide and its corresponding "PDGF" encoding gene or nucleic acid.

[0066] By "PDGF-A" is meant an A chain polypeptide of PDGF and its corresponding encoding gene or nucleic acid.

[0067] By "PDGF-B" is meant a B chain polypeptide of PDGF and its corresponding encoding gene or nucleic acid.

[0068] By "VEGF," or "vascular endothelial growth factor," is meant a mammalian vascular endothelial growth factor that affects angiogenesis or an angiogenic process. As used herein, the term "VEGF" includes the various subtypes of VEGF (also known as vascular permeability factor (VPF) and VEGF-A) (see Figure 2(A) and (B)) that arise by, *e.g.*, alternative splicing of the VEGF-A/VPF gene including VEGF₁₂₁, VEGF₁₆₅ and VEGF₁₈₉. Further, as used herein, the term "VEGF" refers to VEGF-related angiogenic factors such as PlGF (placenta growth factor), VEGF-B, VEGF-C, VEGF-D and VEGF-E that act through a cognate VEGF receptor to stimulate angiogenesis or an angiogenic process.

In particular, the term "VEGF" means any member of the class of growth factors that (i) bind to a VEGF receptor such as VEGFR-1 (Flt-1) (see Figure 4 (A) and (B)), VEGFR-2 (KDR/Flk-1) (see Figure 4 (C) and (D)), or VEGFR-3 (FLT-4); (ii) activates a tyrosine kinase activity associated with the VEGF receptor; and (iii) thereby affects angiogenesis or an angiogenic process. The term "VEGF" is meant to include both a "VEGF" polypeptide and its corresponding "VEGF" encoding gene or nucleic acid.

[0069] By "PDGF antagonist" is meant an agent that reduces, or inhibits, either partially or fully, the activity or production of a PDGF. A PDGF antagonist may directly or indirectly reduce or inhibit a specific PDGF such as PDGF-B. Furthermore, "PDGF antagonists" consistent with the above definition of "antagonist," may include agents that act on either a PDGF ligand or its cognate receptor so as to reduce or inhibit a PDGF-associated receptor signal. Examples of such "PDGF antagonists" thus include, for example: antisense, ribozymes or RNAi compositions targeting a PDGF nucleic acid; anti-PDGF aptamers, anti-PDGF antibodies or soluble PDGF receptor decoys that prevent binding of a PDGF to its cognate receptor; antisense, ribozymes or RNAi compositions targeting a cognate PDGF receptor (PDGFR) nucleic acid; anti-PDGFR aptamers or anti-PDGFR antibodies that bind to a cognate PDGFR receptor; and PDGFR tyrosine kinase inhibitors.

[0070] By "VEGF antagonist" is meant an agent that reduces, or inhibits, either partially or fully, the activity or production of a VEGF. A VEGF antagonist may directly or indirectly reduce or inhibit a specific VEGF such as VEGF₁₆₅. Furthermore, "VEGF antagonists" consistent with the above definition of "antagonist," may include agents that act on either a VEGF ligand or its cognate receptor so as to reduce or inhibit a VEGF-associated receptor signal. Examples of such "VEGF antagonists" thus include, for example: antisense, ribozymes or RNAi compositions targeting a VEGF nucleic acid; anti-VEGF aptamers, anti-VEGF antibodies or soluble VEGF receptor decoys that prevent binding of a VEGF to its cognate receptor; antisense, ribozymes, or RNAi compositions targeting a cognate VEGF receptor (VEGFR) nucleic acid; anti-VEGFR aptamers or anti-VEGFR antibodies that bind to a cognate VEGFR receptor; and VEGFR tyrosine kinase inhibitors.

[0071] By "an amount sufficient to suppress a neovascular disorder" is meant the effective amount of an antagonist, in a combination of the invention, required to treat or prevent a neovascular disorder or symptom thereof. The "effective amount" of active antagonists used to practice the present invention for therapeutic treatment of conditions caused by or contributing to the neovascular disorder varies depending upon the manner of administration, anatomical location of the neovascular disorder, the age, body weight, and general health of the patient. Ultimately, a physician or veterinarian will decide the appropriate amount and dosage regimen. Such amount is referred to as an amount sufficient to suppress a neovascular disorder.

[0072] Other features and advantages of the invention will be apparent from the following detailed description, and from the claims.

[0073] A "variant" of polypeptide X refers to a polypeptide having the amino acid sequence of peptide X in which is altered in one or more amino acid residues. The variant may have "conservative" changes, wherein a substituted amino

acid has similar structural or chemical properties (e.g., replacement of leucine with isoleucine). More rarely, a variant may have "nonconservative" changes (e.g., replacement of glycine with tryptophan). Analogous minor variations may also include amino acid deletions or insertions, or both. Guidance in determining which amino acid residues may be substituted, inserted, or deleted without abolishing biological or immunological activity may be found using computer programs well known in the art, for example, LASERGENE software (DNASTAR).

[0074] The term "variant," when used in the context of a polynucleotide sequence, may encompass a polynucleotide sequence related to that of gene or the coding sequence thereof. This definition may also include, for example, "allelic," "splice," "species," or "polymorphic" variants. A splice variant may have significant identity to a reference molecule, but will generally have a greater or lesser number of polynucleotides due to alternative splicing of exons during mRNA processing. The corresponding polypeptide may possess additional functional domains or an absence of domains. Species variants are polynucleotide sequences that vary from one species to another. The resulting polypeptides generally will have significant amino acid identity relative to each other. A polymorphic variant is a variation in the polynucleotide sequence of a particular gene between individuals of a given species.

[0075] The term "vector" refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked. One type of useful vector is an episome, *i.e.*, a nucleic acid capable of extra-chromosomal replication. Useful vectors are those capable of autonomous replication and/or expression of nucleic acids to which they are linked. Vectors capable of directing the expression of genes to which they are operatively linked are referred to herein as "expression vectors". In general, expression vectors of utility in recombinant DNA techniques are often in the form of "plasmids" which refer generally to circular double stranded DNA loops which, in their vector form are not bound to the chromosome. In the present specification, "plasmid" and "vector" are used interchangeably as the plasmid is the most commonly used form of vector. However, the invention is intended to include such other forms of expression vectors which serve equivalent functions and which become known in the art subsequently hereto.

Combination Therapy

[0076] The invention is based, in part, upon the specific inhibition of both VEGF and PDGF activities using appropriate growth factor antagonists as a potent treatment for patients having a neovascular disorder. The administration of a combination of a PDGF antagonist and a VEGF antagonist affords greater therapeutic benefits for treating an ocular neovascular disorder than either antagonist administered alone. The combined action of anti-VEGF and anti-PDGF agents is unexpected in light of studies evidencing no apparent cooperation between the two factors in stimulating angiogenesis in a retinal endothelial cell system (see Castellon et al., (2001) Exp. Eye Res. 74: 523-35).

PDGF and VEGF are important stimuli for the growth of new blood vessels throughout the body, especially in the eye. Combination therapy directed at inhibiting both PDGF and VEGF biological activities provides a method for treating or preventing the neovascular disorder.

[0077] Accordingly, the invention features methods and compositions for suppressing a neovascular disorder using combination therapy. In particular, the present invention utilizes two distinct intercellular communication signaling pathways operative in vascular cells, namely PDGF and VEGF signaling, as therapeutic targets in the treatment of a neovascular disorder, such as an ocular neovascular disorder. This combination method is especially useful for treating any number of ophthalmological diseases and disorders marked by the development of ocular neovascularization, including, but not limited to, optic disc neovascularization, iris neovascularization, retinal neovascularization, choroidal neovascularization, corneal neovascularization, vitreal neovascularization, glaucoma, pannus, pterygium, macular edema, diabetic macular edema, vascular retinopathy, retinal degeneration, macular degeneration, uveitis, inflammatory diseases of the retina, and proliferative vitreoretinopathy. The combination therapy, consisting of antagonists that inhibit PDGF (such as PDGF-B) and VEGF (such as VEGF-A) signaling results in an increased treatment efficacy compared to either of the two therapies being used independently. While the examples discussed below describe the combination of a single PDGF antagonist and a single VEGF antagonist, it is understood that the combination of multiple antagonistic agents may be desirable.

[0078] Anti-PDGF and anti-VEGF combination therapy according to the invention may be performed alone or in conjunction with another therapy and may be provided at home, the doctor's office, a clinic, a hospital's outpatient department, or a hospital. Treatment generally begins at a hospital so that the doctor can observe the therapy's effects closely and make any adjustments that are needed. The duration of the combination therapy depends on the type of neovascular disorder being treated, the age and condition of the patient, the stage and type of the patient's disease, and how the patient responds to the treatment. Additionally, a person having a greater risk of developing a neovascular disorder (*e.g.*, a diabetic patient) may receive treatment to inhibit or delay the onset of symptoms. One significant advantage provided by the present invention is that the combination of a PDGF antagonist and a VEGF antagonist for the treatment of a neovascular disorder allows for the administration of a low dose of each antagonist and less total active antagonist, thus providing similar efficacy with less toxicity and side effects, and reduced costs.

[0079] The dosage and frequency of administration of each component of the combination can be controlled inde-

pendently. For example, one antagonist may be administered three times per day, while the second antagonist may be administered once per day. Combination therapy may be given in on-and-off cycles that include rest periods so that the patient's body has a chance to recover from any as yet unforeseen side-effects. The antagonists may also be formulated together such that one administration delivers both antagonists.

PDGF and VEGF Antagonist Targets

[0080] PDGF was originally isolated from platelet lysates and identified as the major growth-promoting activity present in serum but not in plasma. The mitogenic activity of PDGF was first shown to act on connective tissue cells, such as fibroblasts and smooth muscle cells, and in glial cells in culture. Two homologous PDGF isoforms have been identified, PDGF A and B, which are encoded by separate genes (on chromosomes 7 and 22). The most abundant species from platelets is the AB heterodimer, although all three possible dimers (AA, AB and BB) occur naturally. Following translation, PDGF dimers are processed into approximately 30 kDa secreted proteins.

Two cell surface proteins that bind PDGF with high affinity have been identified, alpha. and beta. (Heldin et al., (1981) Proc. Natl. Acad. Sci. (USA) 78: 3664; Williams et al., (1981) Proc. Natl. Acad. Sci. (USA) 79: 5867). Both species contain five immunoglobulin-like extracellular domains, a single transmembrane domain and an intracellular tyrosine kinase domain separated by a kinase insert domain. In the last several years, the specificities of the three PDGF isoforms for the three receptor dimers (alpha/alpha, alpha/beta, and beta/beta.) have been elucidated. The alpha-receptor homodimer binds all three PDGF isoforms with high affinity, the beta-receptor homodimer binds only PDGF BB with high affinity and PDGF AB with approximately 10-fold lower affinity, and the alpha/beta.-receptor heterodimer binds PDGF BB and PDGF AB with high affinity (Westermarck & Heldin (1993) Acta Oncologica 32:101). The specificity pattern appears to result from the ability of the A-chain to bind only to the alpha-receptor and of the B-chain to bind to both alpha and beta-receptor subunits with high affinity.

[0081] In general, the invention provides for agents that inhibit one or more PDGF activities. These PDGF-inhibitory agents, or PDGF antagonists may act on one or more forms of the PDGF ligand. Platelet derived growth factors includes homo- or heterodimers of A-chain (PDGF-A) and B-chain (PDGF-B) that exert their action via binding to and dimerization of two related receptor tyrosine kinases, [alpha]-receptors (PDGFR-[alpha]) and [beta]-receptors (PDGFR-[beta]). In addition, PDGF-C and PDGF-D, two new protease-activated ligands for the PDGFR complexes, have been identified (see Li et al., (2000) Nat. Cell. Biol. 2: 302-9; Bergsten et al., (2001) Nat. Cell. Biol. 3: 512-6; and Uutele et al., (2001) Circulation 103: 2242-47). Due to the different ligand binding specificities of the PDGFRs it is known that PDGFR-[alpha][alpha] binds PDGF-AA, PDGF-BB, PDGF-AB, and PDGF-CC; PDGFR-[beta][beta] binds PDGF-BB and PDGF-DD; whereas PDGFR-[alpha][beta] binds PDGF-AB, PDGF-BB, PDGF-CC, and PDGF-DD (see Betsholtz et al., (2001) BioEssays 23: 494-507).

[0082] VEGF is a secreted disulfide-linked homodimer that selectively stimulates endothelial cells to proliferate, migrate, and produce matrix-degrading enzymes (Conn et al., (1990) Proc. Natl. Acad. Sci. (USA) 87:1323-1327); Ferrara and Henzel (1989) Biochem. Biophys. Res. Commun. 161: 851-858; Pepper et al., (1991) Biochem. Biophys. Res. Commun. 181:902-906; Unemori et al., (1992) J. Cell. Physiol. 153:557-562), all of which are processes required for the formation of new vessels. VEGF occurs in four forms (VEGF-121, VEGF-165, VEGF-189, VEGF-206) as a result of alternative splicing of the VEGF gene (Houck et al., (1991) Mol. Endocrinol. 5:1806-1814; Tischer et al., (1991) J. Biol. Chem. 266:11947-11954). The two smaller forms are diffusible whereas the larger two forms remain predominantly localized to the cell membrane as a consequence of their high affinity for heparin. VEGF-165 also binds to heparin and is the most abundant form. VEGF-121, the only form that does not bind to heparin, appears to have a lower affinity for VEGF receptors (Gitay-Goren et al., (1996) J. Biol. Chem. 271:5519-5523) as well as lower mitogenic potency (Keyt et al., (1996) J. Biol. Chem. 271:7788-7795). The biological effects of VEGF are mediated by two tyrosine kinase receptors (Flt-1 and Flk-1/KDR) whose expression is highly restricted to cells of endothelial origin (de Vries et al., (1992) Science 255:989-991; Millauer et al., (1993) Cell 72:835-846; Terman et al., (1991) Oncogene 6:519-524). While the expression of both functional receptors is required for high affinity binding, the chemotactic and mitogenic signaling in endothelial cells appears to occur primarily through the KDR receptor (Park et al., (1994) J. Biol. Chem. 269:25646-25654; Seetharam et al., (1995) Oncogene 10:135-147; Waltenberger et al., (1994) J. Biol. Chem. 269:26988-26995). The importance of VEGF and VEGF receptors for the development of blood vessels has recently been demonstrated in mice lacking a single allele for the VEGF gene (Carmeliet et al., (1996) Nature 380:435-439; Ferrara et al., (1996) Nature 380:439-442) or both alleles of the Flt-1 (Fong et al., (1995) Nature 376:66-70) or Flk-1 genes (Shalaby et al., (1995) Nature 376:62-66). In each case, distinct abnormalities in vessel formation were observed resulting in embryonic lethality.

[0083] Compensatory angiogenesis induced by tissue hypoxia is now known to be mediated by VEGF (Levy et al., (1996) J. Biol. Chem. 271:2746-2753; Shweiki et al., (1992) Nature 359:843-845). Studies in humans have shown that high concentrations of VEGF are present in the vitreous in angiogenic retinal disorders but not in inactive or non-neovascularization disease states. Human choroidal tissue excised after experimental submacular surgery have also shown high VEGF levels.

[0084] In addition to being the only known endothelial cell specific mitogen, VEGF is unique among angiogenic growth factors in its ability to induce a transient increase in blood vessel permeability to macromolecules (hence its original and alternative name, vascular permeability factor, VPF) (see Dvorak et al., (1979) J. Immunol. 122:166-174; Senger et al., (1983) Science 219:983-985; Senger et al., (1986) Cancer Res. 46:5629-5632). Increased vascular permeability and the resulting deposition of plasma proteins in the extravascular space assists the new vessel formation by providing a provisional matrix for the migration of endothelial cells (Dvorak et al., (1995) Am. J. Pathol. 146:1029-1039). Hyperpermeability is indeed a characteristic feature of new vessels, including those associated with tumors.

PDGF and VEGF Antagonists

General

[0085] The invention provides antagonists (*i.e.*, inhibitors) of PDGF and VEGF for use together in combination therapy for neovascular disorders. Specific PDGF antagonists and VEGF antagonists are known in the art and are described briefly in the sections that follow. Still other PDGF antagonists and VEGF antagonists that are now, or that have become, available to the skilled artisan include the antibodies, aptamers, antisense oligomers, ribozymes, and RNAi compositions that may be identified and produced using practices that are routine in the art in conjunction with the teachings and guidance of the specification, including the further-provided sections appearing below.

PDGF Antagonists

[0086] Generally, inhibition of PDGF (for example, PDGF-B) may be accomplished in a variety of ways. For example, a variety of PDGF antagonists that inhibit the activity or production of PDGF are available and can be used in the methods of the present invention. Exemplary PDGF antagonists include nucleic acid ligands or aptamers of PDGF, such as those described below. Alternatively, the PDGF antagonist may be, for example, an anti-PDGF antibody or antibody fragment. Accordingly, the PDGF molecule is rendered inactive by inhibiting its binding to a receptor. In addition, nucleic acid molecules such as antisense RNA, ribozymes, and RNAi molecules that inhibit PDGF expression at the nucleic acid level are useful as antagonists in the invention. Other PDGF antagonists include peptides, proteins, cyclic peptides, or small organic compounds. Furthermore, the signaling activity of PDGF may be inhibited by disrupting its downstream signaling, for example, by using a number of small molecule tyrosine kinase inhibitory antagonists including those described below. The ability of a compound or agent to serve as a PDGF antagonist may be determined according to the methods known in art and, further, as set forth in, *e.g.*, Dai et al., (2001) Genes & Dev. 15: 1913-25; Zippel, et al., (1989) Eur. J. Cell Biol. 50(2):428-34; and Zwiller, et al., (1991) Oncogene 6: 219-21.

[0087] The invention further includes PDGF antagonists known in the art as well as those supported below and any and all equivalents that are within the scope of ordinary skill to create. For example, inhibitory antibodies directed against PDGF are known in the art, *e.g.*, those described in U.S. Patent Nos. 5,976,534, 5,833,986, 5,817,310, 5,882,644, 5,662,904, 5,620,687, 5,468,468, and PCT WO 2003/025019, the contents of which are incorporated by reference in their entirety. In addition, the invention includes N-phenyl-2-pyrimidine-amine derivatives that are PDGF antagonists, such as those disclosed in U. S. Patent No. 5,521,184, as well as WO2003/013541, WO2003/078404, WO2003/099771, WO2003/015282, and WO2004/05282 which are hereby incorporated in their entirety by reference.

[0088] Small molecules that block the action of PDGF are known in the art, *e.g.*, those described in U.S. Patent Nos. 6,528,526 (PDGFR tyrosine kinase inhibitors), 6,524,347 (PDGFR tyrosine kinase inhibitors), 6,482,834 (PDGFR tyrosine kinase inhibitors), 6,472,391 (PDGFR tyrosine kinase inhibitors), 6,696,434, 6,331,555, 6,251,905, 6,245,760, 6,207,667, 5,990,141, 5,700,822, 5,618,837 and 5,731,326, the contents of which are incorporated by reference in their entirety.

[0089] Proteins and polypeptides that block the action of PDGF are known in the art, *e.g.*, those described in U.S. Patent Nos. 6,350,731 (PDGF peptide analogs), 5,952,304, the contents of which are incorporated by reference in their entirety.

[0090] Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase are known in the art, *e.g.*, those described in, *e.g.* U.S. Patent Nos. 5,476,851, 5,480,883, 5,656,643, 5,795,889, and 6,057,320, the contents of which are incorporated by reference in their entirety.

[0091] Antisense oligonucleotides for the inhibition of PDGF are known in the art, *e.g.*, those described in U.S. Patent Nos. 5,869,462, and 5,821,234, the contents of each of which are incorporated by reference in their entirety.

[0092] Aptamers (also known as nucleic acid ligands) for the inhibition of PDGF are known in the art, *e.g.*, those described in, *e.g.*, U.S. Patent Nos. 6,582,918, 6,229,002, 6,207,816, 5,668,264, 5,674,685, and 5,723,594, the contents of each of which are incorporated by reference in their entirety.

[0093] Other compounds for inhibiting PDGF known in the art include those described in U.S. Patent Nos. 5,238,950, 5,418,135, 5,674,892, 5,693,610, 5,700,822, 5,700,823, 5,728,726, 5,795,910, 5,817,310, 5,872,218, 5,932,580, 5,932,602, 5,958,959, 5,990,141, 6,358,954, 6,537,988 and 6,673,798, the contents of each of which are incorporated

by reference in their entirety.

VEGF Antagonists

[0094] Inhibition of VEGF (for example, VEGF-A) is accomplished in a variety of ways. For example, a variety of VEGF antagonists that inhibit the activity or production of VEGF, including nucleic acid molecules such as aptamers, antisense RNA, ribozymes, RNAi molecules, and VEGF antibodies, are available and can be used in the methods of the present invention. Exemplary VEGF antagonists include nucleic acid ligands or aptamers of VEGF, such as those described below. A particularly useful antagonist to VEGF-A is EYE001 (previously referred to as NX1838), which is a modified, PEGylated aptamer that binds with high and specific Affinity to the major soluble human VEGF isoform (see, U.S. Patent Nos. 6,011,020; 6,051,698; and 6,147,204). The aptamer binds and inactivates VEGF in a manner similar to that of a high-affinity antibody directed towards VEGF. Another useful VEGF aptamer is EYE001 in its non-pegylated form. Alternatively, the VEGF antagonist may be, for example, an anti-VEGF antibody or antibody fragment. Accordingly, the VEGF molecule is rendered inactive by inhibiting its binding to a receptor. In addition, nucleic acid molecules such as antisense RNA, ribozymes, and RNAi molecules that inhibit VEGF expression or RNA stability at the nucleic acid level are useful antagonists in the methods and compositions of the invention. Other VEGF antagonists include peptides, proteins, cyclic peptides, and small organic compound. For example, soluble truncated forms of VEGF that bind to the VEGF receptor without concomitant signaling activity also serve as antagonists. Furthermore, the signaling activity of VEGF may be inhibited by disrupting its downstream signaling, for example, by using a number of antagonists including small molecule inhibitors of a VEGF receptor tyrosine kinase activity, as described further below.

[0095] The ability of a compound or agent to serve as a VEGF antagonist may be determined according to any number of standard methods well known in the art. For example, one of the biological activities of VEGF is to increase vascular permeability through specific binding to receptors on vascular endothelial cells. The interaction results in relaxation of the tight endothelial junctions with subsequent leakage of vascular fluid. Vascular leakage induced by VEGF can be measured *in vivo* by following the leakage of Evans Blue Dye from the vasculature of the guinea pig as a consequence of an intradermal injection of VEGF (Dvorak et al., in Vascular Permeability Factor/Vascular Endothelial Growth Factor, Microvascular Hyperpermeability, and Angiogenesis; and (1995) Am. J. Pathol. 146:1029). Similarly, the assay can be used to measure the ability of an antagonist to block this biological activity of VEGF.

[0096] In one useful example of a vascular permeability assay, VEGF₁₆₅ (20-30 nM) is premixed *ex vivo* with EYE001 (30 nM to 1 μ M) or a candidate VEGF antagonist and subsequently administered by intradermal injection into the shaved skin on the dorsum of guinea pigs. Thirty minutes following injection, the Evans Blue dye leakage around the injection sites is quantified according to standard methods by use of a computerized morphometric analysis system. A compound that inhibits VEGF-induced leakage of the indicator dye from the vasculature is taken as being a useful antagonist in the methods and compositions of the invention.

[0097] Another assay for determining whether a compound is a VEGF antagonist is the so-called corneal angiogenesis assay. In this assay, methacrylate polymer pellets containing VEGF₁₆₅ (3 pmol) are implanted into the corneal stroma of rats to induce blood vessel growth into the normally avascular cornea. A candidate VEGF antagonist is then administered intravenously to the rats at doses of 1mg/kg, 3 mg/kg, and 10 mg/kg either once or twice daily for 5 days. At the end of the treatment period, all of the individual corneas are photomicrographed. The extent to which new blood vessels develop in the corneal tissue, and their inhibition by the candidate compound, are then quantified by standardized morphometric analysis of the photomicrographs. A compound that inhibits VEGF-dependent angiogenesis in the cornea when compared to treatment with phosphate buffered saline (PBS) is taken as being a useful antagonist in the methods and compositions of the invention.

[0098] Candidate VEGF antagonists are also identified using the mouse model of retinopathy of prematurity. In one useful example, litters of 9, 8, 8, 7, and 7 mice, respectively, are left in room air or made hyperoxic and are treated intraperitoneally with phosphate buffered saline (PBS) or a candidate VEGF antagonist (for example, at 1 mg/kg, 3 mg/kg, or 10 mg/kg/day). The endpoint of the assay, outgrowth of new capillaries through the inner limiting membrane of the retina into the vitreous humor, is then assessed by microscopic identification and counting of the neovascular buds in 20 histologic sections of each eye from all of the treated and control mice. A reduction in retinal neovascularity in the treated mice relative to the untreated control is taken as identifying a useful VEGF antagonist.

[0099] In still another exemplary screening assay, candidate VEGF antagonists are identified using an *in vivo* human tumor xenograft assay. In this screening assay, *in vivo* efficacy of a candidate VEGF antagonist is tested in human tumor xenografts (A673 rhabdomyosarcoma and Wilms tumor) implanted in nude mice. Mice are then treated with the candidate VEGF antagonist (e.g., 10 mg/kg given intraperitoneally once a day following development of established tumors (200 mg)). Control groups are treated with a control agent. Candidate compounds identified as inhibiting A673 rhabdomyosarcoma tumor growth and Wilms tumor relative to the control are taken as being useful antagonists in the methods and compositions of the invention.

[0100] Additional methods of assaying for a VEGF antagonist activity are known in the art and described in further

detail below.

[0101] The invention further includes VEGF antagonists known in the art as well as those supported below and any and all equivalents that are within the scope of ordinary skill to create. For example, inhibitory antibodies directed against VEGF are known in the art, e.g., those described in U.S. Patent Nos. 6,524,583, 6,451,764 (VRP antibodies), 6,448,077, 6,416,758, 6,403,088 (to VEGF-C), 6,383,484 (to VEGF-D), 6,342,221 (anti-VEGF antibodies), 6,342,219 6,331,301 (VEGF-B antibodies), and 5,730,977, and PCT publications WO96/30046, WO 97/44453, and WO 98/45331, the contents of which are incorporated by reference in their entirety. One example of an anti-VEGF antibody has a heavy chain variable region comprising the sequence of SEQ ID NO: 24 (EVQLVESGGG LVQPGGSLRL SCAASGYDFT HYGMN-WVRQA PGKGLEWVGW INTYTGEPTY AADFKRRFTF SLDTSKSTAY LQMNSLRAED TAVYYCAKYP YYGTSH-WYF DVWGQGT), which corresponds to SEQ ID NO:116 from PCT Application WO 98/45331, incorporated herein by reference in its entirety, and a light chain variable region comprising the sequence of SEQ ID NO: 25 (DIQLTQSPSS LSASVGDRVT ITCASQDIS NYLNWYQQKP GKAPKVLIFY TSSLHSGVPS RFSGSGSGTD FTLTISSLQP EDFATYY-CQQ YSTVPWTFGQ GTKVEIKRTV), which corresponds to SEQ ID NO: 115 from PCT Application WO 98/45331. Another example of an anti-VEGF antibody has a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 26 (EVQLVESGGG LVQPGGSLRL SCAASGYTFT NYGMNWVRQA PGKGLEWVGW INTYTGEPTY AAD-FKRRFTF SLDTSKSTAY LQMNSLRAED TAVYYCAKYP HYYGSSHWYF DVWGQGT), which corresponds to SEQ ID NO:7 from PCT Application WO 98/45331, and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 27 (DIQLTQSPSS LSASVGDRVT ITCASQDIS NYLNWYQQKP GKAPKVLIFY TSSLHSGVPS RF-SGSGSGTD FTLTISSLQP EDFATYYCQQ YSTVPWTFGQ GTKVEIKRTV), which corresponds to SEQ ID NO:8 from PCT Application WO 98/45331, incorporated herein by reference in its entirety.

[0102] Antibodies to VEGF receptors are also known in the art, such as those described in, for example, U.S. Patent Nos. 5,840,301, 5,874,542, 5,955,311, 6,365,157, and PCT publication WO 04/003211, the contents of which are incorporated by reference in their entirety.

[0103] Small molecules that block the action of VEGF by, e.g., inhibiting a VEGFR-associated tyrosine kinase activity, are known in the art, e.g., those described in U.S. Patent Nos. 6,514,971, 6,448,277 6,414,148, 6,362,336, 6,291,455, 6,284,751, 6,177,401, 6,071,921, and 6,001,885 (retinoid inhibitors of VEGF expression), the contents of each of which are incorporated by reference in their entirety.

[0104] Proteins and polypeptides that block the action of VEGF are known in the art, e.g., those described in U.S. Patent Nos. 6,576,608, 6,559,126, 6,541,008, 6,515,105, 6,383,486 (VEGF decoy receptor), 6,375,929 (VEGF decoy receptor), 6,361,946 (VEGF peptide analog inhibitors), 6,348,333 (VEGF decoy receptor), 6,559,126 (polypeptides that bind VEGF and block binding to VEGFR), 6,100,071 (VEGF decoy receptor), and 5,952,199, the contents of each of which are incorporated by reference in their entirety.

[0105] Short interfering nucleic acids (siNA), short interfering RNA (siRNA), double stranded RNA (dsRNA), microRNA (miRNA) and short hairpin RNA (shRNA) capable of mediating RNA interference (RNAi) against VEGF and/or VEGFR gene expression and/or activity are known in the art, for example, as disclosed in PCT publication WO 03/070910, the contents of which is incorporated by reference in its entirety.

[0106] Antisense oligonucleotides for the inhibition of VEGF are known in the art, e.g., those described in, e.g., U.S. Patent Nos. 5,611,135, 5,814,620, 6,399,586, 6,410,322, and 6,291,667, the contents of each of which are incorporated by reference in their entirety.

[0107] Aptamers (also known as nucleic acid ligands) for the inhibition of VEGF are known in the art, e.g., those described in, e.g., U.S. Patent Nos. 6,762,290, 6,426,335, 6,168,778, 6,051,698, and 5,859,228, the contents of each of which are incorporated by reference in their entirety.

Antibody Antagonists

[0108] The invention includes antagonist antibodies directed against PDGF and VEGF as well as their cognate receptors PDGFR and VEGFR. The antibody antagonists of the invention block binding of a ligand with its cognate receptor. Accordingly, a PDGF antagonist antibody of the invention includes antibodies directed against a PDGF as well as a PDGFR target.

[0109] The antagonist antibodies of the invention include monoclonal inhibitory antibodies. Monoclonal antibodies, or fragments thereof, encompass all immunoglobulin classes such as IgM, IgG, IgD, IgE, IgA, or their subclasses, such as the IgG subclasses or mixtures thereof. IgG and its subclasses are useful, such as IgG₁, IgG₂, IgG_{2a}, IgG_{2b}, IgG₃ or IgG_M. The IgG subtypes IgG_{1/kappa} and IgG_{2b/kappa} are included as useful embodiments. Fragments which may be mentioned are all truncated or modified antibody fragments with one or two antigen-complementary binding sites which show high binding and neutralizing activity toward mammalian PDGF or VEGF (or their cognate receptors), such as parts of antibodies having a binding site which corresponds to the antibody and is formed by light and heavy chains, such as Fv, Fab or F(ab')₂ fragments, or single-stranded fragments. Truncated double-stranded fragments such as Fv, Fab or F(ab')₂ are particularly useful. These fragments can be obtained, for example, by enzymatic means by eliminating

the Fc part of the antibody with enzymes such as papain or pepsin, by chemical oxidation or by genetic manipulation of the antibody genes. It is also possible and advantageous to use genetically manipulated, non-truncated fragments. The anti-PDGF or VEGF antibodies or fragments thereof can be used alone or in mixtures.

[0110] The novel antibodies, antibody fragments, mixtures or derivatives thereof advantageously have a binding affinity for PDGF or VEGF (or their cognate receptors) in a range from 1×10^{-7} M to 1×10^{-12} M, or from 1×10^{-8} M to 1×10^{-11} M, or from 1×10^{-9} M to 5×10^{-10} M.

[0111] The antibody genes for the genetic manipulations can be isolated, for example from hybridoma cells, in a manner known to the skilled worker. For this purpose, antibody-producing cells are cultured and, when the optical density of the cells is sufficient, the mRNA is isolated from the cells in a known manner by lysing the cells with guanidinium thiocyanate, acidifying with sodium acetate, extracting with phenol, chloroform/isoamyl alcohol, precipitating with isopropanol and washing with ethanol. cDNA is then synthesized from the mRNA using reverse transcriptase. The synthesized cDNA can be inserted, directly or after genetic manipulation, for example, by site-directed mutagenesis, introduction of insertions, inversions, deletions, or base exchanges, into suitable animal, fungal, bacterial or viral vectors and be expressed in appropriate host organisms. Useful bacterial or yeast vectors are pBR322, pUC18/19, pACYC184, lambda or yeast mu vectors for the cloning of the genes and expression in bacteria such as *E. coli* or in yeasts such as *Saccharomyces cerevisiae*.

[0112] The invention furthermore relates to cells that synthesize PDGF or VEGF antibodies. These include animal, fungal, bacterial cells or yeast cells after transformation as mentioned above. They are advantageously hybridoma cells or trioma cells, typically hybridoma cells. These hybridoma cells can be produced, for example, in a known manner from animals immunized with PDGF or VEGF (or their cognate receptors) and isolation of their antibody-producing B cells, selecting these cells for PDGF or VEGF-binding antibodies and subsequently fusing these cells to, for example, human or animal, for example, mouse myeloma cells, human lymphoblastoid cells or heterohybridoma cells (see, e.g., Koehler et al., (1975) Nature 256: 496) or by infecting these cells with appropriate viruses to produce immortalized cell lines. Hybridoma cell lines produced by fusion are useful and mouse hybridoma cell lines are particularly useful. The hybridoma cell lines of the invention secrete useful antibodies of the IgG type. The binding of the mAb antibodies of the invention bind with high affinity and reduce or neutralize the biological (e.g., angiogenic) activity of PDGF or VEGF.

[0113] The invention further includes derivatives of these anti-PDGF or VEGF antibodies which retain their PDGF or VEGF-inhibiting activity while altering one or more other properties related to their use as a pharmaceutical agent, e.g., serum stability or efficiency of production. Examples of such anti-PDGF or VEGF antibody derivatives include peptides, peptidomimetics derived from the antigen-binding regions of the antibodies, and antibodies, antibody fragments or peptides bound to solid or liquid carriers such as polyethylene glycol, glass, synthetic polymers such as polyacrylamide, polystyrene, polypropylene, polyethylene or natural polymers such as cellulose, Sepharose or agarose, or conjugates with enzymes, toxins or radioactive or nonradioactive markers such as ^3H , ^{123}I , ^{125}I , ^{131}I , ^{32}P , ^{35}S , ^{14}C , ^{51}Cr , ^{36}Cl , ^{57}Co , ^{55}Fe , ^{59}Fe , ^{90}Y , $^{99\text{m}}\text{Tc}$, ^{75}Se , or antibodies, fragments, or peptides covalently bonded to fluorescent/chemiluminescent labels such as rhodamine, fluorescein, isothiocyanate, phycoerythrin, phycocyanin, fluorescamine, metal chelates, avidin, streptavidin or biotin.

[0114] The novel antibodies, antibody fragments, mixtures, and derivatives thereof can be used directly, after drying, for example freeze drying, after attachment to the abovementioned carriers or after formulation with other pharmaceutical active and ancillary substances for producing pharmaceutical preparations. Examples of active and ancillary substances which may be mentioned are other antibodies, antimicrobial active substances with a microbiocidal or microbiostatic action such as antibiotics in general or sulfonamides, antitumor agents, water, buffers, salines, alcohols, fats, waxes, inert vehicles or other substances customary for parenteral products, such as amino acids, thickeners or sugars. These pharmaceutical preparations are used to control diseases, and are useful to control ocular neovascular disorders and diseases including AMD and diabetic retinopathy.

[0115] The novel antibodies, antibody fragments, mixtures or derivatives thereof can be used in therapy or diagnosis directly or after coupling to solid or liquid carriers, enzymes, toxins, radioactive or nonradioactive labels or to fluorescent/chemiluminescent labels as described above.

[0116] The human PDGF or VEGF monoclonal antibodies of the present invention may be obtained by any means known in the art. For example, a mammal is immunized with human PDGF or VEGF (or their cognate receptors). Purified human PDGF and VEGF is commercially available (e.g., from Cell Sciences, Norwood, MA, as well as other commercial vendors). Alternatively, human PDGF or VEGF (or their cognate receptors) may be readily purified from human placental tissue. The mammal used for raising anti-human PDGF or VEGF antibody is not restricted and may be a primate, a rodent (such as mouse, rat or rabbit), bovine, sheep, goat or dog.

[0117] Next, antibody-producing cells such as spleen cells are removed from the immunized animal and are fused with myeloma cells. The myeloma cells are well-known in the art (e.g., p3x63-Ag8-653, NS-0, NS-1 or P3U1 cells may be used). The cell fusion operation may be carried out by any conventional method known in the art.

[0118] The cells, after being subjected to the cell fusion operation, are then cultured in HAT selection medium so as to select hybridomas. Hybridomas which produce antihuman monoclonal antibodies are then screened. This screening

may be carried out by, for example, sandwich enzyme-linked immunosorbent assay (ELISA) or the like in which the produced monoclonal antibodies are bound to the wells to which human PDGF or VEGF (or their cognate receptor) is immobilized. In this case, as the secondary antibody, an antibody specific to the immunoglobulin of the immunized animal, which is labeled with an enzyme such as peroxidase, alkaline phosphatase, glucose oxidase, beta-D-galactosidase, or the like, may be employed. The label may be detected by reacting the labeling enzyme with its substrate and measuring the generated color. As the substrate, 3,3-diaminobenzidine, 2,2-diaminobis-o-dianisidine, 4-chloronaphthol, 4-aminoantipyrine, o-phenylenediamine or the like may be produced.

[0119] By the above-described operation, hybridomas which produce anti-human PDGF or VEGF antibodies can be selected. The selected hybridomas are then cloned by the conventional limiting dilution method or soft agar method. If desired, the cloned hybridomas may be cultured on a large scale using a serum-containing or a serum free medium, or may be inoculated into the abdominal cavity of mice and recovered from ascites, thereby a large number of the cloned hybridomas may be obtained.

[0120] From among the selected anti-human PDGF or VEGF monoclonal antibodies, those that have an ability to prevent binding and activation of the corresponding ligand/ receptor pair (e.g., in a cell-based PDGF or VEGF assay system (see above)) are then chosen for further analysis and manipulation. If the antibody blocks receptor/ligand binding and/or activation, it means that the monoclonal antibody tested has an ability to reduce or neutralize the PDGF or VEGF activity of human PDGF or VEGF. That is, the monoclonal antibody specifically recognizes and/or interferes with the critical binding site of human PDGF or VEGF (or their cognate receptors).

[0121] The monoclonal antibodies herein further include hybrid and recombinant antibodies produced by splicing a variable (including hypervariable) domain of an anti-PDGF or VEGF antibody with a constant domain (e.g., "humanized" antibodies), or a light chain with a heavy chain, or a chain from one species with a chain from another species, or fusions with heterologous proteins, regardless of species of origin or immunoglobulin class or subclass designation, as well as antibody fragments [e.g., Fab, F(ab)₂, and Fv], so long as they exhibit the desired biological activity. [See, e.g., U.S. Patent No. 4,816,567 and Mage & Lamoyi, in *Monoclonal Antibody Production Techniques and Applications*, pp.79-97 (Marcel Dekker, Inc.), New York (1987)].

[0122] Thus, the term "monoclonal" indicates that the character of the antibody obtained is from a substantially homogeneous population of antibodies, and is not to be construed as requiring production of the antibody by any particular method. For example, the monoclonal antibodies to be used in accordance with the present invention may be made by the hybridoma method first described by Kohler & Milstein, *Nature* 256:495 (1975), or may be made by recombinant DNA methods (U.S. Patent No. 4,816,567). The "monoclonal antibodies" may also be isolated from phage libraries generated using the techniques described in McCafferty et al., *Nature* 348:552-554 (1990), for example.

[0123] "Humanized" forms of non-human (e.g., murine) antibodies are specific chimeric immunoglobulins, immunoglobulin chains or fragments thereof (such as Fv, Fab, Fab', F(ab)₂ or other antigen-binding subsequences of antibodies) which contain minimal sequence derived from non-human immunoglobulin. For the most part, humanized antibodies are human immunoglobulins (recipient antibody) in which residues from the complementary determining regions (CDRs) of the recipient antibody are replaced by residues from the CDRs of a non-human species (donor antibody) such as mouse, rat or rabbit having the desired specificity, affinity and capacity. In some instances, Fv framework region (FR) residues of the human immunoglobulin are replaced by corresponding non-human FR residues. Furthermore, the humanized antibody may comprise residues that are found neither in the recipient antibody nor in the imported CDR or FR sequences. These modifications are made to further refine and optimize antibody performance. In general, the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin and all or substantially all of the FR residues are those of a human immunoglobulin consensus sequence. The humanized antibody optimally also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin.

[0124] Methods for humanizing non-human antibodies are well known in the art. Generally, a humanized antibody has one or more amino acid residues introduced into it from a source which is non-human. These non-human amino acid residues are often referred to as "import" residues, which are typically taken from an "import" variable domain. Humanization can be essentially performed following the method of Winter and co-workers (Jones et al., (1986) *Nature* 321: 522-525; Riechmann et al., (1988) *Nature* 332: 323-327; and Verhoeyen et al., (1988) *Science* 239: 1534-1536), by substituting rodent CDRs or CDR sequences for the corresponding sequences of a human antibody. Accordingly, such "humanized" antibodies are chimeric antibodies, wherein substantially less than an intact human variable domain has been substituted by the corresponding sequence from a non-human species. In practice, humanized antibodies are typically human antibodies in which some CDR residues and possibly some FR residues are substituted by residues from analogous sites in rodent antibodies.

[0125] The choice of human variable domains, both light and heavy, to be used in making the humanized antibodies is very important to reduce antigenicity. According to the so-called "best-fit" method, the sequence of the variable domain of a rodent antibody is screened against the entire library of known human variable-domain sequences. The human sequence which is closest to that of the rodent is then accepted as the human framework (FR) for the humanized antibody

(Sims et al., (1993) J. Immunol., 151:2296; and Chothia and Lesk (1987) J. Mol. Biol., 196:901). Another method uses a particular framework derived from the consensus sequence of all human antibodies of a particular subgroup of light or heavy chains. The same framework may be used for several different humanized antibodies (Carter et al., (1992) Proc. Natl. Acad. Sci. (USA), 89: 4285; and Presta et al., (1993) J. Immunol., 151:2623).

[0126] It is further important that antibodies be humanized with retention of high affinity for the antigen and other favorable biological properties. To achieve this goal, according to one useful method, humanized antibodies are prepared by a process of analysis of the parental sequences and various conceptual humanized products using three-dimensional models of the parental and humanized sequences. Three-dimensional immunoglobulin models are commonly available and are familiar to those skilled in the art. Computer programs are available which illustrate and display probable three-dimensional conformational structures of selected candidate immunoglobulin sequences. Inspection of these displays permits analysis of the likely role of the residues in the functioning of the candidate immunoglobulin sequence, i.e., the analysis of residues that influence the ability of the candidate immunoglobulin to bind its antigen. In this way, FR residues can be selected and combined from the consensus and import sequences so that the desired antibody characteristic, such as increased affinity for the target antigen(s), is achieved. In general, the CDR residues are directly and most substantially involved in influencing antigen binding.

[0127] Human monoclonal antibodies directed against PDGF or VEGF are also included in the invention. Such antibodies can be made by the hybridoma method. Human myeloma and mouse-human heteromyeloma cell lines for the production of human monoclonal antibodies have been described, for example, by Kozbor (1984) J. Immunol., 133, 3001; Brodeur, et al., Monoclonal Antibody Production Techniques and Applications, pp.51-63 (Marcel Dekker, Inc., New York, 1987); and Boerner et al., (1991) J. Immunol., 147:86-95.

[0128] It is now possible to produce transgenic animals (e.g., mice) that are capable, upon immunization, of producing a full repertoire of human antibodies in the absence of endogenous immunoglobulin production. For example, it has been described that the homozygous deletion of the antibody heavy-chain joining region (J_H) gene in chimeric and germ-line mutant mice results in complete inhibition of endogenous antibody production. Transfer of the human germ-line immunoglobulin gene array in such germ-line mutant mice will result in the production of human antibodies upon antigen challenge (see, e.g., Jakobovits et al., (1993) Proc. Natl. Acad. Sci. (USA), 90: 2551; Jakobovits et al., (1993) Nature, 362:255-258; and Bruggermann et al., (1993) Year in Immuno., 7:33).

[0129] Alternatively, phage display technology (McCafferty et al., (1990) Nature, 348: 552-553) can be used to produce human antibodies and antibody fragments *in vitro*, from immunoglobulin variable (V) domain gene repertoires from unimmunized donors (for review see, e.g., Johnson et al., (1993) Current Opinion in Structural Biology, 3:564-571). Several sources of V-gene segments can be used for phage display. For example, Clackson et al., ((1991) Nature, 352: 624-628) isolated a diverse array of anti-oxazolone antibodies from a small random combinatorial library of V genes derived from the spleens of immunized mice. A repertoire of V genes from unimmunized human donors can be constructed and antibodies to a diverse array of antigens (including self-antigens) can be isolated essentially following the techniques described by Marks et al., ((1991) J. Mol. Biol., 222:581-597, or Griffith et al., (1993) EMBO J., 12:725-734).

[0130] In a natural immune response, antibody genes accumulate mutations at a high rate (somatic hypermutation). Some of the changes introduced will confer higher affinity, and B cells displaying high-affinity surface immunoglobulin are preferentially replicated and differentiated during subsequent antigen challenge. This natural process can be mimicked by employing the technique known as "chain shuffling" (see Marks et al., (1992) Bio. Technol., 10:779-783). In this method, the affinity of "primary" human antibodies obtained by phage display can be improved by sequentially replacing the heavy and light chain V region genes with repertoires of naturally occurring variants (repertoires) of V domain genes obtained from unimmunized donors. This technique allows the production of antibodies and antibody fragments with affinities in the nM range. A strategy for making very large phage antibody repertoires has been described by Waterhouse et al., ((1993) Nucl. Acids Res., 21:2265-2266).

[0131] Gene shuffling can also be used to derive human antibodies from rodent antibodies, where the human antibody has similar affinities and specificities to the starting rodent antibody. According to this method, which is also referred to as "epitope imprinting", the heavy or light chain V domain gene of rodent antibodies obtained by phage display technique is replaced with a repertoire of human V domain genes, creating rodent-human chimeras. Selection on antigen results in isolation of human variable capable of restoring a functional antigen-binding site, i.e., the epitope governs (imprints) the choice of partner. When the process is repeated in order to replace the remaining rodent V domain, a human antibody is obtained (see PCT WO 93/06213, published 1 Apr. 1993). Unlike traditional humanization of rodent antibodies by CDR grafting, this technique provides completely human antibodies, which have no framework or CDR residues of rodent origin.

Aptamer Antagonists

[0132] The invention provides aptamer antagonists directed against PDGF and/or VEGF (or their cognate receptors). Aptamers, also known as nucleic acid ligands, are non-naturally occurring nucleic acids that bind to and, generally,

antagonize (*i.e.*, inhibit) a pre-selected target.

[0133] Aptamers can be made by any known method of producing oligomers or oligonucleotides. Many synthesis methods are known in the art. For example, 2'-O-allyl modified oligomers that contain residual purine ribonucleotides, and bearing a suitable 3'-terminus such as an inverted thymidine residue (Ortigao et al., *Antisense Research and Development*, 2:129-146 (1992)) or two phosphorothioate linkages at the 3'-terminus to prevent eventual degradation by 3'-exonucleases, can be synthesized by solid phase beta-cyanoethyl phosphoramidite chemistry (Sinha et al., *Nucleic Acids Res.*, 12:4539-4557 (1984)) on any commercially available DNA/RNA synthesizer. One method is the 2'-O-tert-butylidimethylsilyl (TBDMS) protection strategy for the ribonucleotides (Usman et al., *J. Am. Chem. Soc.*, 109:7845-7854 (1987)), and all the required 3'-O-phosphoramidites are commercially available. In addition, aminomethylpolystyrene may be used as the support material due to its advantageous properties (McCollum and Andrus (1991) *Tetrahedron Lett.*, 32:4069-4072). Fluorescein can be added to the 5'-end of a substrate RNA during the synthesis by using commercially available fluorescein phosphoramidites. In general, an aptamer oligomer can be synthesized using a standard RNA cycle. Upon completion of the assembly, all base labile protecting groups are removed by an eight hour treatment at 55° C with concentrated aqueous ammonia/ethanol (3:1 v/v) in a sealed vial. The ethanol suppresses premature removal of the 2'-O-TBDMS groups that would otherwise lead to appreciable strand cleavage at the resulting ribonucleotide positions under the basic conditions of the deprotection (Usman et al., (1987) *J. Am. Chem. Soc.*, 109:7845-7854). After lyophilization, the TBDMS protected oligomer is treated with a mixture of triethylamine trihydrofluoride/triethylamine/N-methylpyrrolidinone for 2 hours at 60° C to afford fast and efficient removal of the silyl protecting groups under neutral conditions (see Wincott et al., (1995) *Nucleic Acids Res.*, 23:2677-2684). The fully deprotected oligomer can then be precipitated with butanol according to the procedure of Cathala and Brunel ((1990) *Nucleic Acids Res.*, 18:201). Purification can be performed either by denaturing polyacrylamide gel electrophoresis or by a combination of ion-exchange HPLC (Sproat et al., (1995) *Nucleosides and Nucleotides*, 14:255-273) and reversed phase HPLC. For use in cells, synthesized oligomers are converted to their sodium salts by precipitation with sodium perchlorate in acetone. Traces of residual salts may then be removed using small disposable gel filtration columns that are commercially available. As a final step the authenticity of the isolated oligomers may be checked by matrix assisted laser desorption mass spectrometry (Pieves et al., (1993) *Nucleic Acids Res.*, 21:3191-3196) and by nucleoside base composition analysis.

[0134] The disclosed aptamers can also be produced through enzymatic methods, when the nucleotide subunits are available for enzymatic manipulation. For example, the RNA molecules can be made through *in vitro* RNA polymerase T7 reactions. They can also be made by strains of bacteria or cell lines expressing T7, and then subsequently isolated from these cells. As discussed below, the disclosed aptamers can also be expressed in cells directly using vectors and promoters.

[0135] The aptamers, like other nucleic acid molecules of the invention, may further contain chemically modified nucleotides. One issue to be addressed in the diagnostic or therapeutic use of nucleic acids is the potential rapid degradation of oligonucleotides in their phosphodiester form in body fluids by intracellular and extracellular enzymes such as endonucleases and exonucleases before the desired effect is manifest. Certain chemical modifications of the nucleic acid ligand can be made to increase the *in vivo* stability of the nucleic acid ligand or to enhance or to mediate the delivery of the nucleic acid ligand (see, *e.g.*, U.S. Patent Application No. 5,660,985, entitled "High Affinity Nucleic Acid Ligands Containing Modified Nucleotides") which is specifically incorporated herein by reference.

[0136] Modifications of the nucleic acid ligands contemplated in this invention include, but are not limited to, those which provide other chemical groups that incorporate additional charge, polarizability, hydrophobicity, hydrogen bonding, electrostatic interaction, and fluxionality to the nucleic acid ligand bases or to the nucleic acid ligand as a whole. Such modifications include, but are not limited to, 2'-position sugar modifications, 5-position pyrimidine modifications, 8-position purine modifications, modifications at exocyclic amines, substitution of 4-thiouridine, substitution of 5-bromo or 5-iodouracil; backbone modifications, phosphorothioate or alkyl phosphate modifications, methylations, unusual base-pairing combinations such as the isobases isocytidine and isoguanidine and the like. Modifications can also include 3' and 5' modifications such as capping or modification with sugar moieties. In some embodiments of the instant invention, the nucleic acid ligands are RNA molecules that are 2'-fluoro (2'-F) modified on the sugar moiety of pyrimidine residues.

[0137] The stability of the aptamer can be greatly increased by the introduction of such modifications and as well as by modifications and substitutions along the phosphate backbone of the RNA. In addition, a variety of modifications can be made on the nucleobases themselves which both inhibit degradation and which can increase desired nucleotide interactions or decrease undesired nucleotide interactions. Accordingly, once the sequence of an aptamer is known, modifications or substitutions can be made by the synthetic procedures described below or by procedures known to those of skill in the art.

[0138] Other modifications include the incorporation of modified bases (or modified nucleoside or modified nucleotides) that are variations of standard bases, sugars and/or phosphate backbone chemical structures occurring in ribonucleic (*i.e.*, A, C, G and U) and deoxyribonucleic (*i.e.*, A, C, G and T) acids. Included within this scope are, for example: Gm (2'-methoxyguanylic acid), Am (2'-methoxyadenylic acid), Cf (2'-fluorocytidylic acid), Uf (2'-fluorouridylic acid), Ar (riboadenylic acid). The aptamers may also include cytosine or any cytosine-related base including 5-methylcytosine, 4-

acetylcytosine, 3-methylcytosine, 5-hydroxymethyl cytosine, 2-thiocytosine, 5-halocytosine (e.g., 5-fluorocytosine, 5-bromocytosine, 5-chlorocytosine, and 5-iodocytosine), 5-propynyl cytosine, 6-azocytosine, 5-trifluoromethylcytosine, N4, N4-ethanocytosine, phenoxazine cytidine, phenothiazine cytidine, carbazole cytidine or pyridindole cytidine. The aptamer may further include guanine or any guanine-related base including 6-methylguanine, 1-methylguanine, 2,2-dimethylguanine, 2-methylguanine, 7-methylguanine, 2-propylguanine, 6-propylguanine, 8-haloguanine (e.g., 8-fluoroguanine, 8-bromoguanine, 8-chloroguanine, and 8-iodoguanine), 8-aminoguanine, 8-sulfhydrylguanine, 8-thioalkylguanine, 8-hydroxylguanine, 7-methylguanine, 8-azaguanine, 7-deazaguanine or 3-deazaguanine. The aptamer may still further include adenine or any adenine-related base including 6-methyladenine, N6-isopentenyladenine, N6-methyladenine, 1-methyladenine, 2-methyladenine, 2-methylthio-N6-isopentenyladenine, 8-haloadenine (e.g., 8-fluoroadenine, 8-bromoadenine, 8-chloroadenine, and 8-iodoadenine), 8-aminoadenine, 8-sulfhydryladenine, 8-thioalkyladenine, 8-hydroxyladenine, 7-methyladenine, 2-haloadenine (e.g., 2-fluoroadenine, 2-bromoadenine, 2-chloroadenine, and 2-iodoadenine), 2-aminoadenine, 8-azaadenine, 7-deazaadenine or 3-deazaadenine. Also included are uracil or any uracil-related base including 5-halouracil (e.g., 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil), 5-(carboxyhydroxymethyl)uracil, 5-carboxymethylaminomethyl-2-thiouracil, 5-carboxymethylaminomethyluracil, dihydrouracil, 1-methylpseudouracil, 5-methoxyaminomethyl-2-thiouracil, 5'-methoxycarbonylmethyluracil, 5-methoxyuracil, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid, pseudouracil, 5-methyl-2-thiouracil, 2-thiouracil, 3-(3-amino-3-N-2-carboxypropyl)uracil, 5-methylaminomethyluracil, 5-propynyl uracil, 6-azouracil, or 4-thiouracil.

[0139] Examples of other modified base variants known in the art include, without limitation, those listed at 37 C.F.R. §1.822(p) (1), e.g., 4-acetylcytidine, 5-(carboxyhydroxymethyl) uridine, 2'-methoxycytidine, 5-carboxymethylaminomethyl-2-thiouridine, 5-carboxymethylaminomethyluridine, dihydrouridine, 2'-O-methylpseudouridine, b-D-galactosylqueosine, inosine, N6-isopentenyladenosine, 1-methyladenosine, 1-methylpseudouridine, 1-methylguanosine, 1-methylinosine, 2,2-dimethylguanosine, 2-methyladenosine, 2-methylguanosine, 3-methylcytidine, 5-methylcytidine, N6-methyladenosine, 7-methylguanosine, 5-methylaminomethyluridine, 5-methoxyaminomethyl-2-thiouridine, b-D-mannosylqueosine, 5-methoxycarbonylmethyluridine, 5-methoxyuridine, 2-methylthio-N6-isopentenyladenosine, N-((9-b-D-ribofuranosyl-2-methylthiopurine-6-yl)carbamoyl)threonine, N-((9-b-D-ribofuranosylpurine-6-yl)N-methyl-carbamoyl)threonine, uridine-5-oxyacetic acid methylester, uridine-5-oxyacetic acid (v), wybutoxosine, pseudouridine, queosine, 2-thiocytidine, 5-methyl-2-thiouridine, 2-thiouridine, 4-thiouridine, 5-methyluridine, N-((9-b-D-ribofuranosylpurine-6-yl)carbamoyl)threonine, 2'-O-methyl-5-methyluridine, 2'-O-methyluridine, wybutosine, 3-(3-amino-3-carboxypropyl)uridine.

[0140] Also included are the modified nucleobases described in U.S. Patent Nos. 3,687,808, 3,687,808, 4,845,205, 5,130,302, 5,134,066, 5,175,273, 5,367,066, 5,432,272, 5,457,187, 5,459,255, 5,484,908, 5,502,177, 5,525,711, 5,552,540, 5,587,469, 5,594,121, 5,596,091, 5,614,617, 5,645,985, 5,830,653, 5,763,588, 6,005,096, and 5,681,941. Examples of modified nucleoside and nucleotide sugar backbone variants known in the art include, without limitation, those having, e.g., 2' ribosyl substituents such as F, SH, SCH₃, OCN, Cl, Br, CN, CF₃, OCF₃, SOCH₃, SO₂, CH₃, ONO₂, NO₂, N₃, NH₂, OCH₂CH₂OCH₃, O(CH₂)₂ON(CH₃)₂, OCH₂OCH₂N(CH₃)₂, O(C1-10 alkyl), O(C2-10 alkenyl), O(C2-10 alkynyl), S(C1-10 alkyl), S(C2-10 alkenyl), S(C2-10 alkynyl), NH(C1-10 alkyl), NH(C2-10 alkenyl), NH(C2-10 alkynyl), and O-alkyl-O-alkyl. Desirable 2' ribosyl substituents include 2'-methoxy (2'-OCH₃), 2'-aminopropoxy (2'-OCH₂CH₂CH₂NH₂), 2'-allyl (2'-CH₂-CH=CH₂), 2'-O-allyl (2'-O-CH₂-CH=CH₂), 2'-amino (2'-NH₂), and 2'-fluoro (2'-F). The 2'-substituent may be in the arabino (up) position or ribo (down) position.

[0141] The aptamers of the invention may be made up of nucleotides and/or nucleotide analogs such as described above, or a combination of both, or are oligonucleotide analogs. The aptamers of the invention may contain nucleotide analogs at positions which do not effect the function of the oligomer to bind PDGF or VEGF (or their cognate receptors).

[0142] There are several techniques that can be adapted for refinement or strengthening of the nucleic acid Ligands binding to a particular target molecule or the selection of additional aptamers. One technique, generally referred to as "in vitro genetics" (see Szostak (1992) TIBS, 19:89), involves isolation of aptamer antagonists by selection from a pool of random sequences. The pool of nucleic acid molecules from which the disclosed aptamers may be isolated may include invariant sequences flanking a variable sequence of approximately twenty to forty nucleotides. This method has been termed Selective Evolution of Ligands by EXponential Enrichment (SELEX). Compositions and methods for generating aptamer antagonists of the invention by SELEX and related methods are known in the art and taught in, for example, U.S. Patent No. 5,475,096 entitled "Nucleic Acid Ligands," and U.S. Patent No. 5,270,163, entitled "Methods for Identifying Nucleic Acid Ligands," each of which is specifically incorporated by reference herein in its entirety. The SELEX process in general, and VEGF and PDGF aptamers and formulations in particular, are further described in, e.g., U.S. Patent Nos. 5,668,264, 5,696,249, 5,670,637, 5,674,685, 5,723,594, 5,756,291, 5,811,533, 5,817,785, 5,958,691, 6,011,020, 6,051,698, 6,147,204, 6,168,778, 6,207,816, 6,229,002, 6,426,335, 6,582,918, the contents of each of which is specifically incorporated by reference herein.

[0143] Briefly, the SELEX method involves selection from a mixture of candidate oligonucleotides and step-wise iterations of binding to a selected target, partitioning and amplification, using the same general selection scheme, to achieve virtually any desired criterion of binding affinity and selectivity. Starting from a mixture of nucleic acids, typically

comprising a segment of randomized sequence, the SELEX method includes steps of contacting the mixture with the target under conditions favorable for binding, partitioning unbound nucleic acids from those nucleic acids which have bound specifically to target molecules, dissociating the nucleic acid-target complexes, amplifying the nucleic acids dissociated from the nucleic acid-target complexes to yield a ligand-enriched mixture of nucleic acids, then reiterating the steps of binding, partitioning, dissociating and amplifying through as many cycles as desired to yield highly specific high affinity nucleic acid ligands to the target molecule.

[0144] The basic SELEX method has been modified to achieve a number of specific objectives. For example, U.S. Patent No. 5,707,796, entitled "Method for Selecting Nucleic Acids on the Basis of Structure," describes the use of the SELEX process in conjunction with gel electrophoresis to select nucleic acid molecules with specific structural characteristics, such as bent DNA. U.S. Patent No. 5,763,177 entitled "Systematic Evolution of Ligands by Exponential Enrichment: Photoselection of Nucleic Acid Ligands and Solution SELEX" describe a SELEX based method for selecting nucleic acid ligands containing photoreactive groups capable of binding and/or photocrosslinking to and/or photoinactivating a target molecule. U.S. Patent No. 5,580,737 entitled "High-Affinity Nucleic Acid Ligands That Discriminate Between Theophylline and Caffeine," describes a method for identifying highly specific nucleic acid ligands able to discriminate between closely related molecules, which can be non-peptidic, termed Counter-SELEX. U.S. Patent No. 5,567,588 entitled "Systematic Evolution of Ligands by EXponential Enrichment: Solution SELEX," describes a SELEX-based method which achieves highly efficient partitioning between oligonucleotides having high and low affinity for a target molecule.

[0145] The SELEX method encompasses the identification of high-affinity nucleic acid ligands containing modified nucleotides conferring improved characteristics on the ligand, such as improved *in vivo* stability or improved delivery characteristics. Examples of such modifications include chemical substitutions at the ribose and/or phosphate and/or base positions. SELEX process-identified nucleic acid ligands containing modified nucleotides are described in U.S. Patent No. 5,660,985 entitled "High Affinity Nucleic Acid Ligands Containing Modified Nucleotides," that describes oligonucleotides containing nucleotide derivatives chemically modified at the 5- and 2'-positions of pyrimidines. U.S. Patent No. 5,580,737, *supra*, describes highly specific nucleic acid ligands containing one or more nucleotides modified with 2'-amino (2'-NH₂), 2'-fluoro (2'-F), and/or 2'-O-methyl (2'-OMe). U.S. Patent Application No. 08/264,029, filed Jun. 22, 1994, entitled "Novel Method of Preparation of Known and Novel 2' Modified Nucleosides by Intramolecular Nucleophilic Displacement," now abandoned, describes oligonucleotides containing various 2'-modified pyrimidines.

[0146] The SELEX method encompasses combining selected oligonucleotides with other selected oligonucleotides and non-oligonucleotide functional units as described in U.S. Patent No. 5,637,459 entitled "Systematic Evolution of Ligands by Exponential Enrichment: Chimeric SELEX," and U.S. Patent No. 5,683,867 entitled "Systematic Evolution of Ligands by Exponential Enrichment: Blended SELEX," respectively. These patents allow for the combination of the broad array of shapes and other properties, and the efficient amplification and replication properties, of oligonucleotides with the desirable properties of other molecules.

[0147] The SELEX method further encompasses combining selected nucleic acid ligands with lipophilic compounds or non-immunogenic, high molecular weight compounds in a diagnostic or therapeutic complex as described in U.S. Patent No. 6,011,020, entitled "Nucleic Acid Ligand Complexes," which is specifically incorporated by reference herein in their entirety.

[0148] The aptamer antagonists can also be refined through the use of computer modeling techniques. Examples of molecular modeling systems are the CHARMM and QUANTA programs, Polygen Corporation (Waltham, Mass.). CHARMM performs the energy minimization and molecular dynamics functions. QUANTA performs the construction, graphic modeling and analysis of molecular structure. QUANTA allows interactive construction, modification, visualization, and analysis of the behavior of molecules with each other. These applications can be adapted to define and display the secondary structure of RNA and DNA molecules.

[0149] Aptamers with these various modifications can then be tested for function using any suitable assay for the PDGF or VEGF function of interest, such as a PDGF cell-based proliferation activity assay.

[0150] The modifications can be pre- or post-SELEX process modifications. Pre-SELEX process modifications yield nucleic acid ligands with both specificity for their SELEX target and improved *in vivo* stability. Post-SELEX process modifications made to 2'-OH nucleic acid ligands can result in improved *in vivo* stability without adversely affecting the binding capacity of the nucleic acid ligand.

[0151] Other modifications useful for producing aptamers of the invention are known to one of ordinary skill in the art. Such modifications may be made post-SELEX process (modification of previously identified unmodified ligands) or by incorporation into the SELEX process.

[0152] It has been observed that aptamers, or nucleic acid ligands, in general, and VEGF aptamers in particular, are most stable, and therefore efficacious when 5'-capped and 3'-capped in a manner which decreases susceptibility to exonucleases and increases overall stability. Accordingly, the invention is based in one embodiment, upon the capping of aptamers in general, and anti-VEGF aptamers in particular, with a 5'-5' inverted nucleoside cap structure at the 5' end and a 3'-3' inverted nucleoside cap structure at the 3' end. Accordingly, the invention provides anti-VEGF and/or

anti-PDGF aptamers, *i.e.*, nucleic acid ligands, that are capped at the 5' end with a 5'-5'- inverted nucleoside cap and at the 3' end with a 3'-3' inverted nucleoside cap.

[0153] Certain particularly useful aptamers of the invention are anti-VEGF aptamer compositions, including, but not limited to, those having both 5'-5' and 3'-3' inverted nucleotide cap structures at their ends. Such anti-VEGF capped aptamers may be RNA aptamers, DNA aptamers or aptamers having a mixed (*i.e.*, both RNA and DNA) composition. Suitable anti-VEGF aptamer sequences of the invention include the nucleotide sequence GAAGAAUUGG (SEQ ID NO: 15); or the nucleotide sequence UUGGACGC (SEQ ID NO: 16); or the nucleotide sequence GUGAAUGC (SEQ ID NO: 17). Particularly useful are capped anti-VEGF aptamers of the invention have the sequence:

X-5'-5'-CGGAAUCAGUGAAUGCUUAUACAUCG-3'-3'-X (SEQ ID NO: 18)

where each C, G, A, and U represents, respectively, the naturally-occurring nucleotides cytidine, guanine, adenine, and uridine, or modified nucleotides corresponding thereto; X-5'-5' is an inverted nucleotide capping the 5' terminus of the aptamer; 3'-3'-X is an inverted nucleotide capping the 3' terminus of the aptamer; and the remaining nucleotides or modified nucleotides are sequentially linked via 5'-3' phosphodiester linkages. In some embodiments, each of the nucleotides of the capped anti-VEGF aptamer, individually carries a 2' ribosyl substitution, such as -OH (which is standard for ribonucleic acids (RNAs)), or -H (which is standard for deoxyribonucleic acids (DNAs)). In other embodiments the 2' ribosyl position is substituted with an O(C₁₋₁₀ alkyl), an O(C₁₋₁₀ alkenyl), a F, an N₃, or an NH₂ substituent.

[0154] In a still more particular non-limiting example, the 5'-5' capped anti-VEGF aptamer may have the structure:

T_d-5'-5'-C_fG_mG_mA_rA_rU_fC_fA_mG_mU_fG_mA_mA_mU_fG_mC_fU_fU_fA_mU_fA_mU_fC_fG_m 3'-3'-T_d (SEQ ID NO: 19)

where "G_m" represents 2'-methoxyguanylic acid, "A_m" represents 2'-methoxyadenylic acid, "C_f" represents 2'-fluorocytidylic acid, "U_f" represents 2'-fluorouridylic acid, "A_r" represents riboadenylic acid, and "T_d" represents deoxyribothymidylic acid.

Antisense, Ribozymes, and DNA Enzyme Antagonists

[0155] Antisense oligonucleotides and ribozymes that are targeted to PDGF and VEGF effect PDGF /VEGF inhibition by inhibiting protein translation from these messenger RNAs or by targeting degradation of the corresponding PDGF or VEGF mRNAs, respectively. These PDGF-and VEGF-targeted nucleic acids described above provide useful sequences for the design and synthesis of these PDGF and VEGF ribozymes and antisense oligonucleotides. Methods of design and synthesis of antisense oligonucleotides and ribozymes are known in the art. Additional guidance is provided herein.

[0156] One issue in designing specific and effective mRNA-targeted oligonucleotides (antisense ODNs) and ribozymes and antisense is that of identifying accessible sites of antisense pairing within the target mRNA (which is itself folded into a partially self-paired secondary structure). A combination of computer-aided algorithms for predicting RNA pairing accessibility and molecular screening allow for the creation of specific and effective ribozymes and/or antisense oligonucleotides directed against most mRNA targets. Indeed several approaches have been described to determine the accessibility of a target RNA molecule to antisense or ribozyme inhibitors. One approach uses an *in vitro* screening assay applying as many antisense oligodeoxynucleotides as possible (see Monia *et al.*, (1996) *Nature Med.*, 2:668-675; and Milner *et al.*, (1997) *Nature Biotechnol.*, 15:537-541). Another utilizes random libraries of ODNs (Ho *et al.*, (1996) *Nucleic Acids Res.*, 24:1901-1907; Birikh *et al.*, (1997) *RNA* 3:429-437; and Lima *et al.*, (1997) *J. Biol. Chem.*, 272:626-638). The accessible sites can be monitored by RNase H cleavage (see Birikh *et al.*, *supra*; and Ho *et al.*, (1998) *Nature Biotechnol.*, 16:59-63). RNase H catalyzes the hydrolytic cleavage of the phosphodiester backbone of the RNA strand of a DNA-RNA duplex.

[0157] In another approach, involving the use of a pool of semi-random, chimeric chemically synthesized ODNs, is used to identify accessible sites cleaved by RNase H on an *in vitro* synthesized RNA target. Primer extension analyses are then used to identify these sites in the target molecule (see Lima *et al.*, *supra*). Other approaches for designing antisense targets in RNA are based upon computer assisted folding models for RNA. Several reports have been published on the use of random ribozyme libraries to screen effective cleavage (see Campbell *et al.*, (1995) *RNA* 1:598-609; Lieber *et al.*, (1995) *Mol. Cell Biol.*, 15: 540-551; and Vaish *et al.*, (1997) *Biochem.*, 36:6459-6501).

[0158] Other *in vitro* approaches, which utilize random or semi-random libraries of ODNs and RNase H may be more useful than computer simulations (Lima *et al.*, *supra*). However, use of *in vitro* synthesized RNA does not predict the accessibility of antisense ODNs *in vivo* because recent observations suggest that annealing interactions of polynucleotides are influenced by RNA-binding proteins (see Tsuchihashi *et al.*, (1993) *Science*, 267:99-102; Portman *et al.*, (1994) *EMBO J.*, 13:213-221; and Bertrand and Rossi (1994) *EMBO J.*, 13:2904-2912). U.S. Patent No. 6,562,570, the contents of which are incorporated herein by reference, provides compositions and methods for determining accessible sites within an mRNA in the presence of a cell extract, which mimics *in vivo* conditions.

[0159] Briefly, this method involves incubation of native or *in vitro*-synthesized RNAs with defined antisense ODNs, ribozymes, or DNAzymes, or with a random or semi-random ODN, ribozyme or DNAzyme library, under hybridization conditions in a reaction medium which includes a cell extract containing endogenous RNA-binding proteins, or which mimics a cell extract due to presence of one or more RNA-binding proteins. Any antisense ODN, Ribozyme, or DNAzyme, which is complementary to an accessible site in the target RNA will hybridize to that site. When defined ODNs or an ODN library is used, RNase H is present during hybridization or is added after hybridization to cleave the RNA where hybridization has occurred. RNase H can be present when ribozymes or DNAzymes are used, but is not required, since the ribozymes and DNAzymes cleave RNA where hybridization has occurred. In some instances, a random or semi-random ODN library in cell extracts containing endogenous mRNA, RNA-binding proteins and RNase H is used.

[0160] Next, various methods can be used to identify those sites on target RNA to which antisense ODNs, ribozymes or DNAzymes have bound and cleavage has occurred. For example, terminal deoxynucleotidyl transferase-dependent polymerase chain reaction (TDPCR) may be used for this purpose (see Komura and Riggs (1998) *Nucleic Acids Res.*, 26:1807-11). A reverse transcription step is used to convert the RNA template to DNA, followed by TDPCR. In this invention, the 3' termini needed for the TDPCR method is created by reverse transcribing the target RNA of interest with any suitable RNA dependent DNA polymerase (e.g., reverse transcriptase). This is achieved by hybridizing a first ODN primer (P1) to the RNA in a region which is downstream (*i.e.*, in the 5' to 3' direction on the RNA molecule) from the portion of the target RNA molecule which is under study. The polymerase in the presence of dNTPs copies the RNA into DNA from the 3' end of P1 and terminates copying at the site of cleavage created by either an antisense ODN/RNase H, a ribozyme or a DNAzyme. The new DNA molecule (referred to as the first strand DNA) serves as first template for the PCR portion of the TDPCR method, which is used to identify the corresponding accessible target sequence present on the RNA.

[0161] For example, the TDPCR procedure may then be used, *i.e.*, the reverse-transcribed DNA with guanosine triphosphate (rGTP) is reacted in the presence of terminal deoxynucleotidyl transferase (TdT) to add an (rG)2-4 tail on the 3' termini of the DNA molecules. Next is ligated a double-stranded ODN linker having a 3'2-4 overhang on one strand that base-pairs with the (rG)2-4 tail. Then two PCR primers are added. The first is a linker primer (LP) that is complementary to the strand of the TDPCR linker which is ligated to the (rG)2-4 tail (sometimes referred to as the lower strand). The other primer (P2) can be the same as P1, but may be nested with respect to P1, *i.e.*, it is complementary to the target RNA in a region which is at least partially upstream (*i.e.*, in the 3' to 5' direction on the RNA molecule) from the region which is bound by P1, but it is downstream of the portion of the target RNA molecule which is under study. That is, the portion of the target RNA molecule, which is under study to determine whether it has accessible binding sites is that portion which is upstream of the region that is complementary to P2. Then PCR is carried out in the known manner in presence of a DNA polymerase and dNTPs to amplify DNA segments defined by primers LP and P2. The amplified product can then be captured by any of various known methods and subsequently sequenced on an automated DNA sequencer, providing precise identification of the cleavage site. Once this identity has been determined, defined sequence antisense DNA or ribozymes can be synthesized for use *in vitro* or *in vivo*.

[0162] Antisense intervention in the expression of specific genes can be achieved by the use of synthetic antisense oligonucleotide sequences (see, e.g., Lefebvre-d'Hellencourt et al., (1995) *Eur. Cyokine Netw.*, 6:7; Agrawal (1996) *TIBTECH*, 14: 376; and Lev-Lehman et al., (1997) *Antisense Therap.* Cohen and Smicek, eds. (Plenum Press, New York)). Briefly, antisense oligonucleotide sequences may be short sequences of DNA, typically 15-30mer but may be as small as 7mer (see Wagner et al., (1994) *Nature*, 372: 333) designed to complement a target mRNA of interest and form an RNA:AS duplex. This duplex formation can prevent processing, splicing, transport or translation of the relevant mRNA. Moreover, certain AS nucleotide sequences can elicit cellular RNase H activity when hybridized with their target mRNA, resulting in mRNA degradation (see Calabretta et al., (1996) *Semin. Oncol.*, 23:78). In that case, RNase H will cleave the RNA component of the duplex and can potentially release the AS to further hybridize with additional molecules of the target RNA. An additional mode of action results from the interaction of AS with genomic DNA to form a triple helix that may be transcriptionally inactive.

[0163] In as a non-limiting example of, addition to, or substituted for, an antisense sequence as discussed herein above, ribozymes may be utilized for suppression of gene function. This is particularly necessary in cases where antisense therapy is limited by stoichiometric considerations. Ribozymes can then be used that will target the same sequence. Ribozymes are RNA molecules that possess RNA catalytic ability that cleave a specific site in a target RNA. The number of RNA molecules that are cleaved by a ribozyme is greater than the number predicted by a 1:1 stoichiometry (see Hampel and Tritz (1989) *Biochem.*, 28: 4929-33; and Uhlenbeck (1987) *Nature*, 328: 596-600). Therefore, the present invention also allows for the use of the ribozyme sequences targeted to an accessible domain of an PDGF or VEGF mRNA species and containing the appropriate catalytic center. The ribozymes are made and delivered as known in the art and discussed further herein. The ribozymes may be used in combination with the antisense sequences.

[0164] Ribozymes catalyze the phosphodiester bond cleavage of RNA. Several ribozyme structural families have been identified including Group I introns, RNase P, the hepatitis delta virus ribozyme, hammerhead ribozymes and the hairpin ribozyme originally derived from the negative strand of the tobacco ringspot virus satellite RNA (sTRSV) (see Sullivan

(1994) *Investig. Dermatolog.*, (Suppl.) 103: 95S; and U.S. Patent No. 5,225,347). The latter two families are derived from viroids and virusoids, in which the ribozyme is believed to separate monomers from oligomers created during rolling circle replication (see Symons (1989) *TIBS*, 14: 445-50; Symons (1992) *Ann. Rev. Biochem.*, 61: 641-71). Hammerhead and hairpin ribozyme motifs are most commonly adapted for trans-cleavage of mRNAs for gene therapy. The ribozyme type utilized in the present invention is selected as is known in the art. Hairpin ribozymes are now in clinical trial and are a particularly useful type. In general the ribozyme is from 30-100 nucleotides in length.

[0165] Ribozyme molecules designed to catalytically cleave a target mRNA transcript are known in the art (e.g., PDGF (SEQ ID NO: 1) or VEGF (SEQ ID NO:3) and can also be used to prevent translation of mRNA (see, e.g., PCT International Pub. WO90/11364 Sarver et al., (1990) *Science*, 247:1222-1225 and U.S. Patent No. 5,093,246). While ribozymes that cleave mRNA at site specific recognition sequences can be used to destroy particular mRNAs, the use of hammerhead ribozymes is particularly useful. Hammerhead ribozymes cleave mRNAs at locations dictated by flanking regions that form complementary base pairs with the target mRNA. The sole requirement is that the target mRNA have the following sequence of two bases: 5'-UG-3'. The construction and production of hammerhead ribozymes is well known in the art and is described more fully in Haseloff and Gerlach ((1988) *Nature*, 334: 585).

[0166] The ribozymes of the present invention also include RNA endoribonucleases (hereinafter "Cech-type ribozymes") such as the one which occurs naturally in *Tetrahymena thermophila* (known as the IVS, or L-19 IVS RNA), and which has been extensively described by Thomas Cech and collaborators (see Zaug et al., (1984) *Science*, 224:574-578; Zaug and Cech (1986) *Science*, 231:470-475; Zaug, et al., (1986) *Nature*, 324:429-433; International patent application No. WO88/04300; Been and Cech (1986) *Cell*, 47:207-216). The Cech-type ribozymes have an eight base pair active site, which hybridizes to a target RNA sequence where after cleavage of the target RNA takes place. The invention encompasses those Cech-type ribozymes, which target eight base-pair active site sequences. While the invention is not limited to a particular theory of operative mechanism, the use of hammerhead ribozymes in the invention may have an advantage over the use of PDGF /VEGF-directed antisense, as recent reports indicate that hammerhead ribozymes operate by blocking RNA translation and/or specific cleavage of the mRNA target.

[0167] As in the antisense approach, the ribozymes can be composed of modified oligonucleotides (e.g., for improved stability, targeting, etc.) and are delivered to cells expressing the target mRNA. A useful method of delivery involves using a DNA construct "encoding" the ribozyme under the control of a strong constitutive pol III or pol II promoter, so that transfected cells will produce sufficient quantities of the ribozyme to destroy targeted messages and inhibit translation. Because ribozymes, unlike antisense molecules, are catalytic, a lower intracellular concentration is required for efficiency.

[0168] As described above, nuclease resistance, where needed, is provided by any method known in the art that does not substantially interfere with biological activity of the antisense oligodeoxynucleotides or ribozymes as needed for the method of use and delivery (Iyer et al., (1990) *J. Org. Chem.*, 55: 4693-99; Eckstein (1985) *Ann. Rev. Biochem.*, 54: 367-402; Spitzer and Eckstein (1988) *Nucleic Acids Res.*, 18: 11691-704; Woolf et al., (1990) *Nucleic Acids Res.*, 18: 1763-69; and Shaw et al., (1991) *Nucleic Acids Res.*, 18: 11691-704). As described above for aptamers, non-limiting representative modifications that can be made to antisense oligonucleotides or ribozymes in order to enhance nuclease resistance include modifying the phosphorous or oxygen heteroatom in the phosphate backbone, short chain alkyl or cycloalkyl intersugar linkages or short chain heteroatomic or heterocyclic intersugar linkages. These include, e.g., preparing 2'-fluoridated, O-methylated, methyl phosphonates, phosphorothioates, phosphorodithioates and morpholino oligomers. For example, the antisense oligonucleotide or ribozyme may have phosphorothioate bonds linking between four to six 3'-terminus nucleotide bases. Alternatively, phosphorothioate bonds may link all the nucleotide bases. Phosphorothioate antisense oligonucleotides do not normally show significant toxicity at concentrations that are effective and exhibit sufficient pharmacodynamic half-lives in animals (see Agarwal et al., (1996) *TIBTECH*, 14: 376) and are nuclease resistant. Alternatively the nuclease resistance for the AS-ODN can be provided by having a 9 nucleotide loop forming sequence at the 3'-terminus having the nucleotide sequence CGCGAAGCG. The use of avidin-biotin conjugation reaction can also be used for improved protection of AS-ODNs against serum nuclease degradation (see Boado and Pardridge (1992) *Bioconi. Chem.*, 3: 519-23). According to this concept the AS-ODN agents are monobiotinylated at their 3'-end. When reacted with avidin, they form tight, nuclease-resistant complexes with 6-fold improved stability over non-conjugated ODNs.

[0169] Other studies have shown extension *in vivo* of antisense oligodeoxynucleotides (Agarwal et al., (1991) *Proc. Natl. Acad. Sci. (USA)* 88: 7595). This process, presumably useful as a scavenging mechanism to remove alien AS-oligonucleotides from the circulation, depends upon the existence of free 3'-termini in the attached oligonucleotides on which the extension occurs. Therefore partial phosphorothioate, loop protection or biotin-avidin at this important position should be sufficient to ensure stability of these AS-oligodeoxynucleotides.

[0170] In addition to using modified bases as described above, analogs of nucleotides can be prepared wherein the structure of the nucleotide is fundamentally altered and that are better suited as therapeutic or experimental reagents. An example of a nucleotide analog is a peptide nucleic acid (PNA) wherein the deoxyribose (or ribose) phosphate backbone in DNA (or RNA) is replaced with a polyamide backbone, which is similar to that found in peptides. PNA analogs have been shown to be resistant to degradation by enzymes and to have extended lives *in vivo* and *in vitro*.

Further, PNAs have been shown to bind stronger to a complementary DNA sequence than a DNA molecule. This observation is attributed to the lack of charge repulsion between the PNA strand and the DNA strand. Other modifications that can be made to oligonucleotides include polymer backbones, morpholino polymer backbones (see, e.g., U.S. Patent No. 5,034,506, the contents of which are incorporated herein by reference), cyclic backbones, or acyclic backbones, sugar mimetics or any other modification including which can improve the pharmacodynamics properties of the oligonucleotide.

[0171] A further aspect of the invention relates to the use of DNA enzymes to decrease expression of the target mRNA as, e.g., PDGF or VEGF. DNA enzymes incorporate some of the mechanistic features of both antisense and ribozyme technologies. DNA enzymes are designed so that they recognize a particular target nucleic acid sequence, much like an antisense oligonucleotide, however much like a ribozyme they are catalytic and specifically cleave the target nucleic acid.

[0172] There are currently two basic types of DNA enzymes, and both of these were identified by Santoro and Joyce (see, for example, U.S. Patent No. 6,110,462). The 10-23 DNA enzyme comprises a loop structure which connects two arms. The two arms provide specificity by recognizing the particular target nucleic acid sequence while the loop structure provides catalytic function under physiological conditions.

[0173] Briefly, to design a DNA enzyme that specifically recognizes and cleaves a target nucleic acid, one of skill in the art must first identify the unique target sequence. This can be done using the same approach as outlined for antisense oligonucleotides. In certain instances, the unique or substantially sequence is a G/C rich of approximately 18 to 22 nucleotides. High G/C content helps insure a stronger interaction between the DNA enzyme and the target sequence.

[0174] When synthesizing the DNA enzyme, the specific antisense recognition sequence that targets the enzyme to the message is divided so that it comprises the two arms of the DNA enzyme, and the DNA enzyme loop is placed between the two specific arms.

[0175] Methods of making and administering DNA enzymes can be found, for example, in U.S. 6110462. Similarly, methods of delivery of DNA ribozymes *in vitro* or *in vivo* include methods of delivery of RNA ribozymes, as outlined herein. Additionally, one of skill in the art will recognize that, like antisense oligonucleotides, DNA enzymes can be optionally modified to improve stability and improve resistance to degradation.

RNAi antagonists

[0176] Some embodiments of the invention make use of materials and methods for effecting repression of VEGF and PDGF by means of RNA interference (RNAi). RNAi is a process of sequence-specific post-transcriptional gene repression that can occur in eukaryotic cells. In general, this process involves degradation of an mRNA of a particular sequence induced by double-stranded RNA (dsRNA) that is homologous to that sequence. For example, the expression of a long dsRNA corresponding to the sequence of a particular single-stranded mRNA (ss mRNA) will inactivate that message, thereby "interfering" with expression of the corresponding gene. Accordingly, any selected gene may be repressed by introducing a dsRNA which corresponds to all or a substantial part of the mRNA for that gene. It appears that when a long dsRNA is expressed, it is initially processed by a ribonuclease III into shorter dsRNA oligonucleotides of as few as 21 to 22 base pairs in length. Accordingly, RNAi may be effected by introduction or expression of relatively short homologous dsRNAs. Indeed the use of relatively short homologous dsRNAs may have certain advantages as discussed below.

[0177] Mammalian cells have at least two pathways that are affected by double-stranded RNA (dsRNA). In the RNAi (sequence-specific) pathway, the initiating dsRNA is first broken into short interfering (si) RNAs, as described above. The siRNAs have sense and antisense strands of about 21 nucleotides that form approximately 19 nucleotide siRNAs with overhangs of two nucleotides at each 3' end. Short interfering RNAs are thought to provide the sequence information that allows a specific messenger RNA to be targeted for degradation. In contrast, the nonspecific pathway is triggered by dsRNA of any sequence, as long as it is at least about 30 base pairs in length. The nonspecific effects occur because dsRNA activates two enzymes: PKR (double-stranded RNA-activated protein kinase), which in its active form phosphorylates the translation initiation factor eIF2 to shut down all protein synthesis, and 2', 5' oligoadenylate synthetase (2', 5'-AS), which synthesizes a molecule that activates RNase L, a nonspecific enzyme that targets all mRNAs. The nonspecific pathway may represent a host response to stress or viral infection, and, in general, the effects of the nonspecific pathway are minimized in particularly useful methods of the present invention. Significantly, longer dsRNAs appear to be required to induce the nonspecific pathway and, accordingly, dsRNAs shorter than about 30 base pairs are particularly useful to effect gene repression by RNAi (see, e.g., Hunter et al., (1975) J. Biol. Chem., 250: 409-17; Manche et al., (1992) Mol. Cell Biol., 12: 5239-48; Minks et al., (1979) J. Biol. Chem., 254: 10180-3; and Elbashir et al., (2001) Nature, 411: 494-8).

[0178] Certain double stranded oligonucleotides used to effect RNAi are less than 30 base pairs in length and may comprise about 25, 24, 23, 22, 21, 20, 19, 18 or 17 base pairs of ribonucleic acid. Optionally, the dsRNA oligonucleotides of the invention may include 3' overhang ends. Non-limiting exemplary 2-nucleotide 3' overhangs may be composed of ribonucleotide residues of any type and may even be composed of 2'-deoxythymidine residues, which lowers the cost of

RNA synthesis and may enhance nuclease resistance of siRNAs in the cell culture medium and within transfected cells (see Elbashi et al., (2001) Nature, 411: 494-8).

[0179] Longer dsRNAs of 50, 75, 100 or even 500 base pairs or more may also be utilized in certain embodiments of the invention. Exemplary concentrations of dsRNAs for effecting RNAi are about 0.05 nM, 0.1 nM, 0.5 nM, 1.0 nM, 1.5 nM, 25 nM or 100 nM, although other concentrations may be utilized depending upon the nature of the cells treated, the gene target and other factors readily discernable to the skilled artisan. Exemplary dsRNAs may be synthesized chemically or produced *in vitro* or *in vivo* using appropriate expression vectors. Exemplary synthetic RNAs include 21 nucleotide RNAs chemically synthesized using methods known in the art (e.g., Expedite RNA phosphoramidites and thymidine phosphoramidite (Proligo, Germany)). Synthetic oligonucleotides may be deprotected and gel-purified using methods known in the art (see e.g., Elbashir et al., (2001) Genes Dev., 15: 188-200). Longer RNAs may be transcribed from promoters, such as T7 RNA polymerase promoters, known in the art. A single RNA target, placed in both possible orientations downstream of an *in vitro* promoter, will transcribe both strands of the target to create a dsRNA oligonucleotide of the desired target sequence.

[0180] The specific sequence utilized in design of the oligonucleotides may be any contiguous sequence of nucleotides contained within the expressed gene message of the target (e.g., of PDGF (e.g., SEQ ID NO:2) or VEGF (e.g., SEQ ID NO: 4). Programs and algorithms, known in the art, may be used to select appropriate target sequences. In addition, optimal sequences may be selected, as described additionally above, utilizing programs designed to predict the secondary structure of a specified single stranded nucleic acid sequence and allow selection of those sequences likely to occur in exposed single stranded regions of a folded mRNA. Methods and compositions for designing appropriate oligonucleotides may be found in, for example, U.S. Patent No. 6,251,588, the contents of which are incorporated herein by reference. mRNA is generally thought of as a linear molecule that contains the information for directing protein synthesis within the sequence of ribonucleotides. However, studies have revealed a number of secondary and tertiary structures exist in most mRNAs. Secondary structure elements in RNA are formed largely by Watson-Crick type interactions between different regions of the same RNA molecule. Important secondary structural elements include intramolecular double stranded regions, hairpin loops, bulges in duplex RNA and internal loops. Tertiary structural elements are formed when secondary structural elements come in contact with each other or with single stranded regions to produce a more complex three-dimensional structure. A number of researchers have measured the binding energies of a large number of RNA duplex structures and have derived a set of rules which can be used to predict the secondary structure of RNA (see e.g., Jaeger et al., (1989) Proc. Natl. Acad. Sci. (USA) 86:7706 (1989); and Turner et al., (1988) Ann. Rev. Biophys. Biophys. Chem., 17:167). The rules are useful in identification of RNA structural elements and, in particular, for identifying single stranded RNA regions, which may represent particularly useful segments of the mRNA to target for silencing RNAi, ribozyme or antisense technologies. Accordingly, particular segments of the mRNA target can be identified for design of the RNAi mediating dsRNA oligonucleotides as well as for design of appropriate ribozyme and hammerhead-ribozyme compositions of the invention.

[0181] The dsRNA oligonucleotides may be introduced into the cell by transfection with an heterologous target gene using carrier compositions such as liposomes, which are known in the art, e.g., Lipofectamine 2000 (Life Technologies, Rockville MD) as described by the manufacturer for adherent cell lines. Transfection of dsRNA oligonucleotides for targeting endogenous genes may be carried out using Oligofectamine (Life Technologies). Transfection efficiency may be checked using fluorescence microscopy for mammalian cell lines after co-transfection of hGFP encoding pAD3 (Kehlenback et al., (1998) J. Cell. Biol., 141: 863-74). The effectiveness of the RNAi may be assessed by any of a number of assays following introduction of the dsRNAs. These include, but are not limited to, Western blot analysis using antibodies which recognize the targeted gene product following sufficient time for turnover of the endogenous pool after new protein synthesis is repressed, and Northern blot analysis to determine the level of existing target mRNA.

[0182] Still further compositions, methods and applications of RNAi technology for use in the invention are provided in U.S. Patent Nos. 6,278,039, 5,723,750 and 5,244,805, which are incorporated herein by reference.

Receptor Tyrosine Kinase Inhibitor Antagonists

[0183] Also included in the invention are tyrosine kinase antagonists known in the art and variants and alternatives thereto that may be obtained using routine skill in the art and the teachings of the art incorporated herein by reference. The extracellular signal of PDGF (and VEGF) is communicated to other parts of the cell via a tyrosine kinase mediated phosphorylation event effected by the PDGF receptor (and VEGF receptor) and which affects substrate proteins downstream of the cell membrane bound signaling complex. Accordingly, antagonists acting at the receptor kinase stage of PDGF (and/or VEGF) signaling are also effective in the method of the invention.

[0184] A number of types of tyrosine kinase inhibitors that are selective for tyrosine kinase receptor enzymes such as PDGFR or VEGFR, are known (see, e.g., Spada and Myers ((1995) Exp. Opin. Ther. Patents, 5: 805) and Bridges ((1995) Exp. Opin. Ther. Patents, 5: 1245). Additionally Law and Lydon have summarized the anticancer potential of tyrosine kinase inhibitors ((1996) Emerging Drugs: The Prospect For Improved Medicines, 241-260). For example, U.S.

Patent No. 6,528,526 describes substituted quinoxaline compounds that exhibit selectively inhibit platelet-derived growth factor-receptor (PDGFR) tyrosine kinase activity. The known inhibitors of PDGFR tyrosine kinase activity includes quinoxaline-based inhibitors reported by Maguire et al., ((1994) J. Med. Chem., 37: 2129), and by Dolle, et al., ((1994) J. Med. Chem., 37: 2627). A class of phenylamino-pyrimidine-based inhibitors was recently reported by Traxler, et al., in EP 564409 and by Zimmerman et al., ((1996) Biorg. Med. Chem. Lett., 6: 1221-1226) and by Buchdunger, et al., ((1995) Proc. Nat. Acad. Sci. (USA), 92: 2558). Quinoxaline derivatives that are useful in inhibiting PDGF receptor tyrosine kinase activity include bismono- and bicyclic aryl compounds and heteroaryl compounds (see, e.g., WO 92/20642), quinoxaline derivatives (see (1994) Cancer Res., 54: 6106-6114), pyrimidine derivatives (Japanese Published Patent Application No. 87834/94) and dimethoxyquinoxaline derivatives (see Abstracts of the 116th Annual Meeting of the Pharmaceutical Society of Japan (Kanazawa), (1996), 2, p. 275, 29(C2) 15-2).

[0185] Examples of VEGFR tyrosine kinase inhibitors include cinnoline derivatives, e.g., those described in U.S. Patent No. 6,514,971, the contents of which are incorporated herein in their entirety. Other such cinnoline derivatives are also known. For example, (1995) J. Med. Chem., 38: 3482-7 discloses 4-(3-bromoanilino)cinnoline; (1968) J. Chem. Soc. C, (9):1152-5 discloses 6-chloro-4-phenoxy-cinnoline; (1984) J. Karnatak Univ., Sci., 29: 82-6 discloses certain 4-anilinocinnolines; and (1973) Indian J. Chem., 11: 211-13 discloses certain 4-phenylthiocinnolines. Furthermore, (1973) J. Karnatak Univ., 18: 25-30 discloses certain 4-phenoxy-cinnolines, (1984) J. Karnatak Univ., Sci., 29: 82-6 discloses two compounds: 4-(4-methoxyanilino)-6,7-dimethoxycinnoline and 4-(3-chloroanilino)-6,7-dimethoxycinnoline. Furthermore, certain cinnolines with a phenyl ring linked via a group selected from -O-, -S-, -NH- and -CH₂- at the 4-position are described in U.S. Patent No. 5,017,579, U.S. Patent No. 4,957,925, U.S. Patent No. 4,994,474, and EP 0302793 A2.

[0186] Still other related compounds for inhibition of VEGFR and/or PDGFR are available by screening novel compounds for their effect on the receptor tyrosine kinase activity of interest using a convention assay. Effective inhibition by a candidate PDGFR or VEGFR small molecule organic inhibitor can be monitored using a cell-based assay system as well as other assay systems known in the art.

[0187] For example, one test for activity against VEGF-receptor tyrosine kinase is as follows. The test is conducted using Flt-1 VEGF-receptor tyrosine kinase. The detailed procedure is as follows: 30 µl kinase solution (10 ng of the kinase domain of Flt-1 (see Shibuya, et al., (1990) Oncogene, 5: 519-24) in 20 mM Tris.HCl pH 7.5, 3 mM manganese dichloride (MnCl₂), 3 mM magnesium chloride (MgCl₂), 10 uM sodium vanadate, 0.25 mg/ml polyethylenglycol (PEG) 20000, 1 mM dithiothreitol and 3 µg/µl poly(Glu,Tyr) 4:1 (Sigma, Buchs, Switzerland), 8 uM [³³P]-ATP (0.2 uCi), 1% dimethyl sulfoxide, and 0 to 100 µM of the compound to be tested are incubated together for 10 minutes at room temperature. The reaction is then terminated by the addition of 10 µl 0.25 M ethylenediaminetetraacetate (EDTA) pH 7. Using a multichannel dispenser (LAB SYSTEMS, USA), an aliquot of 20 µl is applied to a PVDF (=polyvinyl difluoride) Immobilon P membrane (Millipore, USA), through a microtiter filter manifold and connected to a vacuum. Following complete elimination of the liquid, the membrane is washed 4 times successively in a bath containing 0.5% phosphoric acid (H₃PO₄) and once with ethanol, incubated for 10 minutes each time while shaking, then mounted in a Hewlett Packard TopCount Manifold and the radioactivity measured after the addition of 10 µl Microscint.RTM. (beta-scintillation counter liquid). IC₅₀ -values are determined by linear regression analysis of the percentages for the inhibition of each compound in three concentrations (as a rule 0.01 µmol, 0.1 µmol, and 1 µmol). The IC₅₀ -values of active tyrosine inhibitor compounds may be in the range of 0.01 µM to 100 µM.

[0188] Furthermore, inhibition of a VEGF-induced VEGFR tyrosine kinase/ autophosphorylation activity can be confirmed with a further experiment on cells. Briefly, transfected CHO cells, which permanently express human VEGF receptor (VEGFR/KDR), are seeded in complete culture medium (with 10% fetal calf serum (FCS) in 6-well cell-culture plates and incubated at 37°C. under 5% CO₂ until they show about 80% confluency. The compounds to be tested are diluted in culture medium (without FCS, with 0.1% bovine serum albumin) and added to the cells (Controls comprise medium without test compounds). After a two hour incubation at 37°C, recombinant VEGF is added; the final VEGF concentration is 20 ng/ml). After a further five minutes incubation at 37°C, the cells are washed twice with ice-cold PBS) and immediately lysed in 100 µl lysis buffer per well. The lysates are then centrifuged to remove the cell nuclei, and the protein concentrations of the supernatants are determined using a commercial protein assay (BIORAD). The lysates can then either be immediately used or, if necessary, stored at -200 °C.

[0189] A sandwich ELISA is then carried out to measure the KDR-receptor phosphorylation: a monoclonal antibody to KDR is immobilized on black ELISA plates (OptiPlate™, HTRF-96 from Packard). The plates are then washed and the remaining free protein-binding sites are saturated with 1% BSA in PBS. The cell lysates (20 µg protein per well) are then incubated in these plates overnight at 4°C. together with an antiphosphotyrosine antibody coupled with alkaline phosphatase (e.g., PY20:AP from Transduction Laboratories, Lexington, KY). The plates are washed again and the binding of the antiphosphotyrosine antibody to the captured phosphorylated receptor is then demonstrated using a luminescent AP substrate (CDP-Star, ready to use, with Emerald II; Applied-Biosystems TROPIX Bedford, MA). The luminescence is measured in a Packard Top Count Microplate Scintillation Counter. The difference between the signal of the positive control (stimulated with VEGF or PDGF) and that of the negative control (not stimulated with VEGF or PDGF) corresponds to VEGF-induced KDR-receptor phosphorylation (=100%). The activity of the tested substances is

calculated as % inhibition of VEGF-induced KDR-receptor phosphorylation, wherein the concentration of substance that induces half the maximum inhibition is defined as the ED₅₀ (effective dose for 50% inhibition). Active tyrosine inhibitor compound have ED₅₀ values in the range of 0.001 μ M to 6 μ M, typically 0.005 μ M to 0.5 μ M.

5 Pharmaceutical Formulations and Therapeutic Administration

[0190] The anti-VEGF and anti-PDGF agents are useful in the treatment of a neovascular disorder, including psoriasis, rheumatoid arthritis, and ocular neovascular disorders. Of particular interest are therapies using a PDGF-B antagonist compound in combination with a VEGF-A antagonist to suppress an ocular neovascular disorder such as macular degeneration or diabetic retinopathy. Accordingly, once a patient has been diagnosed to be at risk at developing or having a neovascular disorder, the patient is treated by administration of a PDGF antagonist in combination with a VEGF antagonist in order to block respectively the negative effects of PDGF and VEGF, thereby suppressing the development of a neovascular disorder and alleviating deleterious effects associated with neovascularization. The practice of the methods according to the present invention does not result in corneal edema. As is discussed above, a wide variety of PDGF and VEGF antagonists may be used in the present invention.

[0191] Anti-PDGF and anti-VEGF combination therapy according to the invention may be performed alone or in conjunction with another therapy and may be provided at home, the doctor's office, a clinic, a hospital's outpatient department, or a hospital. Treatment generally begins at a hospital so that the doctor can observe the therapy's effects closely and make any adjustments that are needed. The duration of the combination therapy depends on the type of neovascular disorder being treated, the age and condition of the patient, the stage and type of the patient's disease, and how the patient responds to the treatment. Additionally, a person having a greater risk of developing a neovascular disorder (e.g., a diabetic patient) may receive treatment to inhibit or delay the onset of symptoms. One significant advantage provided by the present invention is that the combination of a PDGF antagonist and a VEGF antagonist for the treatment of a neovascular disorder allows for the administration of a low dose of each antagonist and less total active antagonist, thus providing similar efficacy with less toxicity and side effects, and reduced costs.

[0192] Administration of each antagonist of the combination therapy may be by any suitable means that results in a concentration of the antagonist that, combined with the other antagonist, is effective for the treatment of a neovascular disorder. Each antagonist, for example, may be admixed with a suitable carrier substance, and is generally present in an amount of 1-95% by weight of the total weight of the composition. The composition may be provided in a dosage form that is suitable for ophthalmic, oral, parenteral (e.g., intravenous, intramuscular, subcutaneous), rectal, transdermal, nasal, or inhalant administration. Accordingly, the composition may be in form of, e.g., tablets, capsules, pills, powders, granulates, suspensions, emulsions, solutions, gels including hydrogels, pastes, ointments, creams, plasters, delivery devices, suppositories, enemas, injectables, implants, sprays, or aerosols. The pharmaceutical compositions containing a single antagonist or two or more antagonists may be formulated according to conventional pharmaceutical practice (see, e.g., Remington: The Science and Practice of Pharmacy, (20th ed.) ed. A.R Gennaro, 2000, Lippincott Williams & Wilkins, Philadelphia, PA. and Encyclopedia of Pharmaceutical Technology, eds., J. Swarbrick and J. C. Boylan, 1988-2002, Marcel Dekker, New York).

[0193] Combinations of PDGF and VEGF antagonists are, in one useful aspect, administered parenterally (e.g., by intramuscular, intraperitoneal, intravenous, intraocular, intravitreal, retro-bulbar, subconjunctival, subtenon or subcutaneous injection or implant) or systemically. Formulations for parenteral or systemic administration include sterile aqueous or non-aqueous solutions, suspensions, or emulsions. A variety of aqueous carriers can be used, e.g., water, buffered water, saline, and the like. Examples of other suitable vehicles include polypropylene glycol, polyethylene glycol, vegetable oils, gelatin, hydrogels, hydrogenated naphthalenes, and injectable organic esters, such as ethyl oleate. Such formulations may also contain auxiliary substances, such as preserving, wetting, buttering, emulsifying, and/or dispersing agents. Biocompatible, biodegradable lactide polymer, lactide/glycolide copolymer, or polyoxyethylene-polyoxypropylene copolymers may be used to control the release of the active ingredients.

[0194] Alternatively, combinations of PDGF and VEGF antagonists can be administered by oral ingestion. Compositions intended for oral use can be prepared in solid or liquid forms, according to any method known to the art for the manufacture of pharmaceutical compositions.

[0195] Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. Generally, these pharmaceutical preparations contain active ingredients (such as a PDGF small organic molecule antagonist and a VEGF small organic molecule antagonist) admixed with non-toxic pharmaceutically acceptable excipients. These may include, for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, sucrose, glucose, mannitol, cellulose, starch, calcium phosphate, sodium phosphate, kaolin and the like. Binding agents, buffering agents, and/or lubricating agents (e.g., magnesium stearate) may also be used. Tablets and pills can additionally be prepared with enteric coatings. The compositions may optionally contain sweetening, flavoring, coloring, perfuming, and preserving agents in order to provide a more palatable preparation.

[0196] For example, the PDGF and VEGF antagonists may be administer intraocullary by intravitreal injection into the

eye as well as subconjunctival and subtenon injections. Other routes of administration include transcleral, retro bulbar, intraperitoneal, intramuscular, and intravenous. Alternatively, a combination of antagonists may be delivered using a drug delivery device or an intraocular implant (see below).

[0197] Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, and soft gelatin capsules. These forms contain inert diluents commonly used in the art, such as water or an oil medium, and can also include adjuvants, such as wetting agents, emulsifying agents, and suspending agents.

[0198] In some instances, the combination of PDGF and VEGF antagonists can also be administered topically, for example, by patch or by direct application to a region, such as the epidermis or the eye, susceptible to or affected by a neovascular disorder, or by iontophoresis.

[0199] Formulations for ophthalmic use include tablets containing the active ingredient(s) in a mixture with non-toxic pharmaceutically acceptable excipients. These excipients may be, for example, inert diluents or fillers (e.g., sucrose and sorbitol), lubricating agents, glidants, and antiadhesives (e.g., magnesium stearate, zinc stearate, stearic acid, silicas, hydrogenated vegetable oils, or talc).

[0200] The PDGF and VEGF antagonists may be mixed together in a tablet or other vehicle, or may be partitioned. In one example, the first antagonist is contained on the inside of the tablet, and the second antagonist is on the outside, such that a substantial portion of the second antagonist is released prior to the release of the first antagonist. If desired, antagonists in a tablet form may be delivered using a drug delivery device (see below).

[0201] Generally, each of the antagonists should be administered in an amount sufficient to suppress or reduce or eliminate a deleterious effect or a symptom of a neovascular disorder. The amount of an active antagonist ingredient that is combined with the carrier materials to produce a single dosage will vary depending upon the subject being treated and the particular mode of administration.

[0202] The dosage of each antagonist of the claimed combinations depends on several factors including the severity of the condition, whether the condition is to be treated or prevented, and the age, weight, and health of the person to be treated. Additionally, pharmacogenomic (the effect of genotype on the pharmacokinetic, pharmacodynamic or efficacy profile of a therapeutic) information about a particular patient may affect dosage used. Furthermore, one skilled in the art will appreciate that the exact individual dosages may be adjusted somewhat depending on a variety of factors, including the specific combination of PDGF and VEGF antagonists being administered, the time of administration, the route of administration, the nature of the formulation, the rate of excretion, the particular neovascular disorder being treated, the severity of the disorder, and the anatomical location of the neovascular disorder (for example, the eye versus the body cavity). Wide variations in the needed dosage are to be expected in view of the differing efficiencies of the various routes of administration. For instance, oral administration generally would be expected to require higher dosage levels than administration by intravenous or intravitreal injection. Variations in these dosage levels can be adjusted using standard empirical routines for optimization, which are well-known in the art. The precise therapeutically effective dosage levels and patterns are typically determined by the attending physician such as an ophthalmologist in consideration of the above-identified factors.

[0203] Generally, when orally administered to a human, the dosage of the PDGF antagonist or VEGF antagonist is normally about 0.001 mg to about 200 mg per day, desirably about 1 mg to 100 mg per day, and more desirably about 5 mg to about 50 mg per day. Dosages up to about 200 mg per day may be necessary. For administration of the PDGF antagonist or VEGF antagonist by injection, the dosage is normally about 0.1 mg to about 250 mg per day, desirably about 1 mg to about 20 mg per day, or about 3 mg to about 5 mg per day. Injections may be given up to about four times daily. Generally, when parenterally or systemically administered to a human, the dosage of the VEGF antagonist for use in combination with the PDGF antagonist is normally about 0.1 mg to about 1500 mg per day, or about 0.5 mg to 10 about mg per day, or about 0.5 mg to about 5 mg per day. Dosages up to about 3000 mg per day may be necessary.

[0204] When ophthalmologically administered to a human, the dosage of the VEGF antagonist for use in combination with the PDGF antagonist is normally about 0.15 mg to about 3.0 mg per day, or at about 0.3 mg to about 3.0 mg per day, or at about 0.1 mg to 1.0 mg per day.

[0205] For example, for ophthalmic uses, PDGF-B and VEGF-A aptamer drug substances are formulated in phosphate buffered saline at pH 5-7. Sodium hydroxide or hydrochloric acid may be added for pH adjustment. In one working formulation, a PDGF-B aptamer and a VEGF-A aptamer, such as EYE001, are individually formulated at three different concentrations: 3 mg/100 μ l, 2 mg/100 μ l and 1 mg/100 μ l packaged in a sterile 1ml, USP Type I graduated glass syringe fitted with a sterile 27-gauge needle. The combination drug product is preservative-free and intended for single use by intravitreal injection only. The active ingredient is PDGF-B and VEGF-A drug substances, at 30 mg/ml, 20 mg/ml and 10 mg/ml concentrations. The excipients are Sodium Chloride, USP; Sodium Phosphate Monobasic, Monohydrate, USP; Sodium Phosphate Dibasic, Heptahydrate, USP; Sodium Hydroxide, USP; Hydrochloric acid, USP; and Water for injection, USP. In this form the PDGF-B and VEGF-A aptamer drug products are in a ready-to-use sterile solution provided in a single-use glass syringe. The syringe is removed from refrigerated storage at least 30 minutes (but not longer than 4 hours) prior to use to allow the solution to reach room temperature. Administration of the syringe contents involves attaching the threaded plastic plunger rod to the rubber stopper inside the barrel of the syringe. The rubber end cap is

then removed to allow administration of the product. PDGF-B and VEGF-A aptamers are administered as a 100 μ l intravitreal injections on three occasions at 28 day intervals. Patients receive 3 mg/injection per visit. The dose is reduced to 2 mg or 1 mg, and further to 0.1 mg if necessary.

[0206] The specific amounts of drugs administered depend on the specific combination of components. In a desired dose combination, the ratio of PDGF antagonist to VEGF antagonist is about 50:1 by weight, about 20:1 by weight, about 10:1 by weight, or about 4:1, about 2:1, or about 1:1 by weight

[0207] A useful combination therapy includes a PDGF-B aptamer antagonist and a VEGF-A aptamer antagonist. The antagonists are used in combination in a weight ratio range from about 0.1 to about 5.0 to about 5.0 to 0.1 of the PDGF-B aptamer antagonist to VEGF-A aptamer antagonist. A useful range of these two antagonists (PDGF-B to VEGF-A antagonist) is from about 0.5 to about 2.0, or from about 2.0 to 0.5, while another useful ratio is from about 1.0 to about 1.0, depending ultimately on the selection of the PDGF-B aptamer antagonist and the VEGF-A aptamer antagonist.

[0208] Administration of each drug in the combination therapy can, independently, be one to four times daily for one day to one year, and may even be for the life of the patient. Chronic, long-term administration will be indicated in many cases. The dosage may be administered as a single dose or divided into multiple doses. In general, the desired dosage should be administered at set intervals for a prolonged period, usually at least over several weeks, although longer periods of administration of several months or more may be needed.

[0209] In addition to treating pre-existing neovascular disorders, the combination therapy that includes a PDGF antagonist and VEGF antagonist can be administered prophylactically in order to prevent or slow the onset of these disorders. In prophylactic applications, the PDGF and VEGF antagonists are administered to a patient susceptible to or otherwise at risk of a particular neovascular disorder. Again, the precise timing of the administration and amounts that are administered depend on various factors such as the patient's state of health, weight, etc.

[0210] In one working example, the combination of the PDGF antagonist and the VEGF antagonist is administered to a mammal in need of treatment therewith, typically in the form of an injectable pharmaceutical composition. In the combination aspect, for example, a PDGF-B aptamer and a VEGF-A aptamer may be administered either separately or in the pharmaceutical composition comprising both. It is generally preferred that such administration be by injection or by using a drug delivery device. Parenteral, systemic, or transdermal administration is also acceptable.

[0211] As discussed above, when the PDGF antagonist and VEGF antagonist are administered together, such administration can be sequential in time or simultaneous with the sequential method being one mode of administration. When the PDGF and VEGF antagonists are administered sequentially, the administration of each can be by the same or different methods. For sequential administration, however, it is useful that the method employ administration of the PDGF antagonist over about five seconds (up to about three injections) followed by sustained administration every six weeks for up to about nine injections per year of a VEGF antagonist. The PDGF antagonist may be administered at the time of each VEGF antagonist injection or may be given less often, as determined by the physician. Sequential administration also includes a combination where the individual antagonists may be administered at different times or by different routes or both but which act in combination to provide a beneficial effect, for example, to suppress a neovascular disorder. It is also noted that administration by injection is particularly useful.

[0212] Pharmaceutical compositions according to the invention may be formulated to release the active PDGF and VEGF antagonists substantially immediately upon administration or at any predetermined time period after administration, using controlled release formulations. For example, a pharmaceutical composition that includes at least one of each of a PDGF antagonist and a VEGF antagonist may be provided in sustained release compositions. The use of immediate or sustained release compositions depends on the nature of the condition being treated. If the condition consists of an acute or over-acute disorder, treatment with an immediate release form will be typically utilized over a prolonged release composition. For certain preventative or long-term treatments, a sustained released composition may also be appropriate.

[0213] Administration of each of the antagonists in controlled release formulations is useful where the antagonist, either alone or in combination, has (i) a narrow therapeutic index (e.g., the difference between the plasma concentration leading to harmful side effects or toxic reactions and the plasma concentration leading to a therapeutic effect is small; generally, the therapeutic index, TI, is defined as the ratio of median lethal dose (LD_{50}) to median effective dose (ED_{50})); (ii) a narrow absorption window in the gastro-intestinal tract; or (iii) a short biological half-life, so that frequent dosing during a day is required in order to sustain the plasma level at a therapeutic level.

[0214] Many strategies can be pursued to obtain controlled release in which the rate of release outweighs the rate of degradation or metabolism of the therapeutic antagonist. For example, controlled release can be obtained by the appropriate selection of formulation parameters and ingredients, including, e.g., appropriate controlled release compositions and coatings. Examples include single or multiple unit tablet or capsule compositions, oil solutions, suspensions, emulsions, microcapsules, microspheres, nanoparticles, patches, and liposomes. Methods for preparing such sustained or controlled release formulations are well known in the art.

[0215] Pharmaceutical compositions that include a PDGF antagonist and/or a VEGF antagonist or both may also be delivered using a drug delivery device such as an implant. Such implants may be biodegradable and/or biocompatible implants, or may be non-biodegradable implants. The implants may be permeable or impermeable to the active agent.

Ophthalmic drug delivery devices may be inserted into a chamber of the eye, such as the anterior or posterior chambers or may be implanted in or on the sclera, choroidal space, or an avascularized region exterior to the vitreous. In one embodiment, the implant may be positioned over an avascular region, such as on the sclera, so as to allow for transcleral diffusion of the drug to the desired site of treatment, e.g., the intraocular space and macula of the eye. Furthermore, the site of transcleral diffusion may be proximity to a site of neovascularization such as a site proximal to the macula.

[0216] As noted above, the invention relates to combining separate pharmaceutical compositions in a pharmaceutical pack. The combination of the invention is therefore provided as components of a pharmaceutical pack. At least two antagonists can be formulated together or separately and in individual dosage amounts. The antagonists of the invention are also useful when formulated as salts.

[0217] The pharmaceutical pack, in general, includes (1) an amount of a PDGF antagonist, and a pharmaceutically acceptable carrier, vehicle, or diluent in a first unit dosage form; (2) an amount of a VEGF antagonist, and a pharmaceutically acceptable carrier, vehicle, or diluent in a second unit dosage form; and (3) a container. The container is used to separate components and may include, for example, a divided bottle or a divided foil packet. The separate antagonist compositions may also, if desired, be contained within a single, undivided container. The pharmaceutical pack may also include directions for the administration of the separate PDGF and VEGF antagonists. The pharmaceutical pack is particularly advantageous when the separate components are administered in different dosage forms, are administered at different dosage levels, or when titration of the individual components of the combination is desired by the prescribing physician. In one embodiment, the pharmaceutical pack is designed to dispense doses of the PDGF and VEGF antagonists one at a time in the order of their intended use. In another example, a pharmaceutical pack is designed to contain rows of a PDGF antagonist and a VEGF antagonist placed side by side in the pack, with instructions on the pack to convey to the user that one pair of antagonists is to be administered. An exemplary pharmaceutical pack is the so-called blister pack that is well known in the pharmaceutical packaging industry.

Effectiveness

[0218] Suppression of a neovascular disorder is evaluated by any accepted method of measuring whether angiogenesis is slowed or diminished. This includes direct observation and indirect evaluation such as by evaluating subjective symptoms or objective physiological indicators. Treatment efficacy, for example, may be evaluated based on the prevention or reversal of neovascularization, microangiopathy, vascular leakage or vascular edema or any combination thereof. Treatment efficacy for evaluating suppression of an ocular neovascular disorder may also be defined in terms of stabilizing or improving visual acuity.

[0219] In determining the effectiveness of a particular combination therapy in treating or preventing an ocular neovascular disorder, patients may also be clinically evaluated by an ophthalmologist several days after injection and at least one-month later just prior to the next injection. ETDRS visual acuities, kodachrome photography, and fluorescein angiography are also performed monthly for the first 4 months as required by the ophthalmologist.

[0220] For example, in order to assess the effectiveness of combination PDGF antagonist and VEGF antagonist therapy to treat ocular neovascularization, studies are conducted involving the administration of either single or multiple intravitreal injections of a PDGF-B aptamer in combination with a VEGF-A aptamer (for example, a PEGylated form of EYE001) in patients suffering from subfoveal choroidal neovascularization secondary to age-related macular degeneration according to standard methods well known in the ophthalmologic arts. In one working study, patients with subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) receive a single intravitreal injection of a PDGF-B aptamer and a VEGF-A aptamer. Effectiveness of the combination is monitored, for example, by ophthalmic evaluation. Patients showing stable or improved vision three months after treatment, for example, demonstrating a 3-line or greater improvement in vision on the ETDRS chart, are taken as receiving an effective dosage combination of the PDGF-B aptamer and VEGF-A aptamer that suppresses an ocular neovascular disorder.

[0221] In a working study example, patients with subfoveal CNV secondary to age-related macular degeneration and with a visual acuity worse than 20/200 on the ETDRS chart receive a single intravitreal injection of the PDGF-B aptamer and VEGF-A aptamer. The starting dose is 0.25 mg of each antagonist injected once intravitreally. Dosages of 0.5 mg, 1.2 mg and 3 mg of each antagonist are also tested. Complete ophthalmic examination with fundus photography and fluorescein angiography is also performed. The combination drug product is a ready-to-use sterile solution composed of the PDGF-B aptamer and VEGF-A aptamer dissolved in 10 mM sodium phosphate and 0.9% sodium chloride buffer injection in a sterile and pyrogen free 1 cc glass body syringe barrel, with a coated stopper attached to a plastic plunger, and a rubber end cap on the pre-attached 27 gauge needle. The PDGF-B and VEGF-A aptamers are supplied at drug concentrations of 1 mg/ml, 2.5 mg/ml, 5 mg/ml, 10 mg/ml, 20 mg/ml, or 30 mg/ml for each aptamer (expressed as oligonucleotide content) to provide a 100 μ l delivery volume. At approximately 3 months after injection of the PDGF-B and VEGF-A aptamers, acuity studies are performed to evaluate effectiveness of the treatment. Patients showing stable or improved vision after treatment, for example, those showing a 3-line, or greater, increase in vision on the ETDRS chart, are taken as receiving an effective dosage combination of PDGF-B and VEGF-A aptamers that suppresses an

ocular neovascular disorder.

EXAMPLES

[0222] The following examples illustrate certain modes of making and practicing the present invention, but are not meant to limit the scope of the invention since alternative methods may be used to obtain similar results.

Example 1: Corneal Neovascularization (Corneal NV)

[0223] Corneal Neovascularization is a widely used animal model that allows clear visualization of abnormal vascular growth in the eye. The vessels that grow into the normally avascular cornea, can become well established, making this an attractive model to study vessel regression. To induce experimental corneal NV, male C57BL/6 mice (18-20 g; Charles River, Wilmington, MA) were anesthetized with intramuscular ketamine hydrochloride (25 mg/kg) and xylazine (10 mg/kg). NaOH (2ul of 0.2 mM) was applied topically. The corneal and limbal epithelia were removed by applying a rotary motion parallel to the limbus using #21 blade (Feather, Osaka, Japan). After 7 days, mice were treated with intra-peritoneal injections of 25 mg/kg of pegaptanib sodium (Macugen™ (Eyetechnopharmaceuticals, New York, NY), an anti-VEGF aptamer agent also known as EYE001) twice a day or by oral administration of 50 mg/kg of Gleevec®/STI57 ((also known as CGP57148B) a 2-phenylaminopyrimidine-related, tyrosine kinase-inhibiting anti-PDGF agent from Novartis Pharma AG, Basel, Switzerland) by gavage twice a day or both for 7 days. At day 14 following corneal NV induction, mice received 20 ug/g of fluorescein-isothiocyanate coupled concanavalin A lectin (Vector Laboratories, Burlingame, CA) intravenously whilst deeply anesthetized with xylazine hydrochloride and ketamine hydrochloride. Thirty minutes later, mice eyes were enucleated, and the corneas flat-mounted. Corneal NV was visualized using fluorescence microscopy and quantified using Openlab software. The percent of cornea covered by vessels was calculated as a percentage of total corneal area.

[0224] The effects of pegaptanib sodium and Gleevec on neovascularization of the cornea following NaOH application and injury to the epithelia of the limbus and cornea were investigated. Animals treated with pegaptanib sodium (Macugen) showed a 19.6% ($p=0.0014$) decrease in vessel growth as compared to both untreated and Gleevec treated eyes (Figure 5). Animals treated with pegaptanib sodium and Gleevec (Mac+Glee) exhibited significantly less neovascular growth on the cornea (35.6% $p<0.0001$) as compared to controls and animals treated with Gleevec alone (Figure 5). Combination treatment was also more effective than pegaptanib sodium (Macugen) alone at reducing vessel growth (16% $p<0.0145$).

[0225] The results of representative corneal neovascularization experiments are also shown in Figures 6 and 7. Figure 6 (D) is a photographic representation of a fluorescent-microscopic image showing effective inhibition of new blood vessel formation in combination (Mac+Gleevec)-treated corneas, as compared to individual treatments with Macugen (Figure 6 (C)) or Gleevec (Figure 6 (B)). Figure 6 (A) is a photographic representation of a fluorescent-microscopic image showing the extent of neovascularization in a control (PEG-treated) cornea. Figure 7 is a photographic representation of a fluorescent-microscopic image showing that the individual (Figure 7(A) (APB5-treated) and Figure 7(B) (Gleevec-treated)) and combined treatments (Figure 7 (C)) inhibited only new vessel growth, and did not affect established blood vessels. Figure 7 (D) is a photographic representation of a fluorescent-microscopic image showing the extent of neovascularization in a control (PEG-treated) cornea.

Example 2: Choroidal Neovascularization (CNV)

[0226] Experimental CNV is often used as a model for Age-related Macular degeneration (AMD). In this model, vessels of the choroid grow through breaks in Bruch's membrane and into the retina, similar to what is observed in AMD patients. To induce experimental CNV, male C57BL/6 mice (18-20 g; Charles River, Wilmington, MA) were anesthetized with intramuscular ketamine hydrochloride (25 mg/kg) and xylazine (10 mg/kg) and the pupils were dilated with 1% tropicamide. Four burns were generated using diode laser photocoagulation (75- μ m spot size, 0.1-second duration, 90mW, Oculight SL laser, IRIDEX, Mountain View, CA) and a hand-held cover slide as a contact lens. Burns localized to the 3, 6, 9 and 12 o'clock positions of the posterior pole of the retina. Production of a bubble at the time of laser, which indicates rupture of Bruch's membrane, is an important factor in obtaining choroidal neovascularization, so only mice in which a bubble was produced for all four burns were included in the study. After 7 days, mice were treated with intraperitoneal injections of 25 mg/kg of pegaptanib sodium twice a day or 50 mg/kg of Gleevec®/STI57 (Novartis Pharma AG, Basel, Switzerland) by gavage twice a day or both for 7 days. In experiments using APB5 (an anti-mouse PDGFR β (CD140b) antibody (anti-PDGF agent) from eBioscience, San Diego, CA), 5 mg/kg of antibody was administered using intra-peritoneal injections of twice a day. The area of choroidal NV lesions was measured in flat-mounted choroid stained with PECAM. Flat-mounts were examined by fluorescence microscopy and quantified using Openlab software.

[0227] Eyes treated with pegaptanib sodium (Macugen™) showed a 24% ($p=0.007$) decrease in CNV area compared to untreated controls (Figure 8). In contrast, APB5-treated eyes were not significantly different to controls (6.5% decrease

in CNV area compared to control). Eyes treated with both pegaptanib sodium and APB5 showed significantly less (46% $p=0.001$) CNV area as compared to control eyes or to eyes treated with either pegaptanib sodium (22% $p=0.011$) or APB5 (39.5% $p<0.0001$) alone (Figure 8)

[0228] A similar trend was observed when using the PDGFR β inhibitor. Gleevec® treated eyes showed no significant difference to control eyes (4.2%) (Figure 9). The area of CNV in pegaptanib sodium (Macugen™) treated eyes, however, was significantly different to that of controls (27% less $p=0.0034$). Importantly, animals treated with both pegaptanib sodium and Gleevec (Macugen+Gleevec) exhibited the least amount of CNV (46% $p<0.0001$) compared to control eyes and a 19% decrease in the CNV area as compared to pegaptanib sodium alone treated eyes ($p=0.0407$) (Figure 9).

Example 3: Neonatal mouse model

[0229] The effect of administering pegaptanib sodium (Macugen™), and ARC-127 (Archemix Corp., Cambridge, MA), a PEGylated, anti-PDGF aptamer having the sequence CAGGCUACGN CGTAGAGCAU CANTGATCCU GT (SEQ ID NO: 23, which corresponds to SEQ ID NO: 146 from U.S. Pat. No. 6,582,918, incorporated herein by reference in its entirety) having 2'-fluoro-2'-deoxyuridine at positions 6, 20 and 30, 2'-fluoro-2'-deoxycytidine at positions 8, 21, 28, and 29, 2'-O-Methyl-2'-deoxyguanosine at positions 9, 15, 17, and 31, 2'-O-Methyl-2'-deoxyadenosine at position 22, "N" in positions 10 and 23 from a hexaethylene-glycol phosphoramidite, and an inverted orientation T (i.e., 3'-3'-linked) at position 32, or both on the developing vessels of the retina was investigated. Neonatal C57BL/6 mice were injected daily (in the intra-peritoneal cavity) with 100 μ g of ARC-127 or 100 μ g of Macugen or both, starting on postnatal day 0 (P0). Mice eyes were enucleated at P4. The retinal vasculature was visualized in flatmounted retinas by immunostaining with PECAM and NG-2 or by perfusion with ConA-FITC and analyzed by fluorescence microscopy.

Injection of ARC-127 completely blocked mural cell recruitment to the developing vessels of the retina. In addition, less vessel growth was observed at P4 as compared to the control non-treated retina. In contrast, Macugen did not interfere with normal blood vessel development. However, mice treated with both Macugen and ARC-127 exhibited similar but significantly more severe defects than mice treated with ARC-127 alone.

These results, depicted in Figure 10, show that Macugen has no effect on the blood vessels of the developing retina. PDGFR-B antagonist ARC-127 affects vessels outgrowth and morphology. However, Macugen in combination with ARC-127 affects blood vessels more severely than either of them alone.

Example 4: Combination Therapy with anti-PDGF aptamer and anti-VEGF antibody

[0230] In this example, effectiveness of a combination therapy using anti-PDGF aptamers and an anti-VEGF antibody is demonstrated using the corneal neovascularization model described above. To induce experimental corneal NV, male C57BL/6 mice (18-20 g; Charles River, Wilmington, MA) are anesthetized with intramuscular ketamine hydrochloride (25 mg/kg) and xylazine (10 mg/kg). NaOH (2ul of 0.2 mM) are applied topically. The corneal and limbal epithelia are removed by applying a rotary motion parallel to the limbus using #21 blade (Feather, Osaka, Japan). After 7 days, mice are treated with intra-peritoneal injections of

25 mg/kg of an anti-PDGF aptamer having the structure 40Kd PEG-5'-CAGGCTACGCGTAGAGCATCATGATCCTG(iT)-3' (in which iT represents that the final nucleotide is in the inverted orientation (3'-3' linked)) in combination with 100 μ g of the anti-VEGF antibody 2C3 described in U.S. 6,342,221 (incorporated herein by reference). At day 14 following corneal NV induction, mice receive 20 μ g/g of fluorescein-isothiocyanate coupled concanavalin A lectin (Vector Laboratories, Burlingame, CA) intravenously whilst deeply anesthetized with xylazine hydrochloride and ketamine hydrochloride. Thirty minutes later, mice eyes are enucleated, and the corneas flat-mounted. Corneal NV is visualized using fluorescence microscopy and quantified using Openlab software. The percent of cornea covered by vessels is calculated as a percentage of total corneal area. The results demonstrate the efficacy of the combination therapy over individual treatments with the anti-PDGF aptamer or anti-VEGF antibody alone.

[0231] In separate experiments, the effects of two related anti-PDGF aptamers are tested in combination with 100 μ g of the anti-VEGF antibody 2C3 described in U.S. 6,342,221. PEGylated and un-PEGylated versions of the following two anti-PDGF aptamers are tested: (i) CAGGCUACGN CGTAGAGCAU CANTGATCCU GT (SEQ ID NO: 23, which corresponds to SEQ ID NO: 146 from U.S. 6,582,918, incorporated herein by reference in its entirety) having 2'-fluoro-2'-deoxyuridine at positions 6, 20 and 30, 2'-fluoro-2'-deoxycytidine at positions 8, 21, 28, and 29, 2'-O-Methyl-2'-deoxyguanosine at positions 9, 15, 17, and 31, 2'-O-Methyl-2'-deoxyadenosine at position 22, "N" in positions 10 and 23 from a hexaethylene-glycol phosphoramidite, and an inverted orientation T (i.e., 3'-3'-linked) at position 32; and (ii) CAGGCUACGN CGTAGAGCAU CANTGATCCU GT (see SEQ ID NO: 87 from U.S. 5,723,594, incorporated herein by reference in its entirety) having O-methyl-2 - deoxycytidine at C at position 8, 2-O-methyl-2 - deoxyguanosine at Gs at positions 9, 17 and 31, 2-O-methyl-2 - deoxyadenine at A at position 22, 2-O-methyl-2 - deoxyuridine at position 30, 2-fluoro-2-deoxyuridine at U at positions 6 and 20, 2-fluoro-2 - deoxycytidine at C at positions 21, 28 and 29, a pentaethylene glycol phosphoramidite spacer at N at positions 10 and 23, and an inverted orientation T (i.e., 3'-3'-linked) at position

32. Appropriate controls are provided to detect the improved anti-neovascular effect of the combination therapy over individual anti-PDGF aptamer or anti-VEGF antibody treatments. The results demonstrate the efficacy of the combination therapy over individual treatments with the anti-PDGF aptamer or anti-VEGF antibody alone.

Example 5: Combination of anti-PDGF aptamer and anti-VEGF aptamer Block Choroidal Neovascularization (CNV)

[0232] In this example, effectiveness of a combination therapy using anti-PDGF aptamers and anti-VEGF aptamers in blocking choroidal neovascularization is demonstrated using the choroidal neovascularization model described above. Experimental CNV is often used as a model for Age-related Macular degeneration (AMD). In this model, vessels of the choroid grow through breaks in Bruch's membrane and into the retina, similar to what is observed in AMD patients. To induce experimental CNV, male C57BL/6 mice (18-20 g; Charles River, Wilmington, MA) are anesthetized with intramuscular ketamine hydrochloride (25 mg/kg) and xylazine (10 mg/kg) and the pupils are dilated with 1% tropicamide. Four burns are generated using diode laser photocoagulation (75- μ m spot size, 0.1-second duration, 90mW, Oculight SL laser, IRIDEX, Mountain View, CA) and a hand-held cover slide as a contact lens. Burns localized to the 3, 6, 9 and 12 o'clock positions of the posterior pole of the retina. Production of a bubble at the time of laser, which indicates rupture of Bruch's membrane, is an important factor in obtaining choroidal neovascularization, so only mice in which a bubble was produced for all four burns are included in the study. After 7 days, mice are treated with intraperitoneal injections of 25 mg/kg of pegaptanib sodium twice a day. In experiments using anti-PDGF aptamer, 25 mg/kg of an anti-PDGF aptamer having the structure 40Kd PEG-5'-CAGGCTACGCGTAGAGCATCATGA-TCCTG(iT)-3' (in which iT represents that the final nucleotide is in the inverted orientation (3'-3' linked)) is co-administered with pegaptanib sodium. The area of choroidal NV lesions is measured in flat-mounted choroid stained with PECAM. Flat-mounts are examined by fluorescence microscopy and quantified using Openlab software. The results demonstrate that eyes treated with the combination therapy showed significantly less CNV area as compared to control eyes or to eyes treated with either pegaptanib sodium or the anti-PDGF aptamer alone.

[0233] In separate experiments, the effects of two related anti-PDGF aptamers are tested in combination with the anti-VEGF treatment by intraperitoneal injections of 25 mg/kg of pegaptanib sodium twice a day. PEGylated and un-PEGylated versions of the following two anti-PDGF aptamers are tested: (i) CAGGCUACGN CGTAGAGCAU CANTGATCCU GT (SEQ ID NO: 23, which corresponds to SEQ ID NO: 146 from U.S. Pat. No. 6,582,918, incorporated herein by reference in its entirety) having 2'-fluoro-2'-deoxyuridine at positions 6, 20 and 30, 2'-fluoro-2'-deoxycytidine at positions 8, 21, 28, and 29, 2'-O-Methyl-2'-deoxyguanosine at positions 9, 15, 17, and 31, 2'-O-Methyl-2'-deoxyadenosine at position 22, "N" in positions 10 and 23 from a hexaethylene-glycol phosphoramidite, and an inverted orientation T (i.e., 3'-3'-linked) at position 32; and (ii) CAGGCUACGN CGTAGAGCAU CANTGATCCU GT (see SEQ ID NO: 87 from U.S. Pat. No. 5,723,594, incorporated herein by reference in its entirety) having O-methyl-2-deoxycytidine at C at position 8, 2-O-methyl-2-deoxyguanosine at Gs at positions 9, 17 and 31, 2-O-methyl-2-deoxyadenine at A at position 22, 2-O-methyl-2-deoxyuridine at position 30, 2-fluoro-2-deoxyuridine at U at positions 6 and 20, 2-fluoro-2-deoxycytidine at C at positions 21, 28 and 29, a pentaethylene glycol phosphoramidite spacer at N at positions 10 and 23, and an inverted orientation T (i.e., 3'-3'-linked) at position 32. Appropriate controls are provided to detect the improved anti-neovascular effect of the combination therapy over individual anti-PDGF aptamer or anti-VEGF aptamer treatments. The results demonstrate the efficacy of the combination therapy in blocking choroidal neovascularization over individual treatments with either of the anti-PDGF aptamers or the anti-VEGF aptamer alone.

[0234] The corneal NV model of Example 1 was used to investigate the combination of an anti-VEGF aptamer and anti-PDGF aptamer. After 10 days, mice were treated with intra-peritoneal injections of 25 mg/kg of pegaptanib sodium (Macugen™, Eyetech Pharmaceuticals, New York, NY), an anti-VEGF aptamer agent) twice a day and/or of 50 mg/kg of ARC-127 (Archemix Corp., Cambridge, MA, an anti-PDGF aptamer having the structure 40Kd PEG-5'-CAGGCTACGCGTAGAGCATCATGA-TCCTG(iT)-3' (in which iT represents that the final nucleotide is in the inverted orientation (3'-3' linked)) once a day for 10 days. At day 20 following corneal NV induction, eyes were enucleated, and the corneas flat-mounted. Corneal NV was visualized using CD31 staining (BD Biosciences Pharmingen, San Diego, CA) and quantified using Metamorph software. The percent of cornea covered by vessels was calculated as a percentage of total corneal area.

[0235] The effects of pegaptanib sodium and/or ARC-127 on the regression of neovascularization of the cornea following NaOH application and injury to the epithelia of the limbus and cornea are depicted in Figures 11 and 12. Animals treated with ARC-127 did not show a significant decrease in vessel growth as compared to the day 20 control. The day 20 controls showed a 12.92% increase in corneal neovascularization when compared with the day 10 controls. Animals treated with pegaptanib sodium (Macugen) alone showed a 13.81% ($p \leq 0.016$) decrease in vessel growth as compared to day 20 controls. Animals treated with pegaptanib sodium and ARC-127 exhibited significantly less neovascular growth on the cornea (26.85%, $p \leq 0.002$) as compared to control.

Example 7: Corneal Neovasclarization Corneal NV) - Regression

[0236] The corneal NV model of Example 1 was used to investigate the combination of an anti-VEGF aptamer and an antibody against the PDGFB receptor. After 14 days, mice were treated with intra-peritoneal injections of 25 mg/kg of pegaptanib sodium (Macugen, an anti-VEGF aptamer agent) twice a day and/or by oral administration of 50 mg/kg of APB5 (a polyclonal antibody against the PDGFB receptor) by gavage twice a day for 14 days. At day 28 following corneal NV induction, mice received 20 ug/g of fluorescein-isothiocyanate coupled concanavalin A lectin (Vector Laboratories, Burlingame, CA) intravenously whilst deeply anesthetized with xylazine hydrochloride and ketamine hydrochloride. Thirty minutes later, mice eyes were enucleated, and the corneas flat-mounted. Corneal NV was visualized using fluorescence microscopy and quantified using Openlab software. The percent of cornea covered by vessels was calculated as a percentage of total corneal area.

[0237] The effects of pegaptanib sodium and/or APB5 on the regression of neovascularization of the cornea following NaOH application and injury to the epithelia of the limbus and cornea are depicted in Figure 13. Animals treated with pegaptanib sodium (Macugen) showed an 8.3% decrease in vessel growth as compared to control. Animals treated with pegaptanib sodium and APB5 exhibited significantly less neovascular growth on the cornea (21.4%) as compared to control.

Example 8: Corneal Neovasclarization (Corneal NV) - Regression (Order of Addition of Therapeutic Agent)

[0238] The corneal NV model of Example 1 was used to investigate the effect of order of addition of the combination therapy using an anti-VEGF aptamer and an antibody against the PDGFB receptor. After 14 days, mice were treated with intra-peritoneal injections of 25 mg/kg of pegaptanib sodium (Macugen, an anti-VEGF aptamer agent) twice a day and/or by oral administration of 50 mg/kg of APB5 (eBioscience, San Diego, CA), a polyclonal antibody against the PDGFB receptor, by gavage twice a day for 7 days at different timepoints. At day 28 following corneal NV induction, mice received 20 ug/g of fluorescein-isothiocyanate coupled concanavalin A lectin (Vector Laboratories, Burlingame, CA) intravenously whilst deeply anesthetized with xylazine hydrochloride and ketamine hydrochloride. Thirty minutes later, mice eyes were enucleated, and the corneas flat-mounted. Corneal NV was visualized using fluorescence microscopy and quantified using Openlab software. The percent of cornea covered by vessels was calculated as a percentage of total corneal area and the results are depicted in Figure 14.

[0239] The effects of pegaptanib sodium alone from day 21-28 or APB5 alone from day 14-21 followed by no treatment showed little effect compared with control on the regression of neovascularization of the cornea following NaOH application and injury to the epithelia of the limbus and cornea. Animals treated with APB5 from day 14-21 and pegaptanib sodium from day 21-28 exhibited less neovascular growth on the cornea (13.4%) as compared to control.

Equivalents

[0240] Various modifications and variations of the described method and system of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with specific desired embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Those skilled in the art will recognize or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed in the scope of the present invention.

[0241] The following description pages 69-72 contain specific embodiments of the present invention.

1. A method for suppressing a neovascular disorder in a patient in need thereof, the method comprising administering to the patient:

- (i) a PDGF antagonist; and
- (ii) a VEGF antagonist,

wherein the PDGF antagonist and the VEGF antagonist are administered simultaneously or within 90 days of each other, in amounts sufficient to suppress the neovascular disorder in the patient.

2. A method for treating a patient diagnosed with or at risk for developing a neovascular disorder, the method comprising administering to the patient:

- (i) a PDGF antagonist; and
- (ii) a VEGF antagonist,

wherein the PDGF antagonist and the VEGF antagonist are administered simultaneously or within 90 days of each other, in amounts sufficient to treat the patient.

3. The method of 1 or 2, wherein said PDGF antagonist and said VEGF antagonist are administered within 10 days of each other.

4. The method of 3, wherein the PDGF antagonist and said VEGF antagonist are administered within 5 days of each other.

5. The method of 4, wherein the PDGF antagonist and said VEGF antagonist are administered within 24 hours of each other.

6. The method of 5, wherein the PDGF antagonist and said VEGF antagonist are administered simultaneously.

7. The method of 1 or 2, wherein the PDGF antagonist is a PDGF-B antagonist.

8. The method of 1 or 2, wherein the VEGF antagonist is a VEGF-A antagonist.

9. The method of 1 or 2, wherein the PDGF antagonist is a nucleic acid molecule, an aptamer, an antisense RNA molecule, a ribozyme, an RNAi molecule, a protein, a peptide, a cyclic peptide, an antibody, a binding fragment of an antibody, or a small organic compound.

10. The method 1 or 2, wherein the VEGF antagonist is a nucleic acid molecule, an aptamer, an antisense RNA molecule, a ribozyme, an RNAi molecule, a protein, a peptide, a cyclic peptide, an antibody or antibody fragment, a sugar, a polymer or a small organic compound.

11. The method of 10, wherein the VEGF antagonist is an aptamer.

12. The method of 11, wherein the aptamer is EYE001.

13. The method of 10, wherein the VEGF antagonist is an antibody or binding fragment thereof.

14. The method of 1 or 2, wherein the PDGF antagonist is a nucleic acid molecule, an aptamer, an antisense RNA molecule, a ribozyme, an RNAi molecule, a protein, a peptide, a cyclic peptide, an antibody or antibody fragment, a sugar, a polymer or a small organic compound.

15. The method of 14, wherein the PDGF antagonist is an antibody or binding fragment thereof.

16. The method of 14, wherein the PDGF antagonist is an antisense oligonucleotide.

17. The method of 1 or 2, wherein said neovascular disorder is an ocular neovascular disorder.

18. The method of 17, wherein the ocular neovascular disorder is ischemic retinopathy, iris neovascularization, intraocular neovascularization, age-related macular degeneration, corneal neovascularization, retinal neovascularization, choroidal neovascularization, diabetic retinal ischemia, and proliferative diabetic retinopathy.

19. The method of 1 or 2, wherein said neovascular disorder is psoriasis or rheumatoid arthritis.

20. A pharmaceutical composition comprising:

- (i) a PDGF antagonist;
- (ii) a VEGF antagonist; and
- (iii) a pharmaceutically acceptable carrier,

wherein the PDGF antagonist and the VEGF antagonist are present in an amount sufficient to suppress a neovascular disorder in a patient.

21. The composition of 20, wherein the PDGF antagonist is a PDGF-B antagonist.

22. The composition of 20, wherein the VEGF antagonist is a VEGF-A antagonist.

23. The composition of 20, wherein the PDGF antagonist is a nucleic acid molecule, an aptamer, an antisense RNA molecule, a ribozyme, an RNAi molecule, a protein, a peptide, a cyclic peptide, an antibody or antibody fragment, a sugar, a polymer, or a small organic compound.

24. The composition of 20, wherein the VEGF antagonist is a nucleic acid molecule, an aptamer, an antisense RNA molecule, a ribozyme, an RNAi molecule, a protein, a peptide, a cyclic peptide, an antibody or antibody, a binding fragment of an antibody or a small organic compound.

25. The composition of 23, wherein the PDGF antagonist is an antibody or binding fragment thereof.

26. The composition of 23, wherein the PDGF antagonist is an antisense oligonucleotide.

27. The composition of 24, wherein the VEGF antagonist is an aptamer.

28. The composition of 27, wherein the aptamer is EYE001.

29. The composition of 24, wherein the VEGF antagonist is an antibody or binding fragment thereof.

30. A pharmaceutical pack comprising:

- (i) a PDGF antagonist; and
- (ii) a VEGF antagonist.

31. The pharmaceutical pack of 30, wherein the PDGF antagonist is a PDGF-B antagonist.

32. The pharmaceutical pack of 30, wherein said VEGF antagonist is a VEGF-A antagonist.

33. The pharmaceutical pack of 30, wherein the PDGF antagonist and VEGF antagonist are formulated separately and in individual dosage amounts.
34. The pharmaceutical pack of 31, wherein the PDGF antagonist and VEGF antagonist are formulated together.
35. The pharmaceutical pack of 30, wherein the VEGF antagonist is an aptamer.
36. The pharmaceutical pack of 35, wherein the aptamer is EYE001.
37. The pharmaceutical pack of 30, wherein the VEGF antagonist is an antibody or binding fragment thereof.
38. The pharmaceutical pack of 30, wherein the VEGF antagonist is an antisense oligonucleotide.
39. The pharmaceutical pack of 30, wherein the PDGF antagonist is an antibody or binding fragment thereof.
40. The pharmaceutical pack of 30, wherein the PDGF antagonist is an antisense oligonucleotide.
41. The pharmaceutical composition of 20, wherein the pharmaceutically acceptable carrier comprises a microsphere or a hydrogel.
42. The pharmaceutical pack of 30, further comprising a delivery vehicle selected from a microsphere and a hydrogel.
43. The method of any of 1, 2 or 18, wherein said PDGF antagonist is a pro-drug.
44. The method of any of 1, 2 or 18, wherein said VEGF antagonist is a pro-drug.
45. The pharmaceutical composition of 20, wherein said PDGF antagonist is a pro-drug.
46. The pharmaceutical composition of 20, wherein said VEGF antagonist is a pro-drug.
47. The pharmaceutical pack of 30, wherein said PDGF antagonist is a pro-drug.
48. The pharmaceutical pack of 30, wherein said VEGF antagonist is a pro-drug.

EP 3 168 304 A1

SEQUENCE LISTING

5 <110> Ophthotech Corporation
 <120> COMBINATION THERAPY FOR THE TREATMENT OF OCULAR NEOVASCULAR DISORDERS
 <130> E64591PCEPT3
 10 <150> US 60/498,407
 <151> 2003-08-27
 <150> US 60/556,837
 15 <151> 2004-03-26
 <160> 27
 <170> PatentIn version 3.5
 20 <210> 1
 <211> 2137
 <212> DNA
 <213> Homo sapiens
 <400> 1
 25 ccctgcctgc ctccctgcgc acccgcagcc tcccccgctg cctccctagg gctccctcc 60
 ggccgccagc gcccatTTTT cattccctag atagagatac ttTgcgcgca cacacataca 120
 tacgcgcgca aaaaggaaaa aaaaaaaaaa aagcccaccc tccagcctcg ctgcaaagag 180
 30 aaaaccggag cagccgcagc tcgcagctcg cagcccgag cccgcagagg acgcccagag 240
 cggcgagcgg gcgggcagac ggaccgacgg actcgcgcgg cgtccacctg tcggccgggc 300
 ccagccgagc gcgcagcggg cacgccgcgc gcgcggagca gccgtgcccg ccgcccgggc 360
 35 ccgcgcgcag gggcacacag ctcccgcccc cctaccgggc ccgggcggga gtttgcacct 420
 ctccctgccc gggTgctcga gctgccgttg caaagccaac ttTggaaaaa gttttttggg 480
 40 ggagacttgT gccttgaggT gccagctcc gcgctttccg attttggggg cctttccaga 540
 aaatgttgca aaaaagctaa gccggcgggc agaggaaaac gcctgtagcc ggcgagtga 600
 gacgaaccat cgactgccgt gttccttttc ctcttgagg ttggagtccc ctgggcgccc 660
 45 ccacacggct agacgcctcg gctggttcgc gacgcagccc ccgggcctg gatgctgcac 720
 tcgggctcgg gatccgccc ggtagcggc tcggaccag gtccTgcgc caggTcctcc 780
 cctgcccccc agcgacggag ccggggccgg gggcggcggc gccgggggca Tgcgggtgag 840
 50 ccgcggctgc agaggcctga gcgcctgatc gccgcggacc cgagccgagc ccacccccct 900
 cccagcccc ccacctggc cgcgggggcg gcgcgctcga tctacgcgtt cggggccccc 960
 55 cggggccggg ccgggagtcg gcatgaatcg ctgctgggcg ctcttccctgt ctctctgctg 1020
 ctacctgcgt ctggtcagcg ccgaggggga cccattccc gaggagcttt atgagatgct 1080

EP 3 168 304 A1

gagtgaccac tcgatccgct cctttgatga tctccaacgc ctgctgcacg gagaccccg 1140
 agaggaagat ggggccgagt tggacctgaa catgacccgc tcccactctg gaggcgagct 1200
 5 ggagagcttg gctcgtgga gaaggagcct gggttccctg accattgctg agccggccat 1260
 gatcgccgag tgcaagacgc gcaccgaggt gttcgagatc tcccggcgcc tcatagaccg 1320
 caccaacgcc aacttcctgg tgtggccgcc ctgtgtggag gtgcagcgct gctccggctg 1380
 10 ctgcaacaac cgcaacgtgc agtgccgccc caccaggtg cagctgcgac ctgtccaggt 1440
 gagaaagatc gagattgtgc ggaagaagcc aatctttaag aaggccacgg tgacgctgga 1500
 agaccacctg gcatgcaagt gtgagacagt ggcagctgca cggcctgtga cccgaagccc 1560
 15 ggggggttcc caggagcagc gagccaaaac gcccctcact cgggtgacca ttcggacggt 1620
 gcgagtccgc cggcccccca agggcaagca ccggaaattc aagcacacgc atgacaagac 1680
 ggcactgaag gagacccttg gagcctaggg gcatcggcag gagagtgtgt gggcaggggt 1740
 20 atttaatatg gtatttctg tattgcccc atggggcctt ggagtagata atattgtttc 1800
 cctcgtccgt ctgtctcgat gcctgattcg gacggccaat ggtgcctccc ccaccctcc 1860
 25 acgtgtccgt ccacccttcc atcagcgggt ctctctccag cggcctccgg ctcttgccca 1920
 gcagctcaag aagaaaaaga aggactgaac tccatcgcca tcttcttccc ttaactccaa 1980
 gaacttggga taagagtgtg agagagactg atggggctgc tctttggggg aaacgggttc 2040
 30 cttcccctgc acctggcctg ggccacacct gagcgtgtg gactgtcctg aggagccctg 2100
 aggacctctc agcatagcct gcctgatccc tgaaccc 2137

35 <210> 2
 <211> 241
 <212> PRT
 <213> Homo sapiens

40 <400> 2

Met Asn Arg Cys Trp Ala Leu Phe Leu Ser Leu Cys Cys Tyr Leu Arg
 1 5 10 15

45 Leu Val Ser Ala Glu Gly Asp Pro Ile Pro Glu Glu Leu Tyr Glu Met
 20 25 30

50 Leu Ser Asp His Ser Ile Arg Ser Phe Asp Asp Leu Gln Arg Leu Leu
 35 40 45

His Gly Asp Pro Gly Glu Glu Asp Gly Ala Glu Leu Asp Leu Asn Met
 50 55 60

55 Thr Arg Ser His Ser Gly Gly Glu Leu Glu Ser Leu Ala Arg Gly Arg
 65 70 75 80

EP 3 168 304 A1

Arg Ser Leu Gly Ser Leu Thr Ile Ala Glu Pro Ala Met Ile Ala Glu
 85 90 95

5 Cys Lys Thr Arg Thr Glu Val Phe Glu Ile Ser Arg Arg Leu Ile Asp
 100 105 110

10 Arg Thr Asn Ala Asn Phe Leu Val Trp Pro Pro Cys Val Glu Val Gln
 115 120 125

Arg Cys Ser Gly Cys Cys Asn Asn Arg Asn Val Gln Cys Arg Pro Thr
 130 135 140

15 Gln Val Gln Leu Arg Pro Val Gln Val Arg Lys Ile Glu Ile Val Arg
 145 150 155 160

20 Lys Lys Pro Ile Phe Lys Lys Ala Thr Val Thr Leu Glu Asp His Leu
 165 170 175

25 Ala Cys Lys Cys Glu Thr Val Ala Ala Ala Arg Pro Val Thr Arg Ser
 180 185 190

Pro Gly Gly Ser Gln Glu Gln Arg Ala Lys Thr Pro Gln Thr Arg Val
 195 200 205

30 Thr Ile Arg Thr Val Arg Val Arg Arg Pro Pro Lys Gly Lys His Arg
 210 215 220

35 Lys Phe Lys His Thr His Asp Lys Thr Ala Leu Lys Glu Thr Leu Gly
 225 230 235 240

Ala

40

<210> 3
 <211> 1723
 <212> DNA
 <213> Homo sapiens

45

<400> 3
 tcgcggaggc ttggggcagc cgggtagctc ggaggctcgtg gcgctggggg ctagcaccag 60
 cgctctgtcg ggaggcgcag cggttagggtg gaccggctcag cggactcacc ggccagggcg 120
 50 ctcggtgctg gaatttgata ttcatctgac cgggttttat ccctottott ttttcttaaa 180
 catttttttt taaaactgta ttgtttctcg ttttaattta tttttgcttg ccattcccca 240
 cttgaatcgg gccgacggct tggggagatt gctctacttc cccaaatcac tgtggatttt 300
 55 ggaaaccagc agaaagagga aagaggtagc aagagctcca gagagaagtc gaggaagaga 360

EP 3 168 304 A1

gagacggggt cagagagagc gcgcgggctg gcgagcagcg aaagcgacag gggcaaagtg 420
 agtgacctgc ttttgggggt gaccgccgga gcgcggcgtg agccctcccc cttgggatcc 480
 5 cgcagctgac cagtcgcgct gacggacaga cagacagaca ccgccccag cccagctac 540
 cacctcctcc ccggccggcg gcggacagtg gacgcggcgg cgagccgcgg gcaggggccc 600
 gagcccgcgc ccggaggcgg ggtggagggg gtcggggctc gcggcgtcgc actgaaactt 660
 10 ttctgtccaac ttctgggctg ttctcgcttc ggaggagccg tgggtccgcgc gggggaagcc 720
 gagccgagcg gagccgcgag aagtgtctagc tcgggcccgg aggagccgca gccggaggag 780
 ggggaggagg aagaagagaa ggaaggagg agggggccgc agtggcgact cggcgctcgg 840
 15 aagccgggct catggacggg tgaggcggcg gtgtgcgcag acagtgtctc agccgcgcgc 900
 gctccccagg ccctggcccg ggcctcgggc cggggaggaa gagtagctcg ccgaggcgcc 960
 gaggagagcg ggccgcccc aagcccagc cgagagaggga gcgcgagccg cgccggcccc 1020
 20 ggtcgggcct ccgaaaccat gaactttctg ctgtcttggg tgcattggag ccttgccctg 1080
 ctgctctacc tccaccatgc caagtgttcc caggctgcac ccatggcaga aggaggagg 1140
 cagaatcatc acgaagtggg gaagttcatg gatgtctatc agcgcagcta ctgccatcca 1200
 25 atcgagaccc tgggtggacat cttccaggag taccctgatg agatcgagta catcttcaag 1260
 ccacctctgt tgcctctgat gcgatgcggg ggctgctgca atgacgaggg cctggagtgt 1320
 gtgcccactg aggagtcaa catcaccatg cagattatgc ggatcaaacc tcaccaaggc 1380
 cagcacatag gagagatgag cttcctacag cacaacaaat gtgaatgcag accaaagaaa 1440
 gatagagcaa gacaagaaaa aaaatcagtt cgaggaaagg gaaaggggca aaaacgaaag 1500
 35 cgcaagaaat ccggtataa gtcttgagc gttccctgtg ggccttgctc agagcggaga 1560
 aagcatttgt ttgtacaaga tccgcagacg tgtaaagtgt cctgcaaaaa cacagactcg 1620
 cgttgcaagg cgaggcagct tgagttaaac gaacgtactt gcagatgtga caagccgagg 1680
 40 cggtgagccg ggcaggagga aggagcctcc ctcagggttt cgg 1723

<210> 4
 <211> 215
 45 <212> PRT
 <213> Homo sapiens
 <400> 4

Met Asn Phe Leu Leu Ser Trp Val His Trp Ser Leu Ala Leu Leu Leu
 1 5 10 15

Tyr Leu His His Ala Lys Trp Ser Gln Ala Ala Pro Met Ala Glu Gly
 20 25 30

Gly Gly Gln Asn His His Glu Val Val Lys Phe Met Asp Val Tyr Gln

EP 3 168 304 A1

35

40

45

5

Arg Ser Tyr Cys His Pro Ile Glu Thr Leu Val Asp Ile Phe Gln Glu
50 55 60

10

Tyr Pro Asp Glu Ile Glu Tyr Ile Phe Lys Pro Ser Cys Val Pro Leu
65 70 75 80

15

Met Arg Cys Gly Gly Cys Cys Asn Asp Glu Gly Leu Glu Cys Val Pro
85 90 95

Thr Glu Glu Ser Asn Ile Thr Met Gln Ile Met Arg Ile Lys Pro His
100 105 110

20

Gln Gly Gln His Ile Gly Glu Met Ser Phe Leu Gln His Asn Lys Cys
115 120 125

Glu Cys Arg Pro Lys Lys Asp Arg Ala Arg Gln Glu Lys Lys Ser Val
130 135 140

25

Arg Gly Lys Gly Lys Gly Gln Lys Arg Lys Arg Lys Lys Ser Arg Tyr
145 150 155 160

30

Lys Ser Trp Ser Val Pro Cys Gly Pro Cys Ser Glu Arg Arg Lys His
165 170 175

Leu Phe Val Gln Asp Pro Gln Thr Cys Lys Cys Ser Cys Lys Asn Thr
180 185 190

35

Asp Ser Arg Cys Lys Ala Arg Gln Leu Glu Leu Asn Glu Arg Thr Cys
195 200 205

40

Arg Cys Asp Lys Pro Arg Arg
210 215

45

<210> 5
<211> 5598
<212> DNA
<213> Homo sapiens

50

<400> 5
ggcccctcag ccctgctgcc cagcacgagc ctgtgctcgc cctgcccaac gcagacagcc 60

agaccaggg cggcccctct ggcggctctg ctccctccga aggatgcttg gggagtgagg 120

cgaagctggg cgctcctctc ccctacagca gccccttcc tccatccctc tgttctcctg 180

55

agccttcagg agcctgcacc agtcctgcct gtccttctac tcagctgtta cccactctgg 240

gaccagcagt ctttctgata actgggagag ggcagtaagg aggacttcct ggaggggggtg 300

EP 3 168 304 A1

	actgtccaga	gcctggaact	gtgcccacac	cagaagccat	cagcagcaag	gacacccatgc	360
	ggcttccggg	tgcgatgcc	gctctggccc	tcaaaggcga	gctgctgttg	ctgtctctcc	420
5	tgttacttct	ggaaccacag	atctctcagg	gcctggctgt	cacacccccg	gggccagagc	480
	ttgtcctcaa	tgtctccagc	accttcgttc	tgacctgtct	gggttcagct	ccgtgtgtgt	540
	gggaacggat	gtcccaggag	ccccacagg	aaatggccaa	ggcccaggat	ggcaccttct	600
10	ccagcgtgct	cacactgacc	aacctcactg	ggctagacac	gggagaatac	ttttgcaccc	660
	acaatgactc	ccgtggactg	gagaccgatg	agcggaaacg	gctctacatc	tttgtgccag	720
	atcccaccgt	gggcttcctc	cctaatagat	ccgaggaact	attcatcttt	ctcacggaaa	780
15	taactgagat	caccattcca	tgccgagtaa	cagacccaca	gctgggtgtg	acactgcacg	840
	agaagaaagg	ggacgttgca	ctgcctgtcc	cctatgatca	ccaacgtggc	ttttctggta	900
	tctttgagga	cagaagctac	atctgcaaaa	ccaccattgg	ggacagggag	gtggattctg	960
20	atgcctacta	tgtctacaga	ctccaggtgt	catccatcaa	cgtctctgtg	aacgcagtgc	1020
	agactgtggt	ccgccagggg	gagaacatca	ccctcatgtg	cattgtgatc	gggaatgagg	1080
25	tggtaactt	cgagtggaca	tacccccgca	aagaaagtgg	gcggtctgtg	gagccggtga	1140
	ctgacttcct	cttgatatg	ccttaccaca	tccgctccat	cctgcacatc	cccagtgccg	1200
	agttagaaga	ctcggggacc	tacacctgca	atgtgacgga	gagtgtgaat	gaccatcagg	1260
30	atgaaaaggc	catcaacatc	accgtggttg	agagcggcta	cgtgcggctc	ctgggagagg	1320
	tgggcacact	acaatttgct	gagctgcatc	ggagccggac	actgcaggta	gtgttcgagg	1380
	cctaccacac	gcccactgtc	ctgtggttca	aagacaaccg	caccctgggc	gactccagcg	1440
35	ctggcgaaat	cgccctgtcc	acgcgcaacg	tgtcggagac	ccggtatgtg	tcagagctga	1500
	cactggttcg	cgtgaagggt	gcagaggctg	gccactacac	catgcggggc	ttccatgagg	1560
	atgctgaggt	ccagctctcc	ttccagctac	agatcaatgt	ccctgtccga	gtgctggagc	1620
40	taagtgagag	ccaccctgac	agtggggaac	agacagtccg	ctgtcgtggc	cggggcatgc	1680
	cccagccgaa	catcatctgg	tctgcctgca	gagacctcaa	aaggtgtcca	cgtgagctgc	1740
	cgcccacgct	gctgggggaa	agttccgaag	aggagagcca	gctggagact	aacgtgacgt	1800
45	actgggagga	ggagcaggag	tttgaggtgg	tgagcacact	gcgtctgcag	cacgtggatc	1860
	ggccactgtc	ggtgcgctgc	acgctgcgca	acgctgtggg	ccaggacacg	caggaggtca	1920
	tcgtgggtgcc	acactccttg	ccctttaagg	tgggtggtgat	ctcagccatc	ctggccctgg	1980
50	tgggtgctcac	catcatctcc	cttatcatcc	tcatcatgct	ttggcagaag	aagccacggt	2040
	acgagatccg	atggaagggt	attgagtctg	tgagctctga	cggccatgag	tacatctacg	2100
55	tggaccccat	gcagctgccc	tatgactcca	cgtgggagct	gccgcgggac	cagcttgtgc	2160
	tgggacgcac	cctcggctct	ggggcctttg	ggcaggtggt	ggaggccacg	gctcatggcc	2220

EP 3 168 304 A1

	tgagccattc	tcaggccacg	atgaaagtgg	ccgtcaagat	gcttaaatacc	acagcccgcg	2280
	gcagtgagaa	gcaagccctt	atgtcggagc	tgaagatcat	gagtcacctt	gggccccacc	2340
5	tgaacgtggt	caacctgttg	ggggcctgca	ccaaaggagg	acccatctat	atcatcactg	2400
	agtactgccg	ctacggagac	ctggtggact	acctgcaccg	caacaaacac	accttcctgc	2460
	agcaccactc	cgacaagcgc	cgcgcgccca	gcgcggagct	ctacagcaat	gctctgcccg	2520
10	ttgggctccc	cctgcccagc	catgtgtcct	tgaccgggga	gagcgacggg	ggctacatgg	2580
	acatgagcaa	ggacgagtcg	gtggactatg	tgcccatgct	ggacatgaaa	ggagacgtca	2640
	aatatgcaga	catcgagtcc	tccaactaca	tggcccctta	cgataactac	gttcacctctg	2700
15	cccctgagag	gacctgccga	gcaactttga	tcaacgagtc	tccagtgtca	agctacatgg	2760
	acctcgtggg	cttcagctac	cagggtggcca	atggcatgga	gtttctggcc	tccaagaact	2820
20	gcgtccacag	agacctggcg	gctaggaacg	tgctcatctg	tgaaggcaag	ctgggtcaaga	2880
	tctgtgactt	tggcctggct	cgagacatca	tgcgggactc	gaattacatc	tccaaaggca	2940
	gcaccttttt	gcctttaaag	tggatggctc	cggagagcat	cttcaacagc	ctctacacca	3000
25	ccctgagcga	cgtgtggtcc	ttcgggatcc	tgctctggga	gatcttcacc	ttgggtggca	3060
	ccccttacct	agagctgccc	atgaacgagc	agttctacaa	tgccatcaaa	cgggggttacc	3120
	gcatggccca	gcctgcccac	gcctccgacg	agatctatga	gatcatgcag	aagtgtctggg	3180
30	aagagaagtt	tgagattcgg	ccccccctct	cccagctggg	gctgcttctc	gagagactgt	3240
	tgggcgaagg	ttacaaaaag	aagtaccagc	aggtggatga	ggagtttctg	aggagtgacc	3300
35	accagcccat	ccttcggtcc	caggcccgct	tgccctgggtt	ccatggcctc	cgatctcccc	3360
	tggacaccag	ctccgtcctc	tatactgccg	tgcagcccaa	tgagggtgac	aacgactata	3420
	tcacccccct	gcctgacccc	aaaccgcagg	ttgctgacga	gggcccactg	gagggttccc	3480
40	ccagcctagc	cagctccacc	ctgaatgaag	tcaacacctc	ctcaaccatc	tcctgtgaca	3540
	gccccctgga	gccccaggac	gaaccagagc	cagagcccca	gcttgagctc	cagggtggagc	3600
	cggagccaga	gctggaacag	ttgccggatt	cgggggtgcc	tgcgcctcgg	gcggaagcag	3660
45	aggatagctt	cctgtagggg	gctggccccct	accctgccct	gcctgaagct	ccccccctgc	3720
	cagcaccacg	catctcctgg	cctggcctga	ccgggcttcc	tgtcagccag	gctgccctta	3780
	tcagctgtcc	ccttctggaa	gctttctgct	cctgacgtgt	tgtgccccaa	accctggggc	3840
50	tggcttagga	ggcaagaaaa	ctgcaggggc	cgtgaccagc	cctctgcctc	caggggaggcc	3900
	aactgactct	gagccagggt	tccccagggg	aactcagttt	tcccatatgt	aagatgggaa	3960
55	agttaggctt	gatgaccacg	aatctaggat	tctctccctg	gctgacaggt	ggggagaccg	4020
	aatccctccc	tgggaagatt	cttgaggtta	ctgaggtggg	aaattaactt	ttttctgttc	4080

EP 3 168 304 A1

	agccagctac	ccctcaagga	atcatagctc	tctcctcgca	ctttttatcc	accaggagc	4140
	tagggaagag	accctagcct	ccctggctgc	tggctgagct	agggcctagc	cttgagcagt	4200
5	gttgcctcat	ccagaagaaa	gccagtctcc	tccctatgat	gccagtccct	gcgttccctg	4260
	gcccagactg	gtctggggcc	attaggcagc	ctaattaatg	ctggaggctg	agccaagtac	4320
	aggacacccc	cagcctgcag	cccttgccca	gggcacttgg	agcacacgca	gccatagcaa	4380
10	gtgcctgtgt	ccctgtcctt	caggcccatc	agtcctgggg	ctttttcttt	atcacccctca	4440
	gtcttaatcc	atccaccaga	gtctagaagg	ccagacgggc	cccgcactctg	tgatgagaat	4500
	gtaaatgtgc	cagtgtggag	tggccacgtg	tgtgtgccag	tatatggccc	tggctctgca	4560
15	ttggacctgc	tatgaggctt	tggaggaatc	cctcacccctc	tctgggcctc	agtttcccct	4620
	tcaaaaaatg	aataagtcgg	acttattaac	tctgagtgcc	ttgccagcac	taacattcta	4680
20	gagtattcca	ggtggttgca	catttgtcca	gatgaagcaa	ggccatatac	cctaaacttc	4740
	catcctgggg	gtcagctggg	ctcctgggag	attccagatc	acacatcaca	ctctggggac	4800
	tcaggaacca	tgccccttcc	ccaggccccc	agcaagtctc	aagaacacag	ctgcacaggc	4860
25	cttgacttag	agtgacagcc	ggtgtcctgg	aaagccccc	gcagctgccc	cagggacatg	4920
	ggaagaccac	gggacctctt	tcactaccca	cgatgacctc	cgggggtatc	ctgggcaaaa	4980
	gggacaaaga	gggcaaatga	gatcacctcc	tgcagcccac	caactccagca	cctgtgccga	5040
30	ggtctgcgtc	gaagacagaa	tggacagtga	ggacagttat	gtcttgtaaa	agacaagaag	5100
	cttcagatgg	taccccaaga	aggatgtgag	aggtggccgc	ttggagtttg	cccctcacc	5160
	accagctgcc	ccatccctga	ggcagcgtc	catgggggta	tggttttgtc	actgcccaga	5220
35	cctagcagtg	acatctcatt	gtccccagcc	cagtgggcat	tggaggtgcc	aggggagtca	5280
	gggttgtagc	caagacgccc	ccgcacgggg	agggttggga	agggggtgca	ggaagctcaa	5340
40	cccctctggg	caccaaccct	gcattgcagg	ttggcacctt	acttccctgg	gatccccaga	5400
	gttgggtcaa	ggagggagag	tgggttctca	atacgggtacc	aaagatataa	tcacctaggt	5460
	ttacaaatat	ttttaggact	cacgttaact	cacatttata	cagcagaaat	gctattttgt	5520
45	atgctgttaa	gtttttctat	ctgtgtactt	ttttttaagg	gaaagatfff	aatattaaac	5580
	ctggtgcttc	tcactcac					5598
50	<210>	6					
	<211>	1106					
	<212>	PRT					
	<213>	Homo sapiens					
	<400>	6					
55	Met	Arg	Leu	Pro	Gly	Ala	Met
	1				5		
						10	
							15

EP 3 168 304 A1

	Leu	Leu	Leu	Ser	Leu	Leu	Leu	Leu	Leu	Glu	Pro	Gln	Ile	Ser	Gln	Gly	
				20						25				30			
5	Leu	Val	Val	Thr	Pro	Pro	Gly	Pro	Glu	Leu	Val	Leu	Asn	Val	Ser	Ser	
			35				40						45				
	Thr	Phe	Val	Leu	Thr	Cys	Ser	Gly	Ser	Ala	Pro	Val	Val	Trp	Glu	Arg	
10		50					55					60					
	Met	Ser	Gln	Glu	Pro	Pro	Gln	Glu	Met	Ala	Lys	Ala	Gln	Asp	Gly	Thr	
	65					70					75					80	
15	Phe	Ser	Ser	Val	Leu	Thr	Leu	Thr	Asn	Leu	Thr	Gly	Leu	Asp	Thr	Gly	
					85					90					95		
	Glu	Tyr	Phe	Cys	Thr	His	Asn	Asp	Ser	Arg	Gly	Leu	Glu	Thr	Asp	Glu	
20				100					105					110			
	Arg	Lys	Arg	Leu	Tyr	Ile	Phe	Val	Pro	Asp	Pro	Thr	Val	Gly	Phe	Leu	
			115					120					125				
25	Pro	Asn	Asp	Ala	Glu	Glu	Leu	Phe	Ile	Phe	Leu	Thr	Glu	Ile	Thr	Glu	
		130					135					140					
	Ile	Thr	Ile	Pro	Cys	Arg	Val	Thr	Asp	Pro	Gln	Leu	Val	Val	Thr	Leu	
30						150					155					160	
	His	Glu	Lys	Lys	Gly	Asp	Val	Ala	Leu	Pro	Val	Pro	Tyr	Asp	His	Gln	
35					165					170					175		
	Arg	Gly	Phe	Ser	Gly	Ile	Phe	Glu	Asp	Arg	Ser	Tyr	Ile	Cys	Lys	Thr	
				180					185					190			
40	Thr	Ile	Gly	Asp	Arg	Glu	Val	Asp	Ser	Asp	Ala	Tyr	Tyr	Val	Tyr	Arg	
			195					200					205				
	Leu	Gln	Val	Ser	Ser	Ile	Asn	Val	Ser	Val	Asn	Ala	Val	Gln	Thr	Val	
45			210				215					220					
	Val	Arg	Gln	Gly	Glu	Asn	Ile	Thr	Leu	Met	Cys	Ile	Val	Ile	Gly	Asn	
	225					230					235					240	
50	Glu	Val	Val	Asn	Phe	Glu	Trp	Thr	Tyr	Pro	Arg	Lys	Glu	Ser	Gly	Arg	
					245					250					255		
	Leu	Val	Glu	Pro	Val	Thr	Asp	Phe	Leu	Leu	Asp	Met	Pro	Tyr	His	Ile	
55				260					265					270			

EP 3 168 304 A1

	Arg	Ser	Ile	Leu	His	Ile	Pro	Ser	Ala	Glu	Leu	Glu	Asp	Ser	Gly	Thr	
			275					280					285				
5	Tyr	Thr	Cys	Asn	Val	Thr	Glu	Ser	Val	Asn	Asp	His	Gln	Asp	Glu	Lys	
		290					295					300					
10	Ala	Ile	Asn	Ile	Thr	Val	Val	Glu	Ser	Gly	Tyr	Val	Arg	Leu	Leu	Gly	
	305					310					315					320	
15	Glu	Val	Gly	Thr	Leu	Gln	Phe	Ala	Glu	Leu	His	Arg	Ser	Arg	Thr	Leu	
					325					330					335		
20	Gln	Val	Val	Phe	Glu	Ala	Tyr	Pro	Pro	Pro	Thr	Val	Leu	Trp	Phe	Lys	
				340					345					350			
25	Asp	Asn	Arg	Thr	Leu	Gly	Asp	Ser	Ser	Ala	Gly	Glu	Ile	Ala	Leu	Ser	
			355					360					365				
30	Thr	Arg	Asn	Val	Ser	Glu	Thr	Arg	Tyr	Val	Ser	Glu	Leu	Thr	Leu	Val	
		370					375					380					
35	Arg	Val	Lys	Val	Ala	Glu	Ala	Gly	His	Tyr	Thr	Met	Arg	Ala	Phe	His	
	385					390					395					400	
40	Glu	Asp	Ala	Glu	Val	Gln	Leu	Ser	Phe	Gln	Leu	Gln	Ile	Asn	Val	Pro	
					405					410					415		
45	Val	Arg	Val	Leu	Glu	Leu	Ser	Glu	Ser	His	Pro	Asp	Ser	Gly	Glu	Gln	
				420					425					430			
50	Thr	Val	Arg	Cys	Arg	Gly	Arg	Gly	Met	Pro	Gln	Pro	Asn	Ile	Ile	Trp	
			435					440					445				
55	Ser	Ala	Cys	Arg	Asp	Leu	Lys	Arg	Cys	Pro	Arg	Glu	Leu	Pro	Pro	Thr	
		450					455					460					
60	Leu	Leu	Gly	Asn	Ser	Ser	Glu	Glu	Glu	Ser	Gln	Leu	Glu	Thr	Asn	Val	
	465					470					475					480	
65	Thr	Tyr	Trp	Glu	Glu	Glu	Gln	Glu	Phe	Glu	Val	Val	Ser	Thr	Leu	Arg	
				485					490						495		
70	Leu	Gln	His	Val	Asp	Arg	Pro	Leu	Ser	Val	Arg	Cys	Thr	Leu	Arg	Asn	
				500					505					510			
75	Ala	Val	Gly	Gln	Asp	Thr	Gln	Glu	Val	Ile	Val	Val	Pro	His	Ser	Leu	

EP 3 168 304 A1

	515						520					525				
5	Pro	Phe	Lys	Val	Val	Val	Ile	Ser	Ala	Ile	Leu	Ala	Leu	Val	Val	Leu
		530					535					540				
10	Thr	Ile	Ile	Ser	Leu	Ile	Ile	Leu	Ile	Met	Leu	Trp	Gln	Lys	Lys	Pro
	545					550					555					560
15	Arg	Tyr	Glu	Ile	Arg	Trp	Lys	Val	Ile	Glu	Ser	Val	Ser	Ser	Asp	Gly
					565					570					575	
20	His	Glu	Tyr	Ile	Tyr	Val	Asp	Pro	Met	Gln	Leu	Pro	Tyr	Asp	Ser	Thr
				580					585					590		
25	Trp	Glu	Leu	Pro	Arg	Asp	Gln	Leu	Val	Leu	Gly	Arg	Thr	Leu	Gly	Ser
			595					600					605			
30	Gly	Ala	Phe	Gly	Gln	Val	Val	Glu	Ala	Thr	Ala	His	Gly	Leu	Ser	His
		610					615					620				
35	Ser	Gln	Ala	Thr	Met	Lys	Val	Ala	Val	Lys	Met	Leu	Lys	Ser	Thr	Ala
	625					630					635					640
40	Arg	Ser	Ser	Glu	Lys	Gln	Ala	Leu	Met	Ser	Glu	Leu	Lys	Ile	Met	Ser
					645					650					655	
45	His	Leu	Gly	Pro	His	Leu	Asn	Val	Val	Asn	Leu	Leu	Gly	Ala	Cys	Thr
				660					665					670		
50	Lys	Gly	Gly	Pro	Ile	Tyr	Ile	Ile	Thr	Glu	Tyr	Cys	Arg	Tyr	Gly	Asp
			675					680					685			
55	Leu	Val	Asp	Tyr	Leu	His	Arg	Asn	Lys	His	Thr	Phe	Leu	Gln	His	His
		690					695					700				
60	Ser	Asp	Lys	Arg	Arg	Pro	Pro	Ser	Ala	Glu	Leu	Tyr	Ser	Asn	Ala	Leu
	705					710					715					720
65	Pro	Val	Gly	Leu	Pro	Leu	Pro	Ser	His	Val	Ser	Leu	Thr	Gly	Glu	Ser
					725					730					735	
70	Asp	Gly	Gly	Tyr	Met	Asp	Met	Ser	Lys	Asp	Glu	Ser	Val	Asp	Tyr	Val
				740					745					750		
75	Pro	Met	Leu	Asp	Met	Lys	Gly	Asp	Val	Lys	Tyr	Ala	Asp	Ile	Glu	Ser
			755					760					765			

EP 3 168 304 A1

	Ser	Asn	Tyr	Met	Ala	Pro	Tyr	Asp	Asn	Tyr	Val	Pro	Ser	Ala	Pro	Glu	
	770						775					780					
5	Arg	Thr	Cys	Arg	Ala	Thr	Leu	Ile	Asn	Glu	Ser	Pro	Val	Leu	Ser	Tyr	
	785					790					795					800	
	Met	Asp	Leu	Val	Gly	Phe	Ser	Tyr	Gln	Val	Ala	Asn	Gly	Met	Glu	Phe	
10					805					810					815		
	Leu	Ala	Ser	Lys	Asn	Cys	Val	His	Arg	Asp	Leu	Ala	Ala	Arg	Asn	Val	
				820					825					830			
15	Leu	Ile	Cys	Glu	Gly	Lys	Leu	Val	Lys	Ile	Cys	Asp	Phe	Gly	Leu	Ala	
			835					840					845				
	Arg	Asp	Ile	Met	Arg	Asp	Ser	Asn	Tyr	Ile	Ser	Lys	Gly	Ser	Thr	Phe	
20		850					855					860					
	Leu	Pro	Leu	Lys	Trp	Met	Ala	Pro	Glu	Ser	Ile	Phe	Asn	Ser	Leu	Tyr	
25		865				870					875					880	
	Thr	Thr	Leu	Ser	Asp	Val	Trp	Ser	Phe	Gly	Ile	Leu	Leu	Trp	Glu	Ile	
					885					890					895		
30	Phe	Thr	Leu	Gly	Gly	Thr	Pro	Tyr	Pro	Glu	Leu	Pro	Met	Asn	Glu	Gln	
				900					905					910			
	Phe	Tyr	Asn	Ala	Ile	Lys	Arg	Gly	Tyr	Arg	Met	Ala	Gln	Pro	Ala	His	
35			915					920					925				
	Ala	Ser	Asp	Glu	Ile	Tyr	Glu	Ile	Met	Gln	Lys	Cys	Trp	Glu	Glu	Lys	
40			930				935					940					
	Phe	Glu	Ile	Arg	Pro	Pro	Phe	Ser	Gln	Leu	Val	Leu	Leu	Leu	Glu	Arg	
	945					950					955					960	
45	Leu	Leu	Gly	Glu	Gly	Tyr	Lys	Lys	Lys	Tyr	Gln	Gln	Val	Asp	Glu	Glu	
					965					970					975		
	Phe	Leu	Arg	Ser	Asp	His	Pro	Ala	Ile	Leu	Arg	Ser	Gln	Ala	Arg	Leu	
50				980					985					990			
	Pro	Gly	Phe	His	Gly	Leu	Arg	Ser	Pro	Leu	Asp	Thr	Ser	Ser	Val	Leu	
			995					1000					1005				
55	Tyr	Thr	Ala	Val	Gln	Pro	Asn	Glu	Gly	Asp	Asn	Asp	Tyr	Ile	Ile		
	1010						1015					1020					

EP 3 168 304 A1

	Pro Leu	Pro Asp	Pro Lys	Pro	Glu Val	Ala Asp	Glu	Gly Pro	Leu	
	1025			1030			1035			
5	Glu Gly	Ser Pro	Ser Leu	Ala	Ser Ser	Thr Leu	Asn	Glu Val	Asn	
	1040			1045			1050			
10	Thr Ser	Ser Thr	Ile Ser	Cys	Asp Ser	Pro Leu	Glu	Pro Gln	Asp	
	1055			1060			1065			
15	Glu Pro	Glu Pro	Glu Pro	Gln	Leu Glu	Leu Gln	Val	Glu Pro	Glu	
	1070			1075			1080			
20	Pro Glu	Leu Glu	Gln Leu	Pro	Asp Ser	Gly Cys	Pro	Ala Pro	Arg	
	1085			1090			1095			
25	Ala Glu	Ala Glu	Asp Ser	Phe	Leu					
	1100			1105						
	<210>	7								
	<211>	4017								
	<212>	DNA								
	<213>	Homo sapiens								
	<400>	7								
30	atggtcagct	actgggacac	cggggctcctg	ctgtgcgcgc	tgctcagctg	tctgcttctc				60
	acaggatcta	gttcagggttc	aaaattaaaa	gatacctgaac	tgagttttaa	aggcaccacg				120
	cacatcatgc	aagcaggcca	gacactgcat	ctccaatgca	ggggggaagc	agcccataaa				180
35	tggtctttgc	ctgaaatggt	gagtaaggaa	agcgaaaggc	tgagcataac	taaatctgcc				240
	tgtggaagaa	atggcaaaca	attctgcagt	actttaacct	tgaacacagc	tcaagcaaac				300
	cacactggct	tctacagctg	caaatatcta	gctgtaccta	cttcaaagaa	gaaggaaaca				360
40	gaatctgcaa	tctatatatt	tattagtgat	acaggtagac	ctttogtaga	gatgtacagt				420
	gaaatccccg	aaattataca	catgactgaa	ggaagggagc	tcgtcattcc	ctgccggggt				480
	acgtcaccta	acatcactgt	tactttaaaa	aagtttccac	ttgacacttt	gatccctgat				540
45	ggaaaacgca	taatctggga	cagtagaaag	ggcttcatca	tatcaaagtc	aacgtacaaa				600
	gaaatagggc	ttctgacctg	tgaagcaaca	gtcaatgggc	atttgtataa	gacaaactat				660
	ctcacacatc	gacaaaccaa	tacaatcata	gatgtccaaa	taagcacacc	acgccagtc				720
50	aaattactta	gaggccatac	tcttgtcctc	aattgtactg	ctaccactcc	cttgaacacg				780
	agagttcaaa	tgacctggag	ttaccctgat	gaaaaaata	agagagcttc	cgtaaggcga				840
55	cgaattgacc	aaagcaattc	ccatgccaac	atattctaca	gtgttcttac	tattgacaaa				900
	atgcagaaca	aagacaaagg	actttatact	tgctcgtgtaa	ggagtggacc	atcattcaaa				960

EP 3 168 304 A1

	tctgttaaca cctcagtgc tataatatgat aaagcattca tcactgtgaa acatcgaaaa	1020
	cagcaggtgc ttgaaaccgt agctggcaag cggctcttacc ggctctctat gaaagtgaag	1080
5	gcatttccct cgccggaagt tgtatggta aaagatgggt tacctgcgac tgagaaatct	1140
	gctcgctatt tgactcgtgg ctactcgtta attatcaagg acgtaactga agaggatgca	1200
	gggaattata caatcttgct gagcataaaa cagtcaaagt tgtttaaaaa cctcactgcc	1260
10	actctaattg tcaatgtgaa accccagatt tacgaaaagg ccgtgtcatc gtttccagac	1320
	ccggctctct acccactggg cagcagacaa atcctgactt gtaccgcata tggatatccct	1380
	caacctacaa tcaagtgggt ctggcaccct tghtaaccata atcattccga agcaagggtgt	1440
15	gacttttgtt ccaataatga agagtccttt atcctggatg ctgacagcaa catgggaaac	1500
	agaattgaga gcatcactca gcgcatggca ataatagaag gaaagaataa gatggctagc	1560
	accttggttg tggctgactc tagaatttct ggaatctaca tttgcatagc ttccaataaa	1620
20	gttgggactg tgggaagaaa cataagcttt tatatcacag atgtgccaaa tgggtttcat	1680
	gttaacttgg aaaaaatgcc gacggaagga gaggacctga aactgtcttg cacagttaac	1740
	aagttcttat acagagacgt tacttggatt ttactgcgga cagttaataa cagaacaatg	1800
25	cactacagta ttagcaagca aaaaatggcc atcactaagg agcactccat cactcttaat	1860
	cttaccatca tgaatgtttc cctgcaagat tcaggcacct atgcctgcag agccaggaat	1920
	gtatacacag gggaagaaat cctccagaag aaagaaatta caatcagaga tcaggaagca	1980
30	ccatacctcc tgcgaaacct cagtgatcac acagtggcca tcagcagttc caccacttta	2040
	gactgtcatg ctaatgggtgt ccccgagcct cagatcactt ggtttaaaaa caaccacaaa	2100
35	atacaacaag agcctggaat tatttttagga ccaggaagca gcacgctgtt tattgaaaga	2160
	gtcacagaag aggatgaagg tgtctatcac tgcaaagcca ccaaccagaa gggctctgtg	2220
	gaaagttcag catacctcac tgttcaagga acctcggaca agtctaactt ggagctgac	2280
40	actctaacat gcacctgtgt ggctgcgact ctcttctggc tcctattaac cctctttatc	2340
	cgaaaaatga aaaggtcttc ttctgaaata aagactgact acctatcaat tataatggac	2400
	ccagatgaag ttcctttgga tgagcagtggt gagcggctcc cttatgatgc cagcaagtgg	2460
45	gagtttgccc gggagagact taaactgggc aaatcacttg gaagaggggc ttttggaana	2520
	gtggttcaag catcagcatt tggcattaag aaatcaccta cgtgccggac tgtggctgtg	2580
	aaaatgctga aagagggggc cacggccagc gagtacaaag ctctgatgac tgagctaaaa	2640
50	atcttgaccc acattggcca ccatctgaac gtgggttaacc tgctgggagc ctgcaccaag	2700
	caaggagggc ctctgatggt gattgttgaa tactgcaaat atggaaatct ctccaactac	2760
55	ctcaagagca aacgtgactt attttttctc aacaaggatg cagcactaca catggagcct	2820
	aagaaagaaa aaatggagcc aggcctggaa caaggcaaga aaccaagact agatagcgtc	2880

EP 3 168 304 A1

accagcagcg aaagctttgc gagctccggc tttcaggaag ataaaagtct gagtgategtt 2940
gaggaagagg aggattctga cggtttctac aaggagccca tcactatgga agatctgatt 3000
5 tcttacagtt ttcaagtggc cagaggcatg gagttcctgt cttccagaaa gtgcattcat 3060
cgggacctgg cagcgagaaa cattctttta tctgagaaca acgtggtgaa gatttgtgat 3120
tttggccttg cccgggatat ttataagaac cccgattatg tgagaaaagg agatactcga 3180
10 cttcctctga aatggatggc tcctgaatct atctttgaca aaatctacag caccaagagc 3240
gacgtgtggt cttacggagt attgctgtgg gaaatcttct ccttaggtgg gtctccatac 3300
ccaggagtac aaatggatga ggacttttgc agtcgcctga ggaagggcat gaggatgaga 3360
15 gctcctgagt actctactcc tgaaatctat cagatcatgc tggactgctg gcacagagac 3420
ccaaaagaaa ggccaagatt tgcagaactt gtggaaaaac taggtgattt gcttcaagca 3480
20 aatgtacaac aggatggtaa agactacatc ccaatcaatg ccatactgac aggaaatagt 3540
gggtttacat actcaactcc tgccttctct gaggacttct tcaaggaaag tatttcagct 3600
ccgaagttaa attcaggaag ctctgatgat gtcagatatg taaatgcttt caagttcatg 3660
25 agcctggaaa gaatcaaac ctttgaagaa cttttaccga atgccacctc catgtttgat 3720
gactaccagg gcgacagcag cactctgttg gcctctccca tgctgaagcg cttcacctgg 3780
actgacagca aaccaaggc ctgctcaag attgacttga gagtaaccag taaaagtaag 3840
30 gagtcggggc tgtctgatgt cagcaggccc agtttctgcc attccagctg tgggcacgtc 3900
agcgaaggca agcgcagggt cacctacgac cacgtgagc tggaaaggaa aatcgcggtc 3960
35 tgctccccgc cccagacta caactcgggtg gtctgtact ccaccccacc catctag 4017

<210> 8
<211> 1338
40 <212> PRT
<213> Homo sapiens

<400> 8

Met Val Ser Tyr Trp Asp Thr Gly Val Leu Leu Cys Ala Leu Leu Ser
45 1 5 10 15

Cys Leu Leu Leu Thr Gly Ser Ser Ser Gly Ser Lys Leu Lys Asp Pro
50 20 25 30

Glu Leu Ser Leu Lys Gly Thr Gln His Ile Met Gln Ala Gly Gln Thr
55 35 40 45

Leu His Leu Gln Cys Arg Gly Glu Ala Ala His Lys Trp Ser Leu Pro
60 50 55 60

EP 3 168 304 A1

	Glu	Met	Val	Ser	Lys	Glu	Ser	Glu	Arg	Leu	Ser	Ile	Thr	Lys	Ser	Ala	65	70	75	80
5	Cys	Gly	Arg	Asn	Gly	Lys	Gln	Phe	Cys	Ser	Thr	Leu	Thr	Leu	Asn	Thr		85	90	95
10	Ala	Gln	Ala	Asn	His	Thr	Gly	Phe	Tyr	Ser	Cys	Lys	Tyr	Leu	Ala	Val		100	105	110
	Pro	Thr	Ser	Lys	Lys	Lys	Glu	Thr	Glu	Ser	Ala	Ile	Tyr	Ile	Phe	Ile		115	120	125
15	Ser	Asp	Thr	Gly	Arg	Pro	Phe	Val	Glu	Met	Tyr	Ser	Glu	Ile	Pro	Glu		130	135	140
20	Ile	Ile	His	Met	Thr	Glu	Gly	Arg	Glu	Leu	Val	Ile	Pro	Cys	Arg	Val		145	150	155
	Thr	Ser	Pro	Asn	Ile	Thr	Val	Thr	Leu	Lys	Lys	Phe	Pro	Leu	Asp	Thr		165	170	175
25	Leu	Ile	Pro	Asp	Gly	Lys	Arg	Ile	Ile	Trp	Asp	Ser	Arg	Lys	Gly	Phe		180	185	190
30	Ile	Ile	Ser	Asn	Ala	Thr	Tyr	Lys	Glu	Ile	Gly	Leu	Leu	Thr	Cys	Glu		195	200	205
35	Ala	Thr	Val	Asn	Gly	His	Leu	Tyr	Lys	Thr	Asn	Tyr	Leu	Thr	His	Arg		210	215	220
	Gln	Thr	Asn	Thr	Ile	Ile	Asp	Val	Gln	Ile	Ser	Thr	Pro	Arg	Pro	Val		225	230	235
40	Lys	Leu	Leu	Arg	Gly	His	Thr	Leu	Val	Leu	Asn	Cys	Thr	Ala	Thr	Thr		245	250	255
45	Pro	Leu	Asn	Thr	Arg	Val	Gln	Met	Thr	Trp	Ser	Tyr	Pro	Asp	Glu	Lys		260	265	270
	Asn	Lys	Arg	Ala	Ser	Val	Arg	Arg	Arg	Ile	Asp	Gln	Ser	Asn	Ser	His		275	280	285
50	Ala	Asn	Ile	Phe	Tyr	Ser	Val	Leu	Thr	Ile	Asp	Lys	Met	Gln	Asn	Lys		290	295	300
55	Asp	Lys	Gly	Leu	Tyr	Thr	Cys	Arg	Val	Arg	Ser	Gly	Pro	Ser	Phe	Lys		305	310	315
																				320

EP 3 168 304 A1

	Ser	Val	Asn	Thr	Ser	Val	His	Ile	Tyr	Asp	Lys	Ala	Phe	Ile	Thr	Val	
					325					330					335		
5	Lys	His	Arg	Lys	Gln	Gln	Val	Leu	Glu	Thr	Val	Ala	Gly	Lys	Arg	Ser	
				340					345					350			
	Tyr	Arg	Leu	Ser	Met	Lys	Val	Lys	Ala	Phe	Pro	Ser	Pro	Glu	Val	Val	
10			355					360					365				
	Trp	Leu	Lys	Asp	Gly	Leu	Pro	Ala	Thr	Glu	Lys	Ser	Ala	Arg	Tyr	Leu	
		370					375					380					
15	Thr	Arg	Gly	Tyr	Ser	Leu	Ile	Ile	Lys	Asp	Val	Thr	Glu	Glu	Asp	Ala	
	385					390					395					400	
	Gly	Asn	Tyr	Thr	Ile	Leu	Leu	Ser	Ile	Lys	Gln	Ser	Asn	Val	Phe	Lys	
20					405					410					415		
	Asn	Leu	Thr	Ala	Thr	Leu	Ile	Val	Asn	Val	Lys	Pro	Gln	Ile	Tyr	Glu	
25				420					425					430			
	Lys	Ala	Val	Ser	Ser	Phe	Pro	Asp	Pro	Ala	Leu	Tyr	Pro	Leu	Gly	Ser	
			435					440					445				
30	Arg	Gln	Ile	Leu	Thr	Cys	Thr	Ala	Tyr	Gly	Ile	Pro	Gln	Pro	Thr	Ile	
		450					455					460					
	Lys	Trp	Phe	Trp	His	Pro	Cys	Asn	His	Asn	His	Ser	Glu	Ala	Arg	Cys	
35	465					470					475					480	
	Asp	Phe	Cys	Ser	Asn	Asn	Glu	Glu	Ser	Phe	Ile	Leu	Asp	Ala	Asp	Ser	
					485					490					495		
40	Asn	Met	Gly	Asn	Arg	Ile	Glu	Ser	Ile	Thr	Gln	Arg	Met	Ala	Ile	Ile	
				500					505					510			
45	Glu	Gly	Lys	Asn	Lys	Met	Ala	Ser	Thr	Leu	Val	Val	Ala	Asp	Ser	Arg	
			515					520					525				
	Ile	Ser	Gly	Ile	Tyr	Ile	Cys	Ile	Ala	Ser	Asn	Lys	Val	Gly	Thr	Val	
50		530					535					540					
	Gly	Arg	Asn	Ile	Ser	Phe	Tyr	Ile	Thr	Asp	Val	Pro	Asn	Gly	Phe	His	
	545					550					555					560	
55	Val	Asn	Leu	Glu	Lys	Met	Pro	Thr	Glu	Gly	Glu	Asp	Leu	Lys	Leu	Ser	
					565					570					575		

EP 3 168 304 A1

	Cys	Thr	Val	Asn	Lys	Phe	Leu	Tyr	Arg	Asp	Val	Thr	Trp	Ile	Leu	Leu	
				580					585					590			
5	Arg	Thr	Val	Asn	Asn	Arg	Thr	Met	His	Tyr	Ser	Ile	Ser	Lys	Gln	Lys	
			595					600					605				
10	Met	Ala	Ile	Thr	Lys	Glu	His	Ser	Ile	Thr	Leu	Asn	Leu	Thr	Ile	Met	
		610					615					620					
15	Asn	Val	Ser	Leu	Gln	Asp	Ser	Gly	Thr	Tyr	Ala	Cys	Arg	Ala	Arg	Asn	
	625					630					635					640	
20	Val	Tyr	Thr	Gly	Glu	Glu	Ile	Leu	Gln	Lys	Lys	Glu	Ile	Thr	Ile	Arg	
					645					650					655		
25	Asp	Gln	Glu	Ala	Pro	Tyr	Leu	Leu	Arg	Asn	Leu	Ser	Asp	His	Thr	Val	
				660					665					670			
30	Ala	Ile	Ser	Ser	Ser	Thr	Thr	Leu	Asp	Cys	His	Ala	Asn	Gly	Val	Pro	
			675					680					685				
35	Glu	Pro	Gln	Ile	Thr	Trp	Phe	Lys	Asn	Asn	His	Lys	Ile	Gln	Gln	Glu	
		690					695					700					
40	Pro	Gly	Ile	Ile	Leu	Gly	Pro	Gly	Ser	Ser	Thr	Leu	Phe	Ile	Glu	Arg	
	705					710					715					720	
45	Val	Thr	Glu	Glu	Asp	Glu	Gly	Val	Tyr	His	Cys	Lys	Ala	Thr	Asn	Gln	
					725					730					735		
50	Lys	Gly	Ser	Val	Glu	Ser	Ser	Ala	Tyr	Leu	Thr	Val	Gln	Gly	Thr	Ser	
				740					745					750			
55	Asp	Lys	Ser	Asn	Leu	Glu	Leu	Ile	Thr	Leu	Thr	Cys	Thr	Cys	Val	Ala	
		755						760					765				
60	Ala	Thr	Leu	Phe	Trp	Leu	Leu	Leu	Thr	Leu	Phe	Ile	Arg	Lys	Met	Lys	
		770					775					780					
65	Arg	Ser	Ser	Ser	Glu	Ile	Lys	Thr	Asp	Tyr	Leu	Ser	Ile	Ile	Met	Asp	
	785					790					795					800	
70	Pro	Asp	Glu	Val	Pro	Leu	Asp	Glu	Gln	Cys	Glu	Arg	Leu	Pro	Tyr	Asp	
					805					810					815		
75	Ala	Ser	Lys	Trp	Glu	Phe	Ala	Arg	Glu	Arg	Leu	Lys	Leu	Gly	Lys	Ser	

EP 3 168 304 A1

	820							825							830						
5	Leu	Gly	Arg	Gly	Ala	Phe	Gly	Lys	Val	Val	Gln	Ala	Ser	Ala	Phe	Gly					
			835					840					845								
10	Ile	Lys	Lys	Ser	Pro	Thr	Cys	Arg	Thr	Val	Ala	Val	Lys	Met	Leu	Lys					
		850					855					860									
15	Glu	Gly	Ala	Thr	Ala	Ser	Glu	Tyr	Lys	Ala	Leu	Met	Thr	Glu	Leu	Lys					
	865					870					875					880					
20	Ile	Leu	Thr	His	Ile	Gly	His	His	Leu	Asn	Val	Val	Asn	Leu	Leu	Gly					
				885						890					895						
25	Ala	Cys	Thr	Lys	Gln	Gly	Gly	Pro	Leu	Met	Val	Ile	Val	Glu	Tyr	Cys					
				900					905					910							
30	Lys	Tyr	Gly	Asn	Leu	Ser	Asn	Tyr	Leu	Lys	Ser	Lys	Arg	Asp	Leu	Phe					
			915					920					925								
35	Phe	Leu	Asn	Lys	Asp	Ala	Ala	Leu	His	Met	Glu	Pro	Lys	Lys	Glu	Lys					
		930					935					940									
40	Met	Glu	Pro	Gly	Leu	Glu	Gln	Gly	Lys	Lys	Pro	Arg	Leu	Asp	Ser	Val					
	945					950					955					960					
45	Thr	Ser	Ser	Glu	Ser	Phe	Ala	Ser	Ser	Gly	Phe	Gln	Glu	Asp	Lys	Ser					
				965						970					975						
50	Leu	Ser	Asp	Val	Glu	Glu	Glu	Glu	Asp	Ser	Asp	Gly	Phe	Tyr	Lys	Glu					
			980						985					990							
55	Pro	Ile	Thr	Met	Glu	Asp	Leu	Ile	Ser	Tyr	Ser	Phe	Gln	Val	Ala	Arg					
			995					1000					1005								
60	Gly	Met	Glu	Phe	Leu	Ser	Ser	Arg	Lys	Cys	Ile	His	Arg	Asp	Leu						
		1010					1015					1020									
65	Ala	Ala	Arg	Asn	Ile	Leu	Leu	Ser	Glu	Asn	Asn	Val	Val	Lys	Ile						
		1025					1030					1035									
70	Cys	Asp	Phe	Gly	Leu	Ala	Arg	Asp	Ile	Tyr	Lys	Asn	Pro	Asp	Tyr						
		1040					1045					1050									
75	Val	Arg	Lys	Gly	Asp	Thr	Arg	Leu	Pro	Leu	Lys	Trp	Met	Ala	Pro						
		1055					1060					1065									

EP 3 168 304 A1

	Glu	Ser	Ile	Phe	Asp	Lys	Ile	Tyr	Ser	Thr	Lys	Ser	Asp	Val	Trp
	1070						1075					1080			
5	Ser	Tyr	Gly	Val	Leu	Leu	Trp	Glu	Ile	Phe	Ser	Leu	Gly	Gly	Ser
	1085						1090					1095			
10	Pro	Tyr	Pro	Gly	Val	Gln	Met	Asp	Glu	Asp	Phe	Cys	Ser	Arg	Leu
	1100						1105					1110			
	Arg	Glu	Gly	Met	Arg	Met	Arg	Ala	Pro	Glu	Tyr	Ser	Thr	Pro	Glu
	1115						1120					1125			
15	Ile	Tyr	Gln	Ile	Met	Leu	Asp	Cys	Trp	His	Arg	Asp	Pro	Lys	Glu
	1130						1135					1140			
20	Arg	Pro	Arg	Phe	Ala	Glu	Leu	Val	Glu	Lys	Leu	Gly	Asp	Leu	Leu
	1145						1150					1155			
	Gln	Ala	Asn	Val	Gln	Gln	Asp	Gly	Lys	Asp	Tyr	Ile	Pro	Ile	Asn
25	1160						1165					1170			
	Ala	Ile	Leu	Thr	Gly	Asn	Ser	Gly	Phe	Thr	Tyr	Ser	Thr	Pro	Ala
	1175						1180					1185			
30	Phe	Ser	Glu	Asp	Phe	Phe	Lys	Glu	Ser	Ile	Ser	Ala	Pro	Lys	Phe
	1190						1195					1200			
	Asn	Ser	Gly	Ser	Ser	Asp	Asp	Val	Arg	Tyr	Val	Asn	Ala	Phe	Lys
35	1205						1210					1215			
	Phe	Met	Ser	Leu	Glu	Arg	Ile	Lys	Thr	Phe	Glu	Glu	Leu	Leu	Pro
	1220						1225					1230			
40	Asn	Ala	Thr	Ser	Met	Phe	Asp	Asp	Tyr	Gln	Gly	Asp	Ser	Ser	Thr
	1235						1240					1245			
45	Leu	Leu	Ala	Ser	Pro	Met	Leu	Lys	Arg	Phe	Thr	Trp	Thr	Asp	Ser
	1250						1255					1260			
	Lys	Pro	Lys	Ala	Ser	Leu	Lys	Ile	Asp	Leu	Arg	Val	Thr	Ser	Lys
50	1265						1270					1275			
	Ser	Lys	Glu	Ser	Gly	Leu	Ser	Asp	Val	Ser	Arg	Pro	Ser	Phe	Cys
	1280						1285					1290			
55	His	Ser	Ser	Cys	Gly	His	Val	Ser	Glu	Gly	Lys	Arg	Arg	Phe	Thr
	1295						1300					1305			

EP 3 168 304 A1

Tyr Asp His Ala Glu Leu Glu Arg Lys Ile Ala Cys Cys Ser Pro
1310 1315 1320

5 Pro Pro Asp Tyr Asn Ser Val Val Leu Tyr Ser Thr Pro Pro Ile
1325 1330 1335

<210> 9

<211> 5830

<212> DNA

<213> Homo sapiens

<400> 9

actgagtccc gggacccccg gagagcggtc agtgtgtggt cgctgcgttt cctctgcctg 60
cgccggggcat cacttgccgc cgcagaaaag tccgtctggc agcctggata tcctctccta 120
ccggcaccgc cagacgcccc tgcagccgcc ggtcggcgcc cgggctccct agccctgtgc 180
gctcaactgt cctgcgctgc ggggtgccgc gagttccacc tccgcgcctc cttctctaga 240
caggcgctgg gagaaagaac cggctcccca gttctgggca ttctgcccgc ctgcaggtgc 300
aggatgcaga gcaagggtgt gctggccgct gccctgtggc tctgcgtgga gaccggggcc 360
gcctctgtgg gtttgcctag tgtttctctt gatctgcca ggctcagcat acaaaaagac 420
atacttaciaa ttaaggctaa tacaactctt caaattactt gcaggggaca gagggacttg 480
gactggcttt ggcccaataa tcagagtggc agtgagcaaa ggggtggagg gactgagtgc 540
agcgatggcc tcttctgtaa gacactcaca attccaaaag tgatcggaat tgacactgga 600
gcctacaagt gcttctaccg ggaaactgac ttggcctcgg tcatttatgt ctatgttcaa 660
gattacagat ctccatttat tgcttctgtt agtgaccaac atggagtctg gtacattact 720
gagaacaaaa acaaaactgt ggtgattcca tgtctcgggt ccatttcaaa tctcaacgtg 780
tcactttgtg caagataccc agaaaagaga tttgttctct atggtaacag aatttctctg 840
gacagcaaga agggctttac tattcccagc tacatgatca gctatgctgg catggtcttc 900
tgtgaagcaa aaattaatga tgaaagttac cagtctatta tgtacatagt tgtcgttgta 960
gggtatagga tttatgatgt ggttctgagt ccgtctcatg gaattgaact atctgttgga 1020
gaaaagcttg tcttaaattg tacagcaaga actgaactaa atgtggggat tgacttcaac 1080
tgggaatacc cttcttcgaa gcatcagcat aagaaacttg taaaccgaga cctaaaaacc 1140
cagtctggga gtgagatgaa gaaatTTTT agcaccttaa ctatagatgg tgtaaccggg 1200
agtgaccaag gattgtacac ctgtgcagca tccagtgggc tgatgaccaa gaagaacagc 1260
acatttgtca gggcccatga aaaacctttt gttgcttttg gaagtggcat ggaatctctg 1320
gtggaagcca cgggtggggg gcgtgtcaga atccctgcga agtaccttgg ttaccacccc 1380
ccagaaataa aatggtataa aatggaata ccccttgagt ccaatcacac aattaaagcg 1440

EP 3 168 304 A1

	gggcatgtac	tgacgattat	ggaagtgagt	gaaagagaca	caggaaatta	caactgtcatc	1500
	cttaccaatc	ccattttcaaa	ggagaagcag	agccatgtgg	tctctctggt	tgtgtatgtc	1560
5	ccaccccaga	ttggtgagaa	atctctaatac	tctcctgtgg	attcctacca	gtacggcacc	1620
	actcaaacgc	tgacatgtac	ggtctatgcc	attcctcccc	cgcatacat	ccactgggtat	1680
	tggcagttgg	aggaagagtg	cgccaacgag	cccagccaag	ctgtctcagt	gacaaaccca	1740
10	tacccttgtg	aagaatggag	aagtgtggag	gacttccagg	gaggaaataa	aattgaagtt	1800
	aataaaaatc	aatttgctct	aattgaagga	aaaaacaaaa	ctgtaagtac	ccttgttatac	1860
	caagcggcaa	atgtgtcagc	tttgtacaaa	tgtgaagcgg	tcaacaaagt	cgggagagga	1920
15	gagaggggtga	tctccttcca	cgtgaccagg	ggtcctgaaa	ttactttgca	acctgacatg	1980
	cagcccactg	agcaggagag	cgtgtccttg	tggtgactg	cagacagatc	tacgtttgag	2040
	aacctcacat	ggtacaagct	tggccacag	cctctgccaa	tccatgtggg	agagttgccc	2100
20	acacctgttt	gcaagaactt	ggatactctt	tggaaattga	atgccaccat	gttctctaata	2160
	agcacaaatg	acattttgat	catggagctt	aagaatgcat	ccttgacagga	ccaaggagac	2220
25	tatgtctgcc	ttgctcaaga	caggaagacc	aagaaaagac	attgcgtggg	caggcagctc	2280
	acagtcctag	agcgtgtggc	accacagatc	acaggaaacc	tggagaatca	gacgacaagt	2340
	attggggaaa	gcatcgaagt	ctcatgcacg	gcatctggga	atccccctcc	acagatcatg	2400
30	tggtttaaag	ataatgagac	ccttgtagaa	gactcaggca	ttgtattgaa	ggatgggaac	2460
	cggaacctca	ctatccgcag	agtgaggaag	gaggacgaag	gcctctacac	ctgccaggca	2520
	tgcagtgttc	ttggctgtgc	aaaagtggag	gcatttttca	taatagaagg	tgcccaggaa	2580
35	aagacgaact	tggaaatcat	tattctagta	ggcacggcgg	tgattgccat	gttcttctgg	2640
	ctacttcttg	tcatcatcct	acggaccgtt	aagcgggcca	atggagggga	actgaagaca	2700
	ggctacttgt	ccatcgtcat	ggatccagat	gaactcccat	tggatgaaca	ttgtgaacga	2760
40	ctgccttatg	atgccagcaa	atgggaattc	cccagagacc	ggctgaagct	aggtaaacct	2820
	cctggccgtg	gtgccttttg	ccaagtgatt	gaagcagatg	cctttggaat	tgacaagaca	2880
	gcaacttgca	ggacagtagc	agtcaaaatg	ttgaaagaag	gagcaacaca	cagtgaacat	2940
45	cgagctctca	tgtctgaact	caagatcctc	attcatattg	gtcaccatct	caatgtggtc	3000
	aaccttctag	gtgcctgtac	caagccagga	gggccactca	tggtgattgt	ggaattctgc	3060
	aaatttgga	acctgtccac	ttacctgagg	agcaagagaa	atgaatttgt	cccctacaag	3120
50	accaaagggg	cacgattccg	tcaagggaaa	gactacgttg	gagcaatccc	tgtggatctg	3180
	aaacggcgct	tggacagcat	caccagtagc	cagagctcag	ccagctctgg	atttgtggag	3240
55	gagaagtccc	tcagtgatgt	agaagaagag	gaagctcctg	aagatctgta	taaggacttc	3300
	ctgaccttgg	agcatctcat	ctgttacagc	ttccaagtgg	ctaagggcac	ggagttcttg	3360

EP 3 168 304 A1

	gcatcgcgaa agtgtatcca cagggacctg gcggcacgaa atatcctctt atcggagaag	3420
	aacgtgggta aaatctgtga ctttggttg gcccgggata ttataaaga tccagattat	3480
5	gtcagaaaag gagatgctcg cctccctttg aaatggatgg cccagaaac aatttttgac	3540
	agagtgtaca caatccagag tgacgtctgg tcttttggtg ttttgctgtg ggaaatattt	3600
	tccttaggtg cttctccata tcctgggta aagattgatg aagaattttg taggcgattg	3660
10	aaagaaggaa ctagaatgag ggcccctgat tatactacac cagaaatgta ccagaccatg	3720
	ctggactgct ggcacgggga gcccagtcag agaccacgt tttcagagtt ggtggaacat	3780
	ttgggaaatc tcttgcaagc taatgctcag caggatggca aagactacat tgttcttcg	3840
15	atatcagaga ctttgagcat ggaagaggat tctggactct ctctgcctac ctcacctgtt	3900
	tcctgtatgg aggaggagga agtatgtgac cccaaattcc attatgacaa cacagcagga	3960
20	atcagtcagt atctgcagaa cagtaagcga aagagccggc ctgtgagtgt aaaaacattt	4020
	gaagatatcc cgttagaaga accagaagta aaagtaatcc cagatgacaa ccagacggac	4080
	agtggatggt tctctgcctc agaagagctg aaaactttgg aagacagaac caaattatct	4140
25	ccatcttttg gtggaatggt gcccagcaaa agcagggagt ctgtggcatc tgaaggctca	4200
	aaccagacaa gcggctacca gtccggatat cactccgatg acacagacac caccgtgtac	4260
	tccagtgagg aagcagaact tttaaagctg atagagattg gagtgcacaa cggtagcaca	4320
30	gcccagattc tccagcctga ctcggggacc aactgagct ctctcctgt ttaaaaggaa	4380
	gcatccacac cccaactccc ggacatcaca tgagaggtct gctcagattt tgaagtgttg	4440
35	ttctttccac cagcaggaag tagccgcatt tgattttcat ttcgacaaca gaaaaaggac	4500
	ctcggaactgc aggagaccag tcttctagga atatcctgga agaggcttgt gacccaagaa	4560
	tgtgtctgtg tcttctccca gtgttgacct gatcctcttt tttcattcat ttaaaaagca	4620
40	ttatcatgcc cctgctgcgg gtctcaccat gggtttagaa caaagagctt caagcaatgg	4680
	ccccatcctc aaagaagtag cagtacctgg ggagctgaca cttctgtaaa actagaagat	4740
	aaaccaggca acgtaagtgt tcgaggtgtt gaagatggga aggatttgca gggctgagtc	4800
45	tatccaagag gctttgttta ggacgtgggt cccaagccaa gccttaagtg tggaaatcgg	4860
	attgatagaa aggaagacta acgttacctt gctttggaga gtactggagc ctgcaaatgc	4920
	attgtgtttg ctctggtgga ggtgggcatg gggctctgtt tgaaatgtaa agggttcaga	4980
50	cggggtttct ggttttagaa ggttgctgtt tcttcagatt gggctaaagt agagttcgtt	5040
	gtgctgtttc tgactcctaa tgagagttcc ttccagaccg ttagctgtct ccttgccaag	5100
55	ccccaggaag aaaatgatgc agctctggct ccttgtctcc caggctgac ctttattcag	5160
	aataccacaa agaaaggaca ttcagctcaa ggctccctgc cgtgttgaag agttctgact	5220

EP 3 168 304 A1

gcacaaacca gcttctggtt tcttctggaa tgaataccct catatctgtc ctgatgtgat 5280
 atgtctgaga ctgaatgctg gaggttcaat gtgaagctgt gtgtggtgtc aaagtttcag 5340
 5 gaaggatttt acccttttgt tcttccccct gtccccaacc cactctcacc ccgcaaccca 5400
 tcagtatttt agttatttgg cctctactcc agtaaacctg attgggtttg ttactctct 5460
 gaatgattat tagccagact tcaaaattat tttatagccc aaattataac atctattgta 5520
 10 ttatttagac ttttaacata tagagctatt tctactgatt ttgccccttg ttctgtcctt 5580
 tttttcaaaa aagaaaatgt gttttttggt tggtaccata gtgtgaaatg ctggaacaa 5640
 tgactataag acatgctatg gcacatatat ttatagtctg tttatgtaga acaaatgta 5700
 15 atatattaaa gccttatata taatgaactt tgtactattc acattttgta tcagtattat 5760
 gtagcataac aaaggtcata atgctttcag caattgatgt cattttatta aagaacattg 5820
 aaaaacttga 5830

20

<210> 10
 <211> 1356
 <212> PRT
 <213> Homo sapiens

25

<400> 10

Met Gln Ser Lys Val Leu Leu Ala Val Ala Leu Trp Leu Cys Val Glu
 1 5 10 15

30

Thr Arg Ala Ala Ser Val Gly Leu Pro Ser Val Ser Leu Asp Leu Pro
 20 25 30

35

Arg Leu Ser Ile Gln Lys Asp Ile Leu Thr Ile Lys Ala Asn Thr Thr
 35 40 45

40

Leu Gln Ile Thr Cys Arg Gly Gln Arg Asp Leu Asp Trp Leu Trp Pro
 50 55 60

45

Asn Asn Gln Ser Gly Ser Glu Gln Arg Val Glu Val Thr Glu Cys Ser
 65 70 75 80

50

Asp Gly Leu Phe Cys Lys Thr Leu Thr Ile Pro Lys Val Ile Gly Asn
 85 90 95

Asp Thr Gly Ala Tyr Lys Cys Phe Tyr Arg Glu Thr Asp Leu Ala Ser
 100 105 110

55

Val Ile Tyr Val Tyr Val Gln Asp Tyr Arg Ser Pro Phe Ile Ala Ser
 115 120 125

Val Ser Asp Gln His Gly Val Val Tyr Ile Thr Glu Asn Lys Asn Lys

EP 3 168 304 A1

	130					135						140					
5	Thr	Val	Val	Ile	Pro	Cys	Leu	Gly	Ser	Ile	Ser	Asn	Leu	Asn	Val	Ser	
	145					150					155					160	
	Leu	Cys	Ala	Arg	Tyr	Pro	Glu	Lys	Arg	Phe	Val	Pro	Asp	Gly	Asn	Arg	
10					165					170					175		
	Ile	Ser	Trp	Asp	Ser	Lys	Lys	Gly	Phe	Thr	Ile	Pro	Ser	Tyr	Met	Ile	
				180					185					190			
15	Ser	Tyr	Ala	Gly	Met	Val	Phe	Cys	Glu	Ala	Lys	Ile	Asn	Asp	Glu	Ser	
			195					200					205				
	Tyr	Gln	Ser	Ile	Met	Tyr	Ile	Val	Val	Val	Val	Gly	Tyr	Arg	Ile	Tyr	
20		210					215					220					
	Asp	Val	Val	Leu	Ser	Pro	Ser	His	Gly	Ile	Glu	Leu	Ser	Val	Gly	Glu	
	225					230					235					240	
25	Lys	Leu	Val	Leu	Asn	Cys	Thr	Ala	Arg	Thr	Glu	Leu	Asn	Val	Gly	Ile	
					245					250					255		
30	Asp	Phe	Asn	Trp	Glu	Tyr	Pro	Ser	Ser	Lys	His	Gln	His	Lys	Lys	Leu	
				260					265					270			
	Val	Asn	Arg	Asp	Leu	Lys	Thr	Gln	Ser	Gly	Ser	Glu	Met	Lys	Lys	Phe	
35			275					280					285				
	Leu	Ser	Thr	Leu	Thr	Ile	Asp	Gly	Val	Thr	Arg	Ser	Asp	Gln	Gly	Leu	
		290					295					300					
40	Tyr	Thr	Cys	Ala	Ala	Ser	Ser	Gly	Leu	Met	Thr	Lys	Lys	Asn	Ser	Thr	
	305					310					315					320	
	Phe	Val	Arg	Val	His	Glu	Lys	Pro	Phe	Val	Ala	Phe	Gly	Ser	Gly	Met	
45					325					330					335		
	Glu	Ser	Leu	Val	Glu	Ala	Thr	Val	Gly	Glu	Arg	Val	Arg	Ile	Pro	Ala	
50				340					345					350			
	Lys	Tyr	Leu	Gly	Tyr	Pro	Pro	Pro	Glu	Ile	Lys	Trp	Tyr	Lys	Asn	Gly	
			355					360					365				
55	Ile	Pro	Leu	Glu	Ser	Asn	His	Thr	Ile	Lys	Ala	Gly	His	Val	Leu	Thr	
		370					375					380					

EP 3 168 304 A1

	Ile	Met	Glu	Val	Ser	Glu	Arg	Asp	Thr	Gly	Asn	Tyr	Thr	Val	Ile	Leu	385	390	395	400
5	Thr	Asn	Pro	Ile	Ser	Lys	Glu	Lys	Gln	Ser	His	Val	Val	Ser	Leu	Val	405	410		415
10	Val	Tyr	Val	Pro	Pro	Gln	Ile	Gly	Glu	Lys	Ser	Leu	Ile	Ser	Pro	Val	420	425		430
	Asp	Ser	Tyr	Gln	Tyr	Gly	Thr	Thr	Gln	Thr	Leu	Thr	Cys	Thr	Val	Tyr	435	440	445	
15	Ala	Ile	Pro	Pro	Pro	His	His	Ile	His	Trp	Tyr	Trp	Gln	Leu	Glu	Glu	450	455	460	
20	Glu	Cys	Ala	Asn	Glu	Pro	Ser	Gln	Ala	Val	Ser	Val	Thr	Asn	Pro	Tyr	465	470	475	480
	Pro	Cys	Glu	Glu	Trp	Arg	Ser	Val	Glu	Asp	Phe	Gln	Gly	Gly	Asn	Lys	485	490		495
25	Ile	Glu	Val	Asn	Lys	Asn	Gln	Phe	Ala	Leu	Ile	Glu	Gly	Lys	Asn	Lys	500	505		510
30	Thr	Val	Ser	Thr	Leu	Val	Ile	Gln	Ala	Ala	Asn	Val	Ser	Ala	Leu	Tyr	515	520		525
35	Lys	Cys	Glu	Ala	Val	Asn	Lys	Val	Gly	Arg	Gly	Glu	Arg	Val	Ile	Ser	530	535	540	
	Phe	His	Val	Thr	Arg	Gly	Pro	Glu	Ile	Thr	Leu	Gln	Pro	Asp	Met	Gln	545	550	555	560
40	Pro	Thr	Glu	Gln	Glu	Ser	Val	Ser	Leu	Trp	Cys	Thr	Ala	Asp	Arg	Ser	565	570		575
45	Thr	Phe	Glu	Asn	Leu	Thr	Trp	Tyr	Lys	Leu	Gly	Pro	Gln	Pro	Leu	Pro	580	585		590
	Ile	His	Val	Gly	Glu	Leu	Pro	Thr	Pro	Val	Cys	Lys	Asn	Leu	Asp	Thr	595	600	605	
50	Leu	Trp	Lys	Leu	Asn	Ala	Thr	Met	Phe	Ser	Asn	Ser	Thr	Asn	Asp	Ile	610	615	620	
55	Leu	Ile	Met	Glu	Leu	Lys	Asn	Ala	Ser	Leu	Gln	Asp	Gln	Gly	Asp	Tyr	625	630	635	640

EP 3 168 304 A1

	Val	Cys	Leu	Ala	Gln	Asp	Arg	Lys	Thr	Lys	Lys	Arg	His	Cys	Val	Val	
					645					650					655		
5	Arg	Gln	Leu	Thr	Val	Leu	Glu	Arg	Val	Ala	Pro	Thr	Ile	Thr	Gly	Asn	
				660					665					670			
10	Leu	Glu	Asn	Gln	Thr	Thr	Ser	Ile	Gly	Glu	Ser	Ile	Glu	Val	Ser	Cys	
			675					680					685				
15	Thr	Ala	Ser	Gly	Asn	Pro	Pro	Pro	Gln	Ile	Met	Trp	Phe	Lys	Asp	Asn	
		690					695					700					
20	Glu	Thr	Leu	Val	Glu	Asp	Ser	Gly	Ile	Val	Leu	Lys	Asp	Gly	Asn	Arg	
	705					710					715					720	
25	Asn	Leu	Thr	Ile	Arg	Arg	Val	Arg	Lys	Glu	Asp	Glu	Gly	Leu	Tyr	Thr	
				725						730					735		
30	Cys	Gln	Ala	Cys	Ser	Val	Leu	Gly	Cys	Ala	Lys	Val	Glu	Ala	Phe	Phe	
				740					745					750			
35	Ile	Ile	Glu	Gly	Ala	Gln	Glu	Lys	Thr	Asn	Leu	Glu	Ile	Ile	Ile	Leu	
			755					760					765				
40	Val	Gly	Thr	Ala	Val	Ile	Ala	Met	Phe	Phe	Trp	Leu	Leu	Leu	Val	Ile	
		770					775					780					
45	Ile	Leu	Arg	Thr	Val	Lys	Arg	Ala	Asn	Gly	Gly	Glu	Leu	Lys	Thr	Gly	
	785					790					795					800	
50	Tyr	Leu	Ser	Ile	Val	Met	Asp	Pro	Asp	Glu	Leu	Pro	Leu	Asp	Glu	His	
				805						810					815		
55	Cys	Glu	Arg	Leu	Pro	Tyr	Asp	Ala	Ser	Lys	Trp	Glu	Phe	Pro	Arg	Asp	
				820					825					830			
60	Arg	Leu	Lys	Leu	Gly	Lys	Pro	Leu	Gly	Arg	Gly	Ala	Phe	Gly	Gln	Val	
			835					840					845				
65	Ile	Glu	Ala	Asp	Ala	Phe	Gly	Ile	Asp	Lys	Thr	Ala	Thr	Cys	Arg	Thr	
		850					855					860					
70	Val	Ala	Val	Lys	Met	Leu	Lys	Glu	Gly	Ala	Thr	His	Ser	Glu	His	Arg	
	865					870					875					880	
75	Ala	Leu	Met	Ser	Glu	Leu	Lys	Ile	Leu	Ile	His	Ile	Gly	His	His	Leu	
					885					890					895		

EP 3 168 304 A1

	Asn	Val	Val	Asn	Leu	Leu	Gly	Ala	Cys	Thr	Lys	Pro	Gly	Gly	Pro	Leu	
				900					905					910			
5	Met	Val	Ile	Val	Glu	Phe	Cys	Lys	Phe	Gly	Asn	Leu	Ser	Thr	Tyr	Leu	
			915					920					925				
	Arg	Ser	Lys	Arg	Asn	Glu	Phe	Val	Pro	Tyr	Lys	Thr	Lys	Gly	Ala	Arg	
10		930					935					940					
	Phe	Arg	Gln	Gly	Lys	Asp	Tyr	Val	Gly	Ala	Ile	Pro	Val	Asp	Leu	Lys	
	945					950					955					960	
15																	
	Arg	Arg	Leu	Asp	Ser	Ile	Thr	Ser	Ser	Gln	Ser	Ser	Ala	Ser	Ser	Gly	
					965					970						975	
20	Phe	Val	Glu	Glu	Lys	Ser	Leu	Ser	Asp	Val	Glu	Glu	Glu	Glu	Ala	Pro	
				980					985							990	
	Glu	Asp	Leu	Tyr	Lys	Asp	Phe	Leu	Thr	Leu	Glu	His	Leu	Ile	Cys	Tyr	
25			995					1000					1005				
	Ser	Phe	Gln	Val	Ala	Lys	Gly	Met	Glu	Phe	Leu	Ala	Ser	Arg	Lys		
		1010					1015					1020					
30																	
	Cys	Ile	His	Arg	Asp	Leu	Ala	Ala	Arg	Asn	Ile	Leu	Leu	Ser	Glu		
		1025					1030					1035					
	Lys	Asn	Val	Val	Lys	Ile	Cys	Asp	Phe	Gly	Leu	Ala	Arg	Asp	Ile		
35		1040					1045					1050					
	Tyr	Lys	Asp	Pro	Asp	Tyr	Val	Arg	Lys	Gly	Asp	Ala	Arg	Leu	Pro		
		1055					1060					1065					
40																	
	Leu	Lys	Trp	Met	Ala	Pro	Glu	Thr	Ile	Phe	Asp	Arg	Val	Tyr	Thr		
		1070					1075					1080					
45	Ile	Gln	Ser	Asp	Val	Trp	Ser	Phe	Gly	Val	Leu	Leu	Trp	Glu	Ile		
		1085					1090					1095					
	Phe	Ser	Leu	Gly	Ala	Ser	Pro	Tyr	Pro	Gly	Val	Lys	Ile	Asp	Glu		
50		1100					1105					1110					
	Glu	Phe	Cys	Arg	Arg	Leu	Lys	Glu	Gly	Thr	Arg	Met	Arg	Ala	Pro		
		1115					1120					1125					
55																	
	Asp	Tyr	Thr	Thr	Pro	Glu	Met	Tyr	Gln	Thr	Met	Leu	Asp	Cys	Trp		

EP 3 168 304 A1

	1130		1135		1140
5	His Gly 1145	Glu Pro Ser Gln Arg 1150	Pro Thr Phe Ser 1155	Glu Leu Val Glu 1160	
10	His Leu 1160	Gly Asn Leu Leu Gln 1165	Ala Asn Ala Gln Gln 1170	Asp Gly Lys 1175	
15	Asp Tyr 1175	Ile Val Leu Pro Ile 1180	Ser Glu Thr Leu Ser 1185	Met Glu Glu 1190	
20	Asp Ser 1190	Gly Leu Ser Leu Pro 1195	Thr Ser Pro Val Ser 1200	Cys Met Glu 1205	
25	Glu Glu 1205	Glu Val Cys Asp Pro 1210	Lys Phe His Tyr Asp 1215	Asn Thr Ala 1220	
30	Gly Ile 1220	Ser Gln Tyr Leu Gln 1225	Asn Ser Lys Arg Lys 1230	Ser Arg Pro 1235	
35	Val Ser 1235	Val Lys Thr Phe Glu 1240	Asp Ile Pro Leu Glu 1245	Glu Pro Glu 1250	
40	Val Lys 1250	Val Ile Pro Asp Asp 1255	Asn Gln Thr Asp Ser 1260	Gly Met Val 1265	
45	Leu Ala 1265	Ser Glu Glu Leu Lys 1270	Thr Leu Glu Asp Arg 1275	Thr Lys Leu 1280	
50	Ser Pro 1280	Ser Phe Gly Gly Met 1285	Val Pro Ser Lys Ser 1290	Arg Glu Ser 1295	
55	Val Ala 1295	Ser Glu Gly Ser Asn 1300	Gln Thr Ser Gly Tyr 1305	Gln Ser Gly 1310	
	Tyr His 1310	Ser Asp Asp Thr Asp 1315	Thr Thr Val Tyr Ser 1320	Ser Glu Glu 1325	
	Ala Glu 1325	Leu Leu Lys Leu Ile 1330	Glu Ile Gly Val Gln 1335	Thr Gly Ser 1340	
	Thr Ala 1340	Gln Ile Leu Gln Pro 1345	Asp Ser Gly Thr Thr 1350	Leu Ser Ser 1355	
	Pro Pro 1355	Val			

EP 3 168 304 A1

<210> 11
<211> 2305
<212> DNA
<213> Homo sapiens

5
 <400> 11
 ttcttggggc tgatgtccgc aaatatgcag aattaccggc cgggtcgctc ctgaagccag 60
 cgcgggggagc gagcgcgggcg gcggccagca ccgggaacgc accgaggaag aagcccagcc 120
 10 cccgccctcc gccccttccg tccccacccc ctaccggcg gccaggagg ctccccggct 180
 gcggcgcgca ctccctgttt ctctcctcc tggctggcg tgcctgcctc tccgactca 240
 ctgctcgccg ggcgccgtcc gccagctccg tgtccccgc gccaccctcc tccgggccgc 300
 15 gctccctaag ggatggtact gaatttcgcc gccacaggag accggctgga gcgcccgcgc 360
 cgcgccctgc ctctcctccg agcagccagc gcctcgggac gcgatgagga ccttggttg 420
 cctgctgctc ctcggtgcg gatacctcgc ccatgttctg gccgaggaag ccgagatccc 480
 20 ccgcgaggtg atcgagaggc tggcccgag tcagatccac agcatccggg acctccagcg 540
 actcctggag atagactccg tagggagtga ggattctttg gacaccagcc tgagagctca 600
 cggggtccac gccactaagc atgtgcccga gaagcggccc ctgcccattc ggaggaagag 660
 25 aagcatcgag gaagctgtcc ccgctgtctg caagaccagg acggtcattt acgagattcc 720
 tcggagtcag gtgcacccca cgtccgcca attcctgatc tggcccccg gcgtggaggt 780
 30 gaaacgctgc accggctgct gcaacacgag cagtgtcaag tgccagccct cccgcgtcca 840
 ccaccgcagc gtcaaggtgg ccaaggtgga atacgtcagg aagaagccaa aattaaaaga 900
 agtccaggtg aggttagagg agcatttgga gtgcgcctgc gcgaccacaa gcctgaatcc 960
 35 ggattatcgg gaagaggaca cggatgtgag gtgaggatga gccgcagccc tttcctggga 1020
 catggatgta catggcgtgt tacattcctg aacctactat gtacggtgct ttattgccag 1080
 tgtgcggtct ttgttctcct ccgtgaaaaa ctgtgtccga gaacactcgg gagaacaaag 1140
 40 agacagtgca catttgttta atgtgacatc aaagcaagta ttgtagcact cggatgaagca 1200
 gtaagaagct tccttgtcaa aaagagagag agagagagag agagagaaaa caaaaccaca 1260
 aatgacaaaa acaaaacgga ctcaaaaaa tatctaaact cgatgagatg gagggtcgcc 1320
 45 ccgtgggatg gaagtgcaga ggtctcagca gactggattt ctgtccgggt ggtcacaggt 1380
 gcttttttgc cgaggatgca gagcctgctt tgggaacgac tccagagggg tgctggtggg 1440
 ctctgcaggg cccgcaggaa gcaggaatgt cttggaaacc gccacgcgaa ctttagaaac 1500
 50 cacacctcct cgctgtagta tttaagccca tacagaaacc ttcctgagag ccttaagtgg 1560
 tttttttttt tgtttttgtt ttgttttttt tttttttgtt tttttttttt tttttttttt 1620
 ttacaccata aagtgattat taagcttcct tttactcttt ggctagcttt tttttttttt 1680
 55 tttttttttt ttttttttaa ttatctcttg gatgacattt acaccgataa cacacaggct 1740

EP 3 168 304 A1

gctgtaactg tcaggacagt gcgacggtat ttttcctagc aagatgcaaa ctaatgagat 1800

gtattaaaat aaacatggta tacctaccta tgcatacatc cctaaatggt tctggccttg 1860

5 tgtttctccc ttaccctgct ttatttggtta atttaagcca ttttgaaaga actatgcgtc 1920

aaccaatcgt acgccgtccc tgcggcacct gcccagagc ccgtttgtgg ctgagtgaca 1980

acttgttccc cgcagtgcac acctagaatg ctgtgttccc acgcggcacg tgagatgcat 2040

10 tgccgcttct gtctgtgttg ttggtgtgcc ctggtgcgt ggtggcggtc actccctctg 2100

ctgccagtgt ttggacagaa cccaaattct ttatttttgg taagatattg tgctttacct 2160

gtattaacag aaatgtgtgt gtgtggtttg tttttttgta aaggtgaagt ttgtatgttt 2220

15 acctaataatt acctgttttg tatacctgag agcctgctat gttcttcttt tgttgatcca 2280

aaattaaaaa aaaaatacca ccaac 2305

20 <210> 12
<211> 196
<212> PRT
<213> Homo sapiens

25 <400> 12

Met Arg Thr Leu Ala Cys Leu Leu Leu Leu Gly Cys Gly Tyr Leu Ala
1 5 10 15

30 His Val Leu Ala Glu Glu Ala Glu Ile Pro Arg Glu Val Ile Glu Arg
20 25 30

Leu Ala Arg Ser Gln Ile His Ser Ile Arg Asp Leu Gln Arg Leu Leu
35 35 40 45

Glu Ile Asp Ser Val Gly Ser Glu Asp Ser Leu Asp Thr Ser Leu Arg
50 55 60

40 Ala His Gly Val His Ala Thr Lys His Val Pro Glu Lys Arg Pro Leu
65 70 75 80

45 Pro Ile Arg Arg Lys Arg Ser Ile Glu Glu Ala Val Pro Ala Val Cys
85 90 95

Lys Thr Arg Thr Val Ile Tyr Glu Ile Pro Arg Ser Gln Val Asp Pro
50 100 105 110

Thr Ser Ala Asn Phe Leu Ile Trp Pro Pro Cys Val Glu Val Lys Arg
115 120 125

55 Cys Thr Gly Cys Cys Asn Thr Ser Ser Val Lys Cys Gln Pro Ser Arg
130 135 140

EP 3 168 304 A1

Val His His Arg Ser Val Lys Val Ala Lys Val Glu Tyr Val Arg Lys
145 150 155 160

5 Lys Pro Lys Leu Lys Glu Val Gln Val Arg Leu Glu Glu His Leu Glu
165 170 175

10 Cys Ala Cys Ala Thr Thr Ser Leu Asn Pro Asp Tyr Arg Glu Glu Asp
180 185 190

Thr Asp Val Arg
195

15
<210> 13
<211> 6633
<212> DNA
<213> Homo sapiens

20
<400> 13
ttctccccgc cccccagttg ttgtcgaagt ctggggggtg ggactggacc ccctgattgc 60
gtaagagcaa aaagcgaagg cgcaatctgg aactgggag attcggagcg cagggagttt 120
25 gagagaaact tttattttga agagaccaag gttgaggggg ggcttatttc ctgacagcta 180
tttacttaga gcaaatgatt agtttttaga ggatggacta taacattgaa tcaattacaa 240
aacgcggttt ttgagcccat tactgttggg gctacagggg gagaaacagg aggagactgc 300
30 aagagatcat ttgggaaggc cgtgggcacg ctctttactc catgtgtggg acattcattg 360
cggaataaca tcggaggaga agtttcccag agctatgggg acttcccatc cggcgttcct 420
ggctcttaggc tgtcttctca cagggctgag cctaatactc tgccagcttt cattaccctc 480
35 tatccttcca aatgaaaatg aaaagggttg gcagctgaat tcatcctttt ctctgagatg 540
ctttggggag agtgaagtga gctggcagta ccccatgtct gaagaagaga gctccgatgt 600
40 ggaaatcaga aatgaagaaa acaacagcgg cctttttgtg acggtcttgg aagtgagcag 660
tgcctcggcg gccacacag ggttgtacac ttgctattac aaccacactc agacagaaga 720
gaatgagctt gaaggcaggc acatttacat ctatgtgcca gaccagatg tagcctttgt 780
45 acctctagga atgacggatt atttagtcat cgtggaggat gatgattctg ccattatacc 840
ttgtcgaca actgatcccg agactcctgt aaccttacac aacagtgagg gggtggtacc 900
tgcctcctac gacagcagac agggctttta tgggaccttc actgtagggc cctatatctg 960
50 tgaggccacc gtcaaaggaa agaagttcca gaccatccca tttaatgttt atgctttaaa 1020
agcaacatca gagctggatc tagaaatgga agctcttaaa accgtgtata agtcagggga 1080
55 aacgattgtg gtcacctgtg ctgtttttta caatgaggtg gttgaccttc aatggactta 1140
ccctggagaa gtgaaaggca aaggcatcac aatgctggaa gaaatcaaag tcccatccat 1200

EP 3 168 304 A1

	caaattggtg tacactttga cgggtccccga ggccacggtg aaagacagtg gagattacga	1260
	atgtgctgcc cgccaggcta ccaggagggt caaagaaatg aagaaagtca ctatttctgt	1320
5	ccatgagaaa ggtttcattg aaatcaaacc caccttcagc cagttggaag ctgtcaacct	1380
	gcatgaagtc aaacattttg ttgtagaggt gcgggcctac ccacctccca ggatatcctg	1440
	gctgaaaaac aatctgactc tgattgaaaa tctcactgag atcaccactg atgtggaaaa	1500
10	gattcaggaa ataaggatat gaagcaaatt aaagctgac cgtgctaagg aagaagacag	1560
	tggccattat actattgtag ctcaaaatga agatgctgtg aagagctata cttttgaact	1620
	gttaactcaa gttccttcat ccattctgga cttggctgat gatcaccatg gctcaactgg	1680
15	gggacagacg gtgagggtgca cagctgaagg cacgccgctt cctgatattg agtggatgat	1740
	atgcaaagat attaagaaat gtaataatga aacttcctgg actattttgg ccaacaatgt	1800
	ctcaaacatc atcacggaga tccactcccg agacaggagt accgtggagg gccgtgtgac	1860
20	tttcgccaaa gtggaggaga ccatcgccgt gcgatgcctg gctaagaatc tccttgagac	1920
	tgagaaccga gagctgaagc tgggtggctcc caccctgcgt tctgaactca cgggtggctgc	1980
25	tgcagtccctg gtgctgttgg tgatttgtat catctcactt attgtcctgg ttgtcatttg	2040
	gaaacagaaa ccgaggatat aaattcgctg gagggtcatt gaatcaatca gcccggtatg	2100
	acatgaatat atttatgtgg acccgatgca gctgccttat gactcaagat gggagtttcc	2160
30	aagagatgga ctagtgcttg gtcgggtcctt ggggtctgga gcgtttggga aggtggttga	2220
	aggaacagcc tatggattaa gccgggtccca acctgtcatg aaagttgcag tgaagatgct	2280
	aaaacccacg gccagatcca gtgaaaaaca agctctcatg tctgaactga agataatgac	2340
35	tcacctgggg ccacatttga acattgtaaa cttgctggga gcctgcacca agtcaggccc	2400
	catttacatc atcacagagt attgcttcta tggagatttg gtcaactatt tgcataagaa	2460
40	tagggatagc ttcctgagcc accacccaga gaagccaaag aaagagctgg atatctttgg	2520
	attgaaccct gctgatgaaa gcacacggag ctatgttatt ttatcttttg aaaacaatgg	2580
	tgactacatg gacatgaagc aggctgatac tacacagtat gtcccatgc tagaaaggaa	2640
45	agaggtttct aaatattccg acatccagag atcactctat gatcgtccag cctcatataa	2700
	gaagaaatct atgttagact cagaagtcaa aaacctcctt tcagatgata actcagaagg	2760
	ccttacttta ttggatttgt tgagcttcac ctatcaagtt gcccgaggaa tggagttttt	2820
50	ggcttcaaaa aattgtgtcc accgtgatct ggctgctcgc aacgtcctcc tggcacaagg	2880
	aaaaattgtg aagatctgtg actttggcct ggccagagac atcatgcatg attcgaacta	2940
55	tgtgtcgaaa ggcagtacct ttctgcccgt gaagtggatg gtcctgaga gcatctttga	3000
	caacctctac accacactga gtgatgtctg gtcttatggc attctgctct gggagatctt	3060

EP 3 168 304 A1

	ttcccttggg	ggcaccctt	accccgcat	gatggtggat	tctactttct	acaataagat	3120
	caagagtggg	taccggatgg	ccaagcctga	ccacgctacc	agtgaagtct	acgagatcat	3180
5	ggtgaaatgc	tggaacagtg	agccggagaa	gagaccctcc	ttttaccacc	tgagtgagat	3240
	tgtggagaat	ctgctgcctg	gacaatataa	aaagagttat	gaaaaaattc	acctggactt	3300
	cctgaagagt	gaccatcctg	ctgtggcacg	catgcgtgtg	gactcagaca	atgcatacat	3360
10	tgtgtgcacc	tacaaaaacg	aggaagacaa	gctgaaggac	tgggaggggtg	gtctggatga	3420
	gcagagactg	agcgtgaca	gtggctacat	cattcctctg	cctgacattg	accctgtccc	3480
	tgaggaggag	gacctgggca	agaggaacag	acacagctcg	cagacctctg	aagagagtgc	3540
15	cattgagacg	ggttccagca	gttccacctt	catcaagaga	gaggacgaga	ccattgaaga	3600
	catcgacatg	atggacgaca	tcggcataga	ctcttcagac	ctggtggaag	acagcttcct	3660
	gtaactggcg	gattcgaggg	gttccttcca	cttctggggc	cacctctgga	tcccgttcag	3720
20	aaaaccactt	tattgcaatg	cggaggttga	gaggaggact	tggttgatgt	ttaaagagaa	3780
	gttcccagcc	aagggcctcg	gggagcgttc	taaatatgaa	tgaatgggat	attttgaaat	3840
25	gaactttgtc	agtgttgctc	ctcgcaatgc	ctcagtagca	tctcagtggg	gtgtgaagtt	3900
	tggagataga	tggataaggg	aataataggc	cacagaaggt	gaactttgtg	cttcaaggac	3960
	attggtgaga	gtccaacaga	cacaatttat	actgcgacag	aacttcagca	ttgtaattat	4020
30	gtaaataact	ctaaccaagg	ctgtgtttag	attgtattaa	ctatcttctt	tggacttctg	4080
	aagagaccac	tcaatccatc	catgtacttc	cctcttgaaa	cctgatgtca	gctgctgttg	4140
	aactttttta	agaagtgc	gaaaaacat	ttttgaacct	taaaaggtag	tggtagctata	4200
35	gcattttgct	atctttttta	gtgttaagag	ataaagaata	ataattaacc	aaccttggtt	4260
	aatagatttg	ggtcatttag	aagcctgaca	actcattttc	atattgtaat	ctatgtttat	4320
	aatactacta	ctgttatcag	taatgctaaa	tgtgtaataa	tgtaacatga	tttccctcca	4380
40	gagaaagcac	aattttaa	aatccttact	aagtaggtga	tgagtttgac	agtttttgac	4440
	atztatatta	aataacatgt	ttctctataa	agtatggtaa	tagctttagt	gaattaaatt	4500
	tagttgagca	tagagaacaa	agtaaaagta	gtgttggtcca	ggaagtcaga	atttttaact	4560
45	gtactgaata	ggttcccca	tccatcgtat	taaaaaaca	ttaactgccc	tctgaaataa	4620
	tgggattaga	aacaaacaaa	actcttaagt	cctaaaagtt	ctcaatgtag	aggcataaac	4680
	ctgtgctgaa	cataacttct	catgtatatt	acccaatgga	aaatataatg	atcagcaaaa	4740
50	agactggatt	tgcagaagtt	tttttttttt	ttcttcatgc	ctgatgaaag	ctttggcaac	4800
	cccaatatat	gtattttttg	aatctatgaa	cctgaaaagg	gtcagaagga	tgcccagaca	4860
55	tcagcctcct	tctttcaccc	cttaccacca	agagaaagag	tttgaaactc	gagaccataa	4920
	agatattctt	tagtggaggc	tggatgtgca	ttagcctgga	tcctcagttc	tcaaatgtgt	4980

EP 3 168 304 A1

	gtggcagcca ggatgactag atcctggggt tccatccttg agattctgaa gtatgaagtc	5040
	tgaggggaaac cagagtcctgt atttttctaa actccctggc tgttctgata ggccagtttt	5100
5	cggaaacact gacttaggtt tcaggaagtt gccatgggaa acaaataatt tgaactttgg	5160
	aacagggttg gaattcaacc acgcaggaag cctactattt aaatccttgg cttcaggtta	5220
	gtgacattta atgccatcta gctagcaatt gcgaccttaa ttttaactttc cagtcttagc	5280
10	tgaggctgag aaagctaaag tttgggtttg acagggttttc caaaagtaaa gatgctactt	5340
	cccactgtat gggggagatt gaactttccc cgtctcccg tttctgcctc ccactccata	5400
	ccccgccaag gaaaggcatg tacaaaaatt atgcaattca gtgttccaag tctctgtgta	5460
15	accagctcag tgttttggtg gaaaaaacat ttttaagtttt actgataatt tgagggttaga	5520
	tgggaggatg aattgtcaca tctatccaca ctgtcaaaca ggttgggtgtg ggttcattgg	5580
20	cattctttgc aatactgctt aattgctgat accatatgaa tgaaacatgg gctgtgatta	5640
	ctgcaatcac tgtgctatcg gcagatgatg ctttggaaga tgcagaagca ataataaagt	5700
	acttgactac ctactggtgt aatctcaatg caagcccca ctttcttata caactttttc	5760
25	atagtaagtg cgaagactga gccagattgg ccaattaaaa acgaaaacct gactaggttc	5820
	tgtagagcca attagacttg aaatacgttt gtgtttctag aatcacagct caagcattct	5880
	gtttatcgct cactctccct tgtacagcct tattttgttg gtgctttgca ttttgatatt	5940
30	gctgtgagcc ttgcatgaca tcatgaggcc ggatgaaact tctcagtcca gcagtttcca	6000
	gtcctaacaa atgctccac ctgaatttgt atatgactgc atttgtgggt gtgtgtgtgt	6060
35	tttcagcaaa ttccagattt gtttcctttt ggctcctgc aaagtctcca gaagaaaatt	6120
	tgccaatctt tcctactttc tatttttatg atgacaatca aagccggcct gagaaacact	6180
	atgtgtgact ttttaaacga ttagtgatgt ccttaaaatg tggcttgcca atctgtacaa	6240
40	aatggctcta tttttgtgaa gagggacata agataaaatg atgttatata tcaatatgta	6300
	tatatgtatt tctatataga cttggagaat actgccaaaa catttatgac aagctgtatc	6360
	actgccttcg tttatatattt ttttaactgtg ataatcccca caggcacatt aactgttgca	6420
45	cttttgaatg tccaaaattt atattttaga aataataaaa agaaagatac ttacatgttc	6480
	ccaaaacaat ggtgtggtga atgtgtgaga aaaactaact tgatagggtc taccaataca	6540
50	aaatgtatta cgaatgcccc tgttcatgtt tttgttttaa aacgtgtaaa tgaagatctt	6600
	tatatattcaa taaatgatat ataatttaaa gtt	6633
55	<210> 14	
	<211> 1089	
	<212> PRT	
	<213> Homo sapiens	

EP 3 168 304 A1

<400> 14

5	Met	Gly	Thr	Ser	His	Pro	Ala	Phe	Leu	Val	Leu	Gly	Cys	Leu	Leu	Thr
	1				5					10					15	
	Gly	Leu	Ser	Leu	Ile	Leu	Cys	Gln	Leu	Ser	Leu	Pro	Ser	Ile	Leu	Pro
				20					25					30		
10	Asn	Glu	Asn	Glu	Lys	Val	Val	Gln	Leu	Asn	Ser	Ser	Phe	Ser	Leu	Arg
			35					40					45			
	Cys	Phe	Gly	Glu	Ser	Glu	Val	Ser	Trp	Gln	Tyr	Pro	Met	Ser	Glu	Glu
15		50					55					60				
	Glu	Ser	Ser	Asp	Val	Glu	Ile	Arg	Asn	Glu	Glu	Asn	Asn	Ser	Gly	Leu
	65				70						75					80
20	Phe	Val	Thr	Val	Leu	Glu	Val	Ser	Ser	Ala	Ser	Ala	Ala	His	Thr	Gly
					85					90					95	
	Leu	Tyr	Thr	Cys	Tyr	Tyr	Asn	His	Thr	Gln	Thr	Glu	Glu	Asn	Glu	Leu
25				100					105					110		
	Glu	Gly	Arg	His	Ile	Tyr	Ile	Tyr	Val	Pro	Asp	Pro	Asp	Val	Ala	Phe
30			115						120				125			
	Val	Pro	Leu	Gly	Met	Thr	Asp	Tyr	Leu	Val	Ile	Val	Glu	Asp	Asp	Asp
		130					135					140				
35	Ser	Ala	Ile	Ile	Pro	Cys	Arg	Thr	Thr	Asp	Pro	Glu	Thr	Pro	Val	Thr
	145					150					155					160
	Leu	His	Asn	Ser	Glu	Gly	Val	Val	Pro	Ala	Ser	Tyr	Asp	Ser	Arg	Gln
40					165					170					175	
	Gly	Phe	Asn	Gly	Thr	Phe	Thr	Val	Gly	Pro	Tyr	Ile	Cys	Glu	Ala	Thr
				180					185					190		
45	Val	Lys	Gly	Lys	Lys	Phe	Gln	Thr	Ile	Pro	Phe	Asn	Val	Tyr	Ala	Leu
			195					200					205			
	Lys	Ala	Thr	Ser	Glu	Leu	Asp	Leu	Glu	Met	Glu	Ala	Leu	Lys	Thr	Val
50		210					215					220				
	Tyr	Lys	Ser	Gly	Glu	Thr	Ile	Val	Val	Thr	Cys	Ala	Val	Phe	Asn	Asn
	225					230					235					240
55	Glu	Val	Val	Asp	Leu	Gln	Trp	Thr	Tyr	Pro	Gly	Glu	Val	Lys	Gly	Lys

EP 3 168 304 A1

	245	250	255
5	Gly Ile Thr Met 260	Lys Val Pro Ser 265	Ile Lys Leu Val 270
10	Tyr Thr Leu Thr 275	Val Pro Glu Ala 280	Thr Val Lys Asp 285
15	Glu Cys Ala Ala Arg 290	Gln Ala Thr Arg 295	Glu Val Lys Glu Met Lys Lys 300
20	Val Thr Ile Ser Val 305	His Glu Lys Gly Phe 310	Ile Glu Ile Lys Pro Thr 315 320
25	Phe Ser Gln Leu Glu 325	Ala Val Asn Leu His Glu Val 330	Lys His Phe Val 335
30	Val Glu Val Arg 340	Ala Tyr Pro Pro 345	Arg Ile Ser Trp Leu Lys Asn 350
35	Asn Leu Thr Leu Ile Glu 355	Asn Leu Thr Glu Ile Thr 360	Thr Thr Asp Val Glu 365
40	Lys Ile Gln Glu Ile Arg 370	Tyr Arg Ser Lys Leu Lys 375	Leu Ile Arg Ala 380
45	Lys Glu Glu Asp Ser 385	Gly His Tyr Thr Ile 390	Val Ala Gln Asn Glu Asp 395 400
50	Ala Val Lys Ser Tyr 405	Thr Phe Glu Leu Leu Thr 410	Gln Val Pro Ser Ser 415
55	Ile Leu Asp Leu Val Asp 420	Asp His His Gly Ser Thr 425	Gly Gly Gln Thr 430
60	Val Arg Cys Thr Ala Glu Gly 435	Thr Pro Leu Pro Asp 440	Ile Glu Trp Met 445
65	Ile Cys Lys Asp Ile Lys 450	Lys Cys Asn Asn Glu Thr 455	Ser Trp Thr Ile 460
70	Leu Ala Asn Asn Val 465	Ser Asn Ile Ile Thr 470	Glu Ile His Ser Arg Asp 475 480
75	Arg Ser Thr Val Glu 485	Gly Arg Val Thr Phe 490	Ala Lys Val Glu Glu Thr 495

EP 3 168 304 A1

	Ile	Ala	Val	Arg	Cys	Leu	Ala	Lys	Asn	Leu	Leu	Gly	Ala	Glu	Asn	Arg	
				500					505						510		
5	Glu	Leu	Lys	Leu	Val	Ala	Pro	Thr	Leu	Arg	Ser	Glu	Leu	Thr	Val	Ala	
			515					520					525				
	Ala	Ala	Val	Leu	Val	Leu	Leu	Val	Ile	Val	Ile	Ile	Ser	Leu	Ile	Val	
10			530				535					540					
	Leu	Val	Val	Ile	Trp	Lys	Gln	Lys	Pro	Arg	Tyr	Glu	Ile	Arg	Trp	Arg	
	545					550					555					560	
15	Val	Ile	Glu	Ser	Ile	Ser	Pro	Asp	Gly	His	Glu	Tyr	Ile	Tyr	Val	Asp	
					565					570					575		
	Pro	Met	Gln	Leu	Pro	Tyr	Asp	Ser	Arg	Trp	Glu	Phe	Pro	Arg	Asp	Gly	
20				580					585					590			
	Leu	Val	Leu	Gly	Arg	Val	Leu	Gly	Ser	Gly	Ala	Phe	Gly	Lys	Val	Val	
			595					600					605				
25	Glu	Gly	Thr	Ala	Tyr	Gly	Leu	Ser	Arg	Ser	Gln	Pro	Val	Met	Lys	Val	
		610					615					620					
30	Ala	Val	Lys	Met	Leu	Lys	Pro	Thr	Ala	Arg	Ser	Ser	Glu	Lys	Gln	Ala	
	625					630					635					640	
	Leu	Met	Ser	Glu	Leu	Lys	Ile	Met	Thr	His	Leu	Gly	Pro	His	Leu	Asn	
35					645					650					655		
	Ile	Val	Asn	Leu	Leu	Gly	Ala	Cys	Thr	Lys	Ser	Gly	Pro	Ile	Tyr	Ile	
				660					665					670			
40	Ile	Thr	Glu	Tyr	Cys	Phe	Tyr	Gly	Asp	Leu	Val	Asn	Tyr	Leu	His	Lys	
			675					680					685				
	Asn	Arg	Asp	Ser	Phe	Leu	Ser	His	His	Pro	Glu	Lys	Pro	Lys	Lys	Glu	
45			690				695					700					
	Leu	Asp	Ile	Phe	Gly	Leu	Asn	Pro	Ala	Asp	Glu	Ser	Thr	Arg	Ser	Tyr	
	705					710					715					720	
50	Val	Ile	Leu	Ser	Phe	Glu	Asn	Asn	Gly	Asp	Tyr	Met	Asp	Met	Lys	Gln	
					725					730					735		
55	Ala	Asp	Thr	Thr	Gln	Tyr	Val	Pro	Met	Leu	Glu	Arg	Lys	Glu	Val	Ser	
				740					745					750			

EP 3 168 304 A1

	Lys	Tyr	Ser	Asp	Ile	Gln	Arg	Ser	Leu	Tyr	Asp	Arg	Pro	Ala	Ser	Tyr	
			755					760					765				
5	Lys	Lys	Lys	Ser	Met	Leu	Asp	Ser	Glu	Val	Lys	Asn	Leu	Leu	Ser	Asp	
		770					775					780					
	Asp	Asn	Ser	Glu	Gly	Leu	Thr	Leu	Leu	Asp	Leu	Leu	Ser	Phe	Thr	Tyr	
10	785					790				795						800	
	Gln	Val	Ala	Arg	Gly	Met	Glu	Phe	Leu	Ala	Ser	Lys	Asn	Cys	Val	His	
					805					810					815		
15	Arg	Asp	Leu	Ala	Ala	Arg	Asn	Val	Leu	Leu	Ala	Gln	Gly	Lys	Ile	Val	
				820					825					830			
	Lys	Ile	Cys	Asp	Phe	Gly	Leu	Ala	Arg	Asp	Ile	Met	His	Asp	Ser	Asn	
20			835					840					845				
	Tyr	Val	Ser	Lys	Gly	Ser	Thr	Phe	Leu	Pro	Val	Lys	Trp	Met	Ala	Pro	
25		850					855					860					
	Glu	Ser	Ile	Phe	Asp	Asn	Leu	Tyr	Thr	Thr	Leu	Ser	Asp	Val	Trp	Ser	
	865					870					875					880	
30	Tyr	Gly	Ile	Leu	Leu	Trp	Glu	Ile	Phe	Ser	Leu	Gly	Gly	Thr	Pro	Tyr	
				885						890					895		
	Pro	Gly	Met	Met	Val	Asp	Ser	Thr	Phe	Tyr	Asn	Lys	Ile	Lys	Ser	Gly	
35				900					905					910			
	Tyr	Arg	Met	Ala	Lys	Pro	Asp	His	Ala	Thr	Ser	Glu	Val	Tyr	Glu	Ile	
			915					920					925				
40	Met	Val	Lys	Cys	Trp	Asn	Ser	Glu	Pro	Glu	Lys	Arg	Pro	Ser	Phe	Tyr	
		930					935					940					
	His	Leu	Ser	Glu	Ile	Val	Glu	Asn	Leu	Leu	Pro	Gly	Gln	Tyr	Lys	Lys	
45	945					950					955					960	
	Ser	Tyr	Glu	Lys	Ile	His	Leu	Asp	Phe	Leu	Lys	Ser	Asp	His	Pro	Ala	
50					965					970					975		
	Val	Ala	Arg	Met	Arg	Val	Asp	Ser	Asp	Asn	Ala	Tyr	Ile	Gly	Val	Thr	
				980					985					990			
55	Tyr	Lys	Asn	Glu	Glu	Asp	Lys	Leu	Lys	Asp	Trp	Glu	Gly	Gly	Leu	Asp	
			995					1000						1005			

EP 3 168 304 A1

	Glu Gln Arg Leu Ser Ala Asp Ser Gly Tyr Ile Ile Pro Leu Pro	
	1010 1015 1020	
5	Asp Ile Asp Pro Val Pro Glu Glu Glu Asp Leu Gly Lys Arg Asn	
	1025 1030 1035	
10	Arg His Ser Ser Gln Thr Ser Glu Glu Ser Ala Ile Glu Thr Gly	
	1040 1045 1050	
15	Ser Ser Ser Ser Thr Phe Ile Lys Arg Glu Asp Glu Thr Ile Glu	
	1055 1060 1065	
20	Asp Ile Asp Met Met Asp Asp Ile Gly Ile Asp Ser Ser Asp Leu	
	1070 1075 1080	
25	Val Glu Asp Ser Phe Leu	
	1085	
	<210> 15	
	<211> 10	
	<212> RNA	
	<213> Artificial Sequence	
	<220>	
	<223> Synthetic anti-VEGF aptamer	
30	<400> 15	
	gaagaauggg	10
35	<210> 16	
	<211> 8	
	<212> RNA	
	<213> Artificial Sequence	
	<220>	
40	<223> Synthetic anti-VEGF aptamer	
	<400> 16	
	uuggacgc	8
45	<210> 17	
	<211> 8	
	<212> RNA	
	<213> Artificial Sequence	
50	<220>	
	<223> Synthetic anti-VEGF aptamer	
	<400> 17	
	gugaaugc	8
55	<210> 18	

<211> 27
 <212> RNA
 <213> Artificial Sequence
 5 <220>
 <223> Synthetic anti-VEGF aptamer
 <400> 18
 cggaaucagu gaaugcuuau acauccg 27
 10 <210> 19
 <211> 27
 <212> RNA
 <213> Artificial Sequence
 15 <220>
 <223> Synthetic anti-VEGF aptamer
 <400> 19
 cggaaucagu gaaugcuuau acauccg 27
 20 <210> 20
 <211> 32
 <212> DNA
 <213> Artificial Sequence
 25 <220>
 <223> Synthetic anti-PDGF aptamer
 30 <220>
 <221> modified_base
 <222> (10)..(10)
 <223> n=hexaethylene-glycol phosphoramidite
 35 <220>
 <221> misc_feature
 <222> (10)..(10)
 <223> n is a, c, g, t or u
 40 <220>
 <221> modified_base
 <222> (23)..(23)
 <223> n=hexaethylene-glycol phosphoramidite
 45 <220>
 <221> misc_feature
 <222> (23)..(23)
 <223> n is a, c, g, t or u
 <400> 20
 caggcuacgn cgtagagcau cantgatccu gt 32
 50 <210> 21
 <211> 30
 <212> DNA
 <213> Artificial Sequence
 55 <220>
 <223> Synthetic anti-PDGF aptamer

<400> 21
 caggctacgc gtagagcatc atgacacctgt 30

5 <210> 22
 <211> 32
 <212> DNA
 <213> Artificial Sequence

10 <220>
 <223> Synthetic anti-PDGF aptamer

15 <220>
 <221> misc_feature
 <222> (10)..(10)
 <223> n is a, c, g, t or u

20 <220>
 <221> misc_feature
 <222> (23)..(23)
 <223> n is a, c, g, t or u

<400> 22
 caggcuacgn cgtagagcau cantgatccu gt 32

25 <210> 23
 <211> 32
 <212> DNA
 <213> Artificial Sequence

30 <220>
 <223> Synthetic anti-PDGF aptamer

35 <220>
 <221> misc_feature
 <222> (1)..(32)
 <223> U at positions 6, 20 and 30 is 2'-fluoro-2'-deoxyuridine

40 <220>
 <221> misc_feature
 <222> (1)..(32)
 <223> C at positions 8, 21, 28 and 29 is 2'-fluoro-2'-deoxycytidine

45 <220>
 <221> misc_feature
 <222> (1)..(32)
 <223> G at positions 9, 15, 17 and 31 is 2'-O-Methyl-2'-deoxyguanosine

50 <220>
 <221> misc_feature
 <222> (1)..(32)
 <223> A at position 22 is 2'-O-Methyl-2'-deoxyadenosine

55 <220>
 <221> misc_feature
 <222> (1)..(32)
 <223> N at positions 10 and 23 is from a hexaethylene glycol
 phosphoramidite

EP 3 168 304 A1

<220>
 <221> misc_feature
 <222> (32)..(32)
 <223> Nucleotide 32 is an inverted orientation T (3'-3'-linked)
 5
 <400> 23
 caggcuacgn cgtagagcau cantgatccu gt 32

 <210> 24
 <211> 118
 <212> PRT
 <213> Artificial Sequence

 <220>
 <223> Synthetic anti-VEGF antibody
 15
 <400> 24

 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1 5 10 15
 20
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Asp Phe Thr His Tyr
 20 25 30
 25
 Gly Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45
 30
 Gly Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Ala Asp Phe
 50 55 60
 Lys Arg Arg Phe Thr Phe Ser Leu Asp Thr Ser Lys Ser Thr Ala Tyr
 65 70 75 80
 35
 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95
 40
 Ala Lys Tyr Pro Tyr Tyr Tyr Gly Thr Ser His Trp Tyr Phe Asp Val
 100 105 110
 Trp Gly Gln Gly Thr Leu
 115
 45
 <210> 25
 <211> 110
 <212> PRT
 <213> Artificial Sequence
 50
 <220>
 <223> Synthetic anti-VEGF antibody
 <400> 25
 55
 Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
 1 5 10 15

EP 3 168 304 A1

	Asp	Arg	Val	Thr	Ile	Thr	Cys	Ser	Ala	Ser	Gln	Asp	Ile	Ser	Asn	Tyr	
				20					25					30			
5	Leu	Asn	Trp	Tyr	Gln	Gln	Lys	Pro	Gly	Lys	Ala	Pro	Lys	Val	Leu	Ile	
			35					40					45				
	Tyr	Phe	Thr	Ser	Ser	Leu	His	Ser	Gly	Val	Pro	Ser	Arg	Phe	Ser	Gly	
10		50					55						60				
	Ser	Gly	Ser	Gly	Thr	Asp	Phe	Thr	Leu	Thr	Ile	Ser	Ser	Leu	Gln	Pro	
	65					70					75					80	
15																	
	Glu	Asp	Phe	Ala	Thr	Tyr	Tyr	Cys	Gln	Gln	Tyr	Ser	Thr	Val	Pro	Trp	
					85					90					95		
20	Thr	Phe	Gly	Gln	Gly	Thr	Lys	Val	Glu	Ile	Lys	Arg	Thr	Val			
				100					105					110			
25	<210>	26															
	<211>	118															
	<212>	PRT															
	<213>	Artificial Sequence															
	<220>																
30	<223>	Synthetic anti-VEGF antibody															
	<400>	26															
	Glu	Val	Gln	Leu	Val	Glu	Ser	Gly	Gly	Gly	Leu	Val	Gln	Pro	Gly	Gly	
35	1				5					10					15		
	Ser	Leu	Arg	Leu	Ser	Cys	Ala	Ala	Ser	Gly	Tyr	Thr	Phe	Thr	Asn	Tyr	
				20					25					30			
40																	
	Gly	Met	Asn	Trp	Val	Arg	Gln	Ala	Pro	Gly	Lys	Gly	Leu	Glu	Trp	Val	
			35				40						45				
45	Gly	Trp	Ile	Asn	Thr	Tyr	Thr	Gly	Glu	Pro	Thr	Tyr	Ala	Ala	Asp	Phe	
		50					55					60					
	Lys	Arg	Arg	Phe	Thr	Phe	Ser	Leu	Asp	Thr	Ser	Lys	Ser	Thr	Ala	Tyr	
50	65					70					75					80	
	Leu	Gln	Met	Asn	Ser	Leu	Arg	Ala	Glu	Asp	Thr	Ala	Val	Tyr	Tyr	Cys	
					85					90					95		
55	Ala	Lys	Tyr	Pro	His	Tyr	Tyr	Gly	Ser	Ser	His	Trp	Tyr	Phe	Asp	Val	
				100					105					110			

Trp Gly Gln Gly Thr Leu
115

5 <210> 27
 <211> 110
 <212> PRT
 <213> Artificial Sequence

10 <220>
 <223> Synthetic anti-VEGF antibody
 <400> 27

15 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
 1 5 10 15

20 Asp Arg Val Thr Ile Thr Cys Ser Ala Ser Gln Asp Ile Ser Asn Tyr
 20 25 30

25 Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Val Leu Ile
 35 40 45

30 Tyr Phe Thr Ser Ser Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly
 50 55 60

35 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
 65 70 75 80

40 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Ser Thr Val Pro Trp
 85 90 95

45 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val
 100 105 110

Claims

1. A PDGF antagonist and a VEGF antagonist, wherein the PDGF antagonist is STI57 or a pharmaceutically acceptable salt thereof and the VEGF antagonist is a humanized anti-VEGF antibody or binding fragment thereof that binds to VEGF-A, for use in a method for ameliorating wet type age-related macular degeneration, wherein the PDGF antagonist and the VEGF antagonist are administered simultaneously or within 90 days of each other to a mammal in need thereof, and wherein the PDGF antagonist and the VEGF antagonist are administered in an amount effective to ameliorate the wet type age-related macular degeneration.
2. The PDGF antagonist and the VEGF antagonist for use according to claim 1, wherein the PDGF antagonist and the VEGF antagonist are administered within 10 days of each other.
3. The PDGF antagonist and the VEGF antagonist for use according to claim 1, wherein the PDGF antagonist and the VEGF antagonist are administered within 5 days of each other.
4. The PDGF antagonist and the VEGF antagonist for use according to claim 1, wherein the PDGF antagonist and the VEGF antagonist are administered within 24 hours of each other.

5. The PDGF antagonist and the VEGF antagonist for use according to claim 1, wherein the PDGF antagonist and the VEGF antagonist are administered simultaneously.
6. The PDGF antagonist and the VEGF antagonist for use according to claim 1, wherein the PDGF antagonist and VEGF antagonist are administered separately in individual dosage amounts.
7. The PDGF antagonist and the VEGF antagonist for use according to claim 1, wherein the PDGF antagonist and VEGF antagonist are administered together in the same composition.
8. The PDGF antagonist and the VEGF antagonist for use according to claim 1, wherein the mammal is a human.
9. The PDGF antagonist and the VEGF antagonist for use according to claim 1, wherein the VEGF antagonist is a humanized anti-VEGF antibody having a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 26 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 27, or a humanized anti-VEGF antibody binding fragment having a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 25 and a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 24.
10. The PDGF antagonist and the VEGF antagonist for use according to claim 9, wherein the VEGF antagonist is a humanized anti-VEGF antibody binding fragment having a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 24 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 25.
11. The PDGF antagonist and the VEGF antagonist for use according to claim 9, wherein the VEGF antagonist is a humanized anti-VEGF antibody having a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 26 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 27.
12. The PDGF antagonist and the VEGF antagonist for use according to claim 1, wherein the dosage of the PDGF antagonist or the VEGF antagonist is about 0.1 mg to about 250 mg per day.
13. The PDGF antagonist and the VEGF antagonist for use according to claim 12, wherein the dosage of the PDGF antagonist or the VEGF antagonist is about 1 mg to about 20 mg per day.
14. The PDGF antagonist and the VEGF antagonist for use according to claim 13, wherein the dosage of the PDGF antagonist or the VEGF antagonist is about 3 mg to about 5 mg per day.
15. The PDGF antagonist and the VEGF antagonist for use according to claim 12, wherein the dosage of the VEGF antagonist is about 0.15 mg to about 3.0 mg per day.
16. The PDGF antagonist and the VEGF antagonist for use according to claim 15, wherein the dosage of the VEGF antagonist is about 0.3 mg to about 3.0 mg per day.
17. The PDGF antagonist and the VEGF antagonist for use according to claim 16, wherein the dosage of the VEGF antagonist is about 0.1 mg to 1.0 mg per day.

Figure 1 (A) Sequence of PDGF-B nucleic acid (GenBank Accession No. X02811) (SEQ ID NO: 1)

```

1  CCCTGCCTGC CTCCCTGCGC ACCCGCAGCC TCCCCCGCTG CCTCCCTAGG GCTCCCTCC
61  GGCCGCCAGC GCCCATTTTT CATTCCTTAG ATAGAGATAC TTTGCGCGCA CACACATACA
121 TACGCGCGCA AAAAGGAAAA AAAAAAAAAA AAGCCCACCC TCCAGCCTCG CTGCAAAGAG
181 AAAACCGGAG CAGCCGCAGC TCGCAGCTCG CAGCCCGCAG CCCGCAGAGG ACGCCAGAG
241 CGGCGAGCGG GCGGGCAGAC GGACCGACGG ACTCGCGCCG CGTCCACCTG TCGGCCGGGC
301 CCAGCCGAGC GCGCAGCGGG CACGCCGCGC GCGCGGAGCA GCCGTGCCCG CCGCCGGGC
361 CCGCCGCCAG GCGGCACACG CTCCCGCCCC CTACCCGGC CCGGGCGGGA GTTTGCACCT
421 CTCCCTGCCC GGGTGCTCGA GCTGCCGTG CAAAGCCAAC TTTGAAAAA GTTTTTTGGG
481 GGAGACTTGG GCCTTGAGGT GCCCAGCTCC GCGCTTTCCG ATTTTGGGGG CCTTCCAGA
541 AAATGTTGCA AAAAAGCTAA GCCGGCGGGC AGAGGAAAAC GCCTGTAGCC GGCGAGTGAA
601 GACGAACCAT CGACTGCCGT GTTCCTTTTC CTCTTGGAGG TTGGAGTCCC CTGGGCGCCC
661 CCACACGGCT AGACGCCTCG GCTGGTTCGC GACGCAGCCC CCCGGCCGTG GATGCTGCAC
721 TCGGGCTCGG GATCCGCCCA GGTAGCGGCC TCGGACCCAG GTCCTGCGCC CAGGTCCTCC
781 CCTGCCCCCC AGCGACGGAG CCGGGGCCGG GGGCGGCGGC GCCGGGGGCA TGGGGGTGAG
841 CCGCGGCTGC AGAGGCCTGA GCGCCTGATC GCCGCGGACC CGAGCCGAGC CCACCCCCT
901 CCCCAGCCCC CCACCCTGGC CGCGGGGGCG GCGCGCTCGA TCTACGCTT CGGGGCCCCG
961 CGGGGCCGGG CCCGGAGTCG GCATGAATCG CTGCTGGGCG CTCTTCCTGT CTCTCTGCTG
1021 CTACCTGCGT CTGGTCAGCG CCGAGGGGGA CCCCATTCCC GAGGAGCTTT ATGAGATGCT
1081 GAGTGACCAC TCGATCCGCT CCTTTGATGA TCTCCAACGC CTGCTGCACG GAGACCCCGG
1141 AGAGGAAGAT GGGGCCGAGT TGGACCTGAA CATGACCCGC TCCCCTCTG GAGGCGAGCT
1201 GGAGAGCTTG GTCGTGGAA GAAGGAGCCT GGGTTCCTG ACCATTGCTG AGCGGGCCAT
1261 GATCGCCGAG TGCAAGACGC GCACCGAGGT GTTCGAGATC TCCCGGCGCC TCATAGACCG
1321 CACCAACGCC AACTTCCTGG TGTGGCCGCC CTGTGTGGAG GTGCAGCGCT GCTCCGGCTG
1381 CTGCAACAAC CGCAACGTGC AGTGCCGCC CACCAGGTG CAGCTGCGAC CTGTCCAGGT

```

1441 GAGAAAGATC GAGATTGTGC GGAAGAAGCC AATCTTTAAG AAGGCCACGG TGACGCTGGA
 1501 AGACCACCTG GCATGCAAGT GTGAGACAGT GGCAGCTGCA CGGCTGTGA CCCGAAGCCC
 1561 GGGGGGTTCC CAGGAGCAGC GAGCCAAAC GCCCAAAC CGGGTGACCA TTCGGACGGT
 1621 GCGAGTCCGC CGGCCCCCA AGGGCAAGCA CCGGAAATTC AAGCACACGC ATGACAAGAC
 1681 GGCCTGAAG GAGACCCTTG GAGCCTAGGG GCATCGGCAG GAGAGTGTGT GGGCAGGGTT
 1741 ATTTAATATG GTATTTGCTG TATTGCCCC ATGGGGCCTT GGAGTAGATA ATATTGTTTC
 1801 CCTCGTCCGT CTGTCTCGAT GCCTGATTCG GACGGCCAAT GGTGCCTCCC CCACCCCTCC
 1861 ACGTGTCCGT CCACCCCTCC ATCAGCGGGT CTCCTCCCAG CGGCCTCCGG CTCTTGCCCA
 1921 GCAGCTCAAG AAGAAAAGA AGGACTGAAC TCCATCGCCA TCTTCTTCCC TTAAGTCCAA
 1981 GAACTTGGGA TAAGAGTGTG AGAGAGACTG ATGGGGTCGC TCTTTGGGGG AAACGGGTTC
 2041 CTTCCCTGCT ACCTGGCCTG GGCCACACCT GAGCGCTGTG GACTGTCCTG AGGAGCCCTG
 2101 AGGACCTCTC AGCATAGCCT GCCTGATCCC TGAACCC

Figure 1 (B) Sequence of PDGF-B propeptide (GenBank Accession No. CAA26579) (SEQ ID NO: 2)

1 MNRCWALFLS LCCYLRLVSA EGDPIPEELY EMLSDHSIRS FDDLQRL LHG DPGEEDGAEL
61 DLNMTRSHSG GELESLARGR RSLGSLTIAE PAMLAECKTR TEVFEISRRL IDRTNANFLV
121 WPPCVEVQRC SGCCNNRNVQ CRPTQVQLRP VQVRKIEIVR KKPIFKKATV TLEDHLACKC
181 ETVA AARPVT RSPGGSQEQR AKTPQTRVTI RTVRVRRPPK GKHRKFKHTH DKTALKETLG
241 A

Figure 1 (C) Sequence of PDGF-A nucleic acid (GenBank Accession No. X06374) (SEQ ID NO: 11)

```

1  TTCTTGGGGC TGATGTCCGC AAATATGCAG AATTACCGGC CGGGTCGCTC CTGAAGCCAG
61  CGCGGGGAGC GAGCGCGGCG GCGGCCAGCA CCGGGAACGC ACCGAGGAAG AAGCCCAGCC
121 CCCGCCCTCC GCCCCTTCCG TCCCCACCCC CTACCCGGCG GCCCAGGAGG CTCCCCGGCT
181 GCGGCGCGCA CTCCCTGTTT CTCCTCCTCC TGGCTGGCGC TGCCTGCCTC TCCGCACTCA
241 CTGCTCGCCG GGCGCCGTCC GCCAGCTCCG TGCTCCCCGC GCCACCCTCC TCCGGGCCGC
301 GCTCCCTAAG GGATGGTACT GAATTTCGCC GCCACAGGAG ACCGGCTGGA GCGCCCGCCC
361 CGCGCCTCGC CTCTCCTCCG AGCAGCCAGC GCCTCGGGAC GCGATGAGGA CCTTGCGTTG
421 CCTGCTGCTC CTCGGCTGCG GATACCTCGC CCATGTTCTG GCCGAGGAAG CCGAGATCCC
481 CCGCGAGGTG ATCGAGAGGC TGGCCCGCAG TCAGATCCAC AGCATCCGGG ACCTCCAGCG
541 ACTCCTGGAG ATAGACTCCG TAGGGAGTGA GGATTCTTTG GACACCAGCC TGAGAGCTCA
601 CGGGGTCCAC GCCACTAAGC ATGTGCCCCA GAAGCGGCCC CTGCCCATTG GGAGGAAGAG
661 AAGCATCGAG GAAGCTGTCC CCGCTGTCTG CAAGACCAGG ACGGTCATTT ACGAGATTCC
721 TCGGAGTCAG GTCGACCCCA CGTCCGCCAA CTTCTTGATC TGGCCCCCGT GCGTGAGGT
781 GAAACGCTGC ACCGGCTGCT GCAACACGAG CAGTGTC AAG TGCCAGCCCT CCCGCGTCCA
841 CCACCGCAGC GTCAAGGTGG CCAAGGTGGA ATACGTCAGG AAGAAGCCAA AATTAAAAGA
901 AGTCCAGGTG AGGTTAGAGG AGCATTTGGA GTGCGCCTGC GCGACCACAA GCCTGAATCC
961 GGATTATCGG GAAGAGGACA CGGATGTGAG GTGAGGATGA GCCGCAGCCC TTTCTTGGA
1021 CATGGATGTA CATGGCGTGT TACATTCCTG AACCTACTAT GTACGGTGCT TTATTGCCAG
1081 TGTGCGGTCT TTGTTCTCCT CCGTGAAAAA CTGTGTCCGA GAACACTCGG GAGAACAAAG

```

1141 AGACAGTGCA CATTGTGTTA ATGTGACATC AAAGCAAGTA TTGTAGCACT CGGTGAAGCA
1201 GTAAGAAGCT TCCTTGTCAG AAAGAGAGAG AGAGAGAGAG AGAGAGAAAA CAAAACCACA
1261 AATGACAAAA ACAAAACGGA CTCACAAAAA TATCTAAACT CGATGAGATG GAGGGTCGCC
1321 CCGTGGGATG GAAGTGCAGA GGTCTCAGCA GACTGGATTT CTGTCCGGGT GGTCACAGGT
1381 GCTTTTTTGC CGAGGATGCA GAGCCTGCTT TGGGAACGAC TCCAGAGGGG TGCTGGTGGG
1441 CTCTGCAGGG CCCGCAGGAA GCAGGAATGT CTTGGAAACC GCCACGCGAA CTTTAGAAAC
1501 CACACCTCCT CGCTGTAGTA TTTAAGCCCA TACAGAAACC TTCCTGAGAG CTTAAGTGG
1561 TTTTTTTTTT TGTTTTGTT TTGTTTTTTT TTTTTTTGTT TTTTTTTTTT TTTTTTTTTT
1621 TTACACCATA AAGTGATTAT TAAGCTTCCT TTTACTCTTT GGCTAGCTTT TTTTTTTTTT
1681 TTTTTTTTTT TTTTTTTTAA TTATCTCTTG GATGACATTT ACACCGATAA CACACAGGCT
1741 GCTGTAAGTG TCAGGACAGT GCGACGGTAT TTTTCCTAGC AAGATGCAAA CTAATGAGAT
1801 GTATTAAAT AAACATGGTA TACCTACCTA TGCATCATTT CCTAAATGTT TCTGGCTTTG
1861 TGTTTCTCCC TTACCCTGCT TTATTTGTTA ATTTAAGCCA TTTTGAAAGA ACTATGCGTC
1921 AACCAATCGT ACGCCGTCCC TGCGGCACCT GCCCCAGAGC CCGTTTGTGG CTGAGTGACA
1981 ACTTGTTCCC CGCAGTGCAC ACCTAGAATG CTGTGTTCCC ACGCGGCACG TGAGATGCAT
2041 TGCCGCTTCT GTCTGTGTTG TTGGTGTGCC CTGGTGCCGT GGTGGCGGTC ACTCCCTCTG
2101 CTGCCAGTGT TTGGACAGAA CCCAAATTCT TTATTTTGG TAAGATATTG TGCTTTACCT
2161 GTATTAACAG AAATGTGTGT GTGTGGTTTG TTTTTTTGTA AAGGTGAAGT TTGTATGTTT
2221 ACCTAATATT ACCTGTTTTG TATACCTGAG AGCCTGCTAT GTTCTTCTTT TGTTGATCCA
2281 AAATTAAAAA AAAAATACCA CCAAC

Figure 1 (D) Sequence of PDGF-A polypeptide (GenBank Accession No. CAA29677) (SEQ ID NO: 12)

1 MRTLACLLLL GCGYLAHVLA EEAEIPREVI ERLARSQIHS IRDLQRLLEI DSVGSEDSLD
61 TSLRAHGVHA TKHVPEKRPL PIRRKRSIEE AVPAVCKTRT VIYEIPRSQV DPTSANFLIW
121 PPCVEVKRCT GCCNTSSVKC QPSRVHHRVS KVAKVEYVRK KPKLKEVQVR LEEHLECACA
181 TTSLNPDYRE EDTDVR

Figure 2 (A) Sequence of VEGF nucleic acid (GenBank Accession No: NM 003376) (SEQ ID NO: 3)

```

1  TCGCGGAGGC TTGGGGCAGC CGGGTAGCTC GGAGGTCGTG GCGCTGGGGG CTAGCACCAG
61  CGCTCTGTCTG GGAGGCGCAG CGGTTAGGTG GACCGGTCAG CGGACTCACC GGCCAGGGCG
121 CTCGGTGCTG GAATTTGATA TTCATTGATC CGGGTTTTAT CCCTCTTCTT TTTTCTTAAA
181 CATTTTTTTTT TAAAACTGTA TTGTTTCTCG TTTTAATTTA TTTTGTCTTG CCATTCCCCA
241 CTTGAATCGG GCCGACGGCT TGGGGAGATT GCTCTACTTC CCCAAATCAC TGTGGATTTT
301 GGAAACCAGC AGAAAGAGGA AAGAGGTAGC AAGAGCTCCA GAGAGAAGTC GAGGAAGAGA
361 GAGACGGGGT CAGAGAGAGC GCGCGGGCGT GCGAGCAGCG AAAGCGACAG GGGCAAAGTG
421 AGTGACCTGC TTTTGGGGGT GACCGCCGGA GCGCGGCGTG AGCCCTCCCC CTTGGGATCC
481 CGCAGCTGAC CAGTCGCGCT GACGGACAGA CAGACAGACA CCGCCCCCAG CCCAGCTAC
541 CACCTCCTCC CCGGCCGGCG GCGGACAGTG GACGCGGCGG CGAGCCGCGG GCAGGGGCCG
601 GAGCCCGCGC CCGGAGGCGG GGTGGAGGGG GTCGGGGCTC GCGGCGTCGC ACTGAAACTT
661 TTCGTCCAAC TTCTGGGCTG TTCTCGCTTC GGAGGAGCCG TGGTCCGCGC GGGGGAAGCC
721 GAGCCGAGCG GAGCCGCGAG AAGTGCTAGC TCGGGCCGGG AGGAGCCGCA GCCGGAGGAG
781 GGGGAGGAGG AAGAAGAGAA GGAAGAGGAG AGGGGGCCGC AGTGCGGACT CGGCGCTCGG
841 AAGCCGGGCT CATGGACGGG TGAGGCGGCG GTGTGCGCAG ACAGTGCTCC AGCCGCGCGC
901 GCTCCCCAGG CCCTGGCCCG GGCCTCGGGC CGGGGAGGAA GAGTAGCTCG CCGAGGCGCC
961 GAGGAGAGCG GGCCGCCCCA CAGCCCGAGC CGGAGAGGGA GCGCGAGCCG CGCCGGCCCC
1021 GGTCGGGCCT CCGAAACCAT GAACTTTCTG CTGTCTTGGG TGCATTGGAG CTTGCTTG
1081 CTGCTCTACC TCCACCATGC CAAGTGGTCC CAGGCTGCAC CCATGGCAGA AGGAGGAGGG
1141 CAGAATCATC ACGAAGTGGT GAAGTTCATG GATGTCTATC AGCGCAGCTA CTGCCATCCA
1201 ATCAGAGACC TGGTGGACAT CTTCCAGGAG TACCCTGATG AGATCGAGTA CATCTTCAAG
1261 CCATCCTGTG TGCCCTGAT GCGATGCGGG GGCTGCTGCA ATGACGAGGG CCTGGAGTGT
1321 GTGCCCCTG AGGAGTCCAA CATCACCATG CAGATTATGC GGATCAAACC TCACCAAGGC
1381 CAGCACATAG GAGAGATGAG CTTCTACAG CACAACAAAT GTGAATGCAG ACCAAAGAAA

```

1441 GATAGAGCAA GACAAGAAAA AAAATCAGTT CGAGGAAAGG GAAAGGGGCA AAAACGAAAG
1501 CGCAAGAAAT CCCGGTATAA GTCCTGGAGC GTTCCCTGTG GGCCTTGCTC AGAGCGGAGA
1561 AAGCATTTGT TTGTACAAGA TCCGCAGACG TGTAATGTT CCTGCAAAAA CACAGACTCG
1621 CGTTGCAAGG CGAGGCAGCT TGAGTTAAAC GAACGTACTT GCAGATGTGA CAAGCCGAGG
1681 CGGTGAGCCG GGCAGGAGGA AGGAGCCTCC CTCAGGGTTT CGG

Figure 2 (B) Sequence of VEGF polypeptide (GenBank Accession No. NP_003367) (SEQ ID NO: 4)

1 MNFLLSWVHW SLALLLYLHH AKWSQAAPMA EGGGQNHHEV VKFMDVYQRS YCHPIETLVD
 61 IFQEYPDEIE YIFKPSCVPL MRCGGCCNDE GLECVPTES NITMQIMRIK PHQGQHIGEM
 121 SFLQHNKCEC RPKKDRARQE KKSVRGKGKG QKRKRKKSRY KWSVPCGPC SERRKHLFVQ
 181 DPQTCKCCK NTDSRCKARQ LELNERTCRC DKPRR

Figure 3 (A) Sequence of PDGFR-B nucleic acid (GenBank Accession No. NM_002609) (SEQ ID NO: 4)

```

1  GGCCCTCAG CCCTGCTGCC CAGCACGAGC CTGTGCTCGC CCTGCCAAC GCAGACAGCC
61  AGACCCAGGG CGGCCCTCTT GCGGGCTCTG CTCCTCCCGA AGGATGCTTG GGGAGTGAGG
121 CGAAGCTGGG CGCTCCTCTC CCCTACAGCA GCCCCCTTCC TCCATCCCTC TGTTCCTCTG
181 AGCCTTCAGG AGCCTGCACC AGTCCTGCCT GTCCTTCTAC TCAGCTGTTA CCCACTCTGG
241 GACCAGCAGT CTTTCTGATA ACTGGGAGAG GGCAGTAAGG AGGACTTCCT GGAGGGGGTG
301 ACTGTCCAGA GCCTGGAAC TGTGCCACAC CAGAAGCCAT CAGCAGCAAG GACACCATGC
361 GGCTTCCGGG TGCATGCCA GCTCTGGCCC TCAAAGGCGA GCTGCTGTTG CTGTCTCTCC
421 TGTTACTTCT GGAACCACAG ATCTCTCAGG GCCTGGTCGT CACACCCCCG GGGCCAGAGC
481 TTGTCCTCAA TGTCTCCAGC ACCTTCGTTC TGACCTGCTC GGGTTCAGCT CCGGTGGTGT
541 GGGAACGGAT GTCCCAGGAG CCCCCACAGG AAATGGCCAA GGCCCAGGAT GGCACCTTCT
601 CCAGCGTGCT CACACTGACC AACCTCACTG GGCTAGACAC GGGAGAATAC TTTTGCACCC
661 ACAATGACTC CCGTGGACTG GAGACCGATG AGCGGAAACG GCTCTACATC TTTGTGCCAG
721 ATCCCACCGT GGGCTTCCTC CCTAATGATG CCGAGGAACT ATTCATCTTT CTCACGGAAA
781 TAACTGAGAT CACCATTCCA TGCCGAGTAA CAGACCCACA GCTGGTGGTG ACACTGCACG
841 AGAAGAAAGG GGACGTTGCA CTGCCTGTCC CCTATGATCA CCAACGTGGC TTTTCTGGTA
901 TCTTTGAGGA CAGAAGCTAC ATCTGCAAAA CCACCATTGG GGACAGGGAG GTGGATTCTG
961 ATGCCTACTA TGTCTACAGA CTCCAGGTGT CATCCATCAA CGTCTCTGTG AACGCAGTGC
1021 AGACTGTGGT CCGCCAGGGT GAGAACATCA CCCTCATGTG CATTGTGATC GGAATGAGG
1081 TGGTCAACTT CGAGTGGACA TACCCCGCA AAGAAAGTGG GCGGCTGGTG GAGCCGGTGA
1141 CTGACTTCCT CTTGGATATG CCTTACCACA TCCGCTCCAT CCTGCACATC CCCAGTGCCG
1201 AGTTAGAAGA CTCGGGGACC TACACCTGCA ATGTGACGGA GAGTGTGAAT GACCATCAGG
1261 ATGAAAAGGC CATCAACATC ACCGTGGTTG AGAGCGGCTA CGTGCGGCTC CTGGGAGAGG
1321 TGGGCACACT ACAATTGCT GAGCTGCATC GGAGCCGGAC ACTGCAGGTA GTGTTCGAGG
1381 CCTACCCACC GCCCACTGTC CTGTGGTTCA AAGACAACCG CACCCTGGGC GACTCCAGCG

```

1441 CTGGCGAAAT CGCCCTGTCC ACGCGCAACG TGTCGGAGAC CCGGTATGTG TCAGAGCTGA
 1501 CACTGGTTTCG CGTGAAGGTG GCAGAGGCTG GCCACTACAC CATGCGGGCC TTCCATGAGG
 1561 ATGCTGAGGT CCAGCTCTCC TTCCAGCTAC AGATCAATGT CCCTGTCCGA GTGCTGGAGC
 1621 TAAGTGAGAG CCACCCTGAC AGTGGGGAAC AGACAGTCCG CTGTCTGTGGC CGGGGCATGC
 1681 CCCAGCCGAA CATCATCTGG TCTGCCTGCA GAGACCTCAA AAGGTGTCCA CGTGAGCTGC
 1741 CGCCCACGCT GCTGGGGAAC AGTTCCGAAG AGGAGAGCCA GCTGGAGACT AACGTGACGT
 1801 ACTGGGAGGA GGAGCAGGAG TTTGAGGTGG TGAGCACACT GCGTCTGCAG CACGTGGATC
 1861 GGCCACTGTC GGTGCGCTGC ACGCTGCGCA ACGCTGTGGG CCAGGACACG CAGGAGGTCA
 1921 TCGTGGTGCC AACTCCTTG CCCTTTAAGG TGGTGGTGAT CTCAGCCATC CTGGCCCTGG
 1981 TGGTGCTCAC CATCATCTCC CTTATCATCC TCATCATGCT TTGGCAGAAG AAGCCACGTT
 2041 ACGAGATCCG ATGGAAGGTG ATTGAGTCTG TGAGCTCTGA CGGCCATGAG TACATCTACG
 2101 TGGACCCCAT GCAGCTGCCC TATGACTCCA CGTGGGAGCT GCCGCGGGAC CAGCTTGTGC
 2161 TGGGACGCAC CCTCGGCTCT GGGGCCTTTG GGCAGGTGGT GGAGGCCACG GCTCATGGCC
 2221 TGAGCCATTC TCAGGCCACG ATGAAAGTGG CCGTCAAGAT GCTTAAATCC ACAGCCCGCA
 2281 GCAGTGAGAA GCAAGCCCTT ATGTCGGAGC TGAAGATCAT GAGTCACCTT GGGCCCCACC
 2341 TGAACGTGGT CAACCTGTTG GGGGCCTGCA CCAAAGGAGG ACCCATCTAT ATCATCACTG
 2401 AGTACTGCCG CTACGGAGAC CTGGTGGACT ACCTGCACCG CAACAAACAC ACCTTCCTGC
 2461 AGCACCCTC CGACAAGCGC CGCCCGCCCA GCGCGGAGCT CTACAGCAAT GCTCTGCCCG
 2521 TTGGGCTCCC CCTGCCAGC CATGTGTCCT TGACCGGGGA GAGCGACGGT GGCTACATGG
 2581 ACATGAGCAA GGACGAGTCG GTGGACTATG TGCCCATGCT GGACATGAAA GGAGACGTCA
 2641 AATATGCAGA CATCGAGTCC TCCAACTACA TGGCCCCTTA CGATAACTAC GTTCCCTCTG
 2701 CCCCTGAGAG GACCTGCCGA GCAACTTTGA TCAACGAGTC TCCAGTGCTA AGCTACATGG
 2761 ACCTCGTGGG CTTGAGCTAC CAGGTGGCCA ATGGCATGGA GTTCTGGCC TCCAAGAACT
 2821 GCGTCCACAG AGACCTGGCG GCTAGGAACG TGCTCATCTG TGAAGGCAAG CTGGTCAAGA
 2881 TCTGTGACTT TGGCCTGGCT CGAGACATCA TCGGGGACTC GAATTACATC TCCAAAGGCA

2941 GCACCTTTTT GCCTTTAAAG TGGATGGCTC CGGAGAGCAT CTTCAACAGC CTCTACACCA
 3001 CCCTGAGCGA CGTGTGGTCC TTCGGGATCC TGCTCTGGGA GATCTTCACC TTGGGTGGCA
 3061 CCCCTTACCC AGAGCTGCCC ATGAACGAGC AGTTCTACAA TGCCATCAAA CGGGGTACC
 3121 GCATGGCCCA GCCTGCCCAT GCCTCCGACG AGATCTATGA GATCATGCAG AAGTGCTGGG
 3181 AAGAGAAGTT TGAGATTCGG CCCCCCTTCT CCCAGCTGGT GCTGCTTCTC GAGAGACTGT
 3241 TGGGCGAAGG TTACAAAAG AAGTACCAGC AGGTGGATGA GGAGTTTCTG AGGAGTGACC
 3301 ACCCAGCCAT CCTTCGGTCC CAGGCCCGCT TGCCTGGGTT CCATGGCCTC CGATCTCCCC
 3361 TGGACACCAG CTCCGTCCTC TATACTGCCG TGCAGCCCAA TGAGGGTGAC AACGACTATA
 3421 TCATCCCCCT GCCTGACCCC AAACCCGAGG TTGCTGACGA GGGCCCACTG GAGGGTTCCC
 3481 CCAGCCTAGC CAGCTCCACC CTGAATGAAG TCAACACCTC CTCAACCATC TCCTGTGACA
 3541 GCCCCCTGGA GCCCCAGGAC GAACCAGAGC CAGAGCCCCA GCTTGAGCTC CAGGTGGAGC
 3601 CGGAGCCAGA GCTGGAACAG TTGCCGGATT CGGGGTGCCC TGCGCCTCGG GCGGAAGCAG
 3661 AGGATAGCTT CCTGTAGGGG GCTGGCCCCT ACCCTGCCCT GCCTGAAGCT CCCCCCTGC
 3721 CAGCACCAG CATCTCCTGG CCTGGCCTGA CCGGGCTTCC TGTCAGCCAG GCTGCCCTTA
 3781 TCAGCTGTCC CCTTCTGGAA GCTTCTTGCT CCTGACGTGT TGTGCCCAA ACCCTGGGGC
 3841 TGGCTTAGGA GGCAAGAAA CTGCAGGGGCG CGTGACCAGC CCTCTGCCTC CAGGGAGGCC
 3901 AACTGACTCT GAGCCAGGGT TCCCCAGGG AACTCAGTTT TCCCATATGT AAGATGGGAA
 3961 AGTTAGGCTT GATGACCCAG AATCTAGGAT TCTCTCCCTG GCTGACAGGT GGGGAGACCG
 4021 AATCCCTCCC TGGGAAGATT CTTGGAGTGA CTGAGGTGGT AAATTAAGTT TTTTCTGTTC
 4081 AGCCAGCTAC CCCTCAAGGA ATCATAGCTC TCTCCTCGCA CTTTTATCC ACCCAGGAGC
 4141 TAGGGAAGAG ACCCTAGCCT CCCTGGCTGC TGGCTGAGCT AGGGCCTAGC CTTGAGCAGT
 4201 GTTGCCTCAT CCAGAAGAAA GCCAGTCTCC TCCCTATGAT GCCAGTCCCT GCGTTCCCTG
 4261 GCCCGAGCTG GTCTGGGGCC ATTAGGCAGC CTAATTAATG CTGGAGGCTG AGCCAAGTAC
 4321 AGGACACCCC CAGCCTGCAG CCCTTGCCCA GGGCACTTGG AGCACACGCA GCCATAGCAA
 4381 GTGCCTGTGT CCCTGTCCTT CAGGCCCATC AGTCCTGGGG CTTTTCTTT ATCACCCTCA

4441 GTCTTAATCC ATCCACCAGA GTCTAGAAGG CCAGACGGGC CCCGCATCTG TGATGAGAAT
4501 GTAAATGTGC CAGTGTGGAG TGGCCACGTG TGTGTGCCAG TATATGGCCC TGGCTCTGCA
4561 TTGGACCTGC TATGAGGCTT TGGAGGAATC CCTCACCTC TCTGGGCCTC AGTTTCCCCT
4621 TCAAAAAATG AATAAGTCGG ACTTATTAAC TCTGAGTGCC TTGCCAGCAC TAACATTCTA
4681 GAGTATTCCA GGTGGTTGCA CATTTGTCCA GATGAAGCAA GGCCATATAC CCTAAACTTC
4741 CATCCTGGGG GTCAGCTGGG CTCCTGGGAG ATTCCAGATC ACACATCACA CTCTGGGGAC
4801 TCAGGAACCA TGCCCTTCC CCAGGCCCCC AGCAAGTCTC AAGAACACAG CTGCACAGGC
4861 CTTGACTTAG AGTGACAGCC GGTGTCCTGG AAAGCCCCAA GCAGCTGCCC CAGGGACATG
4921 GGAAGACCAC GGGACCTCTT TCACTACCCA CGATGACCTC CGGGGGTATC CTGGGCAAAA
4981 GGGACAAAGA GGGCAAATGA GATCACCTCC TGCAGCCAC CACTCCAGCA CCTGTGCCGA
5041 GGTCTGCGTC GAAGACAGAA TGGACAGTGA GGACAGTTAT GTCTTGTAAG AGACAAGAAG
5101 CTTGAGATGG TACCCCAAGA AGGATGTGAG AGGTGGCCGC TTGGAGTTTG CCCCTCACCC
5161 ACCAGCTGCC CCATCCCTGA GGCAGCGCTC CATGGGGGTA TGGTTTTGTC ACTGCCCAGA
5221 CCTAGCAGTG ACATCTCATT GTCCCCAGCC CAGTGGGCAT TGGAGGTGCC AGGGGAGTCA
5281 GGGTTGTAGC CAAGACGCCC CCGCACGGGG AGGGTTGGGA AGGGGGTGCA GGAAGCTCAA
5341 CCCCTCTGGG CACCAACCCT GCATTGCAGG TTGGCACCTT ACTTCCCTGG GATCCCCAGA
5401 GTTGGTCCAA GGAGGGAGAG TGGGTCTCA ATACGGTACC AAAGATATAA TCACCTAGGT
5461 TTACAAATAT TTTTAGGACT CACGTAACT CACATTTATA CAGCAGAAAT GCTATTTTGT
5521 ATGCTGTAA GTTTTCTAT CTGTGTACTT TTTTAAAGG GAAAGATTTT AATATTAAAC
5581 CTGGTGCTTC TCACTCAC

Figure 3 (B) Sequence of PDGFR-B polypeptide (GenBank Accession No. NP_002600) (SEQ ID NO: 6)

```

1  MRLPGAMPAL ALKGELLLLS LLLLLLEPQIS QGLVVTTPPGP ELVLNVSTTF VLTCSGSAPV
61  VWERMSQEPP QEMAKAQDGT FSSVLTLTNL TGLDTGEYFC THNDSRGLET DERKRLYIFV
121 PDPTVGFLPN DAEELFIFLT EITEITIPCR VTDPQLVVTL HEKKG DVALP VPYDHQRGFS
181 GIFEDRSYIC KTTIGDREVD SDAYVYRLQ VSSINVSUNA VQTVVRQGEN ITLMCIVIGN
241 EVVNFIEWTYP RKESGRLEVP VTDFLLDMPY HIRSILHIPS AELED SGTYT CNVTESVNDH
301 QDEKAINITV VESGYVRLLG EVGTLQFAEL HRSRTLQVVF EAYPPPTVLW FKDNRTL GDS
361 SAGEIALSTR NVSETRYVSE LTLVRVKVAE AGHYTMRAFH EDAEVQLSFQ LQINV PVRVL
421 ELSHPSD SG EQTVRCRGRG MPQPNIIWSA CROLKRCPRE LPPTLLGNSS EEESQLETNV
481 TYWEEEQEFE VVSTLRLQHV DRPLSVRCTL RNAVGQDTQE VIVVPHSLPF KVVVISAILA
541 LVVLTIISLI ILIMLWQKKP RYEIRWKVIE SVSSDGHEYI YVDPMQLPYD STWELPRDQL
601 VLGRTL GSGA FGQVVEATAH GLSHSQATMK VAVKMLKSTA RSSEKQALMS ELKIMSHLGP
661 HLNVVNLLGA CTKGGPIYII TEYCRYGDLV DYLRNKHTF LQHHSDKRRP PSAELYSNAL
721 PVGLPLPSHV SLTGESDGGY MDMKDESVD YVPLDMKGD VKYADIESSN YMAPYDNYVP
781 SAPERTCRAT LINESPVLSY MDLVGFSYQV ANGMEFLASK NCVHRDLAAR NVLICEGKLV
841 KICDFGLARD IMRDSNYISK GSTFLPLKWM APESIFNSLY TTLSDVWSFG ILLWEIFTLG
901 GTPYPELPMN EQFYNAIKRG YRMAQPAHAS DEIYEIMQKC WEEKFEIRPP FSQVLVLLER
961 LLGEGYKKKY QQVDEEFLRS DHPAILRSQA RLPGFHGLRS PLDTSSVLYT AVQPNEGDND
1021 YIIPLPDPKP EVADEGPLEG SPSLASSTLN EVNTSSTISC DSPLEPQDEP EPEPQLELQV
1081 EPEPELEQLP DSGCPAPRAE AEDSFL

```

Figure 3 (C) Sequence of PDGFR-A nucleic acid (GenBank Accession No. NM 006206) (SEQ ID NO: 13)

```

1  TTCTCCCCGC CCCCCAGTTG TTGTCGAAGT CTGGGGGTTG GGACTGGACC CCCTGATTGC
61  GTAAGAGCAA AAAGCGAAGG CGCAATCTGG AACTGGGAG ATTCGGAGCG CAGGGAGTTT
121 GAGAGAAACT TTTATTTTGA AGAGACCAAG GTTGAGGGGG GGCTTATTTT CTGACAGCTA
181 TTTACTTAGA GCAAATGATT AGTTTTAGAA GGATGGACTA TAACATTGAA TCAATTACAA
241 AACGCGGTTT TTGAGCCCAT TACTGTTGGA GCTACAGGGA GAGAAACAGG AGGAGACTGC
301 AAGAGATCAT TTGGGAAGGC CGTGGGCACG CTCTTTACTC CATGTGTGGG ACATTCATTG
361 CGGAATAACA TCGGAGGAGA AGTTTCCCAG AGCTATGGGG ACTTCCCATC CGGCGTTCCT
421 GGTCTTAGGC TGTCTTCTCA CAGGGCTGAG CCTAATCCTC TGCCAGCTTT CATTACCCTC
481 TATCCTTCCA AATGAAAATG AAAAGGTTGT GCAGCTGAAT TCATCCTTTT CTCTGAGATG
541 CTTTGGGGAG AGTGAAGTGA GCTGGCAGTA CCCCATGTCT GAAGAAGAGA GCTCCGATGT
601 GGAAATCAGA AATGAAGAAA ACAACAGCGG CCTTTTTGTG ACGGTCTTGG AAGTGAGCAG
661 TGCTTCGGCG GCCCACACAG GGTGTACAC TTGCTATTAC AACCACACTC AGACAGAAGA
721 GAATGAGCTT GAAGGCAGGC ACATTTACAT CTATGTGCCA GACCCAGATG TAGCCTTTGT
781 ACCTCTAGGA ATGACGGATT ATTTAGTCAT CGTGGAGGAT GATGATTCTG CCATTATACC
841 TTGTGCGACA ACTGATCCCG AGACTCCTGT AACCTTACAC AACAGTGAGG GGGTGGTACC
901 TGCTCCTTAC GACAGCAGAC AGGGCTTTAA TGGGACCTTC ACTGTAGGGC CCTATATCTG
961 TGAGGCCACC GTCAAAGGAA AGAAGTTCCA GACCATCCCA TTTAATGTTT ATGCTTTAAA
1021 AGCAACATCA GAGCTGGATC TAGAAATGGA AGCTCTTAAA ACCGTGTATA AGTCAGGGGA
1081 AACGATTGTG GTCACCTGTG CTGTTTTTAA CAATGAGGTG GTTGACCTTC AATGGACTTA
1141 CCCTGGAGAA GTGAAAGGCA AAGGCATCAC AATGCTGGAA GAAATCAAAG TCCCATCCAT
1201 CAAATTGGTG TACACTTTGA CGGTCCCCGA GGCCACGGTG AAAGACAGTG GAGATTACGA
1261 ATGTGCTGCC CGCCAGGCTA CCAGGGAGGT CAAAGAAAATG AAGAAAAGTCA CTATTTCTGT
1321 CCATGAGAAA GGTTTCATTG AAATCAAACC CACCTTCAGC CAGTTGGAAG CTGTCAACCT

```

1381 GCATGAAGTC AAACATTTTG TTGTAGAGGT GCGGGCCTAC CCACCTCCCA GGATATCCTG
 1441 GCTGAAAAAC AATCTGACTC TGATTGAAAA TCTCACTGAG ATCACCCTG ATGTGGAAAA
 1501 GATTCAAGAA ATAAGGTATC GAAGCAAATT AAAGCTGATC CGTGCTAAGG AAGAAGACAG
 1561 TGGCCATTAT ACTATTGTAG CTCAAAATGA AGATGCTGTG AAGAGCTATA CTTTGAACCT
 1621 GTTAACTCAA GTTCCTTCAT CCATTCTGGA CTTGGTCGAT GATCACCCTG GCTCAACTGG
 1681 GGGACAGACG GTGAGGTGCA CAGCTGAAGG CACGCCGCTT CCTGATATTG AGTGGATGAT
 1741 ATGCAAAGAT ATTAAGAAAT GTAATAATGA AACTTCCTGG ACTATTTTGG CCAACAATGT
 1801 CTCAAACATC ATCACGGAGA TCCACTCCCG AGACAGGAGT ACCGTGGAGG GCCGTGTGAC
 1861 TTTCGCCAAA GTGGAGGAGA CCATCGCCGT GCGATGCCTG GCTAAGAATC TCCTTGGAGC
 1921 TGAGAACCGA GAGCTGAAGC TGGTGGCTCC CACCCTGCGT TCTGAACTCA CGGTGGCTGC
 1981 TGCAGTCCTG GTGCTGTTGG TGATTGTGAT CATCTCACTT ATTGTCTGG TTGTCATTG
 2041 GAAACAGAAA CCGAGGTATG AAATTCGCTG GAGGGTCATT GAATCAATCA GCCCGATGG
 2101 ACATGAATAT ATTTATGTGG ACCCGATGCA GCTGCCTTAT GACTCAAGAT GGGAGTTTCC
 2161 AAGAGATGGA CTAGTGCTTG GTCGGGTCTT GGGGTCTGGA GCGTTTGGGA AGGTGGTTGA
 2221 AGGAACAGCC TATGGATTAA GCCGGTCCCA ACCTGTCATG AAAGTTGCAG TGAAGATGCT
 2281 AAAACCCACG GCCAGATCCA GTGAAAAACA AGCTCTCATG TCTGAACTGA AGATAATGAC
 2341 TCACCTGGGG CCACATTTGA ACATTGTAAA CTTGCTGGGA GCCTGCACCA AGTCAGGCCC
 2401 CATTTACATC ATCACAGAGT ATTGCTTCTA TGGAGATTTG GTCAACTATT TGCATAAGAA
 2461 TAGGGATAGC TTCCTGAGCC ACCACCCAGA GAAGCCAAAG AAAGAGCTGG ATATCTTTGG
 2521 ATTGAACCTT GCTGATGAAA GCACACGGAG CTATGTTATT TTATCTTTTG AAAACAATGG
 2581 TGACTACATG GACATGAAGC AGGCTGATAC TACACAGTAT GTCCCCATGC TAGAAAGGAA
 2641 AGAGGTTTCT AAATATTCCG ACATCCAGAG ATCACTCTAT GATCGTCCAG CCTCATATAA
 2701 GAAGAAATCT ATGTTAGACT CAGAAGTCAA AAACCTCCTT TCAGATGATA ACTCAGAAGG
 2761 CCTTACTTTA TTGGATTTGT TGAGCTTCAC CTATCAAGTT GCCCGAGGAA TGGAGTTTTT
 2821 GGCTTCAAAA AATTGTGTCC ACCGTGATCT GGCTGCTCGC AACGTCCTCC TGGCACAAGG

2881 AAAAATTGTG AAGATCTGTG ACTTTGGCCT GGCCAGAGAC ATCATGCATG ATTCGAACTA
 2941 TGTGTCGAAA GGCAGTACCT TTCTGCCCCG GAAGTGGATG GCTCCTGAGA GCATCTTTGA
 3001 CAACCTCTAC ACCACACTGA GTGATGTCTG GTCTTATGGC ATTCTGCTCT GGGAGATCTT
 3061 TTCCCTTGGT GGCACCCCTT ACCCCGGCAT GATGGTGGAT TCTACTTTCT ACAATAAGAT
 3121 CAAGAGTGGG TACCGGATGG CCAAGCCTGA CCACGCTACC AGTGAAGTCT ACGAGATCAT
 3181 GGTGAAATGC TGGAACAGTG AGCCGGAGAA GAGACCCTCC TTTTACCACC TGAGTGAGAT
 3241 TGTGGAGAAT CTGCTGCCTG GACAATATAA AAAGAGTTAT GAAAAAATC ACCTGGACTT
 3301 CCTGAAGAGT GACCATCCTG CTGTGGCACG CATGCGTGTG GACTCAGACA ATGCATACAT
 3361 TGGTGTCACC TACAAAACG AGGAAGACAA GCTGAAGGAC TGGGAGGGTG GTCTGGATGA
 3421 GCAGAGACTG AGCGCTGACA GTGGCTACAT CATTCCTCTG CCTGACATTG ACCCTGTCCC
 3481 TGAGGAGGAG GACCTGGGCA AGAGGAACAG ACACAGCTCG CAGACCTCTG AAGAGAGTGC
 3541 CATTGAGACG GGTTCAGCA GTTCCACCTT CATCAAGAGA GAGGACGAGA CCATTGAAGA
 3601 CATCGACATG ATGGACGACA TCGGCATAGA CTCTTCAGAC CTGGTGGAAG ACAGCTTCCT
 3661 GTAAC TGGCG GATTCGAGGG GTTCCTTCCA CTTCTGGGGC CACCTCTGGA TCCCGTTCAG
 3721 AAAACCACTT TATTGCAATG CGGAGGTTGA GAGGAGGACT TGGTTGATGT TTAAAGAGAA
 3781 GTTCCCAGCC AAGGGCCTCG GGGAGCGTTC TAAATATGAA TGAATGGGAT ATTTTGAAAT
 3841 GAACTTTGTC AGTGTTGCCT CTCGCAATGC CTCAGTAGCA TCTCAGTGGT GTGTGAAGTT
 3901 TGGAGATAGA TGGATAAGGG AATAATAGGC CACAGAAGGT GAACTTTGTG CTCAAGGAC
 3961 ATTGGTGAGA GTCCAACAGA CACAATTTAT ACTGCGACAG AACTTCAGCA TTGTAATTAT
 4021 GTAAATAACT CTAACCAAGG CTGTGTTTAG ATTGTATTAA CTATCTTCTT TGGACTTCTG
 4081 AAGAGACCAC TCAATCCATC CATGTACTTC CCTCTTGAAA CCTGATGTCA GCTGCTGTTG
 4141 AACTTTTAA AGAAGTGCAT GAAAAACCAT TTTTGAACCT TAAAAGGTAC TGGTACTATA
 4201 GCATTTTGCT ATCTTTTTTA GTGTAAAGAG ATAAAGAATA ATAATTAACC AACCTTGTTT
 4261 AATAGATTTG GGTCAATTTAG AAGCCTGACA ACTCATTTTC ATATTGTAAT CTATGTTTAT
 4321 AATACTACTA CTGTTATCAG TAATGCTAAA TGTGTAATAA TGTAACATGA TTTCCTTCCA

4381 GAGAAAGCAC AATTTAAAAC AATCCTTACT AAGTAGGTGA TGAGTTTGAC AGTTTTTGAC
 4441 ATTTATATTA AATAACATGT TTCTCTATAA AGTATGGTAA TAGCTTTAGT GAATTAAATT
 4501 TAGTTGAGCA TAGAGAACAA AGTAAAAGTA GTGTTGTCCA GGAAGTCAGA ATTTTAACT
 4561 GTACTGAATA GGTTCCCCAA TCCATCGTAT TAAAAAACAA TTAAGTCCCC TCTGAAATAA
 4621 TGGGATTAGA AACAAACAAA ACTCTTAAGT CCTAAAAGTT CTCAATGTAG AGGCATAAAC
 4681 CTGTGCTGAA CATAACTTCT CATGTATATT ACCCAATGGA AAATATAATG ATCAGCAAAA
 4741 AGACTGGATT TGCAGAAGTT TTTTTTTTTT TTCTTCATGC CTGATGAAAG CTTTGGCAAC
 4801 CCCAATATAT GTATTTTTTG AATCTATGAA CCTGAAAAGG GTCAGAAGGA TGCCCAGACA
 4861 TCAGCCTCCT TCTTTCACCC CTTACCCCAA AGAGAAAGAG TTTGAACTC GAGACCATAA
 4921 AGATATTCTT TAGTGGAGGC TGGATGTGCA TTAGCCTGGA TCCTCAGTTC TCAAATGTGT
 4981 GTGGCAGCCA GGATGACTAG ATCCTGGGTT TCCATCCTTG AGATTCTGAA GTATGAAGTC
 5041 TGAGGGAAAC CAGAGTCTGT ATTTTCTTAA ACTCCCTGGC TGTTCTGATC GGCCAGTTTT
 5101 CGGAAACACT GACTTAGGTT TCAGGAAGTT GCCATGGGAA ACAAATAATT TGAACTTTGG
 5161 AACAGGGTTG GAATTCAACC ACGCAGGAAG CCTACTATTT AAATCCTTGG CTTCAGGTTA
 5221 GTGACATTTA ATGCCATCTA GCTAGCAATT GCGACCTTAA TTAACTTTC CAGTCTTAGC
 5281 TGAGGCTGAG AAAGCTAAAG TTTGGTTTTG ACAGGTTTTT CAAAAGTAAA GATGCTACTT
 5341 CCCACTGTAT GGGGGAGATT GAACTTTCCC CGTCTCCCGT CTTCTGCCTC CCACTCCATA
 5401 CCCCGCCAAG GAAAGGCATG TACAAAAATT ATGCAATTCA GTGTTCCAAG TCTCTGTGTA
 5461 ACCAGCTCAG TGTTTTGGTG GAAAAACAT TTAAAGTTTT ACTGATAATT TGAGGTTAGA
 5521 TGGGAGGATG AATTGTCACA TCTATCCACA CTGTCAAACA GGTGGGTGTG GGTTCATTGG
 5581 CATTCTTTGC AATACTGCTT AATTGCTGAT ACCATATGAA TGAAACATGG GCTGTGATTA
 5641 CTGCAATCAC TGTGCTATCG GCAGATGATG CTTTGGGAAGA TGCAGAAGCA ATAATAAAGT
 5701 ACTTGACTAC CTACTGGTGT AATCTCAATG CAAGCCCCAA CTTTCTTATC CAACTTTTTT
 5761 ATAGTAAGTG CGAAGACTGA GCCAGATTGG CCAATTAAAA ACGAAAACCT GACTAGGTTC
 5821 TGTAGAGCCA ATTAGACTTG AAATACGTTT GTGTTTCTAG AATCACAGCT CAAGCATTCT

5881 GTTTATCGCT CACTCTCCCT TGTACAGCCT TATTTTGTTG GTGCTTGCA TTTTGATATT
5941 GCTGTGAGCC TTGCATGACA TCATGAGGCC GGATGAACT TCTCAGTCCA GCAGTTTCCA
6001 GTCCTAACAA ATGCTCCAC CTGAATTTGT ATATGACTGC ATTTGTGGGT GTGTGTGTGT
6061 TTTCAGCAA TTCCAGATTT GTTTCCTTTT GGCTCCTGC AAAGTCTCCA GAAGAAAATT
6121 TGCCAATCTT TCCTACTTTC TATTTTTATG ATGACAATCA AAGCCGGCCT GAGAAACACT
6181 ATTTGTGACT TTTTAAACGA TTAGTGATGT CCTTAAAATG TGGTCTGCCA ATCTGTACAA
6241 AATGGTCCTA TTTTGTGAA GAGGGACATA AGATAAAATG ATGTTATACA TCAATATGTA
6301 TATATGTATT TCTATATAGA CTTGGAGAAT ACTGCCAAAA CATTATGAC AAGCTGTATC
6361 ACTGCCTTCG TTTATATTTT TTTAACTGTG ATAATCCCCA CAGGCACATT AACTGTTGCA
6421 CTTTTGAATG TCCAAAATTT ATATTTTAGA AATAATAAAA AGAAAGATAC TTACATGTTC
6481 CCAAACAAT GGTGTGGTGA ATGTGTGAGA AAACTAACT TGATAGGGTC TACCAATACA
6541 AAATGTATTA CGAATGCCCC TGTTTCATGTT TTTGTTTTAA AACGTGTAAA TGAAGATCTT
6601 TATATTTCAA TAAATGATAT ATAATTTAAA GTT

Figure 3 (D) Sequence of human PDGFR-A polypeptide**(GenBank Accession No. NP_006197) (SEQ ID NO: 14)**

1 MGTSHPAFLV LGCLLTGLSL ILCQLSLPSI LPNENEKVVQ LNSSFSLRCF GESEVSWQYP
 61 MSEEESDVE IRNEENNSGL FVTVLEVSSA SAAHTGLYTC YYNHTQTEEN ELEGRHIYIY
 121 VPDPDVAFVP LGMTDYLIV EDDDSAIIPC RTTDPETPVT LHNSEGVVPA SYDSRQGFNG
 181 TFTVGPIYCE ATVKGKKFQT IPFNVYALKA TSELDLEMEA LKTVYKSGET IVVTCAVFNN
 241 EVVDLQWTYP GEVKGKGITM LEEIKVPSIK LVYTLTVPEA TVKDSGDYEC AARQATREVK
 301 EMKKVTISVH EKGFIKPT FSQLEAVNLH EVKHFVVEVR AYPPPRISWL KNNLTLIENL
 361 TEITTDVEKI QEIRYRSKLK LIRAKEEDSG HYTIVAQNE AVKSYTFELL TQVPSSILD
 421 VDDHHGSTGG QTVRCTAEGT PLPDIEWMIC KDIKKCNET SWTILANNVS NIITEIHSRD
 481 RSTVEGRVTF AKVEETIAVR CLAKNLLGAE NRELKLVAPT LRSELTVA AA VLVLLVIVII
 541 SLIVLVVIWK QKPRYEIRWR VIESISPDGH EYIYVDPMQL PYDSRWEFPR DGLVLGRVLG
 601 SGAFGKVVEG TAYGLSRSQP VMKVAVKMLK PTARSSEKQA LMSELKIMTH LGPHLNIVNL
 661 LGACTKSGPI YIITEYCFYG DLVNYLHKNR DSFLSHHPEK PKKELDIFGL NPADESTRSY
 721 VILSFENNGD YMDMKQADTT QYVPMLEKE VSKYSDIORS LYDRPASYKK KSMLDSEVKN
 781 LLSDDNSEGL TLLDLLSFTY QVARGMEFLA SKNCVHRDLA ARNVLLA QGK IVKICDFGLA
 841 RDIMHDSNYV SKGSTFLPVK WMAPESIFDN LYTTLSDVWS YGILLWEIFS LGGTPYPGMM
 901 VDSTFYNNIK SGYRMAKPDH ATSEVYEIMV KCWNSEPEKR PSFYHLSEIV ENLLPGQYKK
 961 SYEKIHLDFL KSDHPAVARM RVDSDNAYIG VTYKNEEDKL KDWEGGLDEQ RLSADSGYII
 1021 PLPDIDPVPE EEDLGKRRNH SSQTSEESAI ETGSSSSTFI KREDETIEDI DMMDDIGIDS
 1081 SDLVEDSFL

Figure 4 (A) Sequence of VEGFR-1 (Flt-1) nucleic acid**(GenBank Accession No. AF063657) (SEQ ID NO: 7)**

```

1  ATGGTCAGCT ACTGGGACAC CGGGGTCCTG CTGTGCGCGC TGCTCAGCTG TCTGCTTCTC
61  ACAGGATCTA GTTCAGGTTC AAAATTAAAA GATCCTGAAC TGAGTTTAAA AGGCACCCAG
121 CACATCATGC AAGCAGGCCA GACACTGCAT CTCCAATGCA GGGGGGAAGC AGCCCATAAA
181 TGGTCTTTGC CTGAAATGGT GAGTAAGGAA AGCGAAAGGC TGAGCATAAC TAAATCTGCC
241 TGTGGAAGAA ATGGCAAACA ATTCTGCAGT ACTTTAACCT TGAACACAGC TCAAGCAAAC
301 CACACTGGCT TCTACAGCTG CAAATATCTA GCTGTACCTA CTTCAAAGAA GAAGGAAACA
361 GAATCTGCAA TCTATATATT TATTAGTGAT ACAGGTAGAC CTTTCGTAGA GATGTACAGT
421 GAAATCCCCG AAATTATACA CATGACTGAA GGAAGGGAGC TCGTCATTCC CTGCCGGGTT
481 ACGTCACCTA ACATCACTGT TACTTTAAAA AAGTTTCCAC TTGACACTTT GATCCCTGAT
541 GGAAAACGCA TAATCTGGGA CAGTAGAAAG GGCTTCATCA TATCAAATGC AACGTACAAA
601 GAAATAGGGC TTCTGACCTG TGAAGCAACA GTCAATGGGC ATTTGTATAA GACAAACTAT
661 CTCACACATC GACAAACCAA TACAATCATA GATGTCCAAA TAAGCACACC ACGCCCAGTC
721 AAATTACTTA GAGGCCATAC TCTTGTCTC AATTGTACTG CTACCACTCC CTTGAACACG
781 AGAGTTCAAA TGACCTGGAG TTACCCTGAT GAAAAAATA AGAGAGCTTC CGTAAGGCGA
841 CGAATTGACC AAAGCAATTC CCATGCCAAC ATATTCTACA GTGTTCTTAC TATTGACAAA
901 ATGCAGAACA AAGACAAAGG ACTTTATACT TGTCGTGTAA GGAGTGGACC ATCATTCAAA
961 TCTGTTAACA CCTCAGTGCA TATATATGAT AAAGCATTCA TCACTGTGAA ACATCGAAAA
1021 CAGCAGGTGC TTGAAACCGT AGCTGGCAAG CGGTCTTACC GGCTCTCTAT GAAAGTGAAG
1081 GCATTTCCCT CGCCGGAAGT TGTATGGTTA AAAGATGGGT TACCTGCGAC TGAGAAATCT
1141 GCTCGCTATT TGA CTCGTGG CTACTCGTTA ATTATCAAGG ACGTAACTGA AGAGGATGCA
1201 GGAATTATA CAATCTTGCT GAGCATAAAA CAGTCAAATG TGTTTAAAAA CCTCACTGCC
1261 ACTCTAATTG TCAATGTGAA ACCCCAGATT TACGAAAAGG CCGTGTGATC GTTTCCAGAC
1321 CCGGCTCTCT ACCCACTGGG CAGCAGACAA ATCCTGACTT GTACCGCATA TGGTATCCCT

```


1381 CAACCTACAA TCAAGTGGTT CTGGCACCCC TGTAACCATA ATCATTCCGA AGCAAGGTGT
 1441 GACTTTTGTT CCAATAATGA AGAGTCCTTT ATCCTGGATG CTGACAGCAA CATGGGAAAC
 1501 AGAATTGAGA GCATCACTCA GCGCATGGCA ATAATAGAAG GAAAGAATAA GATGGCTAGC
 1561 ACCTTG GTTG TGGCTGACTC TAGAATTTCT GGAATCTACA TTTGCATAGC TTCCAATAAA
 1621 GTTGGGACTG TGGGAAGAAA CATAAGCTTT TATATCACAG ATGTGCCAAA TGGGTTTCAT
 1681 GTTAACTTGG AAAAAATGCC GACGGAAGGA GAGGACCTGA AACTGTCTTG CACAGTTAAC
 1741 AAGTTCTTAT ACAGAGACGT TACTTGGATT TTAGTGGGA CAGTTAATAA CAGAACAATG
 1801 CACTACAGTA TTAGCAAGCA AAAAAATGGCC ATCACTAAGG AGCACTCCAT CACTCTTAAT
 1861 CTTACCATCA TGAATGTTTC CCTGCAAGAT TCAGGCACCT ATGCCTGCAG AGCCAGGAAT
 1921 GTATACACAG GGGGAAGAAAT CCTCCAGAAG AAAGAAATTA CAATCAGAGA TCAGGAAGCA
 1981 CCATACCTCC TGCGAACCT CAGTGATCAC ACAGTGGCCA TCAGCAGTTC CACCACTTTA
 2041 GACTGTCATG CTAATGGTGT CCCCAGAGCT CAGATCACTT GGTTTAAAAA CAACCACAAA
 2101 ATACAACAAG AGCCTGGAAT TATTTTAGGA CCAGGAAGCA GCACGCTGTT TATTGAAAGA
 2161 GTCACAGAAG AGGATGAAGG TGTCTATCAC TGCAAAGCCA CCAACCAGAA GGGCTCTGTG
 2221 GAAAGTTCAG CATACCTCAC TGTTCAGGA ACCTCGGACA AGTCTAATCT GGAGCTGATC
 2281 ACTCTAACAT GCACCTGTGT GGCTGCGACT CTCTTCTGGC TCCTATTAAC CCTCTTTATC
 2341 CGAAAAATGA AAAGGTCTTC TTCTGAAATA AAGACTGACT ACCTATCAAT TATAATGGAC
 2401 CCAGATGAAG TTCCTTTGGA TGAGCAGTGT GAGCGGCTCC CTTATGATGC CAGCAAGTGG
 2461 GAGTTTGCCC GGGAGAGACT TAAACTGGGC AAATCACTTG GAAGAGGGGC TTTTGGA AAA
 2521 GTGGTTCAAG CATCAGCATT TGGCATTAAAG AAATCACCTA CGTGCCGGAC TGTGGCTGTG
 2581 AAAATGCTGA AAGAGGGGGC CACGGCCAGC GAGTACAAAG CTCTGATGAC TGAGCTAAAA
 2641 ATCTTGACCC ACATTGGCCA CCATCTGAAC GTGGTTAACC TGCTGGGAGC CTGCACCAAG
 2701 CAAGGAGGGC CTCTGATGGT GATTGTTGAA TACTGCAAAT ATGGAAATCT CTCCA ACTAC
 2761 CTCAAGAGCA AACGTGACTT ATTTTTTCTC AACAAGGATG CAGCACTACA CATGGAGCCT
 2821 AAGAAAGAAA AAATGGAGCC AGGCCTGGAA CAAGGCAAGA AACCAAGACT AGATAGCGTC

2881 ACCAGCAGCG AAAGCTTTGC GAGCTCCGGC TTTCAGGAAG ATAAAAGTCT GAGTGATGTT
 2941 GAGGAAGAGG AGGATTCTGA CGGTTTCTAC AAGGAGCCCA TCACTATGGA AGATCTGATT
 3001 TCTTACAGTT TTCAAGTGGC CAGAGGCATG GAGTTCCTGT CTTCCAGAAA GTGCATTTCAT
 3061 CGGGACCTGG CAGCGAGAAA CATTCTTTTA TCTGAGAACA ACGTGGTGAA GATTGTGAT
 3121 TTTGGCCTTG CCCGGGATAT TTATAAGAAC CCCGATTATG TGAGAAAAGG AGATACTCGA
 3181 CTTCTCTGA AATGGATGGC TCCTGAATCT ATCTTTGACA AAATCTACAG CACCAAGAGC
 3241 GACGTGTGGT CTTACGGAGT ATTGCTGTGG GAAATCTTCT CCTTAGGTGG GTCTCCATAC
 3301 CCAGGAGTAC AAATGGATGA GGACTTTTGC AGTCGCCTGA GGAAGGCAT GAGGATGAGA
 3361 GCTCCTGAGT ACTCTACTCC TGAAATCTAT CAGATCATGC TGGACTGCTG GCACAGAGAC
 3421 CCAAAGAAA GGCCAAGATT TGCAGAACTT GTGGAAAAAC TAGGTGATTT GCTTCAAGCA
 3481 AATGTACAAC AGGATGGTAA AGACTACATC CCAATCAATG CCATACTGAC AGGAAATAGT
 3541 GGGTTTACAT ACTCAACTCC TGCCTTCTCT GAGGACTTCT TCAAGGAAAAG TATTTAGCT
 3601 CCGAAGTTTA ATTTCAGGAAG CTCTGATGAT GTCAGATATG TAAATGCTTT CAAGTTCATG
 3661 AGCCTGGAAA GAATCAAAAC CTTTGAAGAA CTTTACCAG ATGCCACCTC CATGTTTGAT
 3721 GACTACCAGG GCGACAGCAG CACTCTGTTG GCCTCTCCCA TGCTGAAGCG CTTACCTGG
 3781 ACTGACAGCA AACCCAAGGC CTCGCTCAAG ATTGACTTGA GAGTAACCAG TAAAAGTAAG
 3841 GAGTCGGGGC TGTCTGATGT CAGCAGGCC AGTTTCTGCC ATTCCAGCTG TGGGCACGTC
 3901 AGCGAAGGCA AGCGCAGGTT CACCTACGAC CACGCTGAGC TGGAAAGGAA AATCGCGTGC
 3961 TGCTCCCCGC CCCAGACTA CAACTCGGTG GTCCTGTACT CCACCCACC CATCTAG

Figure 4 (B) Sequence of VEGFR-1 (Flt-1) polypeptide (GenBank Accession No.) (SEQ ID NO: 8)

1 MVS YWDTGVL LCALLSCLLL TGSSSGSKLK DPESLSLKGTO HIMQAGQTLH LQCRGEAAHK
 61 WSLPEMVSKE SERLSITKSA CGRNGKQFCS TLT LNTAQAN HTGFYSCKYL AVPTSKKKET
 121 ESAIYIFISD TGRPFVEMYS EIPEIIHMT E GRELVIPCRV TSPNITVTLK KFPLDTLIPD
 181 GKRIIWSRK GFIISNATYK EIGLLTCEAT VNGHLYKTN LTHRQNTNII DVQISTPRPV
 241 KLLRGHTLVL NCTATTPLNT RVQMTWSYPD EKNKRASVRR RIDQSN SHAN IFYSVLTIDK
 301 MQNKDKGLYT CRVRSGPSFK SVNTSVHIYD KAFITVKHRK QQVLETVAGK RSYRLSMKVK
 361 AFPSPEVVWL KDGLPATEKS ARYLTRGYSL IIKDVTEEDA GNYTILLSIK QSNVFKNLTA
 421 TLIVNVKPQI YEKAVSSFPD PALYPLGSRQ ILTCTAYGIP OPTIKWFWHP CNHNHSEARC
 481 DFCSNNEESF ILDADSNMGN RIESITQMA IIEGKNKMAS TLVVADSRIS GIYICIASNK
 541 VGTVGRNISE YITDVPNGFH VNLEKMPTEG EDLKL SCTVN KFLYRDVTWI LLRTVNNRTM
 601 HYSISKQKMA ITKEHSITLN LTIMNVSLQD SGTYACRARN VYTGE EILQK KEITIRDQEA
 661 PYLLRNLS DH TVAISSTTL DCHANGVPEP QITWFKNNHK IQQEPGIILG PGSSTLFIER
 721 VTEEDEGVYH CKATNQKGSV ESSAYLTVQG TSDKSNLELI TLTCTCVAAT LFWLLLT LFI
 781 RKMKRSSSEI KTDYLSIIMD PDEVPLDEQC ERLPYDASKW EFARERLKLK KSLGRGAFGK
 841 VVQASAFGIK KSPTCRTVAV KMLKEGATAS EYKALMTELK ILTHIGHHLN VVNLLGACTK
 901 QGGPLMVIVE YCKYGNLSNY LKSKRDLFFL NKDAALHMEP KKEKMEPGLE QGKKPRLDSV
 961 TSSESFASSG FQEDKSLSDV EEEEDSDGFY KEPITMEDLI SYSFQVARGM EFLSSRKCIH
 1021 RDLAARNILL SENNVVKICD FGLARDIYKN PDYVRKGDTR LPLKWMAPES IFDKIYSTKS
 1081 DVWSYGVLLW EIFSLGGSPY PGVQMD EFC SRLREGMRMR APEYSTPEIY QIMLDCWHRD
 1141 PKERPRFAEL VEKLGDLLQA NVQQDGKDYI PINAILTGNS GFTYSTPAFS EDDFKESIS A
 1201 PKFNSGSSDD VRYVNAFKFM SLERIKTFEE LLPNATSMFD DYQGDSS TLL ASPMLKRFTW
 1261 TDSKPKASLK IDLRVTSKSK ESGLS DVS RP SFCHSSCGHV SEGKRRFTYD HAELERK IAC
 1321 CSPPPDYNSV VLYSTPPI

Figure 4 (C) Sequence of VEGFR-2 (KDR/Flk-1) nucleic acid
(GenBank Accession No. AF035121) (SEQ ID NO: 9)

```

1  ACTGAGTCCC GGGACCCCGG GAGAGCGGTC AGTGTGTGGT CGCTGCGTTT CCTCTGCCTG
61  CGCCGGGCAT CACTTGCGCG CCGCAGAAAG TCCGTCTGGC AGCCTGGATA TCCTCTCCTA
121  CCGGCACCCG CAGACGCCCC TGCAGCCGCC GGTCGGCGCC CGGGCTCCCT AGCCCTGTGC
181  GCTCAACTGT CCTGCGCTGC GGGGTGCCGC GAGTTCCACC TCCGCGCCTC CTTCTCTAGA
241  CAGGCGCTGG GAGAAAGAAC CGGCTCCCGA GTTCTGGGCA TTTCGCCCCG CTCGAGGTGC
301  AGGATGCAGA GCAAGGTGCT GCTGGCCGTC GCCCTGTGGC TCTGCGTGGA GACCCGGGCC
361  GCCTCTGTGG GTTTGCCTAG TGTTTCTCTT GATCTGCCCA GGCTCAGCAT ACAAAAAGAC
421  ATACTTACAA TTAAGGCTAA TACAACTCTT CAAATTACTT GCAGGGGACA GAGGGACTTG
481  GACTGGCTTT GGCCAATAA TCAGAGTGGC AGTGAGCAAA GGGTGGAGGT GACTGAGTGC
541  AGCGATGGCC TCTTCTGTAA GACACTCACA ATTCCAAAAG TGATCGGAAA TGACACTGGA
601  GCCTACAAGT GCTTCTACCG GGAACTGAC TTGGCCTCGG TCATTTATGT CTATGTTCAA
661  GATTACAGAT CTCCATTTAT TGCTTCTGTT AGTGACCAAC ATGGAGTCGT GTACATTACT
721  GAGAACAAAA ACAAACTGT GGTGATTCCA TGTCTCGGGT CCATTTCAA TCTCAACGTG
781  TCACTTTGTG CAAGATACCC AGAAAAGAGA TTTGTTCTG ATGGTAACAG AATTTCTGG
841  GACAGCAAGA AGGGCTTTAC TATTCCCAGC TACATGATCA GCTATGCTGG CATGGTCTTC
901  TGTGAAGCAA AAATTAATGA TGAAAGTTAC CAGTCTATTA TGTACATAGT TGTCGTTGTA
961  GGGTATAGGA TTTATGATGT GGTTCTGAGT CCGTCTCATG GAATTGAACT ATCTGTTGGA
1021  GAAAAGCTTG TCTTAAATTG TACAGCAAGA ACTGAACTAA ATGTGGGGAT TGACTTCAAC
1081  TGGGAATACC CTTCTTCGAA GCATCAGCAT AAGAACTTG TAAACCGAGA CCTAAAAACC
1141  CAGTCTGGGA GTGAGATGAA GAAATTTTGT AGCACCTTAA CTATAGATGG TGTAACCCGG
1201  AGTGACCAAG GATTGTACAC CTGTGCAGCA TCCAGTGGGC TGATGACCAA GAAGAACAGC
1261  ACATTTGTCA GGGTCCATGA AAAACCTTTT GTTGCTTTTG GAAGTGGCAT GGAATCTCTG
1321  GTGAAGCCA CGGTGGGGGA GCGTGTGAGA ATCCCTGCGA AGTACCTTGG TTACCCACCC

```

1381 CCAGAAATAA AATGGTATAA AAATGGAATA CCCCTTGAGT CCAATCACAC AATTAAAGCG
 1441 GGGCATGTAC TGACGATTAT GGAAGTGAGT GAAAGAGACA CAGGAAATTA CACTGTCATC
 1501 CTTACCAATC CCATTTCAAA GGAGAAGCAG AGCCATGTGG TCTCTCTGGT TGTGTATGTC
 1561 CCACCCCAAG TTGGTGAGAA ATCTCTAATC TCTCCTGTGG ATTCCCTACCA GTACGGCACC
 1621 ACTCAAACGC TGACATGTAC GGTCTATGCC ATTCCTCCCC CGCATCACAT CCACTGGTAT
 1681 TGGCAGTTGG AGGAAGAGTG CGCCAACGAG CCCAGCCAAG CTGTCTCAGT GACAAACCCA
 1741 TACCCTTGTG AAGAATGGAG AAGTGTGGAG GACTTCCAGG GAGGAAATAA AATTGAAGTT
 1801 AATAAAAATC AATTTGCTCT AATTGAAGGA AAAAACAAAA CTGTAAGTAC CCTTGTTATC
 1861 CAAGCGGCAA ATGTGTCAGC TTTGTACAAA TGTGAAGCGG TCAACAAAGT CGGGAGAGGA
 1921 GAGAGGGTGA TCTCCTTCCA CGTGACCAGG GGTCTGAAA TTAATTTGCA ACCTGACATG
 1981 CAGCCCACTG AGCAGGAGAG CGTGTCTTTG TGGTGCACTG CAGACAGATC TACGTTTGAG
 2041 AACCTCACAT GGTACAAGCT TGGCCACAG CCTCTGCCAA TCCATGTGGG AGAGTTGCCC
 2101 ACACCTGTTT GCAAGAACTT GGATACTCTT TGGAAATTGA ATGCCACCAT GTTCTCTAAT
 2161 AGCACAAATG ACATTTTGAT CATGGAGCTT AAGAATGCAT CCTTGCAGGA CCAAGGAGAC
 2221 TATGTCTGCC TTGCTCAAGA CAGGAAGACC AAGAAAAGAC ATTGCGTGGT CAGGCAGCTC
 2281 ACAGTCCTAG AGCGTGTGGC ACCCACGATC ACAGGAAACC TGGAGAATCA GACGACAAGT
 2341 ATTGGGGAAA GCATCGAAGT CTCATGCACG GCATCTGGGA ATCCCCCTCC ACAGATCATG
 2401 TGGTTTAAAG ATAATGAGAC CCTTGTAGAA GACTCAGGCA TTGTATTGAA GGATGGGAAC
 2461 CGGAACCTCA CTATCCGAG AGTGAGGAAG GAGGACGAAG GCCTCTACAC CTGCCAGGCA
 2521 TGCAGTGTTT TTGGCTGTGC AAAAGTGGAG GCATTTTCA TAATAGAAGG TGCCAGGAA
 2581 AAGACGAACT TGGAAATCAT TATTCTAGTA GGCACGGCGG TGATTGCCAT GTTCTTCTGG
 2641 CTACTTCTTG TCATCATCCT ACGGACCGTT AAGCGGGCCA ATGGAGGGGA ACTGAAGACA
 2701 GGCTACTTGT CCATCGTCAT GGATCCAGAT GAACTCCCAT TGGATGAACA TTGTGAACGA
 2761 CTGCCTTATG ATGCCAGCAA ATGGGAATTC CCCAGAGACC GGCTGAAGCT AGGTAAGCCT
 2821 CTTGGCCGTG GTGCCTTTGG CCAAGTGATT GAAGCAGATG CCTTTGGAAT TGACAAGACA

2881 GCAACTTGCA GGACAGTAGC AGTCAAAATG TTGAAAGAAG GAGCAACACA CAGTGAGCAT
 2941 CGAGCTCTCA TGTCTGAACT CAAGATCCTC ATTCATATTG GTCACCATCT CAATGTGGTC
 3001 AACCTTCTAG GTGCCTGTAC CAAGCCAGGA GGGCCACTCA TGGTGATTGT GGAATTCTGC
 3061 AAATTTGGAA ACCTGTCCAC TTACCTGAGG AGCAAGAGAA ATGAATTTGT CCCCTACAAG
 3121 ACCAAAGGGG CACGATTCCG TCAAGGGAAA GACTACGTTG GAGCAATCCC TGTGGATCTG
 3181 AAACGGCGCT TGGACAGCAT CACCAGTAGC CAGAGCTCAG CCAGCTCTGG ATTTGTGGAG
 3241 GAGAAGTCCC TCAGTGATGT AGAAGAAGAG GAAGCTCCTG AAGATCTGTA TAAGGACTTC
 3301 CTGACCTTGG AGCATCTCAT CTGTTACAGC TTCCAAGTGG CTAAGGGCAT GGAGTTCTTG
 3361 GCATCGCGAA AGTGTATCCA CAGGGACCTG GCGGCACGAA ATATCCTCTT ATCGGAGAAG
 3421 AACGTGGTTA AAATCTGTGA CTTTGGCTTG GCCCGGGATA TTTATAAAGA TCCAGATTAT
 3481 GTCAGAAAAG GAGATGCTCG CCTCCCTTTG AAATGGATGG CCCAGAAAC AATTTTGTGAC
 3541 AGAGTGATACA CAATCCAGAG TGACGTCTGG TCTTTTGGTG TTTTGCTGTG GGAAATATTT
 3601 TCCTTAGGTG CTTCTCCATA TCCTGGGGTA AAGATTGATG AAGAATTTTG TAGGCGATTG
 3661 AAAGAAGGAA CTAGAATGAG GGCCCTGAT TATACTACAC CAGAAATGTA CCAGACCATG
 3721 CTGGACTGCT GGCACGGGGA GCCCAGTCAG AGACCCACGT TTTCAGAGTT GGTGGAACAT
 3781 TTGGGAAATC TCTTGCAAGC TAATGCTCAG CAGGATGGCA AAGACTACAT TGTCTTCCG
 3841 ATATCAGAGA CTTTGAGCAT GGAAGAGGAT TCTGGACTCT CTCTGCCTAC CTCACCTGTT
 3901 TCCTGTATGG AGGAGGAGGA AGTATGTGAC CCCAAATTCC ATTATGACAA CACAGCAGGA
 3961 ATCAGTCAGT ATCTGCAGAA CAGTAAGCGA AAGAGCCGGC CTGTGAGTGT AAAAACATTT
 4021 GAAGATATCC CGTTAGAAGA ACCAGAAGTA AAAGTAATCC CAGATGACAA CCAGACGGAC
 4081 AGTGGTATGG TTCTTGCCTC AGAAGAGCTG AAAACTTTGG AAGACAGAAC CAAATTATCT
 4141 CCATCTTTTG GTGGAATGGT GCCCAGCAA AGCAGGGAGT CTGTGGCATC TGAAGGCTCA
 4201 AACCAGACAA GCGGCTACCA GTCCGGATAT CACTCCGATG ACACAGACAC CACCGTGTAC
 4261 TCCAGTGAGG AAGCAGAACT TTAAAGCTG ATAGAGATTG GAGTGCAAAC CGGTAGCACA
 4321 GCCCAGATTC TCCAGCCTGA CTCGGGGACC AACTGAGCT CTCCTCCTGT TTAAAGGAA

4381 GCATCCACAC CCCAACTCCC GGACATCACA TGAGAGGTCT GCTCAGATTT TGAAGTGTG
 4441 TTCTTTCCAC CAGCAGGAAG TAGCCGCATT TGATTTTCAT TTCGACAACA GAAAAAGGAC
 4501 CTCGGACTGC AGGGAGCCAG TCTTCTAGGC ATATCCTGGA AGAGGCTTGT GACCCAAGAA
 4561 TGTGTCTGTG TCTTCTCCCA GTGTTGACCT GATCCTCTTT TTTCATTCAT TTAAAAAGCA
 4621 TTATCATGCC CCTGCTGCGG GTCTCACCAT GGGTTTAGAA CAAAGAGCTT CAAGCAATGG
 4681 CCCCATCCTC AAAGAAGTAG CAGTACCTGG GGAGCTGACA CTTCTGTAAA ACTAGAAGAT
 4741 AAACCAGGCA ACGTAAGTGT TCGAGGTGTT GAAGATGGGA AGGATTTGCA GGGCTGAGTC
 4801 TATCCAAGAG GCTTTGTTTA GGACGTGGGT CCCAAGCCAA GCCTTAAGTG TGGAAATCGG
 4861 ATTGATAGAA AGGAAGACTA ACGTTACCTT GCTTTGGAGA GTACTGGAGC CTGCAAATGC
 4921 ATTGTGTTTG CTCTGGTGGG GGTGGGCATG GGGTCTGTTC TGAAATGTAA AGGGTTCAGA
 4981 CGGGGTTTCT GGTTTTAGAA GGTTCGTGT TCTTCGAGTT GGGCTAAAGT AGAGTTCGTT
 5041 GTGCTGTTTC TGAATCCTAA TGAGAGTTCC TTCCAGACCG TTAGCTGTCT CCTTGCCAAG
 5101 CCCAGGAAG AAAATGATGC AGCTCTGGCT CTTGTCTCC CAGGCTGATC CTTTATTCAG
 5161 AATACCACAA AGAAAGGACA TTCAGCTCAA GGCTCCCTGC CGTGTGAAG AGTTCTGACT
 5221 GCACAAACCA GCTTCTGGTT TCTTCTGGAA TGAATACCCT CATATCTGTC CTGATGTGAT
 5281 ATGTCTGAGA CTGAATGCGG GAGGTTC AAT GTGAAGCTGT GTGTGGTGTC AAAGTTTCAG
 5341 GAAGGATTTT ACCCTTTTGT TCTTCCCCCT GTCCCCAACC CACTCTCACC CCGCAACCCA
 5401 TCAGTATTTT AGTTATTTGG CCTCTACTCC AGTAAACCTG ATTGGGTTTG TCACTCTCT
 5461 GAATGATTAT TAGCCAGACT TCAAAATTAT TTTATAGCCC AAATTATAAC ATCTATTGTA
 5521 TTATTTAGAC TTTTAACATA TAGAGCTATT TCTACTGATT TTTGCCCTTG TTCTGTCCCT
 5581 TTTTCAAAA AAGAAAATGT GTTTTTGTG TGGTACCATA GTGTGAAATG CTGGGAACAA
 5641 TGAATAAAG ACATGCTATG GCACATATAT TTATAGCTG TTTATGTAGA AACAAATGTA
 5701 ATATATTAAA GCCTTATATA TAATGAACTT TGTACTATTC ACATTTTGTA TCAGTATTAT
 5761 GTAGCATAAC AAAGGTCATA ATGCTTTCAG CAATTGATGT CATTTTATTA AAGAACATTG
 5821 AAAAACTGA

Figure 4 (D) Sequence of VEGFR-2 (KDR/Flk-1) polypeptide
(GenBank Accession No. AAB88005) (SEQ ID NO: 10)


```

1  MQSKVLLAVA LWLCVETRAA SVGLPSVSLD LPRLSIQKDI LTIKANTTLQ ITCRGQRDLQ
61  WLWPNNQSGS EQRVEVTECS DGLFCKTLTI PKVIGNDTGA YKCFYRETDL ASVIYVYVQD
121 YRSPFIASVS DQHGCVYITE NKNKTVVIPC LGSISNLNVS LCARYPEKRF VPDGNRISWD
181 SKKGFTIPSY MISYAGMVFC EAKINDESYQ SIMYIVVVVG YRIYDVVLSP SHGIELSVGE
241 KLVLNCTART ELNVGIDFNW EYPSSKHQHK KLVNRDLKTQ SGSEMKKFLS TLTIDGVTRS
301 DQGLYTCAAS SGLMTKKNST FVRVHEKPFV AFGSGMESLV EATVGERVRI PAKYLGYPFP
361 EIKWYKNGIP LESNHTIKAG HVLTIMEVSE RDTGNYTVIL TNPISKEKQS HVVSLVYVVP
421 PQIGEKSLIS PVDSYQYGT TLTCTVYAI PPPHHIHWYW QLEEECANEP SQAVSVTNPY
481 PCEEWRSVED FQGGNKIEVN KNQFALIEGK NKTVSTLVIQ AANVSALYKC EAVNKVGRGE
541 RVISFHVTRG PEITLQPDQ PTEQESVSLW CTADRSTFEN LTWYKLGQPQ LPIHVGELPT
601 PVCKNLDTLW KLNATMFSNS TNDILIMELK NASLQDQGDY VCLAQDRKTK KRHCVVRLT
661 VLERVAPTIT GNLENQTTSI GESIEVSCTA SGNPPPQIMW FKDNELTVED SGIVLKDGNR
721 NLTIKRRVRKE DEGLYTCQAC SVLGCAKVEA FFIIEGAQEK TNLEIIILVG TAVIAMFFWL
781 LLVIILRTVK RANGGELKTG YLSIVMDPDE LPLDEHCERL PYDASKWEFF RDRLKLGKPL
841 GRGAFGQVIE ADAFGIDKTA TCRTVAVKML KEGATHSEHR ALMSELKILI HIGHHLNVVN
901 LLGACTKPGG PLMVIVEFCK FGNLSTYLRN KRNEFVPHYK KGARFRQGKD YVGAIPVDLK
961 RRLDSITSSQ SSASSGFVEE KSLSDVEEEE APEDLYKDFL TLEHLICYSF QVAKGMEFLA
1021 SRKCIHRDLA ARNILLSEKN VVKICDFGLA RDIYKDPDYV RKGDA RLPLK WMAPETIFDR
1081 VYTIQSDVWS FGVLLWEIFS LGASPYPGVK IDEEFCRRLK EGTRMRAPDY TTPEMYQTML
1141 DCWHGEPSQR PTFSELVEHL GNLLQANAQQ DGKDYIVLPI SETLSMEEDS GLSLPTSPVS
1201 CMEEEEVCDP KFHYDNTAGI SQYLQNSKRK SRPVSVKTFE DIPLEEPEVK VIPDDNQDTS
1261 GMVLASEELK TLEDRTKLSP SFGGMVPSKS RESVASEGSN QTSGYQSGYH SDDTDTTVYS
1321 SEEAELLKLI EIGVQTGSTA QILQPDSGTT LSSPPV

```


FIGURE 5

Effect of blocking PDGFR β and VEGF signaling on corneal neovascularization



Area of CNV

Animals were treated for one week, 7 days after induction of corneal neovascularization

FIGURE 6




FIGURE 7

Effect of PDGFR β and VEGF signaling inhibitors on normal vasculature

The vasculature of control eyes was unaffected by administration of Gleevec, APB5, PEG or Macugen suggesting that blocking either PDGFR β or VEGF signaling or both targets new and not established blood vessels.




FIGURE 8

Area of Choroidal Neovascularization following treatment with APB5 antibody and Macugen

All treatment was for one week, starting on day 7 after laser-burned

25mg/kg of Macugen and 5mg/kg of APB5 were injected twice a day by IP




FIGURE 9

Area of Choroidal Neovascularization following treatment with Gleevec and Macugen

All treatment was for one week, starting on day 7 after laser-burned

25mg/kg of Macugen were injected twice a day by IP

50mg/kg of Gleevec were administered by gavage twice a day




FIGURE 10




FIGURE 11




FIGURE 12




FIGURE 13





FIGURE 14





EUROPEAN SEARCH REPORT

 Application Number
 EP 16 00 2068

5

10

15

20

25

30

35

40

45

50

55

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (IPC)
X	CAMPOCHIARO PETER A: "Retinal and choroidal neovascularization", JOURNAL OF CELLULAR PHYSIOLOGY, WILEY LISS, NEW YORK, NY, US, vol. 184, no. 3, 1 September 2000 (2000-09-01), pages 301-310, XP002442268, ISSN: 0021-9541, DOI: DOI:10.1002/1097-4652(200009)184:3<LT,301: :AID-JCP3>,3.0.CO,2-H * page 305, left-hand column, last paragraph - page 306, left-hand column, paragraph 2 *	1-17	INV. C12N15/11
X	----- OZAKI H ET AL: "Blockade of vascular endothelial cell growth factor receptor signaling is sufficient to completely prevent retinal neovascularization", AMERICAN JOURNAL OF PATHOLOGY, AMERICAN SOCIETY FOR INVESTIGATIVE PATHOLOGY, US, vol. 156, no. 2, 1 February 2000 (2000-02-01), pages 697-707, XP002267465, ISSN: 0002-9440 * abstract *	1-17	TECHNICAL FIELDS SEARCHED (IPC) C12N
A	----- BERGERS GABRIELE ET AL: "Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors.", JOURNAL OF CLINICAL INVESTIGATION, vol. 111, no. 9, May 2003 (2003-05), pages 1287-1295, XP002317731, ISSN: 0021-9738 * abstract; figures 4,5 * ----- -/-	1-17	
The present search report has been drawn up for all claims			
Place of search Munich		Date of completion of the search 21 February 2017	Examiner Dolce, Luca
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document	

EPO FORM 1503 03.82 (P04C01)



EUROPEAN SEARCH REPORT

Application Number
EP 16 00 2068

5

10

15

20

25

30

35

40

45

50

55

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (IPC)
X	WO 98/45331 A2 (GENENTECH INC [US]; BACA MANUEL [US]; WELLS JAMES A [US]; PRESTA LEONA) 15 October 1998 (1998-10-15) * pages 46-47, line 19 * -----	1-17	
			TECHNICAL FIELDS SEARCHED (IPC)
The present search report has been drawn up for all claims			
Place of search Munich		Date of completion of the search 21 February 2017	Examiner Dolce, Luca
<p>CATEGORY OF CITED DOCUMENTS</p> <p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p> <p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document</p>			

EPO FORM 1503 03/82 (P04C01)

**ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.**

EP 16 00 2068

5 This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.
The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

21-02-2017

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9845331	A2	15-10-1998	
		AT 293640 T	15-05-2005
		AT 349470 T	15-01-2007
		AU 743758 B2	07-02-2002
		BR 9809387 A	11-09-2001
		CA 2286330 A1	15-10-1998
		CN 1259962 A	12-07-2000
		DE 69829891 D1	25-05-2005
		DE 69829891 T2	06-10-2005
		DE 69836729 T2	13-12-2007
		DE 122005000026 I1	04-08-2005
		DE 122005000050 I1	29-12-2005
		DE 122007000021 I1	24-05-2007
		DK 0973804 T3	07-05-2007
		DK 1325932 T3	30-05-2005
		EP 0973804 A2	26-01-2000
		EP 1325932 A2	09-07-2003
		EP 1650220 A2	26-04-2006
		EP 1787999 A1	23-05-2007
		ES 2236634 T3	16-07-2005
		ES 2273415 T3	01-05-2007
		HK 1023577 A1	30-03-2007
		HK 1084402 A1	23-11-2007
		JP 3957765 B2	15-08-2007
		JP 2001509817 A	24-07-2001
		KR 20080003452 A	07-01-2008
		KR 20080003453 A	07-01-2008
		LU 91167 I2	20-06-2005
		LU 91320 I2	30-04-2007
		NL 300193 I1	01-07-2005
		NL 300278 I1	01-06-2007
		NO 994869 A	06-12-1999
		NO 2007014 I1	14-01-2008
		NO 2007015 I1	14-01-2008
		NZ 500078 A	26-10-2001
		PT 1325932 E	30-06-2005
		SI 1325932 T1	31-08-2005
		TR 9903123 T2	22-05-2000
		US 7060269 B1	13-06-2006
		US 2005112126 A1	26-05-2005
		WO 9845331 A2	15-10-1998

EPO FORM P0459

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- US 49840703 P [0001]
- US 55683704 P [0001]
- US 5976534 A [0087]
- US 5833986 A [0087]
- US 5817310 A [0087] [0093]
- US 5882644 A [0087]
- US 5662904 A [0087]
- US 5620687 A [0087]
- US 5468468 A [0087]
- WO 2003025019 A [0087]
- US 5521184 A [0087]
- WO 2003013541 A [0087]
- WO 2003078404 A [0087]
- WO 2003099771 A [0087]
- WO 2003015282 A [0087]
- WO 200405282 A [0087]
- US 6528526 B [0088] [0184]
- US 6524347 B [0088]
- US 6482834 B [0088]
- US 6472391 B [0088]
- US 6696434 B [0088]
- US 6331555 B [0088]
- US 6251905 B [0088]
- US 6245760 B [0088]
- US 6207667 B [0088]
- US 5990141 A [0088] [0093]
- US 5700822 A [0088] [0093]
- US 5618837 A [0088]
- US 5731326 A [0088]
- US 6350731 B [0089]
- US 5952304 A [0089]
- US 5476851 A [0090]
- US 5480883 A [0090]
- US 5656643 A [0090]
- US 5795889 A [0090]
- US 6057320 A [0090]
- US 5869462 A [0091]
- US 5821234 A [0091]
- US 6582918 B [0092] [0142] [0229] [0231] [0233]
- US 6229002 B [0092] [0142]
- US 6207816 B [0092] [0142]
- US 5668264 A [0092] [0142]
- US 5674685 A [0092] [0142]
- US 5723594 A [0092] [0142] [0231] [0233]
- US 5238950 A [0093]
- US 5418135 A [0093]
- US 5674892 A [0093]
- US 5693610 A [0093]
- US 5700823 A [0093]
- US 5728726 A [0093]
- US 5795910 A [0093]
- US 5872218 A [0093]
- US 5932580 A [0093]
- US 5932602 A [0093]
- US 5958959 A [0093]
- US 6358954 B [0093]
- US 6537988 B [0093]
- US 6673798 B [0093]
- US 6011020 A [0094] [0142] [0147]
- US 6051698 A [0094] [0107] [0142]
- US 6147204 A [0094] [0142]
- US 6524583 B [0101]
- US 6451764 B [0101]
- US 6448077 B [0101]
- US 6416758 B [0101]
- US 6403088 B [0101]
- US 6383484 B [0101]
- US 6342221 B [0101] [0230] [0231]
- US 6342219 B [0101]
- US 6331301 B [0101]
- US 5730977 A [0101]
- WO 9630046 A [0101]
- WO 9744453 A [0101]
- WO 9845331 A [0101]
- US 5840301 A [0102]
- US 5874542 A [0102]
- US 5955311 A [0102]
- US 6365157 B [0102]
- WO 04003211 A [0102]
- US 6514971 B [0103] [0185]
- US 6448277 B [0103]
- US 6414148 B [0103]
- US 6362336 B [0103]
- US 6291455 B [0103]
- US 6284751 B [0103]
- US 6177401 B [0103]
- US 6071921 A [0103]
- US 6001885 A [0103]
- US 6576608 B [0104]
- US 6559126 B [0104]
- US 6541008 B [0104]
- US 6515105 B [0104]
- US 6383486 B [0104]
- US 6375929 B [0104]
- US 6361946 B [0104]
- US 6348333 B [0104]
- US 6100071 A [0104]
- US 5952199 A [0104]

- WO 03070910 PCT [0105]
- US 5611135 A [0106]
- US 5814620 A [0106]
- US 6399586 B [0106]
- US 6410322 B [0106]
- US 6291667 B [0106]
- US 6762290 B [0107]
- US 6426335 B [0107] [0142]
- US 6168778 B [0107] [0142]
- US 5859228 A [0107]
- US 4816567 A [0121] [0122]
- WO 9306213 A [0131]
- US 5660985 A [0135] [0145]
- US 3687808 A [0140]
- US 4845205 A [0140]
- US 5130302 A [0140]
- US 5134066 A [0140]
- US 5175273 A [0140]
- US 5367066 A [0140]
- US 5432272 A [0140]
- US 5457187 A [0140]
- US 5459255 A [0140]
- US 5484908 A [0140]
- US 5502177 A [0140]
- US 5525711 A [0140]
- US 5552540 A [0140]
- US 5587469 A [0140]
- US 5594121 A [0140]
- US 5596091 A [0140]
- US 5614617 A [0140]
- US 5645985 A [0140]
- US 5830653 A [0140]
- US 5763588 A [0140]
- US 6005096 A [0140]
- US 5681941 A [0140]
- US 5475096 A [0142]
- US 5270163 A [0142]
- US 5696249 A [0142]
- US 5670637 A [0142]
- US 5756291 A [0142]
- US 5811533 A [0142]
- US 5817785 A [0142]
- US 5958691 A [0142]
- US 5707796 A [0144]
- US 5763177 A [0144]
- US 5580737 A [0144] [0145]
- US 5567588 A [0144]
- US 26402994 A [0145]
- US 5637459 A [0146]
- US 5683867 A [0146]
- US 6562570 B [0158]
- US 5225347 A [0164]
- WO 9011364 A [0165]
- US 5093246 A [0165]
- WO 8804300 A [0166]
- US 5034506 A [0170]
- US 6110462 A [0172] [0175]
- US 6251588 B [0180]
- US 6278039 B [0182]
- US 5723750 A [0182]
- US 5244805 A [0182]
- EP 564409 A, Traxler [0184]
- WO 9220642 A [0184]
- US 8783494 B [0184]
- US 5017579 A [0185]
- US 4957925 A [0185]
- US 4994474 A [0185]
- EP 0302793 A2 [0185]

Non-patent literature cited in the description

- **WEIDNER et al.** *J. Natl. Cancer Inst.*, 1992, vol. 84, 1875-1887 [0004]
- **WEIDNER et al.** *Am. J. Pathol.*, 1993, vol. 143, 401-409 [0004]
- **LI et al.** *Lancet*, 1994, vol. 344, 82-86 [0004]
- **FOSS et al.** *Cancer Res.*, 1996, vol. 56, 2900-2903 [0004]
- **FAN et al.** *Trends Pharmacol. Sci.*, 1995, vol. 16, 57 [0004]
- **FOLKMAN.** *Nature Med.*, 1995, vol. 1, 27 [0004]
- **CULLINAN-BOVE et al.** *Endocrinol.*, 1993, vol. 133, 829 [0004]
- **SENGER et al.** *Cancer and Metastasis Reviews*, 1993, vol. 12, 303 [0004]
- **BROWN et al.** Control of Angiogenesis. 1996 [0010]
- **BIRKHAUSER ; BASEL ; THOMAS.** *J. Biol. Chem.*, 1996, vol. 271, 603-606 [0010]
- **CAMPOCHIARO.** *J. Cell. Physiol.*, 2000, vol. 184, 301-10 [0011]
- *Methods in Enzymology. Computer Methods for Macromolecular Sequence Analysis.* Academic Press, Inc, 1996, vol. 266 [0053]
- *Meth. Mol. Biol.*, 1997, vol. 70, 173-187 [0053]
- *Sequence, Structure, and Databanks: A Practical Approach.* Oxford University Press, 2000 [0053]
- *Bioinformatics: Databases and Systems.* Kluwer Academic Publishers, 1999 [0053]
- *Methods in Enzymology* [0053]
- **CASTELLON et al.** *Exp. Eve Res.*, 2001, vol. 74, 523-35 [0076]
- **HELDIN et al.** *Proc. Natl. Acad. Sci. (USA)*, 1981, vol. 78, 3664 [0080]
- **WILLIAMS et al.** *Proc. Natl. Acad. Sci. (USA)*, 1981, vol. 79, 5867 [0080]
- **WESTERMARK ; HELDIN.** *Acta Oncologica*, 1993, vol. 32, 101 [0080]
- **LI et al.** *Nat. Cell. Biol.*, 2000, vol. 2, 302-9 [0081]
- **BERGSTEN et al.** *Nat. Cell. Biol.*, 2001, vol. 3, 512-6 [0081]

- **UUTELE et al.** *Circulation*, 2001, vol. 103, 2242-47 [0081]
- **BETSHOLTZ et al.** *BioEssays*, 2001, vol. 23, 494-507 [0081]
- **CONN et al.** *Proc. Natl. Acad. Sci. (USA)*, 1990, vol. 87, 1323-1327 [0082]
- **FERRARA ; HENZEL.** *Biochem. Biophys. Res. Commun.*, 1989, vol. 161, 851-858 [0082]
- **PEPPER et al.** *Biochem. Biophys. Res. Commun.*, 1991, vol. 181, 902-906 [0082]
- **UNEMORI et al.** *J. Cell. Physiol.*, 1992, vol. 153, 557-562 [0082]
- **HOUCK et al.** *Mol. Endocrinol.*, 1991, vol. 5, 1806-1814 [0082]
- **TISCHER et al.** *J. Biol. Chem.*, 1991, vol. 266, 11947-11954 [0082]
- **GITAY-GOREN et al.** *J. Biol. Chem.*, 1996, vol. 271, 5519-5523 [0082]
- **KEYT et al.** *J. Biol. Chem.*, 1996, vol. 271, 7788-7795 [0082]
- **DE VRIES et al.** *Science*, 1992, vol. 255, 989-991 [0082]
- **MILLAUER et al.** *Cell*, 1993, vol. 72, 835-846 [0082]
- **TERMAN et al.** *Oncogene*, 1991, vol. 6, 519-524 [0082]
- **PARK et al.** *J. Biol. Chem.*, 1994, vol. 269, 25646-25654 [0082]
- **SEETHARAM et al.** *Oncogene*, 1995, vol. 10, 135-147 [0082]
- **WALTENBERGER et al.** *J. Biol. Chem.*, 1994, 26988-26995 [0082]
- **CARMELET et al.** *Nature*, 1996, vol. 380, 435-439 [0082]
- **FERRARA et al.** *Nature*, 1996, vol. 380, 439-442 [0082]
- **FONG et al.** *Nature*, 1995, vol. 376, 66-70 [0082]
- **SHALABY et al.** *Nature*, 1995, vol. 376, 62-66 [0082]
- **LEVY et al.** *J. Biol. Chem.*, 1996, 2746-2753 [0083]
- **SHWEIKI et al.** *Nature*, 1992, vol. 359, 843-845 [0083]
- **DVORAK et al.** *J. Immunol.*, 1979, vol. 122, 166-174 [0084]
- **SENGER et al.** *Science*, 1983, vol. 219, 983-985 [0084]
- **SENGER et al.** *Cancer Res.*, 1986, vol. 46, 5629-5632 [0084]
- **DVORAK et al.** *Am. J. Pathol.*, 1995, vol. 146, 1029-1039 [0084]
- **DAI et al.** *Genes & Dev.*, 2001, vol. 15, 1913-25 [0086]
- **ZIPPEL et al.** *Eur. J. Cell Biol.*, 1989, vol. 50 (2), 428-34 [0086]
- **ZWILLER et al.** *Oncogene*, 1991, vol. 6, 219-21 [0086]
- **DVORAK et al.** *Vascular Permeability Factor/Vascular Endothelial Growth Factor, Microvascular Hyperpermeability, and Angiogenesis* [0095]
- *Am. J. Pathol.*, 1995, vol. 146, 1029 [0095]
- **KOEHLER et al.** *Nature*, 1975, vol. 256, 496 [0112]
- **MAGE ; LAMOYI.** *Monoclonal Antibody Production Techniques and Applications.* Marcel Dekker, Inc, 1987, 79-97 [0121]
- **KOHLER ; MILSTEIN.** *Nature*, 1975, vol. 256, 495 [0122]
- **MCCAFFERTY et al.** *Nature*, 1990, vol. 348, 552-554 [0122]
- **JONES et al.** *Nature*, 1986, vol. 321, 522-525 [0124]
- **RIECHMANN et al.** *Nature*, 1988, vol. 332, 323-327 [0124]
- **VERHOEYEN et al.** *Science*, 1988, vol. 239, 1534-1536 [0124]
- **SIMS et al.** *J. Immunol.*, 1993, vol. 151, 2296 [0125]
- **CHOTHIA ; LESK.** *J. Mol. Biol.*, 1987, vol. 196, 901 [0125]
- **CARTER et al.** *Proc. Natl. Acad. Sci. (USA)*, 1992, vol. 89, 4285 [0125]
- **PRESTA et al.** *J. Immunol.*, 1993, vol. 151, 2623 [0125]
- **KOZBOR.** *J. Immunol.*, 1984, vol. 133, 3001 [0127]
- **BRODEUR et al.** *Monoclonal Antibody Production Techniques and Applications.* Marcel Dekker, Inc, 1987, 51-63 [0127]
- **BOERNER et al.** *J. Immunol.*, 1991, vol. 147, 86-95 [0127]
- **JAKOBOVITS et al.** *Proc. Natl. Acad. Sci.*, 1993, vol. 90, 2551 [0128]
- **JAKOBOVITS et al.** *Nature*, 1993, vol. 362, 255-258 [0128]
- **BRUGGERMANN et al.** *Year in Immuno.*, 1993, vol. 7, 33 [0128]
- **MCCAFFERTY et al.** *Nature*, 1990, vol. 348, 552-553 [0129]
- **JOHNSON et al.** *Current Opinion in Structural Biology*, 1993, vol. 3, 564-571 [0129]
- **CLACKSON et al.** *Nature*, 1991, vol. 352, 624-628 [0129]
- **MARKS et al.** *J. Mol. Biol.*, 1991, vol. 222, 581-597 [0129]
- **GRIFFITH et al.** *EMBO J.*, 1993, vol. 12, 725-734 [0129]
- **MARKS et al.** *Bio. Technol.*, 1992, vol. 10, 779-783 [0130]
- **WATERHOUSE et al.** *Nucl. Acids Res.*, 1993, vol. 21, 2265-2266 [0130]
- **ORTIGAO et al.** *Antisense Research and Development*, 1992, vol. 2, 129-146 [0133]
- **SINHA et al.** *Nucleic Acids Res.*, 1984, vol. 12, 4539-4557 [0133]
- **USMAN et al.** *J. Am. Chem. Soc.*, 1987, vol. 109, 7845-7854 [0133]
- **MCCOLLUM ; ANDRUS.** *Tetrahedron Lett.*, 1991, vol. 32, 4069-4072 [0133]
- **WINCOTT et al.** *Nucleic Acids Res.*, 1995, vol. 23, 2677-2684 [0133]
- **CATHALA ; BRUNEL.** *Nucleic Acids Res.*, 1990, vol. 18, 201 [0133]

- **SPROAT et al.** *Nucleosides and Nucleotides*, 1995, vol. 14, 255-273 [0133]
- **PIELES et al.** *Nucleic Acids Res.*, 1993, vol. 21, 3191-3196 [0133]
- **SZOSTAK.** *TIBS*, 1992, vol. 19, 89 [0142]
- **MONIA et al.** *Nature Med.*, 1996, vol. 2, 668-675 [0156]
- **MILNER et al.** *Nature Biotechnol.*, 1997, vol. 15, 537-541 [0156]
- **HO et al.** *Nucleic Acids Res.*, 1996, vol. 24, 1901-1907 [0156]
- **BIRIKH et al.** *RNA*, 1997, vol. 3, 429-437 [0156]
- **LIMA et al.** *J. Biol. Chem.*, 1997, vol. 272, 626-638 [0156]
- **HO et al.** *Nature Biotechnol.*, 1998, vol. 16, 59-63 [0156]
- **CAMPBELL et al.** *RNA*, 1995, vol. 1, 598-609 [0157]
- **LIEBER et al.** *Mol. Cell Biol.*, 1995, vol. 15, 540-551 [0157]
- **VAISH et al.** *Biochem.*, 1997, vol. 36, 6459-6501 [0157]
- **TSUCHIHASHI et al.** *Science*, 1993, vol. 267, 99-102 [0158]
- **PORTMAN et al.** *EMBO J.*, 1994, vol. 13, 213-221 [0158]
- **BERTRAND ; ROSSI.** *EMBO J.*, 1994, vol. 13, 2904-2912 [0158]
- **KOMURA ; RIGGS.** *Nucleic Acids Res.*, 1998, vol. 26, 1807-11 [0160]
- **LEFEBVRE-D'HELLENCOURT et al.** *Eur. Cyokine Netw.*, 1995, vol. 6, 7 [0162]
- **AGRAWAL.** *TIBTECH*, 1996, vol. 14, 376 [0162]
- **LEV-LEHMAN et al.** *Antisense Therap.* Plenum Press, 1997 [0162]
- **WAGNER et al.** *Nature*, 1994, vol. 372, 333 [0162]
- **CALABRETTA et al.** *Semin. Oncol.*, 1996, vol. 23, 78 [0162]
- **HAMPEL ; TRITZ.** *Biochem.*, 1989, vol. 28, 4929-33 [0163]
- **UHLENBECK.** *Nature*, 1987, vol. 328, 596-600 [0163]
- **SULLIVAN.** *Investig. Dermatolog.*, 1994, vol. 103, 95S [0164]
- **SYMONS.** *TIBS*, 1989, vol. 14, 445-50 [0164]
- **SYMONS.** *Ann. Rev. Biochem.*, 1992, vol. 61, 641-71 [0164]
- **SARVER et al.** *Science*, 1990, vol. 247, 1222-1225 [0165]
- **HASELOFF AND GERLACH.** *Nature*, 1988, vol. 334, 585 [0165]
- **ZAUG et al.** *Science*, 1984, vol. 224, 574-578 [0166]
- **ZAUG ; CECH.** *Science*, 1986, vol. 231, 470-475 [0166]
- **ZAUG et al.** *Nature*, 1986, vol. 324, 429-433 [0166]
- **BEEN ; CECH.** *Cell*, 1986, vol. 47, 207-216 [0166]
- **IYER et al.** *J. Org. Chem.*, 1990, vol. 55, 4693-99 [0168]
- **ECKSTEIN.** *Ann. Rev. Biochem.*, 1985, vol. 54, 367-402 [0168]
- **SPITZER ; ECKSTEIN.** *Nucleic Acids Res.*, 1988, vol. 18, 11691-704 [0168]
- **WOOLF et al.** *Nucleic Acids Res.*, 1990, vol. 18, 1763-69 [0168]
- **SHAW et al.** *Nucleic Acids Res.*, 1991, vol. 18, 11691-704 [0168]
- **AGARWAL et al.** *TIBTECH*, 1996, vol. 14, 376 [0168]
- **BOADO ; PARDRIDGE.** *Bioconi. Chem.*, 1992, vol. 3, 519-23 [0168]
- **AGARWAL et al.** *Proc. Natl. Acad. Sci. (USA)*, 1991, vol. 88, 7595 [0169]
- **HUNTER et al.** *J. Biol. Chem.*, 1975, vol. 250, 409-17 [0177]
- **MANCHE et al.** *Mol. Cell Biol.*, 1992, vol. 12, 5239-48 [0177]
- **MINKS et al.** *J. Biol. Chem.*, 1979, vol. 254, 10180-3 [0177]
- **ELBASHIR et al.** *Nature*, 2001, vol. 411, 494-8 [0177]
- **ELBASHI et al.** *Nature*, 2001, vol. 411, 494-8 [0178]
- **ELBASHIR et al.** *Genes Dev.*, 2001, vol. 15, 188-200 [0179]
- **JAEGER et al.** *Proc. Natl. Acad. Sci. (USA)*, 1989, vol. 86, 7706 [0180]
- **TURNER et al.** *Ann. Rev. Biophys. Biophys. Chem.*, 1988, vol. 17, 167 [0180]
- **KEHLENBACK et al.** *J. Cell. Biol.*, 1998, vol. 141, 863-74 [0181]
- **SPADA ; MYERS.** *Exp. Opin. Ther. Patents*, 1995, vol. 5, 805 [0184]
- **BRIDGES.** *Exp. Opin. Ther. Patents*, 1995, vol. 5, 1245 [0184]
- *Emerging Drugs: The Prospect For Improved Medicines*, 1996, 241-260 [0184]
- **MAGUIRE et al.** *J. Med. Chem.*, 1994, vol. 37, 2129 [0184]
- **DOLLE et al.** *J. Med. Chem.*, 1994, vol. 37, 2627 [0184]
- **ZIMMERMAN et al.** *Biorg. Med. Chem. Lett.*, 1996, vol. 6, 1221-1226 [0184]
- **BUCHDUNGER et al.** *Proc. Nat. Acad. Sci. (USA)*, 1995, vol. 92, 2558 [0184]
- *Cancer Res.*, 1994, vol. 54, 6106-6114 [0184]
- *Abstracts of the 116th Annual Meeting of the Pharmaceutical Society of Japan (Kanazawa)*, 1996, vol. 2, 275 [0184]
- *J. Med. Chem.*, 1995, vol. 38, 3482-7 [0185]
- *J. Chem. Soc. C*, 1968, vol. 9, 1152-5 [0185]
- *J. Karnatak Univ., Sci.*, 1984, vol. 29, 82-6 [0185]
- *Indian J. Chem.*, 1973, vol. 11, 211-13 [0185]
- *J. Karnatak Univ.*, 1973, vol. 18, 25-30 [0185]
- *J. Karnatak Univ., Sci.*, 1984, vol. 29, 82-6 [0185]
- **SHIBUYA et al.** *Oncogene*, 1990, vol. 5, 519-24 [0187]

EP 3 168 304 A1

- **REMINGTON.** The Science and Practice of Pharmacy. Lippincott Williams & Wilkins, 2000 **[0192]**
- Encyclopedia of Pharmaceutical Technology. Marcel Dekker, 1988 **[0192]**